_id,pubchem_id,generic_name,trade_name,orphan_designation,umls,parsed_text,designated_date,designation_status,approval_status,approved_labeled_indication,marketing_approval_date,exclusivity_end_date,exclusivity_protected_indication,sponsor
440234753,440234753,apadamtase alfa,,Treatment of Sickle Cell Disease,C0002895,Sickle Cell Disease,09/28/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Baxalta US Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States
404772603,404772603,apadamtase alfa,,Treatment of Sickle Cell Disease,C0002895,Sickle Cell Disease,09/28/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Baxalta US Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States
381128258,381128258,apadamtase alfa,,Treatment of Sickle Cell Disease,C0002895,Sickle Cell Disease,09/28/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Baxalta US Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States
405023558,405023558,"1-118-signal regulatory protein alpha (human) fusion protein with immunoglobulin G1 (human Fc fragment), dimer",,Treatment of Cutaneous T-Cell Lymphoma,C0079773,cutaneous T-cell lymphoma,03/08/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Trillium Therapeutics Inc.|2488 Dunwin Drive|Mississauga|Canada
332853708,332853708,"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",,Treatment of idiopathic pulmonary fibrosis.,C1800706,Idiopathic Pulmonary Fibrosis,09/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,GenKyoTex S.A.|14 Chemin des Aulx|Geneva|Switzerland
319393237,319393237,"2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one",,Treatment of Myelodysplastic Syndrome,C3463824,MYELODYSPLASTIC SYNDROME,04/11/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Aprea Therapeutics AB|Nobels Vag 3|Solna,|Sweden"
369038179,369038179,2-hydroxypropyl-B-cyclodextrin,,"Treatment of Niemann Pick disease, type C.",C0220756,"Niemann Pick Disease, Type C",02/18/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Vtesse, Inc.|700 Technology Square|Third Floor|Cambridge|Massachusetts|2139|United States"
255374991,255374991,2-hydroxypropyl-B-cyclodextrin,,"Treatment of Niemann Pick disease, type C.",C0220756,"Niemann Pick Disease, Type C",02/18/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Vtesse, Inc.|700 Technology Square|Third Floor|Cambridge|Massachusetts|2139|United States"
254764800,254764800,2-hydroxypropyl-B-cyclodextrin,,"Treatment of Niemann Pick disease, type C.",C0220756,"Niemann Pick Disease, Type C",02/18/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Vtesse, Inc.|700 Technology Square|Third Floor|Cambridge|Massachusetts|2139|United States"
404772496,404772496,225Ac-lintuzumab,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,11/25/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Actinium Pharmaceuticals, Inc.|379 Thornall Avenue|6th Floor|Edison|New Jersey|8837|United States"
402426007,402426007,225Ac-lintuzumab,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,11/25/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Actinium Pharmaceuticals, Inc.|379 Thornall Avenue|6th Floor|Edison|New Jersey|8837|United States"
223844000,223844000,"4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",,Treatment of cerebral cavernous malformation.,C2919945,Cerebral Cavernous Malformation,09/29/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Recursion Pharmaceuticals, LLC|383 S. Colorow Drive|Salt Lake City|Utah|84108|United States"
117651832,117651832,"4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",,Treatment of cerebral cavernous malformation.,C2919945,Cerebral Cavernous Malformation,09/29/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Recursion Pharmaceuticals, LLC|383 S. Colorow Drive|Salt Lake City|Utah|84108|United States"
53789268,53789268,"4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",,Treatment of cerebral cavernous malformation.,C2919945,Cerebral Cavernous Malformation,09/29/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Recursion Pharmaceuticals, LLC|383 S. Colorow Drive|Salt Lake City|Utah|84108|United States"
319393478,319393478,"4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid",,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,05/19/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Roche Genentech|F. Hoffmann-La Roche Ltd.|430 East 29th Street|New York|New York|10016|United States
160687627,160687627,90Y-hPAMA4,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,01/29/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
404719631,404719631,A-dmDT390-bisFv(UCHT1),,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,10/09/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Angimmune, LLC|American Red Cross Holland Laboratory|15601 Crabbs Branch Way|Rockville|Maryland|20855|United States"
255366256,255366256,abagovomab,,Treatment of epithelial ovarian cancer,C4721610,Epithelial Ovarian Cancer,11/25/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Menarini Ricerche S.p.A.|Via Tito Speri 10|Pomezia|Roma|Italy
252166477,252166477,abagovomab,,Treatment of epithelial ovarian cancer,C4721610,Epithelial Ovarian Cancer,11/25/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Menarini Ricerche S.p.A.|Via Tito Speri 10|Pomezia|Roma|Italy
160693407,160693407,abagovomab,,Treatment of epithelial ovarian cancer,C4721610,Epithelial Ovarian Cancer,11/25/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Menarini Ricerche S.p.A.|Via Tito Speri 10|Pomezia|Roma|Italy
135318753,135318753,abagovomab,,Treatment of epithelial ovarian cancer,C4721610,Epithelial Ovarian Cancer,11/25/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Menarini Ricerche S.p.A.|Via Tito Speri 10|Pomezia|Roma|Italy
441072535,441072535,abatacept,,Treatment of type 1 diabetes mellitus patients with residual beta cell function,C0011854,Type 1 diabetes mellitus,05/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States
440790639,440790639,abatacept,,Treatment of type 1 diabetes mellitus patients with residual beta cell function,C0011854,Type 1 diabetes mellitus,05/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States
386474197,386474197,abatacept,,Treatment of type 1 diabetes mellitus patients with residual beta cell function,C0011854,Type 1 diabetes mellitus,05/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States
386467149,386467149,abatacept,,Treatment of type 1 diabetes mellitus patients with residual beta cell function,C0011854,Type 1 diabetes mellitus,05/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States
178103473,178103473,abatacept,,Treatment of type 1 diabetes mellitus patients with residual beta cell function,C0011854,Type 1 diabetes mellitus,05/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States
135355129,135355129,abatacept,,Treatment of type 1 diabetes mellitus patients with residual beta cell function,C0011854,Type 1 diabetes mellitus,05/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States
103771521,103771521,abatacept,,Treatment of type 1 diabetes mellitus patients with residual beta cell function,C0011854,Type 1 diabetes mellitus,05/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States
50070209,50070209,abatacept,,Treatment of type 1 diabetes mellitus patients with residual beta cell function,C0011854,Type 1 diabetes mellitus,05/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States
46509198,46509198,abatacept,,Treatment of type 1 diabetes mellitus patients with residual beta cell function,C0011854,Type 1 diabetes mellitus,05/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC|64 Aspinwall Avenue|Brookline|Massachusetts|2446|United States
441072535,441072535,abatacept,,Prevention of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,12/26/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States
440790639,440790639,abatacept,,Prevention of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,12/26/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States
386474197,386474197,abatacept,,Prevention of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,12/26/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States
386467149,386467149,abatacept,,Prevention of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,12/26/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States
178103473,178103473,abatacept,,Prevention of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,12/26/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States
135355129,135355129,abatacept,,Prevention of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,12/26/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States
103771521,103771521,abatacept,,Prevention of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,12/26/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States
50070209,50070209,abatacept,,Prevention of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,12/26/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States
46509198,46509198,abatacept,,Prevention of Graft versus Host Disease,C0018133,GRAFT VERSUS HOST DISEASE,12/26/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.|P. O. Box 5326|Princeton|New Jersey|8543|United States
441072535,441072535,Abatacept,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
440790639,440790639,Abatacept,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
386474197,386474197,Abatacept,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
386467149,386467149,Abatacept,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
178103473,178103473,Abatacept,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
135355129,135355129,Abatacept,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
103771521,103771521,Abatacept,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
50070209,50070209,Abatacept,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
46509198,46509198,Abatacept,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
441072535,441072535,abatacept,,Treatment of idiopathic inflammatory myopathy (IIM),"C0751356,C3888318","idiopathic inflammatory myopathy , IIM",02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
440790639,440790639,abatacept,,Treatment of idiopathic inflammatory myopathy (IIM),"C0751356,C3888318","idiopathic inflammatory myopathy , IIM",02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
386474197,386474197,abatacept,,Treatment of idiopathic inflammatory myopathy (IIM),"C0751356,C3888318","idiopathic inflammatory myopathy , IIM",02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
386467149,386467149,abatacept,,Treatment of idiopathic inflammatory myopathy (IIM),"C0751356,C3888318","idiopathic inflammatory myopathy , IIM",02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
178103473,178103473,abatacept,,Treatment of idiopathic inflammatory myopathy (IIM),"C0751356,C3888318","idiopathic inflammatory myopathy , IIM",02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
135355129,135355129,abatacept,,Treatment of idiopathic inflammatory myopathy (IIM),"C0751356,C3888318","idiopathic inflammatory myopathy , IIM",02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
103771521,103771521,abatacept,,Treatment of idiopathic inflammatory myopathy (IIM),"C0751356,C3888318","idiopathic inflammatory myopathy , IIM",02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
50070209,50070209,abatacept,,Treatment of idiopathic inflammatory myopathy (IIM),"C0751356,C3888318","idiopathic inflammatory myopathy , IIM",02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
46509198,46509198,abatacept,,Treatment of idiopathic inflammatory myopathy (IIM),"C0751356,C3888318","idiopathic inflammatory myopathy , IIM",02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development|Marketed Products Development - Regulatory Strategy|P.O. Box 5326|Princeton|New Jersey|8543|United States
404770371,404770371,Abetimus,,Treatment of lupus nephritis.,C0024143,Lupus Nephritis,07/28/2000,Designated,Not FDA Approved for Orphan Indication,,,,,La Jolla Pharmaceutical Co.|6455 Nancy Ridge Dr.|San Diego|California|92121|United States
160687556,160687556,Abetimus,,Treatment of lupus nephritis.,C0024143,Lupus Nephritis,07/28/2000,Designated,Not FDA Approved for Orphan Indication,,,,,La Jolla Pharmaceutical Co.|6455 Nancy Ridge Dr.|San Diego|California|92121|United States
135325229,135325229,Abetimus,,Treatment of lupus nephritis.,C0024143,Lupus Nephritis,07/28/2000,Designated,Not FDA Approved for Orphan Indication,,,,,La Jolla Pharmaceutical Co.|6455 Nancy Ridge Dr.|San Diego|California|92121|United States
441072525,441072525,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
440790468,440790468,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
387061214,387061214,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
385327551,385327551,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
384647094,384647094,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
354355035,354355035,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
329976965,329976965,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
178101561,178101561,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
135335742,135335742,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
103771314,103771314,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
50070208,50070208,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
46504982,46504982,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older., 09/30/2014 , 09/30/2021 ,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
441072525,441072525,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
440790468,440790468,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
387061214,387061214,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
385327551,385327551,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
384647094,384647094,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
354355035,354355035,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
329976965,329976965,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
178101561,178101561,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
135335742,135335742,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
103771314,103771314,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
50070208,50070208,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
46504982,46504982,adalimumab,Humira,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,05/11/2011,Designated/Approved,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older, 02/24/2021 ,,,"AbbVie, Inc.|1 North Waukegan Rd|Dept PA72; Bldg AP30-4|North Chicago|Illinois|60064|United States"
441072525,441072525,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
440790468,440790468,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
387061214,387061214,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
385327551,385327551,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
384647094,384647094,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
354355035,354355035,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
329976965,329976965,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
178101561,178101561,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
135335742,135335742,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
103771314,103771314,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
50070208,50070208,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
46504982,46504982,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa, 09/09/2015 , 09/09/2022 ,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
441072525,441072525,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
440790468,440790468,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
387061214,387061214,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
385327551,385327551,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
384647094,384647094,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
354355035,354355035,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
329976965,329976965,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
178101561,178101561,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
135335742,135335742,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
103771314,103771314,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
50070208,50070208,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
46504982,46504982,adalimumab,HUMIRA,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,10/19/2006,Designated/Approved,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.", 09/23/2014 , 09/23/2021 ,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.|1 N. Waukegan Road|Bldg AP30, Dept. PA77|North Chicago|Illinois|60064|United States"
441072525,441072525,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
440790468,440790468,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
387061214,387061214,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
385327551,385327551,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
384647094,384647094,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
354355035,354355035,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
329976965,329976965,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
178101561,178101561,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
135335742,135335742,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
103771314,103771314,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
50070208,50070208,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
46504982,46504982,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients", 06/30/2016 , 06/30/2023 ,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
441072525,441072525,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
440790468,440790468,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
387061214,387061214,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
385327551,385327551,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
384647094,384647094,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
354355035,354355035,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
329976965,329976965,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
178101561,178101561,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
135335742,135335742,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
103771314,103771314,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
50070208,50070208,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
46504982,46504982,adalimumab,Humira,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,03/21/2005,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older., 02/21/2008 , 02/21/2015 ,,AbbVie Inc.|1 North Waukegan Road|Bldg. AP-30|North Chicago|Illinois|60064|United States
441072525,441072525,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
440790468,440790468,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
387061214,387061214,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
385327551,385327551,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
384647094,384647094,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
354355035,354355035,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
329976965,329976965,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
178101561,178101561,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
135335742,135335742,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
103771314,103771314,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
50070208,50070208,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
46504982,46504982,adalimumab,Humira,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis","C0009450,C0030343,C0339317,C0751438","Infectious , Panuveitis , Non-infectious anterior uveitis , Posterior",05/13/2014,Designated/Approved,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older", 09/28/2018 , 09/28/2025 ,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
441072525,441072525,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
440790468,440790468,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
387061214,387061214,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
385327551,385327551,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
384647094,384647094,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
354355035,354355035,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
329976965,329976965,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
178101561,178101561,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
135335742,135335742,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
103771314,103771314,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
50070208,50070208,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
46504982,46504982,adalimumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Mucora|32b Eisenberg St|Rehovot 7628810|Israel
441072525,441072525,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
440790468,440790468,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
387061214,387061214,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
385327551,385327551,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
384647094,384647094,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
354355035,354355035,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
329976965,329976965,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
178101561,178101561,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
135335742,135335742,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
103771314,103771314,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
50070208,50070208,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
46504982,46504982,adalimumab,HUMIRA,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),C0162836,Hidradenitis Suppurativa,05/13/2015,Designated/Approved,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older., 10/16/2018 , 10/16/2025 ,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.|1 North Waukegan Road|North Chicago|Illinois|60064|United States"
441071826,441071826,aflibercept,,Treatment of Retinopathy of Prematurity,C0035344,Retinopathy of Prematurity,07/23/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
354355041,354355041,aflibercept,,Treatment of Retinopathy of Prematurity,C0035344,Retinopathy of Prematurity,07/23/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
349353151,349353151,aflibercept,,Treatment of Retinopathy of Prematurity,C0035344,Retinopathy of Prematurity,07/23/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
347910379,347910379,aflibercept,,Treatment of Retinopathy of Prematurity,C0035344,Retinopathy of Prematurity,07/23/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
178103392,178103392,aflibercept,,Treatment of Retinopathy of Prematurity,C0035344,Retinopathy of Prematurity,07/23/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
135347926,135347926,aflibercept,,Treatment of Retinopathy of Prematurity,C0035344,Retinopathy of Prematurity,07/23/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
134445687,134445687,aflibercept,,Treatment of Retinopathy of Prematurity,C0035344,Retinopathy of Prematurity,07/23/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
440790670,440790670,agalsidase beta,Fabrazyme,Treatment of Fabry's disease.,C0002986,Fabry's Disease,01/19/1988,Designated/Approved,,treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease, 03/11/2021 , 03/11/2028 ,treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease,Genzyme Corporation|50 Binney Street|Cambridge|Massachusetts|2142|United States
160682349,160682349,agalsidase beta,Fabrazyme,Treatment of Fabry's disease.,C0002986,Fabry's Disease,01/19/1988,Designated/Approved,,treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease, 03/11/2021 , 03/11/2028 ,treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease,Genzyme Corporation|50 Binney Street|Cambridge|Massachusetts|2142|United States
135311478,135311478,agalsidase beta,Fabrazyme,Treatment of Fabry's disease.,C0002986,Fabry's Disease,01/19/1988,Designated/Approved,,treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease, 03/11/2021 , 03/11/2028 ,treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease,Genzyme Corporation|50 Binney Street|Cambridge|Massachusetts|2142|United States
46508538,46508538,agalsidase beta,Fabrazyme,Treatment of Fabry's disease.,C0002986,Fabry's Disease,01/19/1988,Designated/Approved,,treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease, 03/11/2021 , 03/11/2028 ,treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease,Genzyme Corporation|50 Binney Street|Cambridge|Massachusetts|2142|United States
404772796,404772796,aganirsen,,Prevention of corneal graft rejection.,C0339303,Corneal graft rejection,11/07/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Gene Signal International SA|Route Cantonale|Lausanne|Vaud|Switzerland
381126369,381126369,aganirsen,,Prevention of corneal graft rejection.,C0339303,Corneal graft rejection,11/07/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Gene Signal International SA|Route Cantonale|Lausanne|Vaud|Switzerland
160693050,160693050,aganirsen,,Prevention of corneal graft rejection.,C0339303,Corneal graft rejection,11/07/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Gene Signal International SA|Route Cantonale|Lausanne|Vaud|Switzerland
440790979,440790979,Aldesleukin,Proleukin,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,09/14/1988,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma., 05/05/1992 , 05/05/1999 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
178101682,178101682,Aldesleukin,Proleukin,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,09/14/1988,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma., 05/05/1992 , 05/05/1999 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
135273161,135273161,Aldesleukin,Proleukin,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,09/14/1988,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma., 05/05/1992 , 05/05/1999 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
134224532,134224532,Aldesleukin,Proleukin,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,09/14/1988,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma., 05/05/1992 , 05/05/1999 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
103771288,103771288,Aldesleukin,Proleukin,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,09/14/1988,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma., 05/05/1992 , 05/05/1999 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
49985142,49985142,Aldesleukin,Proleukin,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,09/14/1988,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma., 05/05/1992 , 05/05/1999 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
46508054,46508054,Aldesleukin,Proleukin,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,09/14/1988,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma., 05/05/1992 , 05/05/1999 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
597554,597554,Aldesleukin,Proleukin,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,09/14/1988,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma., 05/05/1992 , 05/05/1999 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
10105,10105,Aldesleukin,Proleukin,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,09/14/1988,Designated/Approved,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma., 05/05/1992 , 05/05/1999 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
440790979,440790979,Aldesleukin,,Treatment of primary immunodeficiency disease associated with T-cell defects.,C0398686,Primary Immunodeficiency Disease,03/22/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
178101682,178101682,Aldesleukin,,Treatment of primary immunodeficiency disease associated with T-cell defects.,C0398686,Primary Immunodeficiency Disease,03/22/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
135273161,135273161,Aldesleukin,,Treatment of primary immunodeficiency disease associated with T-cell defects.,C0398686,Primary Immunodeficiency Disease,03/22/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
134224532,134224532,Aldesleukin,,Treatment of primary immunodeficiency disease associated with T-cell defects.,C0398686,Primary Immunodeficiency Disease,03/22/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
103771288,103771288,Aldesleukin,,Treatment of primary immunodeficiency disease associated with T-cell defects.,C0398686,Primary Immunodeficiency Disease,03/22/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
49985142,49985142,Aldesleukin,,Treatment of primary immunodeficiency disease associated with T-cell defects.,C0398686,Primary Immunodeficiency Disease,03/22/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
46508054,46508054,Aldesleukin,,Treatment of primary immunodeficiency disease associated with T-cell defects.,C0398686,Primary Immunodeficiency Disease,03/22/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
597554,597554,Aldesleukin,,Treatment of primary immunodeficiency disease associated with T-cell defects.,C0398686,Primary Immunodeficiency Disease,03/22/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
10105,10105,Aldesleukin,,Treatment of primary immunodeficiency disease associated with T-cell defects.,C0398686,Primary Immunodeficiency Disease,03/22/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
440790979,440790979,Aldesleukin,Proleukin,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,09/10/1996,Designated/Approved,,Treatment of adults with metastatic melanoma., 01/09/1998 , 01/09/2005 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
178101682,178101682,Aldesleukin,Proleukin,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,09/10/1996,Designated/Approved,,Treatment of adults with metastatic melanoma., 01/09/1998 , 01/09/2005 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
135273161,135273161,Aldesleukin,Proleukin,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,09/10/1996,Designated/Approved,,Treatment of adults with metastatic melanoma., 01/09/1998 , 01/09/2005 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
134224532,134224532,Aldesleukin,Proleukin,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,09/10/1996,Designated/Approved,,Treatment of adults with metastatic melanoma., 01/09/1998 , 01/09/2005 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
103771288,103771288,Aldesleukin,Proleukin,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,09/10/1996,Designated/Approved,,Treatment of adults with metastatic melanoma., 01/09/1998 , 01/09/2005 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
49985142,49985142,Aldesleukin,Proleukin,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,09/10/1996,Designated/Approved,,Treatment of adults with metastatic melanoma., 01/09/1998 , 01/09/2005 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
46508054,46508054,Aldesleukin,Proleukin,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,09/10/1996,Designated/Approved,,Treatment of adults with metastatic melanoma., 01/09/1998 , 01/09/2005 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
597554,597554,Aldesleukin,Proleukin,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,09/10/1996,Designated/Approved,,Treatment of adults with metastatic melanoma., 01/09/1998 , 01/09/2005 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
10105,10105,Aldesleukin,Proleukin,Treatment of metastatic melanoma.,C0278883,Metastatic melanoma,09/10/1996,Designated/Approved,,Treatment of adults with metastatic melanoma., 01/09/1998 , 01/09/2005 ,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
440790979,440790979,Aldesleukin,,For the treatment non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,11/24/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
178101682,178101682,Aldesleukin,,For the treatment non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,11/24/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
135273161,135273161,Aldesleukin,,For the treatment non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,11/24/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
134224532,134224532,Aldesleukin,,For the treatment non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,11/24/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
103771288,103771288,Aldesleukin,,For the treatment non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,11/24/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
49985142,49985142,Aldesleukin,,For the treatment non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,11/24/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
46508054,46508054,Aldesleukin,,For the treatment non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,11/24/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
597554,597554,Aldesleukin,,For the treatment non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,11/24/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
10105,10105,Aldesleukin,,For the treatment non-Hodgkin's lymphoma.,C0024305,Non-Hodgkin's Lymphoma,11/24/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
440790979,440790979,Aldesleukin,,Treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,07/31/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
178101682,178101682,Aldesleukin,,Treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,07/31/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
135273161,135273161,Aldesleukin,,Treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,07/31/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
134224532,134224532,Aldesleukin,,Treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,07/31/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
103771288,103771288,Aldesleukin,,Treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,07/31/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
49985142,49985142,Aldesleukin,,Treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,07/31/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
46508054,46508054,Aldesleukin,,Treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,07/31/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
597554,597554,Aldesleukin,,Treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,07/31/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
10105,10105,Aldesleukin,,Treatment of acute myelogenous leukemia.,C0023467,Acute myelogenous leukemia,07/31/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation|4560 Horton Street|Emeryville|California|94608|United States
440790979,440790979,Aldesleukin,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,04/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
178101682,178101682,Aldesleukin,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,04/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
135273161,135273161,Aldesleukin,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,04/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
134224532,134224532,Aldesleukin,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,04/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
103771288,103771288,Aldesleukin,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,04/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
49985142,49985142,Aldesleukin,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,04/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
46508054,46508054,Aldesleukin,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,04/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
597554,597554,Aldesleukin,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,04/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
10105,10105,Aldesleukin,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,04/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.|790 Township Line Road|Suite 120|Yardley|Pennsylvania|19067|United States"
440790671,440790671,alemtuzumab,Campath,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,10/20/1997,Designated/Approved,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy., 05/07/2001 , 05/07/2008 ,,Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States
329976974,329976974,alemtuzumab,Campath,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,10/20/1997,Designated/Approved,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy., 05/07/2001 , 05/07/2008 ,,Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States
178103376,178103376,alemtuzumab,Campath,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,10/20/1997,Designated/Approved,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy., 05/07/2001 , 05/07/2008 ,,Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States
135330159,135330159,alemtuzumab,Campath,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,10/20/1997,Designated/Approved,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy., 05/07/2001 , 05/07/2008 ,,Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States
103771414,103771414,alemtuzumab,Campath,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,10/20/1997,Designated/Approved,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy., 05/07/2001 , 05/07/2008 ,,Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States
50070197,50070197,alemtuzumab,Campath,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,10/20/1997,Designated/Approved,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy., 05/07/2001 , 05/07/2008 ,,Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States
46507379,46507379,alemtuzumab,Campath,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,10/20/1997,Designated/Approved,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy., 05/07/2001 , 05/07/2008 ,,Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States
7978474,7978474,alemtuzumab,Campath,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,10/20/1997,Designated/Approved,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy., 05/07/2001 , 05/07/2008 ,,Genzyme Corporation|4545 Horizon Hill Blvd.|San Antonio|Texas|78229|United States
160693092,160693092,algenpantucel-L,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,10/21/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,NewLink Genetics Corporation|2503 S. Loop Drive|Ames|Iowa|50010|United States
438448225,438448225,alirocumab,Praluent,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,06/15/2017,Designated/Approved,,As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C., 04/01/2021 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
381126738,381126738,alirocumab,Praluent,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,06/15/2017,Designated/Approved,,As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C., 04/01/2021 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
375563015,375563015,alirocumab,Praluent,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,06/15/2017,Designated/Approved,,As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C., 04/01/2021 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
354355043,354355043,alirocumab,Praluent,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,06/15/2017,Designated/Approved,,As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C., 04/01/2021 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
348653637,348653637,alirocumab,Praluent,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,06/15/2017,Designated/Approved,,As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C., 04/01/2021 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
347910431,347910431,alirocumab,Praluent,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,06/15/2017,Designated/Approved,,As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C., 04/01/2021 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
178103355,178103355,alirocumab,Praluent,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,06/15/2017,Designated/Approved,,As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C., 04/01/2021 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
160709254,160709254,alirocumab,Praluent,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,06/15/2017,Designated/Approved,,As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C., 04/01/2021 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
349986622,349986622,alpha melanotropin,,Treatment of chronic beryllium disease,C0221052,Chronic beryllium disease,09/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,mondoBIOTECH Laboratories AG|Herrengasse 21|Furstentum Liechtenstein|Germany
53790846,53790846,alpha melanotropin,,Treatment of chronic beryllium disease,C0221052,Chronic beryllium disease,09/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,mondoBIOTECH Laboratories AG|Herrengasse 21|Furstentum Liechtenstein|Germany
404719581,404719581,alpha-1 proteinase inhibitor (human),,Prevention of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,07/31/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Kamada, Ltd.|2 Holtzman Street|Rehovot|Israel"
46506364,46506364,alpha-1 proteinase inhibitor (human),,Prevention of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,07/31/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Kamada, Ltd.|2 Holtzman Street|Rehovot|Israel"
404719581,404719581,alpha-1 proteinase inhibitor (human),,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,10/23/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.|2 Holtsman Street|Rehovot|Center District|Israel
46506364,46506364,alpha-1 proteinase inhibitor (human),,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,10/23/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.|2 Holtsman Street|Rehovot|Center District|Israel
135311478,135311478,Alpha-galactosidase A,,Treatment of Fabry's disease.,C0002986,Fabry's Disease,07/20/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Desnick, Robert J. M.D.|The Mount Sinai School Of Medicine|Fifth Avenue at 100th Street, Box 1203|New York|New York|10029|United States"
46508538,46508538,Alpha-galactosidase A,,Treatment of Fabry's disease.,C0002986,Fabry's Disease,07/20/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Desnick, Robert J. M.D.|The Mount Sinai School Of Medicine|Fifth Avenue at 100th Street, Box 1203|New York|New York|10029|United States"
135311478,135311478,Alpha-galactosidase A,,Long-term enzyme replacement therapy for the treatment of Fabry disease,C0002986,Fabry Disease,06/22/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc.|700 Main Street|Cambridge|Massachusetts|2139|United States"
46508538,46508538,Alpha-galactosidase A,,Long-term enzyme replacement therapy for the treatment of Fabry disease,C0002986,Fabry Disease,06/22/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc.|700 Main Street|Cambridge|Massachusetts|2139|United States"
135311478,135311478,Alpha-galactosidase A,,Treatment of alpha-galactosidase A deficiency (Fabry's disease).,C0002986,alpha-Galactosidase A Deficiency,06/17/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"David Calhoun, Ph.D.|Department of Chemistry|Convent Avenue & 138th Street|New York|New York|10031|United States"
46508538,46508538,Alpha-galactosidase A,,Treatment of alpha-galactosidase A deficiency (Fabry's disease).,C0002986,alpha-Galactosidase A Deficiency,06/17/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"David Calhoun, Ph.D.|Department of Chemistry|Convent Avenue & 138th Street|New York|New York|10031|United States"
404719581,404719581,Alpha1-proteinase inhibitor (human),Prolastin,For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.,"C0162429,C0333006","Deficiency state , congenital deficiency",12/07/1984,Designated/Approved,,For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema., 12/02/1987 , 12/02/1994 ,,"Bayer Corporation|Pharmaceutical Division, Biological Products|400 Morgan Lane|New Haven|Connecticut|6516|United States"
46506364,46506364,Alpha1-proteinase inhibitor (human),Prolastin,For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.,"C0162429,C0333006","Deficiency state , congenital deficiency",12/07/1984,Designated/Approved,,For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema., 12/02/1987 , 12/02/1994 ,,"Bayer Corporation|Pharmaceutical Division, Biological Products|400 Morgan Lane|New Haven|Connecticut|6516|United States"
404719581,404719581,alpha1-proteinase inhibitor (human),,Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,03/03/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.|8368 US Business Hwy 70 West|Clayton|North Carolina|27520|United States"
46506364,46506364,alpha1-proteinase inhibitor (human),,Treatment of Type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,03/03/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.|8368 US Business Hwy 70 West|Clayton|North Carolina|27520|United States"
404719581,404719581,alpha1-proteinase inhibitor (human),,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.|8368 US 70 BUS Hwy W.|Clayton|North Carolina|27520|United States"
46506364,46506364,alpha1-proteinase inhibitor (human),,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.|8368 US 70 BUS Hwy W.|Clayton|North Carolina|27520|United States"
404719581,404719581,Alpha1-proteinase inhibitor (human),,For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.,"C0034067,C0242656","Emphysema , Progression",11/24/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,CSL Behring L.L.C.|1020 First Ave.|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
46506364,46506364,Alpha1-proteinase inhibitor (human),,For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.,"C0034067,C0242656","Emphysema , Progression",11/24/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,CSL Behring L.L.C.|1020 First Ave.|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
404719581,404719581,alpha1-proteinase inhibitor (human),,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,02/20/2009,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring LLC|1020 First Avenue|P. O. Box 61501|King of Prussia|Pennsylvania|19406|United States
46506364,46506364,alpha1-proteinase inhibitor (human),,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,02/20/2009,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring LLC|1020 First Avenue|P. O. Box 61501|King of Prussia|Pennsylvania|19406|United States
404719581,404719581,Alpha1-Proteinase Inhibitor (Human),,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,09/01/2004,Designated,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.|7 Sapir Street|Ness Ziona|Israel
46506364,46506364,Alpha1-Proteinase Inhibitor (Human),,Treatment of cystic fibrosis,C0010674,Cystic Fibrosis,09/01/2004,Designated,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.|7 Sapir Street|Ness Ziona|Israel
440790675,440790675,alteplase,,Treatment of plastic bronchitis,C0264342,Plastic bronchitis,10/20/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States"
135358863,135358863,alteplase,,Treatment of plastic bronchitis,C0264342,Plastic bronchitis,10/20/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States"
134222947,134222947,alteplase,,Treatment of plastic bronchitis,C0264342,Plastic bronchitis,10/20/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States"
103771263,103771263,alteplase,,Treatment of plastic bronchitis,C0264342,Plastic bronchitis,10/20/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States"
50018415,50018415,alteplase,,Treatment of plastic bronchitis,C0264342,Plastic bronchitis,10/20/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States"
46507035,46507035,alteplase,,Treatment of plastic bronchitis,C0264342,Plastic bronchitis,10/20/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States"
7978677,7978677,alteplase,,Treatment of plastic bronchitis,C0264342,Plastic bronchitis,10/20/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Kathleen A Stringer, PharmD, FCCP - Professor|University of %i|428 Church St.|Ann Arbor|Michigan|48109|United States"
440790675,440790675,alteplase,,Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,"C0240059,C2937358","Intraventricular hemorrhage , Intracerebral Hemorrhage",01/27/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States"
135358863,135358863,alteplase,,Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,"C0240059,C2937358","Intraventricular hemorrhage , Intracerebral Hemorrhage",01/27/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States"
134222947,134222947,alteplase,,Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,"C0240059,C2937358","Intraventricular hemorrhage , Intracerebral Hemorrhage",01/27/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States"
103771263,103771263,alteplase,,Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,"C0240059,C2937358","Intraventricular hemorrhage , Intracerebral Hemorrhage",01/27/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States"
50018415,50018415,alteplase,,Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,"C0240059,C2937358","Intraventricular hemorrhage , Intracerebral Hemorrhage",01/27/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States"
46507035,46507035,alteplase,,Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,"C0240059,C2937358","Intraventricular hemorrhage , Intracerebral Hemorrhage",01/27/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States"
7978677,7978677,alteplase,,Treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,"C0240059,C2937358","Intraventricular hemorrhage , Intracerebral Hemorrhage",01/27/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Daniel F. Hanley, MD|Johns Hopkins University|600 N. Wolfe St., Jefferson 1-109|Baltimore|Maryland|21287|United States"
347911395,347911395,amatuximab,,Treatment of mesothelioma,C0025500,Mesothelioma,09/28/2012,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States
223366083,223366083,amatuximab,,Treatment of mesothelioma,C0025500,Mesothelioma,09/28/2012,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States
160704149,160704149,amatuximab,,Treatment of mesothelioma,C0025500,Mesothelioma,09/28/2012,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States
135289484,135289484,amatuximab,,Treatment of mesothelioma,C0025500,Mesothelioma,09/28/2012,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States
349940505,349940505,Ancrod,,To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.,C2919015,ANTICOAGULATION,10/20/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States"
347909946,347909946,Ancrod,,To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.,C2919015,ANTICOAGULATION,10/20/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States"
160698415,160698415,Ancrod,,To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.,C2919015,ANTICOAGULATION,10/20/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States"
135349930,135349930,Ancrod,,To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.,C2919015,ANTICOAGULATION,10/20/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States"
134222369,134222369,Ancrod,,To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.,C2919015,ANTICOAGULATION,10/20/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States"
50026835,50026835,Ancrod,,To establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.,C2919015,ANTICOAGULATION,10/20/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Knoll Pharmaceutical Company|3000 Continental Dr., North|Mt. Olive|New Jersey|7828|United States"
404772536,404772536,anfibatide,,Treatment of thrombotic thrombocytopenic purpura.,C0857305,Thrombocytopenic purpura,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Lee's Pharmaceutical (Hong Kong) Limited|Unit 110-11, Bio-Informatics Centre|Hong Kong Science Park|Shatin, Hong Kong|China"
404719663,404719663,anfibatide,,Treatment of thrombotic thrombocytopenic purpura.,C0857305,Thrombocytopenic purpura,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Lee's Pharmaceutical (Hong Kong) Limited|Unit 110-11, Bio-Informatics Centre|Hong Kong Science Park|Shatin, Hong Kong|China"
381127770,381127770,anfibatide,,Treatment of thrombotic thrombocytopenic purpura.,C0857305,Thrombocytopenic purpura,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Lee's Pharmaceutical (Hong Kong) Limited|Unit 110-11, Bio-Informatics Centre|Hong Kong Science Park|Shatin, Hong Kong|China"
440234910,440234910,ansuvimab,,Post-exposure prophylaxis against Ebola virus infection,C0282687,Ebola Virus Infection,03/30/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Ridgeback Biotherapeutics LP|3162 Commodore Plaza|Suite 3E|Miami|Florida|33133-|United States
433770931,433770931,ansuvimab,,Post-exposure prophylaxis against Ebola virus infection,C0282687,Ebola Virus Infection,03/30/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Ridgeback Biotherapeutics LP|3162 Commodore Plaza|Suite 3E|Miami|Florida|33133-|United States
433770931,433770931,ansuvimab-zykl,EBANGA,Treatment of Ebola Virus Disease,C0282687,Ebola Virus Disease,05/08/2019,Designated/Approved,,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection", 12/21/2020 , 12/21/2027 ,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection","Ridgeback Biotherapeutics, LP|3480 Main Highway|Unit 402|Miami|Florida|33133|United States"
347910401,347910401,anthrax immune globulin (human),,Treatment of inhalational anthrax,C0155866,Inhalational anthrax,07/29/2008,Designated/Approved,,Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs, 03/24/2015 , 03/24/2022 ,Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs,"Cangene Corp. - Emergent Biosolutions|155 Innovation Drive|R3T 5Y3|Winnipeg, MB|Canada"
381125967,381125967,Anthrax Vaccine Adsorbed,BioThrax,For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure,C0003175,Anthrax disease,04/11/2014,Designated/Approved,,"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.", 11/23/2015 , 11/23/2022 ,"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",Emergent BioDefense Operations Lansing LLC|300 Proessional Drive|Gaithersburg|Maryland|20879|United States
347911075,347911075,Anthrax Vaccine Adsorbed,BioThrax,For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure,C0003175,Anthrax disease,04/11/2014,Designated/Approved,,"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.", 11/23/2015 , 11/23/2022 ,"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",Emergent BioDefense Operations Lansing LLC|300 Proessional Drive|Gaithersburg|Maryland|20879|United States
381127989,381127989,Anti-eTau Humanized IgG4 Monoclonal Antibody,,Treatment of Progressive Supranuclear Palsy,C0038868,Progressive supranuclear palsy,05/13/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.|225 Binney Street|Cambridge|Massachusetts|2142|United States"
404719773,404719773,anti-inhibitor coagulant complex,FEIBA,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,C0019069,Hemophilia A,04/12/2013,Designated/Approved,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors, 12/16/2013 , 12/16/2020 ,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,"Baxalta US, Inc.|One Baxter Way|West Lake Village|California|91362|United States"
347911435,347911435,anti-inhibitor coagulant complex,FEIBA,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,C0019069,Hemophilia A,04/12/2013,Designated/Approved,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors, 12/16/2013 , 12/16/2020 ,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,"Baxalta US, Inc.|One Baxter Way|West Lake Village|California|91362|United States"
135300895,135300895,anti-inhibitor coagulant complex,FEIBA,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,C0019069,Hemophilia A,04/12/2013,Designated/Approved,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors, 12/16/2013 , 12/16/2020 ,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,"Baxalta US, Inc.|One Baxter Way|West Lake Village|California|91362|United States"
46506920,46506920,"anti-T-lymphocyte immune globulin, rabbit",,Prevention of graft versus host disease (GVHD),C0018133,GRAFT VERSUS HOST DISEASE,03/26/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Neovii Biotech NA, Inc.|6 Liberty Square|PMB #295|Boston|Massachusetts|2109|United States"
46506920,46506920,"anti-T-lymphocyte immune globulin, rabbit",,Prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation,C1735634,Acute allograft rejection,09/12/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Neovii Biotech NA, Inc.|6 Liberty Square|PMB #295|Boston|Massachusetts|2109|United States"
134223943,134223943,anti-thymocyte Globulin (rabbit),,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,09/06/2000,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation|A Sanofi Company|500 Kendall Street|Cambridge|Massachusetts|2142|United States
46506920,46506920,anti-thymocyte Globulin (rabbit),,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,09/06/2000,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation|A Sanofi Company|500 Kendall Street|Cambridge|Massachusetts|2142|United States
135293379,135293379,Antihemophilic factor (recombinant),"ReFacto, Xyntha",For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).,"C0019069,C2674164","Hemophilia A , Hemorrhagic episodes",02/08/1996,Designated/Approved,,, 03/06/2000 ,,,"Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Philadelphia|Pennsylvania|19101|United States"
46506209,46506209,Antihemophilic factor (recombinant),"ReFacto, Xyntha",For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).,"C0019069,C2674164","Hemophilia A , Hemorrhagic episodes",02/08/1996,Designated/Approved,,, 03/06/2000 ,,,"Wyeth Pharmaceuticals, Inc.|P. O. Box 8299|Philadelphia|Pennsylvania|19101|United States"
135293379,135293379,Antihemophilic factor (recombinant),Kogenate,Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.,C0019069,Hemophilia A,09/25/1989,Designated/Approved,,Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease), 02/25/1993 , 02/25/2000 ,,Bayer Corporation|1884 Miles Avenue|Elkhart|Indiana|46515|United States
46506209,46506209,Antihemophilic factor (recombinant),Kogenate,Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.,C0019069,Hemophilia A,09/25/1989,Designated/Approved,,Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease), 02/25/1993 , 02/25/2000 ,,Bayer Corporation|1884 Miles Avenue|Elkhart|Indiana|46515|United States
347911209,347911209,Antithrombin III (human),Thrombate III,For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.,C0333006,congenital deficiency,11/26/1984,Designated/Approved,,, 12/30/1991 , 12/30/1998 ,,"Bayer Corporation|Pharmaceutical Division, Biological Products|400 Morgan Lane|New Haven|Connecticut|6516|United States"
135346995,135346995,Antithrombin III (human),Thrombate III,For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.,C0333006,congenital deficiency,11/26/1984,Designated/Approved,,, 12/30/1991 , 12/30/1998 ,,"Bayer Corporation|Pharmaceutical Division, Biological Products|400 Morgan Lane|New Haven|Connecticut|6516|United States"
347911209,347911209,Antithrombin III (human),ATnativ,For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.,"C0040038,C2586031","Thromboembolism , Hereditary antithrombin III deficiency",02/08/1985,Designated/Approved,,, 12/13/1989 , 12/13/1996 ,,Pharmacia & Upjohn AB|Lindhagensgatan 133|Stockholm|Sweden
135346995,135346995,Antithrombin III (human),ATnativ,For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.,"C0040038,C2586031","Thromboembolism , Hereditary antithrombin III deficiency",02/08/1985,Designated/Approved,,, 12/13/1989 , 12/13/1996 ,,Pharmacia & Upjohn AB|Lindhagensgatan 133|Stockholm|Sweden
347911209,347911209,Antithrombin III human,,Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.,"C0302148,C3714660","Thrombosis , Trauma",01/02/1986,Designated,Not FDA Approved for Orphan Indication,,,,,American National Red Cross|9312 Old Georgetown Road|Bethesda|Maryland|20814|United States
160693080,160693080,Antithrombin III human,,Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.,"C0302148,C3714660","Thrombosis , Trauma",01/02/1986,Designated,Not FDA Approved for Orphan Indication,,,,,American National Red Cross|9312 Old Georgetown Road|Bethesda|Maryland|20814|United States
135346995,135346995,Antithrombin III human,,Preventing or arresting episodes of thrombosis in patients with congenital AT-III deficiency and/or to prevent the occurrence of thrombosis in patients with AT-III deficiency who have undergone trauma or who are about to undergo surgery or parturition.,"C0302148,C3714660","Thrombosis , Trauma",01/02/1986,Designated,Not FDA Approved for Orphan Indication,,,,,American National Red Cross|9312 Old Georgetown Road|Bethesda|Maryland|20814|United States
404771575,404771575,Antivenin crotaline (pit-viper) equine immune F(ab)2),Anavip,Treatment of envenomation by Crotaline snakes,C0040533,Envenomation,01/29/2004,Designated/Approved,,Management of adult and pediatric patients with North American rattlesnake envenomation, 05/06/2015 , 05/06/2022 ,Management of adult and pediatric patients with North American rattlesnake envenomation,"Rare Disease Therapeutics, Inc.|12975 Brookprinter Place|Suite 170|Poway|California|92064|United States"
404859132,404859132,apraglutide,,Treatment of short bowel syndrome (SBS),C0036992,Short Bowel Syndrome,12/20/2018,Designated,Not FDA Approved for Orphan Indication,,,,,VectivBio AG|36 Aeschenvorstadt|Basel|Basel-Stadt|Switzerland
384061881,384061881,apraglutide,,Treatment of short bowel syndrome (SBS),C0036992,Short Bowel Syndrome,12/20/2018,Designated,Not FDA Approved for Orphan Indication,,,,,VectivBio AG|36 Aeschenvorstadt|Basel|Basel-Stadt|Switzerland
384060674,384060674,apraglutide,,Treatment of short bowel syndrome (SBS),C0036992,Short Bowel Syndrome,12/20/2018,Designated,Not FDA Approved for Orphan Indication,,,,,VectivBio AG|36 Aeschenvorstadt|Basel|Basel-Stadt|Switzerland
381126894,381126894,apraglutide,,Treatment of short bowel syndrome (SBS),C0036992,Short Bowel Syndrome,12/20/2018,Designated,Not FDA Approved for Orphan Indication,,,,,VectivBio AG|36 Aeschenvorstadt|Basel|Basel-Stadt|Switzerland
160671599,160671599,Arcitumomab,,"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",C0238462,Medullary thyroid carcinoma,05/10/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
135345795,135345795,Arcitumomab,,"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",C0238462,Medullary thyroid carcinoma,05/10/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
131277390,131277390,Arcitumomab,,"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",C0238462,Medullary thyroid carcinoma,05/10/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
50070172,50070172,Arcitumomab,,"Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",C0238462,Medullary thyroid carcinoma,05/10/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
381128718,381128718,Arenegyr,,Treatment of malignant pleural mesothelioma,C0812413,Malignant Pleural Mesothelioma,08/22/2008,Designated,Not FDA Approved for Orphan Indication,,,,,MolMed S.p.A.|Via Olgettina 58|Milan|Italy
381126438,381126438,Asfotase alfa,Strensiq,Treatment of hypophosphatasia,C0020630,Hypophosphatasia,09/12/2008,Designated/Approved,,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP), 10/23/2015 , 10/23/2022 ,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP),"Alexion Pharmaceuticals, Inc.|100 College St.|New Haven|Connecticut|6510|United States"
347910406,347910406,Asfotase alfa,Strensiq,Treatment of hypophosphatasia,C0020630,Hypophosphatasia,09/12/2008,Designated/Approved,,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP), 10/23/2015 , 10/23/2022 ,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP),"Alexion Pharmaceuticals, Inc.|100 College St.|New Haven|Connecticut|6510|United States"
160682278,160682278,Asfotase alfa,Strensiq,Treatment of hypophosphatasia,C0020630,Hypophosphatasia,09/12/2008,Designated/Approved,,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP), 10/23/2015 , 10/23/2022 ,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP),"Alexion Pharmaceuticals, Inc.|100 College St.|New Haven|Connecticut|6510|United States"
404772371,404772371,astuprotimut-R,,Treatment of MAGE-A3 positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,05/29/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.|Rue de I'Institut 89|B-1330 Rixensart|Belgium"
160693090,160693090,astuprotimut-R,,Treatment of MAGE-A3 positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,05/29/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.|Rue de I'Institut 89|B-1330 Rixensart|Belgium"
135342748,135342748,astuprotimut-R,,Treatment of MAGE-A3 positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,05/29/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.|Rue de I'Institut 89|B-1330 Rixensart|Belgium"
404772371,404772371,astuprotimut-R,,Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma,C0025202,Malignant Melanoma,05/29/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.|Rue de l'Institut 89|B-1330 Rixensart|Belgium"
160693090,160693090,astuprotimut-R,,Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma,C0025202,Malignant Melanoma,05/29/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.|Rue de l'Institut 89|B-1330 Rixensart|Belgium"
135342748,135342748,astuprotimut-R,,Treatment of MAGE-A3 positive stages IIb to IV malignant melanoma,C0025202,Malignant Melanoma,05/29/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.|Rue de l'Institut 89|B-1330 Rixensart|Belgium"
387061104,387061104,atezolizumab,TECENTRIQ,Treatment of small cell lung cancer (SCLC),"C0149925,C0262584,C3540630","Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer",10/13/2016,Designated/Approved,,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)", 03/18/2019 , 03/18/2026 ,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385327550,385327550,atezolizumab,TECENTRIQ,Treatment of small cell lung cancer (SCLC),"C0149925,C0262584,C3540630","Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer",10/13/2016,Designated/Approved,,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)", 03/18/2019 , 03/18/2026 ,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
384647093,384647093,atezolizumab,TECENTRIQ,Treatment of small cell lung cancer (SCLC),"C0149925,C0262584,C3540630","Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer",10/13/2016,Designated/Approved,,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)", 03/18/2019 , 03/18/2026 ,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
377483935,377483935,atezolizumab,TECENTRIQ,Treatment of small cell lung cancer (SCLC),"C0149925,C0262584,C3540630","Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer",10/13/2016,Designated/Approved,,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)", 03/18/2019 , 03/18/2026 ,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355059,354355059,atezolizumab,TECENTRIQ,Treatment of small cell lung cancer (SCLC),"C0149925,C0262584,C3540630","Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer",10/13/2016,Designated/Approved,,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)", 03/18/2019 , 03/18/2026 ,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
347911207,347911207,atezolizumab,TECENTRIQ,Treatment of small cell lung cancer (SCLC),"C0149925,C0262584,C3540630","Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer",10/13/2016,Designated/Approved,,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)", 03/18/2019 , 03/18/2026 ,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
318464470,318464470,atezolizumab,TECENTRIQ,Treatment of small cell lung cancer (SCLC),"C0149925,C0262584,C3540630","Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer",10/13/2016,Designated/Approved,,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)", 03/18/2019 , 03/18/2026 ,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
249565671,249565671,atezolizumab,TECENTRIQ,Treatment of small cell lung cancer (SCLC),"C0149925,C0262584,C3540630","Small Cell Lung Cancer , SCLC , Small Cell Lung Cancer",10/13/2016,Designated/Approved,,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)", 03/18/2019 , 03/18/2026 ,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061104,387061104,Atezolizumab,,treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
385327550,385327550,Atezolizumab,,treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
384647093,384647093,Atezolizumab,,treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
377483935,377483935,Atezolizumab,,treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
354355059,354355059,Atezolizumab,,treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
347911207,347911207,Atezolizumab,,treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
318464470,318464470,Atezolizumab,,treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
249565671,249565671,Atezolizumab,,treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
387061104,387061104,Atezolizumab,,Treatment of esophageal cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
385327550,385327550,Atezolizumab,,Treatment of esophageal cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
384647093,384647093,Atezolizumab,,Treatment of esophageal cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
377483935,377483935,Atezolizumab,,Treatment of esophageal cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
354355059,354355059,Atezolizumab,,Treatment of esophageal cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
347911207,347911207,Atezolizumab,,Treatment of esophageal cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
318464470,318464470,Atezolizumab,,Treatment of esophageal cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
249565671,249565671,Atezolizumab,,Treatment of esophageal cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
387061104,387061104,atezolizumab,TECENTRIQ,"Treatment of Stage llb, llc, lll and IV melanoma",C0025202,melanoma,02/13/2017,Designated/Approved,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, 07/30/2020 , 07/30/2027 ,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
385327550,385327550,atezolizumab,TECENTRIQ,"Treatment of Stage llb, llc, lll and IV melanoma",C0025202,melanoma,02/13/2017,Designated/Approved,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, 07/30/2020 , 07/30/2027 ,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
384647093,384647093,atezolizumab,TECENTRIQ,"Treatment of Stage llb, llc, lll and IV melanoma",C0025202,melanoma,02/13/2017,Designated/Approved,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, 07/30/2020 , 07/30/2027 ,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
377483935,377483935,atezolizumab,TECENTRIQ,"Treatment of Stage llb, llc, lll and IV melanoma",C0025202,melanoma,02/13/2017,Designated/Approved,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, 07/30/2020 , 07/30/2027 ,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
354355059,354355059,atezolizumab,TECENTRIQ,"Treatment of Stage llb, llc, lll and IV melanoma",C0025202,melanoma,02/13/2017,Designated/Approved,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, 07/30/2020 , 07/30/2027 ,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
347911207,347911207,atezolizumab,TECENTRIQ,"Treatment of Stage llb, llc, lll and IV melanoma",C0025202,melanoma,02/13/2017,Designated/Approved,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, 07/30/2020 , 07/30/2027 ,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
318464470,318464470,atezolizumab,TECENTRIQ,"Treatment of Stage llb, llc, lll and IV melanoma",C0025202,melanoma,02/13/2017,Designated/Approved,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, 07/30/2020 , 07/30/2027 ,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
249565671,249565671,atezolizumab,TECENTRIQ,"Treatment of Stage llb, llc, lll and IV melanoma",C0025202,melanoma,02/13/2017,Designated/Approved,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, 07/30/2020 , 07/30/2027 ,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
387061104,387061104,Atezolizumab,,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",C0025202,melanoma,02/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
385327550,385327550,Atezolizumab,,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",C0025202,melanoma,02/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
384647093,384647093,Atezolizumab,,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",C0025202,melanoma,02/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
377483935,377483935,Atezolizumab,,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",C0025202,melanoma,02/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
354355059,354355059,Atezolizumab,,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",C0025202,melanoma,02/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
347911207,347911207,Atezolizumab,,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",C0025202,melanoma,02/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
318464470,318464470,Atezolizumab,,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",C0025202,melanoma,02/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
249565671,249565671,Atezolizumab,,"Treatment of patients with stage IIb, IIc, III, and IV melanoma",C0025202,melanoma,02/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
440234488,440234488,autologous umbilical cord blood,,Treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury,"C0007789,C0270611","Cerebral Palsy , Brain Injury",07/24/2012,Designated,Not FDA Approved for Orphan Indication,,,,,Duke University|2301 Erwin Road|Durham|North Carolina|27710|United States
440234715,440234715,avalglucosidase alfa,,Treatment of Pompe Disease,C0017921,Pompe Disease,11/19/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Genzyme, a Sanofi Company|500 Kendall Street|Cambridge|Massachusetts|2142|United States"
381128032,381128032,avalglucosidase alfa,,Treatment of Pompe Disease,C0017921,Pompe Disease,11/19/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Genzyme, a Sanofi Company|500 Kendall Street|Cambridge|Massachusetts|2142|United States"
381127599,381127599,avelumab,,Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ),C0024623,Gastric Cancer,10/11/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States"
355203157,355203157,avelumab,,Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ),C0024623,Gastric Cancer,10/11/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States"
355203045,355203045,avelumab,,Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ),C0024623,Gastric Cancer,10/11/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States"
347911260,347911260,avelumab,,Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ),C0024623,Gastric Cancer,10/11/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States"
336908606,336908606,avelumab,,Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ),C0024623,Gastric Cancer,10/11/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States"
252827393,252827393,avelumab,,Treatment of gastric cancer (GC) including cancer of the gastroesophageal junction (GEJ),C0024623,Gastric Cancer,10/11/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.|45A Middlesex Turnpike|Billerica|Massachusetts|1821|United States"
440234879,440234879,axatilimab,,Treatment of Idiopathic Pulmonary Fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,04/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Syndax Pharmaceuticals, Inc.|35 Gatehouse Drive|Building D, Floor 3|Waltham|Massachusetts|2451|United States"
402425985,402425985,axatilimab,,Treatment of Idiopathic Pulmonary Fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,04/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Syndax Pharmaceuticals, Inc.|35 Gatehouse Drive|Building D, Floor 3|Waltham|Massachusetts|2451|United States"
440234879,440234879,axatilimab,,Treatment of chronic graft versus host disease.,C0867389,Chronic Graft Versus Host Disease,03/29/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Syndax Pharmaceuticals, Inc.|35 Gatehouse Drive|Waltham|Massachusetts|2451|United States"
402425985,402425985,axatilimab,,Treatment of chronic graft versus host disease.,C0867389,Chronic Graft Versus Host Disease,03/29/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Syndax Pharmaceuticals, Inc.|35 Gatehouse Drive|Waltham|Massachusetts|2451|United States"
381129647,381129647,axicabtagene ciloleucel,Yescarta,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,04/20/2016,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma", 10/18/2017 , 10/18/2024 ,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma","Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
374364294,374364294,axicabtagene ciloleucel,Yescarta,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,04/20/2016,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma", 10/18/2017 , 10/18/2024 ,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma","Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
347911476,347911476,axicabtagene ciloleucel,Yescarta,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,04/20/2016,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma", 10/18/2017 , 10/18/2024 ,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma","Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
381129647,381129647,axicabtagene ciloleucel,Yescarta,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,04/25/2016,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma", 10/18/2017 , 10/18/2024 ,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma","Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
374364294,374364294,axicabtagene ciloleucel,Yescarta,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,04/25/2016,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma", 10/18/2017 , 10/18/2024 ,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma","Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
347911476,347911476,axicabtagene ciloleucel,Yescarta,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,04/25/2016,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma", 10/18/2017 , 10/18/2024 ,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma","Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
381129647,381129647,axicabtagene ciloleucel,Yescarta,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,03/27/2014,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma", 10/18/2017 , 10/18/2024 ,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma","Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
374364294,374364294,axicabtagene ciloleucel,Yescarta,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,03/27/2014,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma", 10/18/2017 , 10/18/2024 ,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma","Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
347911476,347911476,axicabtagene ciloleucel,Yescarta,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,03/27/2014,Designated/Approved,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma", 10/18/2017 , 10/18/2024 ,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma","Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
381129647,381129647,axicabtagene ciloleucel,,Treatment of nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,03/24/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States"
374364294,374364294,axicabtagene ciloleucel,,Treatment of nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,03/24/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States"
347911476,347911476,axicabtagene ciloleucel,,Treatment of nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,03/24/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States"
381129647,381129647,axicabtagene ciloleucel,Yescarta,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,04/25/2016,Designated/Approved,,Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, 03/05/2021 ,,,Kite Pharma Inc.|2400 Broadway|Santa Monica|California|90404|United States
374364294,374364294,axicabtagene ciloleucel,Yescarta,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,04/25/2016,Designated/Approved,,Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, 03/05/2021 ,,,Kite Pharma Inc.|2400 Broadway|Santa Monica|California|90404|United States
347911476,347911476,axicabtagene ciloleucel,Yescarta,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,04/25/2016,Designated/Approved,,Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, 03/05/2021 ,,,Kite Pharma Inc.|2400 Broadway|Santa Monica|California|90404|United States
381129647,381129647,axicabtagene ciloleucel,,Treatment of extranodal marginal zone lymphoma,C1367654,Marginal zone lymphoma,03/23/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States"
374364294,374364294,axicabtagene ciloleucel,,Treatment of extranodal marginal zone lymphoma,C1367654,Marginal zone lymphoma,03/23/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States"
347911476,347911476,axicabtagene ciloleucel,,Treatment of extranodal marginal zone lymphoma,C1367654,Marginal zone lymphoma,03/23/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.|2400 Broadway|Santa Monica|California|90404|United States"
381125720,381125720,Azurin-p28,,Treatment of glioma,C0017638,Glioma,12/02/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"CDG Therapeutics, Inc.|840 South Wood Street|M/C 820|Chicago|Illinois|60612|United States"
160693120,160693120,Bacillus Calmette-Guerin vaccine,,Treatment of stage IIb through IV metastatic melanoma,C0278883,Metastatic melanoma,08/09/2006,Designated,Not FDA Approved for Orphan Indication,,,,,OncoVac Corporation|P. O. Box 970|Pacific Palisades|California|90272|United States
441073676,441073676,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
440701517,440701517,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
440064057,440064057,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
439508002,439508002,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
438644584,438644584,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
438536569,438536569,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
405235684,405235684,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
404614577,404614577,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
387113800,387113800,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
385840929,385840929,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
385834696,385834696,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
384385661,384385661,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
383548014,383548014,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
381395584,381395584,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
377311345,377311345,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
376051446,376051446,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
348746094,348746094,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
348397129,348397129,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
347913992,347913992,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
347636808,347636808,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
342544612,342544612,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
340507965,340507965,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
318153988,318153988,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
313075802,313075802,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
176331282,176331282,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
162224794,162224794,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
50071585,50071585,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
50071584,50071584,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
50071583,50071583,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
49873563,49873563,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
605350,605350,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
4814,4814,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
387079919,387079919,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
377014793,377014793,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
404425800,404425800,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
387079921,387079921,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
387079920,387079920,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
316962251,316962251,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
315444088,315444088,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
252402155,252402155,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
144206731,144206731,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
144204057,144204057,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
144074916,144074916,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
126676473,126676473,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
546764,546764,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
440790689,440790689,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
438474345,438474345,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
406582657,406582657,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
374155019,374155019,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
346444061,346444061,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
335958847,335958847,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
318238404,318238404,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
316898684,316898684,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
254759847,254759847,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
204380020,204380020,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
196105735,196105735,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
163814587,163814587,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
126655275,126655275,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
126629464,126629464,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
440681435,440681435,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
387166216,387166216,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
376227004,376227004,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
341139910,341139910,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
268734448,268734448,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
162228041,162228041,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
124766072,124766072,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
103914703,103914703,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
52518470,52518470,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
8149211,8149211,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
434131544,434131544,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
373567635,373567635,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
310267241,310267241,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
162180419,162180419,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
52518469,52518469,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
7978755,7978755,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
438451119,438451119,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
434142455,434142455,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
433925319,433925319,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
350086297,350086297,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
349989661,349989661,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
348283279,348283279,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
347673985,347673985,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
312693845,312693845,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
312228282,312228282,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
224054832,224054832,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
134981168,134981168,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
103770541,103770541,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
99381480,99381480,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
46504727,46504727,Bacitracin,,Treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins A and B elaborated by Clostridium difficile.,C0014358,Pseudomembranous enterocolitis,03/13/1984,Designated,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.|One Executive Drive|P.O. Box 1399|Fort Lee|New Jersey|7024|United States"
440790690,440790690,Basiliximab,Simulect,Prophylaxis of solid organ rejection.,C0815080,organ rejection,12/12/1997,Designated/Approved,,Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids., 05/12/1998 , 05/12/2005 ,,Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States
178103461,178103461,Basiliximab,Simulect,Prophylaxis of solid organ rejection.,C0815080,organ rejection,12/12/1997,Designated/Approved,,Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids., 05/12/1998 , 05/12/2005 ,,Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States
135321271,135321271,Basiliximab,Simulect,Prophylaxis of solid organ rejection.,C0815080,organ rejection,12/12/1997,Designated/Approved,,Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids., 05/12/1998 , 05/12/2005 ,,Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States
103771251,103771251,Basiliximab,Simulect,Prophylaxis of solid organ rejection.,C0815080,organ rejection,12/12/1997,Designated/Approved,,Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids., 05/12/1998 , 05/12/2005 ,,Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States
50067184,50067184,Basiliximab,Simulect,Prophylaxis of solid organ rejection.,C0815080,organ rejection,12/12/1997,Designated/Approved,,Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids., 05/12/1998 , 05/12/2005 ,,Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States
46505169,46505169,Basiliximab,Simulect,Prophylaxis of solid organ rejection.,C0815080,organ rejection,12/12/1997,Designated/Approved,,Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids., 05/12/1998 , 05/12/2005 ,,Novartis Pharmaceuticals Corporation|59 Route 10|East Hanover|New Jersey|7936|United States
434122177,434122177,belantamab mafodotin-blmf,BLENREP,Treatment of multiple myeloma,C0026764,Multiple Myeloma,06/22/2017,Designated/Approved,,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent", 08/05/2020 , 08/05/2027 ,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",GlaxoSmithKline Intellectual Property Development Ltd.|980 GREAT WEST ROAD|BRENTFORD|MIDDLESEX|TW89GS|United Kingdom
405226462,405226462,belantamab mafodotin-blmf,BLENREP,Treatment of multiple myeloma,C0026764,Multiple Myeloma,06/22/2017,Designated/Approved,,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent", 08/05/2020 , 08/05/2027 ,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",GlaxoSmithKline Intellectual Property Development Ltd.|980 GREAT WEST ROAD|BRENTFORD|MIDDLESEX|TW89GS|United Kingdom
404719842,404719842,belantamab mafodotin-blmf,BLENREP,Treatment of multiple myeloma,C0026764,Multiple Myeloma,06/22/2017,Designated/Approved,,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent", 08/05/2020 , 08/05/2027 ,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",GlaxoSmithKline Intellectual Property Development Ltd.|980 GREAT WEST ROAD|BRENTFORD|MIDDLESEX|TW89GS|United Kingdom
347910359,347910359,belatacept,Nulojix,Prophylaxis of organ rejection in renal allograft recipients,C0815080,organ rejection,02/20/2008,Designated/Approved,,Prophylaxis of organ rejection in adult patients receiving kidney transplants, 06/15/2011 , 06/15/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
178103474,178103474,belatacept,Nulojix,Prophylaxis of organ rejection in renal allograft recipients,C0815080,organ rejection,02/20/2008,Designated/Approved,,Prophylaxis of organ rejection in adult patients receiving kidney transplants, 06/15/2011 , 06/15/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
135283321,135283321,belatacept,Nulojix,Prophylaxis of organ rejection in renal allograft recipients,C0815080,organ rejection,02/20/2008,Designated/Approved,,Prophylaxis of organ rejection in adult patients receiving kidney transplants, 06/15/2011 , 06/15/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
131287524,131287524,belatacept,Nulojix,Prophylaxis of organ rejection in renal allograft recipients,C0815080,organ rejection,02/20/2008,Designated/Approved,,Prophylaxis of organ rejection in adult patients receiving kidney transplants, 06/15/2011 , 06/15/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
404859106,404859106,bempegaldesleukin,,Treatment of Stage IIb to Stage IV melanoma,C0025202,melanoma,04/17/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States"
404772580,404772580,bempegaldesleukin,,Treatment of Stage IIb to Stage IV melanoma,C0025202,melanoma,04/17/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States"
404720042,404720042,bempegaldesleukin,,Treatment of Stage IIb to Stage IV melanoma,C0025202,melanoma,04/17/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States"
381128181,381128181,bempegaldesleukin,,Treatment of Stage IIb to Stage IV melanoma,C0025202,melanoma,04/17/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Nektar Therapeutics|455 Mission Bay Blvd, South|San Francisco|California|94158|United States"
402356184,402356184,benralizumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,08/26/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States
402355846,402355846,benralizumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,08/26/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States
347911271,347911271,benralizumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,08/26/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States
223366009,223366009,benralizumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,08/26/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States
160704150,160704150,benralizumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,08/26/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States
135339902,135339902,benralizumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,08/26/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|P.O. Box 8355|Wilmington|Delaware|19803|United States
402356184,402356184,benralizumab,,Treatment of eosinophilic granulomatosis with polyangiitis,C0008728,Eosinophilic granulomatosis with polyangiitis,11/21/2018,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
402355846,402355846,benralizumab,,Treatment of eosinophilic granulomatosis with polyangiitis,C0008728,Eosinophilic granulomatosis with polyangiitis,11/21/2018,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
347911271,347911271,benralizumab,,Treatment of eosinophilic granulomatosis with polyangiitis,C0008728,Eosinophilic granulomatosis with polyangiitis,11/21/2018,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
223366009,223366009,benralizumab,,Treatment of eosinophilic granulomatosis with polyangiitis,C0008728,Eosinophilic granulomatosis with polyangiitis,11/21/2018,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
160704150,160704150,benralizumab,,Treatment of eosinophilic granulomatosis with polyangiitis,C0008728,Eosinophilic granulomatosis with polyangiitis,11/21/2018,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
135339902,135339902,benralizumab,,Treatment of eosinophilic granulomatosis with polyangiitis,C0008728,Eosinophilic granulomatosis with polyangiitis,11/21/2018,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
402356184,402356184,benralizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
402355846,402355846,benralizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
347911271,347911271,benralizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
223366009,223366009,benralizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
160704150,160704150,benralizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
135339902,135339902,benralizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|P. O. Box 8355|1800 Concord Pike|Wilmington|Delaware|19803|United States
347910369,347910369,Beractant,,"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.","C0025048,C0031190,C0032285,C0243026,C1145670","Meconium Aspiration Syndrome , Persistent pulmonary hypertension of the newborn , Pneumonia , Sepsis , Respiratory Failure",12/20/1993,Designated,Not FDA Approved for Orphan Indication,,,,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
135335308,135335308,Beractant,,"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.","C0025048,C0031190,C0032285,C0243026,C1145670","Meconium Aspiration Syndrome , Persistent pulmonary hypertension of the newborn , Pneumonia , Sepsis , Respiratory Failure",12/20/1993,Designated,Not FDA Approved for Orphan Indication,,,,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
103771378,103771378,Beractant,,"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.","C0025048,C0031190,C0032285,C0243026,C1145670","Meconium Aspiration Syndrome , Persistent pulmonary hypertension of the newborn , Pneumonia , Sepsis , Respiratory Failure",12/20/1993,Designated,Not FDA Approved for Orphan Indication,,,,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
53789802,53789802,Beractant,,"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.","C0025048,C0031190,C0032285,C0243026,C1145670","Meconium Aspiration Syndrome , Persistent pulmonary hypertension of the newborn , Pneumonia , Sepsis , Respiratory Failure",12/20/1993,Designated,Not FDA Approved for Orphan Indication,,,,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
50070149,50070149,Beractant,,"Treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.","C0025048,C0031190,C0032285,C0243026,C1145670","Meconium Aspiration Syndrome , Persistent pulmonary hypertension of the newborn , Pneumonia , Sepsis , Respiratory Failure",12/20/1993,Designated,Not FDA Approved for Orphan Indication,,,,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
347910369,347910369,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation", 07/01/1991 , 07/01/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
135335308,135335308,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation", 07/01/1991 , 07/01/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
103771378,103771378,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation", 07/01/1991 , 07/01/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
53789802,53789802,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation", 07/01/1991 , 07/01/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
50070149,50070149,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation", 07/01/1991 , 07/01/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
347910369,347910369,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency, 07/02/1991 , 07/02/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
135335308,135335308,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency, 07/02/1991 , 07/02/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
103771378,103771378,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency, 07/02/1991 , 07/02/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
53789802,53789802,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency, 07/02/1991 , 07/02/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
50070149,50070149,Beractant,Survanta intratracheal suspension,Treatment of neonatal respiratory distress syndrome,C0035220,Neonatal Respiratory Distress Syndrome,02/05/1986,Designated/Approved,,Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency, 07/02/1991 , 07/02/1998 ,,Ross Laboratories|625 Cleveland Avenue|Columbus|Ohio|43215|United States
349016377,349016377,bertilimumab,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,08/17/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
160698501,160698501,bertilimumab,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,08/17/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
135341000,135341000,bertilimumab,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,08/17/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
441072526,441072526,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/20/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way, MS #242|South San Francisco|California|94080|United States"
441072526,441072526,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
441072526,441072526,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
441072526,441072526,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
441072526,441072526,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
441072526,441072526,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Treatment of fallopian tube carcinoma,C0238122,Fallopian Tube Carcinoma,11/23/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
441072526,441072526,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,,Treatment of mesothelioma,C0025500,Mesothelioma,01/27/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790701,440790701,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,12/05/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States"
404720407,404720407,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,12/05/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States"
135351517,135351517,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,12/05/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States"
81065599,81065599,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,12/05/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States"
49895113,49895113,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,12/05/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States"
46505347,46505347,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,12/05/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States"
10147,10147,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,12/05/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|3rd Floor|Basking Ridge|New Jersey|7920|United States"
312525292,312525292,Botulinum toxin type F,,Treatment of spasmodic torticollis (cervical dystonia).,C0152116,Spasmodic torticollis,10/24/1991,Designated,Not FDA Approved for Orphan Indication,,,,,Ipsen Limited|27 Maple Street|Milford|Massachusetts|1757|United States
404720159,404720159,Ciliary neurotrophic factor,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,01/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
381123584,381123584,Ciliary neurotrophic factor,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,01/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
347910092,347910092,Ciliary neurotrophic factor,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,01/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
178101597,178101597,Ciliary neurotrophic factor,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,01/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
160745599,160745599,Ciliary neurotrophic factor,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,01/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
160745588,160745588,Ciliary neurotrophic factor,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,01/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
160745577,160745577,Ciliary neurotrophic factor,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,01/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
56311848,56311848,Ciliary neurotrophic factor,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,01/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
7978945,7978945,Ciliary neurotrophic factor,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,01/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
404772201,404772201,mecasermin rinfabate,Iplex,Treatment of growth hormone insensitivity syndrome (GHIS),C4318479,Growth Hormone Insensitivity Syndrome,05/17/2002,Designated/Approved,,Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone, 12/12/2005 , 12/12/2012 ,,"Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States"
135325697,135325697,mecasermin rinfabate,Iplex,Treatment of growth hormone insensitivity syndrome (GHIS),C4318479,Growth Hormone Insensitivity Syndrome,05/17/2002,Designated/Approved,,Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone, 12/12/2005 , 12/12/2012 ,,"Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States"
103771459,103771459,mecasermin rinfabate,Iplex,Treatment of growth hormone insensitivity syndrome (GHIS),C4318479,Growth Hormone Insensitivity Syndrome,05/17/2002,Designated/Approved,,Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone, 12/12/2005 , 12/12/2012 ,,"Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States"
440790866,440790866,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.", 04/17/2014 , 04/17/2021 ,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
387060162,387060162,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.", 04/17/2014 , 04/17/2021 ,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910355,347910355,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.", 04/17/2014 , 04/17/2021 ,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
329976991,329976991,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.", 04/17/2014 , 04/17/2021 ,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
178103384,178103384,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.", 04/17/2014 , 04/17/2021 ,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
135302238,135302238,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.", 04/17/2014 , 04/17/2021 ,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
103771534,103771534,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.", 04/17/2014 , 04/17/2021 ,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
426391582,426391582,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.", 04/17/2014 , 04/17/2021 ,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
349995626,349995626,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.", 04/17/2014 , 04/17/2021 ,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
433770930,433770930,Penpulimab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,02/23/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Akeso Biopharma, Inc.|6 Shennong Road, Torch Development Zone|Zhongshan|Guangdong|528437|China"
404772511,404772511,pexastimogene devacirepvec,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,05/06/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"SillaJen Biotherapeutics, Inc.|450 Sansome Street|Suite 200|San Francisco|California|94111|United States"
174489633,174489633,pexastimogene devacirepvec,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,05/06/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"SillaJen Biotherapeutics, Inc.|450 Sansome Street|Suite 200|San Francisco|California|94111|United States"
135314152,135314152,pexastimogene devacirepvec,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,05/06/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"SillaJen Biotherapeutics, Inc.|450 Sansome Street|Suite 200|San Francisco|California|94111|United States"
347910027,347910027,rozrolimupab,,Treatment of primary immune thrombocytopenia.,C0242584,Immune thrombocytopenia,09/13/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Symphogen A/S|Pederstrupvej 93|Ballerup|Denmark
160676887,160676887,rozrolimupab,,Treatment of primary immune thrombocytopenia.,C0242584,Immune thrombocytopenia,09/13/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Symphogen A/S|Pederstrupvej 93|Ballerup|Denmark
135318292,135318292,rozrolimupab,,Treatment of primary immune thrombocytopenia.,C0242584,Immune thrombocytopenia,09/13/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Symphogen A/S|Pederstrupvej 93|Ballerup|Denmark
374364310,374364310,tabelecleucel,,Treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disorders,"C0014644,C0024314","Epstein-Barr virus , Lymphoproliferative Disorders",02/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"ATARA Biotherapeutics, Inc.|4360 Park Terrace Drive|Suite 100|Westlake Village|California|91361|United States"
441072526,441072526,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who rece", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790701,440790701,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above), 12/30/1989 , 12/30/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
404720407,404720407,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above), 12/30/1989 , 12/30/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
135351517,135351517,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above), 12/30/1989 , 12/30/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
81065599,81065599,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above), 12/30/1989 , 12/30/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
49895113,49895113,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above), 12/30/1989 , 12/30/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
46505347,46505347,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above), 12/30/1989 , 12/30/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
10147,10147,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above), 12/30/1989 , 12/30/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
347910350,347910350,C1 esterase inhibitor (human),Cinryze(r),Treatment of angioedema,C0002994,Angioedema,07/16/2004,Designated/Approved,,"CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).", 06/20/2018 , 06/20/2025 ,CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in pediatric patients ages 6-11 with Hereditary Angioedema (HAE).,"ViroPharma Biologics, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
333495402,333495402,C1 esterase inhibitor (human),Cinryze(r),Treatment of angioedema,C0002994,Angioedema,07/16/2004,Designated/Approved,,"CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).", 06/20/2018 , 06/20/2025 ,CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in pediatric patients ages 6-11 with Hereditary Angioedema (HAE).,"ViroPharma Biologics, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
441072534,441072534,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
440790407,440790407,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
387061216,387061216,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
384060698,384060698,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
384060466,384060466,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
329976962,329976962,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
178103395,178103395,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
135343504,135343504,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
103771203,103771203,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
50059111,50059111,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
46506732,46506732,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
7979194,7979194,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
10099,10099,Etanercept,,Treatment of Wegener's granulomatosis.,C3495801,Wegener's Granulomatosis,04/06/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
349427652,349427652,etaracizumab,,"For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",C0278883,stage iv melanoma,04/14/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
347911300,347911300,etaracizumab,,"For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",C0278883,stage iv melanoma,04/14/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
178103209,178103209,etaracizumab,,"For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",C0278883,stage iv melanoma,04/14/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
160666626,160666626,etaracizumab,,"For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",C0278883,stage iv melanoma,04/14/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
135323725,135323725,etaracizumab,,"For the treatment of of stage IIb, stage IIc, stage III and stage IV melanoma",C0278883,stage iv melanoma,04/14/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
347911285,347911285,gevokizumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/27/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
178103966,178103966,gevokizumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/27/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
160704155,160704155,gevokizumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/27/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
135322326,135322326,gevokizumab,,Treatment of Behcet's disease,C0004943,Behcet Syndrome,07/27/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
404772323,404772323,lintuzumab,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,01/30/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
249565664,249565664,lintuzumab,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,01/30/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
160671685,160671685,lintuzumab,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,01/30/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135336964,135336964,lintuzumab,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,01/30/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
347910234,347910234,Recombinant human relaxin,,Treatment of progressive systemic sclerosis.,C1258104,Progressive systemic sclerosis,11/03/1995,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Connetics Corporation|3400 West Bayshore Road|Palo Alto|California|94303|United States
441072531,441072531,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
387061212,387061212,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
385327556,385327556,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
384647099,384647099,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
365372203,365372203,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
354355036,354355036,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
348838049,348838049,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
329976960,329976960,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
319478935,319478935,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
319435463,319435463,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
178103386,178103386,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
135341754,135341754,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
103771410,103771410,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
57288666,57288666,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
56314417,56314417,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
50070184,50070184,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
46505820,46505820,rituximab,Rituxan,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,01/29/2004,Designated/Approved,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide, 02/18/2010 , 02/18/2017 ,,"Genentech, Inc.|1DNA Way|MS 241A|South San Francisco|California|94080|United States"
381127826,381127826,vestronidase alfa-vjbk,Mepsevii,"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",C0085132,Mucopolysaccharidosis VII,02/16/2012,Designated/Approved,,"Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).", 11/15/2017 , 11/15/2024 ,"Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).","Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Novato|California|94949|United States"
374364116,374364116,vestronidase alfa-vjbk,Mepsevii,"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",C0085132,Mucopolysaccharidosis VII,02/16/2012,Designated/Approved,,"Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).", 11/15/2017 , 11/15/2024 ,"Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).","Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Novato|California|94949|United States"
347911326,347911326,vestronidase alfa-vjbk,Mepsevii,"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",C0085132,Mucopolysaccharidosis VII,02/16/2012,Designated/Approved,,"Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).", 11/15/2017 , 11/15/2024 ,"Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).","Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Novato|California|94949|United States"
342581841,342581841,vestronidase alfa-vjbk,Mepsevii,"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)",C0085132,Mucopolysaccharidosis VII,02/16/2012,Designated/Approved,,"Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).", 11/15/2017 , 11/15/2024 ,"Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).","Ultragenyx Pharmaceutical, Inc.|60 Leveroni Court|Novato|California|94949|United States"
349272539,349272539,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
347827764,347827764,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
135263533,135263533,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
104234375,104234375,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
386330730,386330730,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
349995325,349995325,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
349980335,349980335,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
341169549,341169549,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
319392962,319392962,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
440790775,440790775,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
438456323,438456323,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
434252117,434252117,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
162064792,162064792,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
134979978,134979978,ferumoxytol,,"For use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)","C0006826,C0280099","MALIGNANCIES , Solid Tumor",04/06/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC|38 Frederick Street|Newton|Massachusetts|2460|United States"
441072532,441072532,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
440790288,440790288,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
404336834,404336834,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
349720813,349720813,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
329976984,329976984,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
178103381,178103381,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
135302348,135302348,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
103771356,103771356,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
53787868,53787868,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
46505767,46505767,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Mylotarg is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older., 06/16/2020 ,,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
404772710,404772710,marzeptacog alfa (activated),,Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors,C0019069,Hemophilia A,11/30/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Biosciences, Inc.|260 Littlefield Avenue|South San Francisco|California|94080|United States"
404719844,404719844,marzeptacog alfa (activated),,Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors,C0019069,Hemophilia A,11/30/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Biosciences, Inc.|260 Littlefield Avenue|South San Francisco|California|94080|United States"
381127677,381127677,marzeptacog alfa (activated),,Routine prophylaxis to prevent bleeding episodes in patients with hemophilia A and B patients with inhibitors,C0019069,Hemophilia A,11/30/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Biosciences, Inc.|260 Littlefield Avenue|South San Francisco|California|94080|United States"
440790866,440790866,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)., 08/30/2016 ,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
387060162,387060162,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)., 08/30/2016 ,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910355,347910355,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)., 08/30/2016 ,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
329976991,329976991,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)., 08/30/2016 ,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
178103384,178103384,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)., 08/30/2016 ,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
135302238,135302238,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)., 08/30/2016 ,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
103771534,103771534,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)., 08/30/2016 ,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
426391582,426391582,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)., 08/30/2016 ,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
349995626,349995626,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)., 08/30/2016 ,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
404772397,404772397,pamrevlumab,,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,04/11/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.|409 Illinois Street|San Francisco|California|94158|United States"
310264709,310264709,pamrevlumab,,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,04/11/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.|409 Illinois Street|San Francisco|California|94158|United States"
160709238,160709238,pamrevlumab,,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,04/11/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.|409 Illinois Street|San Francisco|California|94158|United States"
135282565,135282565,pamrevlumab,,Treatment of Duchenne Muscular Dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,04/11/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.|409 Illinois Street|San Francisco|California|94158|United States"
440790883,440790883,Pegademase bovine,Adagen,For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.,"C0085110,C0268124","Severe Combined Immunodeficiency , ADA deficiency",05/29/1984,Designated/Approved,,, 03/21/1990 , 03/21/1997 ,,"Sigma-tau Pharmaceuticals, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States"
135304022,135304022,Pegademase bovine,Adagen,For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.,"C0085110,C0268124","Severe Combined Immunodeficiency , ADA deficiency",05/29/1984,Designated/Approved,,, 03/21/1990 , 03/21/1997 ,,"Sigma-tau Pharmaceuticals, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States"
103771230,103771230,Pegademase bovine,Adagen,For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.,"C0085110,C0268124","Severe Combined Immunodeficiency , ADA deficiency",05/29/1984,Designated/Approved,,, 03/21/1990 , 03/21/1997 ,,"Sigma-tau Pharmaceuticals, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States"
50070156,50070156,Pegademase bovine,Adagen,For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.,"C0085110,C0268124","Severe Combined Immunodeficiency , ADA deficiency",05/29/1984,Designated/Approved,,, 03/21/1990 , 03/21/1997 ,,"Sigma-tau Pharmaceuticals, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States"
46508490,46508490,Pegademase bovine,Adagen,For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.,"C0085110,C0268124","Severe Combined Immunodeficiency , ADA deficiency",05/29/1984,Designated/Approved,,, 03/21/1990 , 03/21/1997 ,,"Sigma-tau Pharmaceuticals, Inc.|9841 Washingtonian Blvd|Suite 500|Gaithersburg|Maryland|20878|United States"
440790368,440790368,peginterferon alfa-2b,Sylatron,Treatment of malignant melanoma stages IIb through IV.,C0025202,Malignant Melanoma,04/09/2008,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, 03/29/2011 ,,,"Merck, Sharpe & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
348903861,348903861,peginterferon alfa-2b,Sylatron,Treatment of malignant melanoma stages IIb through IV.,C0025202,Malignant Melanoma,04/09/2008,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, 03/29/2011 ,,,"Merck, Sharpe & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
187051765,187051765,peginterferon alfa-2b,Sylatron,Treatment of malignant melanoma stages IIb through IV.,C0025202,Malignant Melanoma,04/09/2008,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, 03/29/2011 ,,,"Merck, Sharpe & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
135317436,135317436,peginterferon alfa-2b,Sylatron,Treatment of malignant melanoma stages IIb through IV.,C0025202,Malignant Melanoma,04/09/2008,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, 03/29/2011 ,,,"Merck, Sharpe & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
103771448,103771448,peginterferon alfa-2b,Sylatron,Treatment of malignant melanoma stages IIb through IV.,C0025202,Malignant Melanoma,04/09/2008,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, 03/29/2011 ,,,"Merck, Sharpe & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
56365878,56365878,peginterferon alfa-2b,Sylatron,Treatment of malignant melanoma stages IIb through IV.,C0025202,Malignant Melanoma,04/09/2008,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, 03/29/2011 ,,,"Merck, Sharpe & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
50069692,50069692,peginterferon alfa-2b,Sylatron,Treatment of malignant melanoma stages IIb through IV.,C0025202,Malignant Melanoma,04/09/2008,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, 03/29/2011 ,,,"Merck, Sharpe & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
46506669,46506669,peginterferon alfa-2b,Sylatron,Treatment of malignant melanoma stages IIb through IV.,C0025202,Malignant Melanoma,04/09/2008,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, 03/29/2011 ,,,"Merck, Sharpe & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
535230,535230,peginterferon alfa-2b,Sylatron,Treatment of malignant melanoma stages IIb through IV.,C0025202,Malignant Melanoma,04/09/2008,Designated/Approved,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy, 03/29/2011 ,,,"Merck, Sharpe & Dohme Corp.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
404772364,404772364,rozanolixizumab,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.|1950 Lake Park Drive Building 2100|Smyrna|Georgia|30080|United States"
404719939,404719939,rozanolixizumab,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.|1950 Lake Park Drive Building 2100|Smyrna|Georgia|30080|United States"
381127650,381127650,rozanolixizumab,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.|1950 Lake Park Drive Building 2100|Smyrna|Georgia|30080|United States"
354702273,354702273,rozanolixizumab,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.|1950 Lake Park Drive Building 2100|Smyrna|Georgia|30080|United States"
434122242,434122242,concizumab,,Treatment of hemophilia B,C0008533,Hemophilia B,07/22/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P.O Box 846|Plainsboro|New Jersey|8536|United States"
404719421,404719421,concizumab,,Treatment of hemophilia B,C0008533,Hemophilia B,07/22/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P.O Box 846|Plainsboro|New Jersey|8536|United States"
381126946,381126946,concizumab,,Treatment of hemophilia B,C0008533,Hemophilia B,07/22/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P.O Box 846|Plainsboro|New Jersey|8536|United States"
347911387,347911387,concizumab,,Treatment of hemophilia B,C0008533,Hemophilia B,07/22/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P.O Box 846|Plainsboro|New Jersey|8536|United States"
349990153,349990153,DEAE-rebeccamycin,,Treatment of bile duct tumors,C0027651,Tumors,03/01/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Helsinn Healthcare SA|Via Pian Scairolo, 6912 Pazzallo|Lugano|Switzerland"
347909859,347909859,epratuzumab,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,09/30/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
249565768,249565768,epratuzumab,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,09/30/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
160682287,160682287,epratuzumab,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,09/30/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
135308971,135308971,epratuzumab,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,09/30/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
440234774,440234774,human recombinant bone morphogenetic protein 4,,Treatment of glioblastoma multiforme.,C0017636,Glioblastoma multiforme,05/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"HyperStem Therapeutics, Inc.|13223-1 Black Mountain Road|San Diego|California|92129|United States"
404772690,404772690,imlifidase,,Treatment of Guillain-Barr頓yndrome (GBS),C0018378,GBS,02/14/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Hansa Medical AB|Scheelev䧥n 22, P. O. Box 785|SE-220 07|Lund|Sweden"
404720323,404720323,imlifidase,,Treatment of Guillain-Barr頓yndrome (GBS),C0018378,GBS,02/14/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Hansa Medical AB|Scheelev䧥n 22, P. O. Box 785|SE-220 07|Lund|Sweden"
377716581,377716581,imlifidase,,Treatment of Guillain-Barr頓yndrome (GBS),C0018378,GBS,02/14/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Hansa Medical AB|Scheelev䧥n 22, P. O. Box 785|SE-220 07|Lund|Sweden"
440791025,440791025,Interferon gamma-1b,Actimmune,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.","C0242656,C4272578","Disease Progression , Malignant Osteopetrosis",09/30/1996,Designated/Approved,,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.", 02/10/2000 , 02/10/2007 ,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
135032842,135032842,Interferon gamma-1b,Actimmune,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.","C0242656,C4272578","Disease Progression , Malignant Osteopetrosis",09/30/1996,Designated/Approved,,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.", 02/10/2000 , 02/10/2007 ,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
103771226,103771226,Interferon gamma-1b,Actimmune,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.","C0242656,C4272578","Disease Progression , Malignant Osteopetrosis",09/30/1996,Designated/Approved,,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.", 02/10/2000 , 02/10/2007 ,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
46507194,46507194,Interferon gamma-1b,Actimmune,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.","C0242656,C4272578","Disease Progression , Malignant Osteopetrosis",09/30/1996,Designated/Approved,,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.", 02/10/2000 , 02/10/2007 ,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
347911334,347911334,Interleukin-3 human (recombinant),,Promotion of erythropoiesis in Diamond-Blackfan anemia (congenital pure red cell aplasia).,"C1260899,C1335641","Diamond-Blackfan anemia , Diamond-Blackfan anemia",05/20/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
381129185,381129185,Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis,,Prevention of necrotizing enterocolitis (NEC) in premature infants with very low birth weight less than or equal to 1500 grams,"C0206695,C0282666,C0520459,C4082937","NEC , Very Low Birth Weight , Necrotizing Enterocolitis , Necrotizing enterocolitis",03/24/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.|9841 Washingtonian Blvd.|Suite 500|Gaithersburg|Maryland|20878|United States"
440790923,440790923,Rilonacept,Arcalyst,Treatment of CIAS1-Associated Periodic Syndromes,"C0039082,C1424250","Syndromes , CIAS1",12/20/2004,Designated/Approved,,Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS), 02/27/2008 , 02/27/2015 ,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
349081322,349081322,Rilonacept,Arcalyst,Treatment of CIAS1-Associated Periodic Syndromes,"C0039082,C1424250","Syndromes , CIAS1",12/20/2004,Designated/Approved,,Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS), 02/27/2008 , 02/27/2015 ,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
347910349,347910349,Rilonacept,Arcalyst,Treatment of CIAS1-Associated Periodic Syndromes,"C0039082,C1424250","Syndromes , CIAS1",12/20/2004,Designated/Approved,,Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS), 02/27/2008 , 02/27/2015 ,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
178103396,178103396,Rilonacept,Arcalyst,Treatment of CIAS1-Associated Periodic Syndromes,"C0039082,C1424250","Syndromes , CIAS1",12/20/2004,Designated/Approved,,Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS), 02/27/2008 , 02/27/2015 ,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
135350808,135350808,Rilonacept,Arcalyst,Treatment of CIAS1-Associated Periodic Syndromes,"C0039082,C1424250","Syndromes , CIAS1",12/20/2004,Designated/Approved,,Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS), 02/27/2008 , 02/27/2015 ,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
103771528,103771528,Rilonacept,Arcalyst,Treatment of CIAS1-Associated Periodic Syndromes,"C0039082,C1424250","Syndromes , CIAS1",12/20/2004,Designated/Approved,,Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS), 02/27/2008 , 02/27/2015 ,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
440962803,440962803,romiplostim,,Treatment of thrombocytopenia associated with myelodysplasia syndrome,"C0039082,C0040034,C3463824","Syndrome , Thrombocytopenia , Myelodysplasia",10/31/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States
440790928,440790928,romiplostim,,Treatment of thrombocytopenia associated with myelodysplasia syndrome,"C0039082,C0040034,C3463824","Syndrome , Thrombocytopenia , Myelodysplasia",10/31/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States
349975939,349975939,romiplostim,,Treatment of thrombocytopenia associated with myelodysplasia syndrome,"C0039082,C0040034,C3463824","Syndrome , Thrombocytopenia , Myelodysplasia",10/31/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States
348939083,348939083,romiplostim,,Treatment of thrombocytopenia associated with myelodysplasia syndrome,"C0039082,C0040034,C3463824","Syndrome , Thrombocytopenia , Myelodysplasia",10/31/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States
347910087,347910087,romiplostim,,Treatment of thrombocytopenia associated with myelodysplasia syndrome,"C0039082,C0040034,C3463824","Syndrome , Thrombocytopenia , Myelodysplasia",10/31/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States
178103553,178103553,romiplostim,,Treatment of thrombocytopenia associated with myelodysplasia syndrome,"C0039082,C0040034,C3463824","Syndrome , Thrombocytopenia , Myelodysplasia",10/31/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States
135347108,135347108,romiplostim,,Treatment of thrombocytopenia associated with myelodysplasia syndrome,"C0039082,C0040034,C3463824","Syndrome , Thrombocytopenia , Myelodysplasia",10/31/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States
103771530,103771530,romiplostim,,Treatment of thrombocytopenia associated with myelodysplasia syndrome,"C0039082,C0040034,C3463824","Syndrome , Thrombocytopenia , Myelodysplasia",10/31/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States
440962803,440962803,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.", 12/14/2018 , 12/14/2025 ,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
440790928,440790928,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.", 12/14/2018 , 12/14/2025 ,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
349975939,349975939,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.", 12/14/2018 , 12/14/2025 ,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
348939083,348939083,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.", 12/14/2018 , 12/14/2025 ,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
347910087,347910087,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.", 12/14/2018 , 12/14/2025 ,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
178103553,178103553,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.", 12/14/2018 , 12/14/2025 ,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
135347108,135347108,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.", 12/14/2018 , 12/14/2025 ,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
103771530,103771530,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.", 12/14/2018 , 12/14/2025 ,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
135361268,135361268,Synsorb Pk,,Treatment of verocytotoxogenic E. coli infections.,C0014836,E. Coli Infections,07/17/1995,Designated,Not FDA Approved for Orphan Indication,,,,,"Synsorb Biotech Inc.|201, 1204 Kensington Road, N.W.|Calgary|Canada"
349981258,349981258,Tobramycin for inhalation,TOBI,Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.,"C0010674,C0033809,C3714514","Cystic Fibrosis , Pseudomonas aeruginosa , Infections",10/13/1994,Designated/Approved,,Management of cystic fibrosis patients with P.aeruginosa., 12/22/1997 , 12/22/2004 ,,Mylan Specialty LP|781 Chestnut Ridge Road|Regulatory Affairs-Greenbag Road|Morgantown|West Virginia|26505|United States
50047871,50047871,Tobramycin for inhalation,TOBI,Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.,"C0010674,C0033809,C3714514","Cystic Fibrosis , Pseudomonas aeruginosa , Infections",10/13/1994,Designated/Approved,,Management of cystic fibrosis patients with P.aeruginosa., 12/22/1997 , 12/22/2004 ,,Mylan Specialty LP|781 Chestnut Ridge Road|Regulatory Affairs-Greenbag Road|Morgantown|West Virginia|26505|United States
347910376,347910376,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone", 11/16/2018 , 11/16/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
329976977,329976977,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone", 11/16/2018 , 11/16/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
178103378,178103378,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone", 11/16/2018 , 11/16/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
135300399,135300399,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone", 11/16/2018 , 11/16/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
131277422,131277422,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone", 11/16/2018 , 11/16/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
404772524,404772524,Cabiralizumab,,Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,"C0039106,C1318543","Pigmented villonodular synovitis , Tenosynovial Giant Cell Tumor",01/11/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Five Prime Therapeutics, Inc.|111 Oyster Point Boulevard|South San Francisco|California|94080|United States"
404720169,404720169,Cabiralizumab,,Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,"C0039106,C1318543","Pigmented villonodular synovitis , Tenosynovial Giant Cell Tumor",01/11/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Five Prime Therapeutics, Inc.|111 Oyster Point Boulevard|South San Francisco|California|94080|United States"
381127724,381127724,Cabiralizumab,,Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,"C0039106,C1318543","Pigmented villonodular synovitis , Tenosynovial Giant Cell Tumor",01/11/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Five Prime Therapeutics, Inc.|111 Oyster Point Boulevard|South San Francisco|California|94080|United States"
315661192,315661192,Cabiralizumab,,Treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,"C0039106,C1318543","Pigmented villonodular synovitis , Tenosynovial Giant Cell Tumor",01/11/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Five Prime Therapeutics, Inc.|111 Oyster Point Boulevard|South San Francisco|California|94080|United States"
318464596,318464596,daxibotulinumtoxinA,,Treatment of cervical dystonia,C0152116,Cervical Dystonia,11/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Revance Therapeutics, Inc.|7555 Gateway Boulevard|Newark|California|94560|United States"
135274028,135274028,glycosylated recombinant human interleukin-7,,Treatment of progressive multifocal leukoencephalopathy,C0023524,Progressive multifocal leukoencephalopathy,09/27/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Cytheris, Inc.|1700 Rockville Pike|Suite 230|Rockville|Maryland|20852|United States"
440790807,440790807,Imiglucerase,Cerezyme,"Replacement therapy in patients with types I, II, and III Gaucher's disease.",C0017205,Gaucher's Disease,11/05/1991,Designated/Approved,,Enzyme replacement therapy in patients with type I Gaucher's disease., 05/23/1994 , 05/23/2001 ,,Genzyme Corporation|One Kendall Square|Cambridge|Massachusetts|2139|United States
135313172,135313172,Imiglucerase,Cerezyme,"Replacement therapy in patients with types I, II, and III Gaucher's disease.",C0017205,Gaucher's Disease,11/05/1991,Designated/Approved,,Enzyme replacement therapy in patients with type I Gaucher's disease., 05/23/1994 , 05/23/2001 ,,Genzyme Corporation|One Kendall Square|Cambridge|Massachusetts|2139|United States
135297248,135297248,Imiglucerase,Cerezyme,"Replacement therapy in patients with types I, II, and III Gaucher's disease.",C0017205,Gaucher's Disease,11/05/1991,Designated/Approved,,Enzyme replacement therapy in patients with type I Gaucher's disease., 05/23/1994 , 05/23/2001 ,,Genzyme Corporation|One Kendall Square|Cambridge|Massachusetts|2139|United States
103771228,103771228,Imiglucerase,Cerezyme,"Replacement therapy in patients with types I, II, and III Gaucher's disease.",C0017205,Gaucher's Disease,11/05/1991,Designated/Approved,,Enzyme replacement therapy in patients with type I Gaucher's disease., 05/23/1994 , 05/23/2001 ,,Genzyme Corporation|One Kendall Square|Cambridge|Massachusetts|2139|United States
49902687,49902687,Imiglucerase,Cerezyme,"Replacement therapy in patients with types I, II, and III Gaucher's disease.",C0017205,Gaucher's Disease,11/05/1991,Designated/Approved,,Enzyme replacement therapy in patients with type I Gaucher's disease., 05/23/1994 , 05/23/2001 ,,Genzyme Corporation|One Kendall Square|Cambridge|Massachusetts|2139|United States
46508744,46508744,Imiglucerase,Cerezyme,"Replacement therapy in patients with types I, II, and III Gaucher's disease.",C0017205,Gaucher's Disease,11/05/1991,Designated/Approved,,Enzyme replacement therapy in patients with type I Gaucher's disease., 05/23/1994 , 05/23/2001 ,,Genzyme Corporation|One Kendall Square|Cambridge|Massachusetts|2139|United States
178103396,178103396,Interleukin-1 Trap,,Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease,"C0085253,C0087031,C3495559","Adult-Onset Still's Disease , Still's disease , Juvenile rheumatoid arthritis",04/04/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
135350808,135350808,Interleukin-1 Trap,,Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease,"C0085253,C0087031,C3495559","Adult-Onset Still's Disease , Still's disease , Juvenile rheumatoid arthritis",04/04/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
103771528,103771528,Interleukin-1 Trap,,Treatment of Still's disease including juvenile rheumatoid arthritis and adult-onset Still's disease,"C0085253,C0087031,C3495559","Adult-Onset Still's Disease , Still's disease , Juvenile rheumatoid arthritis",04/04/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
160962728,160962728,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
57390683,57390683,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
53789135,53789135,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
50345834,50345834,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
312234637,312234637,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
50345835,50345835,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
4086,4086,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
375655702,375655702,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
375106517,375106517,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
348285398,348285398,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
252351549,252351549,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
162179098,162179098,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
12014855,12014855,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
404772808,404772808,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
404719176,404719176,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
386569644,386569644,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
385733023,385733023,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
355178380,355178380,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
348275442,348275442,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
319062690,319062690,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
318161548,318161548,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
250052449,250052449,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
164228543,164228543,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
135230302,135230302,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
134971654,134971654,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
49996662,49996662,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
70547,70547,menaquinone,,Treatment of calciphylaxis,C0006666,Calciphylaxis,09/04/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC|428 East Thunderbird Road|Suite 510|Phoenix|Alaska|85022|United States"
348823674,348823674,"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide",,Treatment of tuberculosis.,C0041296,Tuberculosis,02/04/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Sequella, Inc.|9610 Medical Center Drive|Suite 200|Rockville|Maryland|20820|United States"
319226965,319226965,"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide",,Treatment of tuberculosis.,C0041296,Tuberculosis,02/04/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Sequella, Inc.|9610 Medical Center Drive|Suite 200|Rockville|Maryland|20820|United States"
387061105,387061105,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection., 02/15/2019 , 02/15/2026 ,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
385327548,385327548,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection., 02/15/2019 , 02/15/2026 ,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
384647091,384647091,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection., 02/15/2019 , 02/15/2026 ,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
377483934,377483934,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection., 02/15/2019 , 02/15/2026 ,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
354355033,354355033,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection., 02/15/2019 , 02/15/2026 ,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
347910395,347910395,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection., 02/15/2019 , 02/15/2026 ,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
194140938,194140938,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection., 02/15/2019 , 02/15/2026 ,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
187051801,187051801,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection., 02/15/2019 , 02/15/2026 ,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
135335872,135335872,Recombinant human granulocyte colony stimulating factor,,Prevention of implantation failure and unexplained recurrent miscarriage,C0000809,Recurrent miscarriage,07/24/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Nora Therapeutics, Inc.|530 Lytton Avenue|2nd Floor|Palo Alto|California|94301|United States"
404772182,404772182,Tagraxofusp-erzs,ELZONRIS,Treatment of blastic plasmacytoid dendritic cell neoplasm,C1301363,Blastic plasmacytoid dendritic cell neoplasm,06/06/2013,Designated/Approved,,ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older., 12/21/2018 , 12/21/2025 ,ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,"Stemline Therapeutics, Inc.|750 Lexington Avenue|11th floor|New York|New York|10022|United States"
404719949,404719949,Tagraxofusp-erzs,ELZONRIS,Treatment of blastic plasmacytoid dendritic cell neoplasm,C1301363,Blastic plasmacytoid dendritic cell neoplasm,06/06/2013,Designated/Approved,,ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older., 12/21/2018 , 12/21/2025 ,ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,"Stemline Therapeutics, Inc.|750 Lexington Avenue|11th floor|New York|New York|10022|United States"
384585336,384585336,Tagraxofusp-erzs,ELZONRIS,Treatment of blastic plasmacytoid dendritic cell neoplasm,C1301363,Blastic plasmacytoid dendritic cell neoplasm,06/06/2013,Designated/Approved,,ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older., 12/21/2018 , 12/21/2025 ,ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,"Stemline Therapeutics, Inc.|750 Lexington Avenue|11th floor|New York|New York|10022|United States"
405092064,405092064,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061215,387061215,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385327557,385327557,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385326041,385326041,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355060,354355060,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
349016747,349016747,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
347910344,347910344,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976997,329976997,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103463,178103463,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135345962,135345962,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
104253153,104253153,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 04/29/2013 , 04/29/2020 ,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
347911276,347911276,trebananib,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,08/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
252166624,252166624,trebananib,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,08/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
160671634,160671634,trebananib,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,08/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
135285829,135285829,trebananib,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,08/30/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
381127169,381127169,ulocuplumab,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,01/12/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Bristol-Myers Squibb Company|3401 Princeton Pike, B-3043C|Lawrence Township|New Jersey|8648|United States"
347911270,347911270,ulocuplumab,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,01/12/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Bristol-Myers Squibb Company|3401 Princeton Pike, B-3043C|Lawrence Township|New Jersey|8648|United States"
315661244,315661244,ulocuplumab,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,01/12/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Bristol-Myers Squibb Company|3401 Princeton Pike, B-3043C|Lawrence Township|New Jersey|8648|United States"
174489632,174489632,ulocuplumab,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,01/12/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Bristol-Myers Squibb Company|3401 Princeton Pike, B-3043C|Lawrence Township|New Jersey|8648|United States"
438569805,438569805,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
386974820,386974820,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
355256567,355256567,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276501,348276501,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276500,348276500,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276499,348276499,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276498,348276498,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276497,348276497,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276496,348276496,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276494,348276494,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276493,348276493,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276492,348276492,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
272905041,272905041,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
268737906,268737906,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
254788936,254788936,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
252215122,252215122,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
175442953,175442953,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
170474130,170474130,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
103405507,103405507,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
92303614,92303614,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
81058765,81058765,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
53788801,53788801,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
50105927,50105927,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
24702115,24702115,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
3495,3495,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
386483748,386483748,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
385647348,385647348,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
375933688,375933688,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
318152877,318152877,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
163687306,163687306,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
26759549,26759549,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
381341086,381341086,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
127269519,127269519,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
127269518,127269518,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
7890560,7890560,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
386393077,386393077,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
382159772,382159772,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
376192238,376192238,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348964523,348964523,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276495,348276495,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
315707078,315707078,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
241181861,241181861,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
135252244,135252244,ceramide,,Treatment of liver cancer,C0220630,Liver Cancer,08/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
438569805,438569805,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
386974820,386974820,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
355256567,355256567,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276501,348276501,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276500,348276500,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276499,348276499,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276498,348276498,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276497,348276497,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276496,348276496,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276494,348276494,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276493,348276493,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276492,348276492,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
272905041,272905041,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
268737906,268737906,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
254788936,254788936,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
252215122,252215122,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
175442953,175442953,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
170474130,170474130,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
103405507,103405507,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
92303614,92303614,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
81058765,81058765,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
53788801,53788801,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
50105927,50105927,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
24702115,24702115,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
3495,3495,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
386483748,386483748,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
385647348,385647348,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
375933688,375933688,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
318152877,318152877,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
163687306,163687306,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
26759549,26759549,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
381341086,381341086,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
127269519,127269519,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
127269518,127269518,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
7890560,7890560,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
386393077,386393077,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
382159772,382159772,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
376192238,376192238,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348964523,348964523,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276495,348276495,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
315707078,315707078,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
241181861,241181861,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
135252244,135252244,ceramide,,Treatment of Acute Myeloid Leukemia,C0023467,Acute myeloid leukemia,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
441072527,441072527,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
440790714,440790714,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
387061106,387061106,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
354355046,354355046,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
350080042,350080042,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
348892040,348892040,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
348480208,348480208,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
329976961,329976961,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
178103464,178103464,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
135293496,135293496,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
103771411,103771411,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
56313965,56313965,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
56313468,56313468,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
56312188,56312188,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
46507042,46507042,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
532611,532611,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
495888,495888,cetuximab,Erbitux,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,"C0007137,C0278996","Squamous Cell Cancer , Cancer of the Head and Neck",07/03/2000,Designated/Approved,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed", 03/01/2006 , 03/01/2013 ,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
349991504,349991504,dacetuzumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,08/13/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
347911348,347911348,dacetuzumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,08/13/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
160666624,160666624,dacetuzumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,08/13/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135323347,135323347,dacetuzumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,08/13/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
404720031,404720031,Envafolimab,,Treatment of biliary tract cancer,C0750952,Biliary Tract Cancer,01/16/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"3D Medicines (Sichuan) Co., Ltd|64-66, Jiaogui Second Lane, Jinniu District|Chengdu|Sichuan|China"
387065574,387065574,Envafolimab,,Treatment of biliary tract cancer,C0750952,Biliary Tract Cancer,01/16/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"3D Medicines (Sichuan) Co., Ltd|64-66, Jiaogui Second Lane, Jinniu District|Chengdu|Sichuan|China"
381609252,381609252,Envafolimab,,Treatment of biliary tract cancer,C0750952,Biliary Tract Cancer,01/16/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"3D Medicines (Sichuan) Co., Ltd|64-66, Jiaogui Second Lane, Jinniu District|Chengdu|Sichuan|China"
381128286,381128286,humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA) and CD3 epsilon chain (CD3e) on T-cells,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,07/27/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 35-5E|South San Francisco|California|94080|United States"
440791159,440791159,mecasermin,,Treatment of myotonic dystrophy,C0027126,Myotonic Dystrophy,12/03/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.|10 Finderne Avenue|Building 10|Bridgewater|New Jersey|8817|United States"
178101669,178101669,mecasermin,,Treatment of myotonic dystrophy,C0027126,Myotonic Dystrophy,12/03/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.|10 Finderne Avenue|Building 10|Bridgewater|New Jersey|8817|United States"
160698630,160698630,mecasermin,,Treatment of myotonic dystrophy,C0027126,Myotonic Dystrophy,12/03/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.|10 Finderne Avenue|Building 10|Bridgewater|New Jersey|8817|United States"
135330509,135330509,mecasermin,,Treatment of myotonic dystrophy,C0027126,Myotonic Dystrophy,12/03/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.|10 Finderne Avenue|Building 10|Bridgewater|New Jersey|8817|United States"
49985113,49985113,mecasermin,,Treatment of myotonic dystrophy,C0027126,Myotonic Dystrophy,12/03/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.|10 Finderne Avenue|Building 10|Bridgewater|New Jersey|8817|United States"
46504889,46504889,mecasermin,,Treatment of myotonic dystrophy,C0027126,Myotonic Dystrophy,12/03/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.|10 Finderne Avenue|Building 10|Bridgewater|New Jersey|8817|United States"
404770141,404770141,Nimotuzumab,,Treatment of glioma,C0017638,Glioma,11/17/2004,Designated,Not FDA Approved for Orphan Indication,,,,,InnoKeys PTE Ltd.|26 Bukit Batok East Avenue 2|#03-10|Singapore
349341271,349341271,Nimotuzumab,,Treatment of glioma,C0017638,Glioma,11/17/2004,Designated,Not FDA Approved for Orphan Indication,,,,,InnoKeys PTE Ltd.|26 Bukit Batok East Avenue 2|#03-10|Singapore
249565669,249565669,Nimotuzumab,,Treatment of glioma,C0017638,Glioma,11/17/2004,Designated,Not FDA Approved for Orphan Indication,,,,,InnoKeys PTE Ltd.|26 Bukit Batok East Avenue 2|#03-10|Singapore
160698394,160698394,Nimotuzumab,,Treatment of glioma,C0017638,Glioma,11/17/2004,Designated,Not FDA Approved for Orphan Indication,,,,,InnoKeys PTE Ltd.|26 Bukit Batok East Avenue 2|#03-10|Singapore
135356483,135356483,Nimotuzumab,,Treatment of glioma,C0017638,Glioma,11/17/2004,Designated,Not FDA Approved for Orphan Indication,,,,,InnoKeys PTE Ltd.|26 Bukit Batok East Avenue 2|#03-10|Singapore
347910417,347910417,pegloticase,Krystexxa,To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.,"C0018099,C0740394","Gout , Hyperuricemia",02/21/2001,Designated/Approved,,Treatment of chronic gout in adult patients refractory to conventional treatment, 09/14/2010 , 09/14/2017 ,,"Horizon Pharma Rheumatology, LLC|150 S. Saunders RoadDrive|Suite 400|Lake Forest|Illinois|60045|United States"
210024028,210024028,pegloticase,Krystexxa,To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.,"C0018099,C0740394","Gout , Hyperuricemia",02/21/2001,Designated/Approved,,Treatment of chronic gout in adult patients refractory to conventional treatment, 09/14/2010 , 09/14/2017 ,,"Horizon Pharma Rheumatology, LLC|150 S. Saunders RoadDrive|Suite 400|Lake Forest|Illinois|60045|United States"
187051766,187051766,pegloticase,Krystexxa,To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.,"C0018099,C0740394","Gout , Hyperuricemia",02/21/2001,Designated/Approved,,Treatment of chronic gout in adult patients refractory to conventional treatment, 09/14/2010 , 09/14/2017 ,,"Horizon Pharma Rheumatology, LLC|150 S. Saunders RoadDrive|Suite 400|Lake Forest|Illinois|60045|United States"
135362375,135362375,pegloticase,Krystexxa,To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.,"C0018099,C0740394","Gout , Hyperuricemia",02/21/2001,Designated/Approved,,Treatment of chronic gout in adult patients refractory to conventional treatment, 09/14/2010 , 09/14/2017 ,,"Horizon Pharma Rheumatology, LLC|150 S. Saunders RoadDrive|Suite 400|Lake Forest|Illinois|60045|United States"
104253156,104253156,pegloticase,Krystexxa,To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.,"C0018099,C0740394","Gout , Hyperuricemia",02/21/2001,Designated/Approved,,Treatment of chronic gout in adult patients refractory to conventional treatment, 09/14/2010 , 09/14/2017 ,,"Horizon Pharma Rheumatology, LLC|150 S. Saunders RoadDrive|Suite 400|Lake Forest|Illinois|60045|United States"
440790702,440790702,Botulinum toxin type B,Myobloc,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,01/16/1992,Designated/Approved,,Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia., 12/08/2000 , 12/08/2007 ,,"Soltice Neurosciences, LLC|4010 Dupont Circle|Suite L-07|Louisville|Kentucky|40207|United States"
160676993,160676993,Botulinum toxin type B,Myobloc,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,01/16/1992,Designated/Approved,,Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia., 12/08/2000 , 12/08/2007 ,,"Soltice Neurosciences, LLC|4010 Dupont Circle|Suite L-07|Louisville|Kentucky|40207|United States"
103771219,103771219,Botulinum toxin type B,Myobloc,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,01/16/1992,Designated/Approved,,Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia., 12/08/2000 , 12/08/2007 ,,"Soltice Neurosciences, LLC|4010 Dupont Circle|Suite L-07|Louisville|Kentucky|40207|United States"
85286164,85286164,Botulinum toxin type B,Myobloc,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,01/16/1992,Designated/Approved,,Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia., 12/08/2000 , 12/08/2007 ,,"Soltice Neurosciences, LLC|4010 Dupont Circle|Suite L-07|Louisville|Kentucky|40207|United States"
46504750,46504750,Botulinum toxin type B,Myobloc,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,01/16/1992,Designated/Approved,,Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia., 12/08/2000 , 12/08/2007 ,,"Soltice Neurosciences, LLC|4010 Dupont Circle|Suite L-07|Louisville|Kentucky|40207|United States"
347910376,347910376,brentuximab vedotin,,Treatment of adult T-cell leukemia/lymphoma,C0023493,adult T-cell leukemia/lymphoma,05/23/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
329976977,329976977,brentuximab vedotin,,Treatment of adult T-cell leukemia/lymphoma,C0023493,adult T-cell leukemia/lymphoma,05/23/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
178103378,178103378,brentuximab vedotin,,Treatment of adult T-cell leukemia/lymphoma,C0023493,adult T-cell leukemia/lymphoma,05/23/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135300399,135300399,brentuximab vedotin,,Treatment of adult T-cell leukemia/lymphoma,C0023493,adult T-cell leukemia/lymphoma,05/23/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
131277422,131277422,brentuximab vedotin,,Treatment of adult T-cell leukemia/lymphoma,C0023493,adult T-cell leukemia/lymphoma,05/23/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
347910376,347910376,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.", 03/20/2018 , 03/20/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
329976977,329976977,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.", 03/20/2018 , 03/20/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
178103378,178103378,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.", 03/20/2018 , 03/20/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
135300399,135300399,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.", 03/20/2018 , 03/20/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
131277422,131277422,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.", 03/20/2018 , 03/20/2025 ,"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.",Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
404720085,404720085,Coagulation factor VIIa (recombinant),NovoSeven,Prevention of bleeding episodes in patients with congenital Factor VII deficiency,C0015503,Factor VII Deficiency,09/10/2004,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency, 07/11/2005 , 07/11/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
135284356,135284356,Coagulation factor VIIa (recombinant),NovoSeven,Prevention of bleeding episodes in patients with congenital Factor VII deficiency,C0015503,Factor VII Deficiency,09/10/2004,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency, 07/11/2005 , 07/11/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
135275129,135275129,Coagulation factor VIIa (recombinant),NovoSeven,Prevention of bleeding episodes in patients with congenital Factor VII deficiency,C0015503,Factor VII Deficiency,09/10/2004,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency, 07/11/2005 , 07/11/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
46507544,46507544,Coagulation factor VIIa (recombinant),NovoSeven,Prevention of bleeding episodes in patients with congenital Factor VII deficiency,C0015503,Factor VII Deficiency,09/10/2004,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency, 07/11/2005 , 07/11/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
440791136,440791136,golimumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,11/02/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
354355047,354355047,golimumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,11/02/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
349071996,349071996,golimumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,11/02/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
347910358,347910358,golimumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,11/02/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
329976985,329976985,golimumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,11/02/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
178103382,178103382,golimumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,11/02/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
135329319,135329319,golimumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,11/02/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
103771531,103771531,golimumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,11/02/2004,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
135298609,135298609,Growth hormone releasing factor,,For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,08/07/1989,Designated,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America|700 Route 202/206|Bridgewater|New Jersey|8807|United States
85086507,85086507,Growth hormone releasing factor,,For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,08/07/1989,Designated,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America|700 Route 202/206|Bridgewater|New Jersey|8807|United States
50068351,50068351,Growth hormone releasing factor,,For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,08/07/1989,Designated,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America|700 Route 202/206|Bridgewater|New Jersey|8807|United States
7979467,7979467,Growth hormone releasing factor,,For the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,08/07/1989,Designated,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America|700 Route 202/206|Bridgewater|New Jersey|8807|United States
347911341,347911341,Molgramostim,,Treatment of aplastic anemia.,C0002874,Aplastic Anemia,09/25/1989,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States
160682377,160682377,Molgramostim,,Treatment of aplastic anemia.,C0002874,Aplastic Anemia,09/25/1989,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States
135351789,135351789,Molgramostim,,Treatment of aplastic anemia.,C0002874,Aplastic Anemia,09/25/1989,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States
53787494,53787494,Molgramostim,,Treatment of aplastic anemia.,C0002874,Aplastic Anemia,09/25/1989,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States
387061103,387061103,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, 12/20/2017 , 12/20/2024 ,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, 12/20/2017 , 12/20/2024 ,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, 12/20/2017 , 12/20/2024 ,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, 12/20/2017 , 12/20/2024 ,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, 12/20/2017 , 12/20/2024 ,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, 12/20/2017 , 12/20/2024 ,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, 12/20/2017 , 12/20/2024 ,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, 12/20/2017 , 12/20/2024 ,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, 12/20/2017 , 12/20/2024 ,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
162248492,162248492,"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate",,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/16/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"JSK Therapeutics, Inc.|1567 W. Silver Springs Road|Park City|Utah|84098|United States"
440798422,440798422,obinutuzumab,,Treatment of diffuse large B cell lymphoma,C0079744,diffuse large b cell lymphoma,02/17/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
387060188,387060188,obinutuzumab,,Treatment of diffuse large B cell lymphoma,C0079744,diffuse large b cell lymphoma,02/17/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
385327553,385327553,obinutuzumab,,Treatment of diffuse large B cell lymphoma,C0079744,diffuse large b cell lymphoma,02/17/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
384647096,384647096,obinutuzumab,,Treatment of diffuse large B cell lymphoma,C0079744,diffuse large b cell lymphoma,02/17/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
347910388,347910388,obinutuzumab,,Treatment of diffuse large B cell lymphoma,C0079744,diffuse large b cell lymphoma,02/17/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
178103523,178103523,obinutuzumab,,Treatment of diffuse large B cell lymphoma,C0079744,diffuse large b cell lymphoma,02/17/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
160682610,160682610,obinutuzumab,,Treatment of diffuse large B cell lymphoma,C0079744,diffuse large b cell lymphoma,02/17/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
135332744,135332744,obinutuzumab,,Treatment of diffuse large B cell lymphoma,C0079744,diffuse large b cell lymphoma,02/17/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
381129324,381129324,Oxalobacter formigenes,,Treatment of primary hyperoxaluria,C0020501,Primary Hyperoxaluria,03/29/2006,Designated,Not FDA Approved for Orphan Indication,,,,,OxThera Inc.|Regeringsgatan 111|Stockholm|Sweden
347910255,347910255,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
160715320,160715320,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
160715319,160715319,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
160715317,160715317,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
160693012,160693012,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
135651867,135651867,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
135311565,135311565,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
135285246,135285246,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
117682973,117682973,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
50002275,50002275,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
47205361,47205361,parathyroid hormone,Natpara,Treatment of hypoparathyroidism,C0020626,Hypoparathyroidism,08/31/2007,Designated/Approved,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism, 01/23/2015 , 01/23/2022 ,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Shire-NPS Pharmaceuticals, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
404719850,404719850,pegcetacoplan,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.|6400 Westwind Way|Suite A|Crestwood|Kentucky|40014|United States"
381128213,381128213,pegcetacoplan,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.|6400 Westwind Way|Suite A|Crestwood|Kentucky|40014|United States"
381127197,381127197,pelareorep,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,02/11/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
312467919,312467919,pelareorep,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,02/11/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
440791207,440791207,Sacrosidase,Sucraid,Treatment of congenital sucrase-isomaltase deficiency,C1283620,Congenital Sucrase-Isomaltase Deficiency,12/10/1993,Designated/Approved,,"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.", 04/09/1998 , 04/09/2005 ,,"QOL Medical, LLC|4445 North Highway A1A, 241|Vero Beach|Florida|32963|United States"
347910368,347910368,Sacrosidase,Sucraid,Treatment of congenital sucrase-isomaltase deficiency,C1283620,Congenital Sucrase-Isomaltase Deficiency,12/10/1993,Designated/Approved,,"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.", 04/09/1998 , 04/09/2005 ,,"QOL Medical, LLC|4445 North Highway A1A, 241|Vero Beach|Florida|32963|United States"
135339374,135339374,Sacrosidase,Sucraid,Treatment of congenital sucrase-isomaltase deficiency,C1283620,Congenital Sucrase-Isomaltase Deficiency,12/10/1993,Designated/Approved,,"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.", 04/09/1998 , 04/09/2005 ,,"QOL Medical, LLC|4445 North Highway A1A, 241|Vero Beach|Florida|32963|United States"
103771432,103771432,Sacrosidase,Sucraid,Treatment of congenital sucrase-isomaltase deficiency,C1283620,Congenital Sucrase-Isomaltase Deficiency,12/10/1993,Designated/Approved,,"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.", 04/09/1998 , 04/09/2005 ,,"QOL Medical, LLC|4445 North Highway A1A, 241|Vero Beach|Florida|32963|United States"
50636523,50636523,Sacrosidase,Sucraid,Treatment of congenital sucrase-isomaltase deficiency,C1283620,Congenital Sucrase-Isomaltase Deficiency,12/10/1993,Designated/Approved,,"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.", 04/09/1998 , 04/09/2005 ,,"QOL Medical, LLC|4445 North Highway A1A, 241|Vero Beach|Florida|32963|United States"
50070146,50070146,Sacrosidase,Sucraid,Treatment of congenital sucrase-isomaltase deficiency,C1283620,Congenital Sucrase-Isomaltase Deficiency,12/10/1993,Designated/Approved,,"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.", 04/09/1998 , 04/09/2005 ,,"QOL Medical, LLC|4445 North Highway A1A, 241|Vero Beach|Florida|32963|United States"
135311612,135311612,Secretory leukocyte protease inhibitor,,Treatment of bronchopulmonary dysplasia.,C0006287,Bronchopulmonary Dysplasia,06/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,"Synergen, Inc.|1885 33rd Street|Boulder|Colorado|80301|United States"
604614,604614,Secretory leukocyte protease inhibitor,,Treatment of bronchopulmonary dysplasia.,C0006287,Bronchopulmonary Dysplasia,06/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,"Synergen, Inc.|1885 33rd Street|Boulder|Colorado|80301|United States"
404772338,404772338,spartalizumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
404720473,404720473,spartalizumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
381128172,381128172,spartalizumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
381118850,381118850,spartalizumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
347911239,347911239,tremelimumab,,Treatment of malignant mesothelioma,C0345967,Malignant mesothelioma,03/18/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
252166672,252166672,tremelimumab,,Treatment of malignant mesothelioma,C0345967,Malignant mesothelioma,03/18/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
160698442,160698442,tremelimumab,,Treatment of malignant mesothelioma,C0345967,Malignant mesothelioma,03/18/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
135304002,135304002,tremelimumab,,Treatment of malignant mesothelioma,C0345967,Malignant mesothelioma,03/18/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
440790971,440790971,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
387060191,387060191,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
385327552,385327552,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
384647095,384647095,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
354355053,354355053,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
349905851,349905851,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
347910190,347910190,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
178103467,178103467,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
135302166,135302166,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
103771533,103771533,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
387124020,387124020,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
377017835,377017835,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
355433663,355433663,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
349984255,349984255,ustekinumab,,Treatment of pediatric systemic lupus erythematosus,C0024141,SYSTEMIC LUPUS ERYTHEMATOSUS,07/18/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
347910376,347910376,Brentuximab vedotin,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,02/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
329976977,329976977,Brentuximab vedotin,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,02/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
178103378,178103378,Brentuximab vedotin,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,02/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
135300399,135300399,Brentuximab vedotin,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,02/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
131277422,131277422,Brentuximab vedotin,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,02/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
319423538,319423538,Epoetin alpha,,Treatment of anemia of prematurity in preterm infants.,C0158996,Anemia of prematurity,07/21/1988,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
135310353,135310353,Epoetin alpha,,Treatment of anemia of prematurity in preterm infants.,C0158996,Anemia of prematurity,07/21/1988,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
49965745,49965745,Epoetin alpha,,Treatment of anemia of prematurity in preterm infants.,C0158996,Anemia of prematurity,07/21/1988,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
354702230,354702230,Fibromun,,Treatment of Soft Tissue Sarcoma,C1261473,Soft tissue sarcoma,12/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Philogen S.p.A.|La Lizza 7|I-53100 Siena|Siena|Tuscany|Italy
440790804,440790804,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
348892445,348892445,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
329976986,329976986,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
178103383,178103383,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
160703840,160703840,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
135305414,135305414,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
103771271,103771271,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
50070194,50070194,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
46506112,46506112,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
319416193,319416193,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
185992960,185992960,ibritumomab tiuxetan,Zevalin,Treatment of B-cell non-Hodgkin's lymphoma.,C0079731,B-cell non-Hodgkin's lymphoma,09/06/1994,Designated/Approved,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma", 02/19/2002 , 02/19/2009 ,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
46506712,46506712,Interferon alfa-2a (recombinant),Roferon-A,Treatment of AIDS related Kaposi's sarcoma.,C0276535,AIDS Related Kaposi's Sarcoma,12/14/1987,Designated/Approved,,, 11/21/1988 , 11/21/1995 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
318161374,318161374,irinotecan liposome injection,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,07/21/2011,Designated/Approved,,"For use in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy", 10/22/2015 , 10/22/2022 ,"For use in combination with 5-fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy","Ipsen Bioscience,Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States"
347911256,347911256,lebrikizumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,03/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
223366019,223366019,lebrikizumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,03/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
160693416,160693416,lebrikizumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,03/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135312293,135312293,lebrikizumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,03/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061105,387061105,pembrolizumab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,10/11/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
385327548,385327548,pembrolizumab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,10/11/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
384647091,384647091,pembrolizumab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,10/11/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
377483934,377483934,pembrolizumab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,10/11/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
354355033,354355033,pembrolizumab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,10/11/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
347910395,347910395,pembrolizumab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,10/11/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
194140938,194140938,pembrolizumab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,10/11/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
187051801,187051801,pembrolizumab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,10/11/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp., a subsidiary of Merck & Co.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
381127448,381127448,reveglucosidase alfa,,Treatment of Pompe disease.,C0017921,Pompe Disease,08/20/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
318464532,318464532,reveglucosidase alfa,,Treatment of Pompe disease.,C0017921,Pompe Disease,08/20/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
440790923,440790923,rilonacept,Arcalyst,Treatment of deficiency of interleukin-1 receptor antagonist (DIRA),C2748507,Deficiency of interleukin-1 receptor antagonist,05/09/2017,Designated/Approved,,maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg, 12/18/2020 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
349081322,349081322,rilonacept,Arcalyst,Treatment of deficiency of interleukin-1 receptor antagonist (DIRA),C2748507,Deficiency of interleukin-1 receptor antagonist,05/09/2017,Designated/Approved,,maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg, 12/18/2020 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
347910349,347910349,rilonacept,Arcalyst,Treatment of deficiency of interleukin-1 receptor antagonist (DIRA),C2748507,Deficiency of interleukin-1 receptor antagonist,05/09/2017,Designated/Approved,,maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg, 12/18/2020 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
178103396,178103396,rilonacept,Arcalyst,Treatment of deficiency of interleukin-1 receptor antagonist (DIRA),C2748507,Deficiency of interleukin-1 receptor antagonist,05/09/2017,Designated/Approved,,maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg, 12/18/2020 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
135350808,135350808,rilonacept,Arcalyst,Treatment of deficiency of interleukin-1 receptor antagonist (DIRA),C2748507,Deficiency of interleukin-1 receptor antagonist,05/09/2017,Designated/Approved,,maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg, 12/18/2020 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
103771528,103771528,rilonacept,Arcalyst,Treatment of deficiency of interleukin-1 receptor antagonist (DIRA),C2748507,Deficiency of interleukin-1 receptor antagonist,05/09/2017,Designated/Approved,,maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg, 12/18/2020 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
347911239,347911239,tremelimumab,,Treatment of stage IIb to stage IV metastatic melanoma,C0278883,Metastatic melanoma,09/18/2006,Designated,Not FDA Approved for Orphan Indication,,,,,MedImmune|One Medimmune Way|Gaithersburg|Maryland|20878|United States
252166672,252166672,tremelimumab,,Treatment of stage IIb to stage IV metastatic melanoma,C0278883,Metastatic melanoma,09/18/2006,Designated,Not FDA Approved for Orphan Indication,,,,,MedImmune|One Medimmune Way|Gaithersburg|Maryland|20878|United States
160698442,160698442,tremelimumab,,Treatment of stage IIb to stage IV metastatic melanoma,C0278883,Metastatic melanoma,09/18/2006,Designated,Not FDA Approved for Orphan Indication,,,,,MedImmune|One Medimmune Way|Gaithersburg|Maryland|20878|United States
135304002,135304002,tremelimumab,,Treatment of stage IIb to stage IV metastatic melanoma,C0278883,Metastatic melanoma,09/18/2006,Designated,Not FDA Approved for Orphan Indication,,,,,MedImmune|One Medimmune Way|Gaithersburg|Maryland|20878|United States
164133228,164133228,dasiprotimut-T,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,10/28/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Biovest International, Inc.|324 S. Hyde Park Avenue|Suite 350|Tampa|Florida|33606|United States"
438517829,438517829,Dextran sulfate sodium,,Treatment of aquired immunodeficiency syndrome.,C0021051,Immunodeficiency Syndrome,11/19/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Ueno Fine Chemicals Industry, Ltd.|2-31 Koraibashi, Higashi-ku|Osaka 541|Japan"
363898146,363898146,Dextran sulfate sodium,,Treatment of aquired immunodeficiency syndrome.,C0021051,Immunodeficiency Syndrome,11/19/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Ueno Fine Chemicals Industry, Ltd.|2-31 Koraibashi, Higashi-ku|Osaka 541|Japan"
160677024,160677024,Dextran sulfate sodium,,Treatment of aquired immunodeficiency syndrome.,C0021051,Immunodeficiency Syndrome,11/19/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Ueno Fine Chemicals Industry, Ltd.|2-31 Koraibashi, Higashi-ku|Osaka 541|Japan"
135346937,135346937,Dextran sulfate sodium,,Treatment of aquired immunodeficiency syndrome.,C0021051,Immunodeficiency Syndrome,11/19/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Ueno Fine Chemicals Industry, Ltd.|2-31 Koraibashi, Higashi-ku|Osaka 541|Japan"
135030727,135030727,Dextran sulfate sodium,,Treatment of aquired immunodeficiency syndrome.,C0021051,Immunodeficiency Syndrome,11/19/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Ueno Fine Chemicals Industry, Ltd.|2-31 Koraibashi, Higashi-ku|Osaka 541|Japan"
53788809,53788809,Dextran sulfate sodium,,Treatment of aquired immunodeficiency syndrome.,C0021051,Immunodeficiency Syndrome,11/19/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Ueno Fine Chemicals Industry, Ltd.|2-31 Koraibashi, Higashi-ku|Osaka 541|Japan"
49857284,49857284,Dextran sulfate sodium,,Treatment of aquired immunodeficiency syndrome.,C0021051,Immunodeficiency Syndrome,11/19/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Ueno Fine Chemicals Industry, Ltd.|2-31 Koraibashi, Higashi-ku|Osaka 541|Japan"
440790757,440790757,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
404609547,404609547,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
387060186,387060186,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
354355052,354355052,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
329976982,329976982,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
178103466,178103466,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
135288438,135288438,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
103771526,103771526,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
50070199,50070199,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
46505429,46505429,eculizumab,Soliris,Treatment of atypical hemolytic uremic syndrome,C2931788,Atypical Hemolytic Uremic Syndrome,04/29/2009,Designated/Approved,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS), 09/23/2011 , 09/23/2018 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
347910066,347910066,Girentuximab,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,03/22/2001,Designated,Not FDA Approved for Orphan Indication,,,,,Heidelberg Pharma AG|101 Schriesheimer Straߥ|Ladenburg|Baden-Wrttemberg|Germany
249565668,249565668,Girentuximab,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,03/22/2001,Designated,Not FDA Approved for Orphan Indication,,,,,Heidelberg Pharma AG|101 Schriesheimer Straߥ|Ladenburg|Baden-Wrttemberg|Germany
160666627,160666627,Girentuximab,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,03/22/2001,Designated,Not FDA Approved for Orphan Indication,,,,,Heidelberg Pharma AG|101 Schriesheimer Straߥ|Ladenburg|Baden-Wrttemberg|Germany
135336444,135336444,Girentuximab,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,03/22/2001,Designated,Not FDA Approved for Orphan Indication,,,,,Heidelberg Pharma AG|101 Schriesheimer Straߥ|Ladenburg|Baden-Wrttemberg|Germany
440791151,440791151,laronidase,Aldurazyme,Treatment of patients with mucopolysaccharidosis-I.,C0026703,Mucopolysaccharidosis,09/24/1997,Designated/Approved,,Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms, 04/30/2003 , 04/30/2010 ,,"BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
135343996,135343996,laronidase,Aldurazyme,Treatment of patients with mucopolysaccharidosis-I.,C0026703,Mucopolysaccharidosis,09/24/1997,Designated/Approved,,Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms, 04/30/2003 , 04/30/2010 ,,"BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
103771231,103771231,laronidase,Aldurazyme,Treatment of patients with mucopolysaccharidosis-I.,C0026703,Mucopolysaccharidosis,09/24/1997,Designated/Approved,,Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms, 04/30/2003 , 04/30/2010 ,,"BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
50070196,50070196,laronidase,Aldurazyme,Treatment of patients with mucopolysaccharidosis-I.,C0026703,Mucopolysaccharidosis,09/24/1997,Designated/Approved,,Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms, 04/30/2003 , 04/30/2010 ,,"BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
46505612,46505612,laronidase,Aldurazyme,Treatment of patients with mucopolysaccharidosis-I.,C0026703,Mucopolysaccharidosis,09/24/1997,Designated/Approved,,Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms, 04/30/2003 , 04/30/2010 ,,"BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
404771478,404771478,Marijuana,,Treatment of HIV-associated wasting syndrome.,"C0019682,C0039082","HIV , Syndrome",05/25/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Multidisciplinary Association for Psychedelic Studies, Inc.|3 Francis St.|Belmont|Massachusetts|2478|United States"
135360080,135360080,Marijuana,,Treatment of HIV-associated wasting syndrome.,"C0019682,C0039082","HIV , Syndrome",05/25/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Multidisciplinary Association for Psychedelic Studies, Inc.|3 Francis St.|Belmont|Massachusetts|2478|United States"
49898702,49898702,Marijuana,,Treatment of HIV-associated wasting syndrome.,"C0019682,C0039082","HIV , Syndrome",05/25/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Multidisciplinary Association for Psychedelic Studies, Inc.|3 Francis St.|Belmont|Massachusetts|2478|United States"
423122,423122,Marijuana,,Treatment of HIV-associated wasting syndrome.,"C0019682,C0039082","HIV , Syndrome",05/25/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Multidisciplinary Association for Psychedelic Studies, Inc.|3 Francis St.|Belmont|Massachusetts|2478|United States"
135280317,135280317,oncophage,,Treatment of glioma,C0017638,Glioma,04/14/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Agenus, Inc.|3 Forbes Road|Lexington|Massachusetts|2421|United States"
381127197,381127197,pelareorep,,Treatment of gastric cancer,C0024623,Gastric Cancer,05/04/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
312467919,312467919,pelareorep,,Treatment of gastric cancer,C0024623,Gastric Cancer,05/04/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
349976299,349976299,Reviparin sodium,,Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients,C0034065,Pulmonary Embolism,06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
347910423,347910423,Reviparin sodium,,Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients,C0034065,Pulmonary Embolism,06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
160676892,160676892,Reviparin sodium,,Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients,C0034065,Pulmonary Embolism,06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
135297230,135297230,Reviparin sodium,,Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients,C0034065,Pulmonary Embolism,06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
134224897,134224897,Reviparin sodium,,Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients,C0034065,Pulmonary Embolism,06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
49975203,49975203,Reviparin sodium,,Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients,C0034065,Pulmonary Embolism,06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
347911263,347911263,rilotumumab,,Treatment of gastric cancer including gastroesophageal junction adenocarcinoma,"C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/18/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|M/S 17-2-B|Thousand Oaks|California|91320|United States"
249565667,249565667,rilotumumab,,Treatment of gastric cancer including gastroesophageal junction adenocarcinoma,"C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/18/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|M/S 17-2-B|Thousand Oaks|California|91320|United States"
160698799,160698799,rilotumumab,,Treatment of gastric cancer including gastroesophageal junction adenocarcinoma,"C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/18/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|M/S 17-2-B|Thousand Oaks|California|91320|United States"
135262715,135262715,rilotumumab,,Treatment of gastric cancer including gastroesophageal junction adenocarcinoma,"C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/18/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|M/S 17-2-B|Thousand Oaks|California|91320|United States"
440962803,440962803,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 08/22/2008 , 08/22/2015 ,,"Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
440790928,440790928,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 08/22/2008 , 08/22/2015 ,,"Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
349975939,349975939,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 08/22/2008 , 08/22/2015 ,,"Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
348939083,348939083,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 08/22/2008 , 08/22/2015 ,,"Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
347910087,347910087,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 08/22/2008 , 08/22/2015 ,,"Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
178103553,178103553,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 08/22/2008 , 08/22/2015 ,,"Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
135347108,135347108,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 08/22/2008 , 08/22/2015 ,,"Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
103771530,103771530,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 08/22/2008 , 08/22/2015 ,,"Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
131408714,131408714,Seneca Valley virus,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,08/22/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Seneca Therapeutics, Inc.|202 St. Andrews Court|Blue Bell|Pennsylvania|19422|United States"
387060190,387060190,Vedolizumab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
385327554,385327554,Vedolizumab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
384647097,384647097,Vedolizumab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
354355051,354355051,Vedolizumab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
347910392,347910392,Vedolizumab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
178104009,178104009,Vedolizumab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
160666632,160666632,Vedolizumab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
135277804,135277804,Vedolizumab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
404770048,404770048,veltuzumab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,08/28/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
349278123,349278123,veltuzumab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,08/28/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
252166480,252166480,veltuzumab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,08/28/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
160687965,160687965,veltuzumab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,08/28/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
135330261,135330261,veltuzumab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,08/28/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
347910376,347910376,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation., 08/17/2015 , 08/17/2022 ,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
329976977,329976977,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation., 08/17/2015 , 08/17/2022 ,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
178103378,178103378,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation., 08/17/2015 , 08/17/2022 ,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
135300399,135300399,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation., 08/17/2015 , 08/17/2022 ,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
131277422,131277422,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation., 08/17/2015 , 08/17/2022 ,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
354355039,354355039,denosumab,Xgeva,Treatment of patients with giant cell tumor of bone,C0206638,Giant Cell Tumor of Bone,12/20/2010,Designated/Approved,,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity., 06/13/2013 , 06/13/2020 ,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
347910354,347910354,denosumab,Xgeva,Treatment of patients with giant cell tumor of bone,C0206638,Giant Cell Tumor of Bone,12/20/2010,Designated/Approved,,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity., 06/13/2013 , 06/13/2020 ,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
342576979,342576979,denosumab,Xgeva,Treatment of patients with giant cell tumor of bone,C0206638,Giant Cell Tumor of Bone,12/20/2010,Designated/Approved,,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity., 06/13/2013 , 06/13/2020 ,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
329976981,329976981,denosumab,Xgeva,Treatment of patients with giant cell tumor of bone,C0206638,Giant Cell Tumor of Bone,12/20/2010,Designated/Approved,,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity., 06/13/2013 , 06/13/2020 ,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
178103468,178103468,denosumab,Xgeva,Treatment of patients with giant cell tumor of bone,C0206638,Giant Cell Tumor of Bone,12/20/2010,Designated/Approved,,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity., 06/13/2013 , 06/13/2020 ,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
135285955,135285955,denosumab,Xgeva,Treatment of patients with giant cell tumor of bone,C0206638,Giant Cell Tumor of Bone,12/20/2010,Designated/Approved,,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity., 06/13/2013 , 06/13/2020 ,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
104253154,104253154,denosumab,Xgeva,Treatment of patients with giant cell tumor of bone,C0206638,Giant Cell Tumor of Bone,12/20/2010,Designated/Approved,,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity., 06/13/2013 , 06/13/2020 ,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91320|United States"
402356185,402356185,dupilumab,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,08/21/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
402355847,402355847,dupilumab,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,08/21/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
377014283,377014283,dupilumab,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,08/21/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
347911292,347911292,dupilumab,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,08/21/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
223365910,223365910,dupilumab,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,08/21/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
160682326,160682326,dupilumab,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,08/21/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
347911362,347911362,moxetumomab pasudotox-tdfk,LUMOXITI,Treatment of hairy cell leukemia,C0023443,Hairy Cell Leukemia,11/15/2007,Designated/Approved,,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).", 09/13/2018 , 09/13/2025 ,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
223366010,223366010,moxetumomab pasudotox-tdfk,LUMOXITI,Treatment of hairy cell leukemia,C0023443,Hairy Cell Leukemia,11/15/2007,Designated/Approved,,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).", 09/13/2018 , 09/13/2025 ,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
160704159,160704159,moxetumomab pasudotox-tdfk,LUMOXITI,Treatment of hairy cell leukemia,C0023443,Hairy Cell Leukemia,11/15/2007,Designated/Approved,,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).", 09/13/2018 , 09/13/2025 ,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
135626666,135626666,moxetumomab pasudotox-tdfk,LUMOXITI,Treatment of hairy cell leukemia,C0023443,Hairy Cell Leukemia,11/15/2007,Designated/Approved,,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).", 09/13/2018 , 09/13/2025 ,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
387061103,387061103,nivolumab,OPDIVO,Treatment of esophageal cancer,C0014859,esophageal cancer,08/22/2016,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.", 06/10/2020 , 06/10/2027 ,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,OPDIVO,Treatment of esophageal cancer,C0014859,esophageal cancer,08/22/2016,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.", 06/10/2020 , 06/10/2027 ,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,OPDIVO,Treatment of esophageal cancer,C0014859,esophageal cancer,08/22/2016,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.", 06/10/2020 , 06/10/2027 ,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,OPDIVO,Treatment of esophageal cancer,C0014859,esophageal cancer,08/22/2016,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.", 06/10/2020 , 06/10/2027 ,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,OPDIVO,Treatment of esophageal cancer,C0014859,esophageal cancer,08/22/2016,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.", 06/10/2020 , 06/10/2027 ,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,OPDIVO,Treatment of esophageal cancer,C0014859,esophageal cancer,08/22/2016,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.", 06/10/2020 , 06/10/2027 ,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,OPDIVO,Treatment of esophageal cancer,C0014859,esophageal cancer,08/22/2016,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.", 06/10/2020 , 06/10/2027 ,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,OPDIVO,Treatment of esophageal cancer,C0014859,esophageal cancer,08/22/2016,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.", 06/10/2020 , 06/10/2027 ,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,OPDIVO,Treatment of esophageal cancer,C0014859,esophageal cancer,08/22/2016,Designated/Approved,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.", 06/10/2020 , 06/10/2027 ,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
347911234,347911234,onartuzumab,,Treatment of gastric cancer including gastroesophageal cancer,"C0024623,C1112160","Gastric Cancer , gastroesophageal cancer",01/23/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
310264746,310264746,onartuzumab,,Treatment of gastric cancer including gastroesophageal cancer,"C0024623,C1112160","Gastric Cancer , gastroesophageal cancer",01/23/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
160693418,160693418,onartuzumab,,Treatment of gastric cancer including gastroesophageal cancer,"C0024623,C1112160","Gastric Cancer , gastroesophageal cancer",01/23/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
135324888,135324888,onartuzumab,,Treatment of gastric cancer including gastroesophageal cancer,"C0024623,C1112160","Gastric Cancer , gastroesophageal cancer",01/23/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
381127197,381127197,pelareorep,,Treatment of malignant glioma,C0555198,Malignant Glioma,04/15/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
312467919,312467919,pelareorep,,Treatment of malignant glioma,C0555198,Malignant Glioma,04/15/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
387060193,387060193,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.", 11/05/2014 ,,,Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
385327559,385327559,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.", 11/05/2014 ,,,Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
384647101,384647101,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.", 11/05/2014 ,,,Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
354355038,354355038,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.", 11/05/2014 ,,,Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
347910183,347910183,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.", 11/05/2014 ,,,Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
178103962,178103962,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.", 11/05/2014 ,,,Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
160666631,160666631,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.", 11/05/2014 ,,,Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
135285364,135285364,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.", 11/05/2014 ,,,Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
131408697,131408697,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.", 11/05/2014 ,,,Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
440790918,440790918,rasburicase,Elitek,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,"C0006826,C0740394","Malignancy , Hyperuricemia",10/11/2000,Designated/Approved,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.", 07/12/2002 , 07/12/2009 ,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
348708880,348708880,rasburicase,Elitek,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,"C0006826,C0740394","Malignancy , Hyperuricemia",10/11/2000,Designated/Approved,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.", 07/12/2002 , 07/12/2009 ,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
187051770,187051770,rasburicase,Elitek,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,"C0006826,C0740394","Malignancy , Hyperuricemia",10/11/2000,Designated/Approved,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.", 07/12/2002 , 07/12/2009 ,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
135272107,135272107,rasburicase,Elitek,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,"C0006826,C0740394","Malignancy , Hyperuricemia",10/11/2000,Designated/Approved,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.", 07/12/2002 , 07/12/2009 ,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
103771220,103771220,rasburicase,Elitek,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,"C0006826,C0740394","Malignancy , Hyperuricemia",10/11/2000,Designated/Approved,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.", 07/12/2002 , 07/12/2009 ,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
50067710,50067710,rasburicase,Elitek,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,"C0006826,C0740394","Malignancy , Hyperuricemia",10/11/2000,Designated/Approved,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.", 07/12/2002 , 07/12/2009 ,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
46504490,46504490,rasburicase,Elitek,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,"C0006826,C0740394","Malignancy , Hyperuricemia",10/11/2000,Designated/Approved,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.", 07/12/2002 , 07/12/2009 ,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
536215,536215,rasburicase,Elitek,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,"C0006826,C0740394","Malignancy , Hyperuricemia",10/11/2000,Designated/Approved,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.", 07/12/2002 , 07/12/2009 ,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
404772451,404772451,sevuparin,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,03/17/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Modus Therapeutics|Sankt Eriksgatan 117|SE-113 43|Stockholm|Sweden
404720353,404720353,sevuparin,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,03/17/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Modus Therapeutics|Sankt Eriksgatan 117|SE-113 43|Stockholm|Sweden
347910394,347910394,siltuximab,SYLVANT,Treatment of Castleman's disease,C0017531,Castleman's Disease,05/26/2006,Designated/Approved,,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative., 04/23/2014 , 04/23/2021 ,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,EUSA Pharma (UK) Ltd.|Breakspear Park|Breakspear Way|Hertfordshire|United Kingdom
178103968,178103968,siltuximab,SYLVANT,Treatment of Castleman's disease,C0017531,Castleman's Disease,05/26/2006,Designated/Approved,,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative., 04/23/2014 , 04/23/2021 ,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,EUSA Pharma (UK) Ltd.|Breakspear Park|Breakspear Way|Hertfordshire|United Kingdom
160687961,160687961,siltuximab,SYLVANT,Treatment of Castleman's disease,C0017531,Castleman's Disease,05/26/2006,Designated/Approved,,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative., 04/23/2014 , 04/23/2021 ,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,EUSA Pharma (UK) Ltd.|Breakspear Park|Breakspear Way|Hertfordshire|United Kingdom
135263755,135263755,siltuximab,SYLVANT,Treatment of Castleman's disease,C0017531,Castleman's Disease,05/26/2006,Designated/Approved,,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative., 04/23/2014 , 04/23/2021 ,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,EUSA Pharma (UK) Ltd.|Breakspear Park|Breakspear Way|Hertfordshire|United Kingdom
347911284,347911284,sotatercept,,Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.,"C0002871,C1301355,C3463824","Anemias , myelodysplastic/myeloproliferative neoplasms , MYELODYSPLASTIC SYNDROME",04/28/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
160698801,160698801,sotatercept,,Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.,"C0002871,C1301355,C3463824","Anemias , myelodysplastic/myeloproliferative neoplasms , MYELODYSPLASTIC SYNDROME",04/28/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
135278235,135278235,sotatercept,,Treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.,"C0002871,C1301355,C3463824","Anemias , myelodysplastic/myeloproliferative neoplasms , MYELODYSPLASTIC SYNDROME",04/28/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
404772367,404772367,Tislelizumab,,Treatment of Hepatocellular Carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/20/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
404720526,404720526,Tislelizumab,,Treatment of Hepatocellular Carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/20/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
377483943,377483943,Tislelizumab,,Treatment of Hepatocellular Carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/20/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
340590223,340590223,Tislelizumab,,Treatment of Hepatocellular Carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/20/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
440235124,440235124,Vasomera,,"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP).","C0013264,C0339510,C0878544,C0917713,C1414083,C1512016,C3668940","DUCHENNE MUSCULAR DYSTROPHY , BMD , Cardiomyopathy , Becker Muscular Dystrophy , DMD , DMD , X-linked dilated cardiomyopathy",11/19/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"PhaseBio Pharmaceuticals, Inc.|1 Great Valley Parkway|Suite 30|Malvern|Pennsylvania|19355|United States"
381127311,381127311,Vasomera,,"Treatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and X-linked dilated cardiomyopathy (XL-dCMP).","C0013264,C0339510,C0878544,C0917713,C1414083,C1512016,C3668940","DUCHENNE MUSCULAR DYSTROPHY , BMD , Cardiomyopathy , Becker Muscular Dystrophy , DMD , DMD , X-linked dilated cardiomyopathy",11/19/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"PhaseBio Pharmaceuticals, Inc.|1 Great Valley Parkway|Suite 30|Malvern|Pennsylvania|19355|United States"
441072526,441072526,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Treatment of primary peritoneal carcinoma.,C1514428,Primary peritoneal carcinoma,11/02/2010,Designated/Approved,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who recei", 06/13/2018 , 06/13/2025 ,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
347910376,347910376,brentuximab vedotin,,Treatment of patients with diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,01/31/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
329976977,329976977,brentuximab vedotin,,Treatment of patients with diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,01/31/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
178103378,178103378,brentuximab vedotin,,Treatment of patients with diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,01/31/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135300399,135300399,brentuximab vedotin,,Treatment of patients with diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,01/31/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
131277422,131277422,brentuximab vedotin,,Treatment of patients with diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,01/31/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
404719767,404719767,calmangafodipir,,Treatment of acetaminophen overdose.,C0572025,Acetaminophen overdose,03/15/2019,Designated,Not FDA Approved for Orphan Indication,,,,,PledPharma AB|Grev Turegatan 11c|Stockholm|Sweden
381608948,381608948,calmangafodipir,,Treatment of acetaminophen overdose.,C0572025,Acetaminophen overdose,03/15/2019,Designated,Not FDA Approved for Orphan Indication,,,,,PledPharma AB|Grev Turegatan 11c|Stockholm|Sweden
134222734,134222734,calmangafodipir,,Treatment of acetaminophen overdose.,C0572025,Acetaminophen overdose,03/15/2019,Designated,Not FDA Approved for Orphan Indication,,,,,PledPharma AB|Grev Turegatan 11c|Stockholm|Sweden
319423538,319423538,Epoetin alpha,,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",08/27/1987,Designated,Not FDA Approved for Orphan Indication,,,,,R. W. Johnson Pharmaceutical Research Institute|Route 202 South|P.O. Box 300|Raritan|New Jersey|8869|United States
135310353,135310353,Epoetin alpha,,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",08/27/1987,Designated,Not FDA Approved for Orphan Indication,,,,,R. W. Johnson Pharmaceutical Research Institute|Route 202 South|P.O. Box 300|Raritan|New Jersey|8869|United States
49965745,49965745,Epoetin alpha,,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",08/27/1987,Designated,Not FDA Approved for Orphan Indication,,,,,R. W. Johnson Pharmaceutical Research Institute|Route 202 South|P.O. Box 300|Raritan|New Jersey|8869|United States
404772034,404772034,patisiran,ONPATTRO,Treatment of transthyretin-mediated amyloidosis,C0002726,Amyloidosis,06/14/2012,Designated/Approved,,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults., 08/10/2018 , 08/10/2025 ,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,"Alnylam Pharmaceuticals, Inc.|300 Third Street|Cambridge|Maryland|2142|United States"
374364158,374364158,patisiran,ONPATTRO,Treatment of transthyretin-mediated amyloidosis,C0002726,Amyloidosis,06/14/2012,Designated/Approved,,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults., 08/10/2018 , 08/10/2025 ,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,"Alnylam Pharmaceuticals, Inc.|300 Third Street|Cambridge|Maryland|2142|United States"
350082694,350082694,patisiran,ONPATTRO,Treatment of transthyretin-mediated amyloidosis,C0002726,Amyloidosis,06/14/2012,Designated/Approved,,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults., 08/10/2018 , 08/10/2025 ,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,"Alnylam Pharmaceuticals, Inc.|300 Third Street|Cambridge|Maryland|2142|United States"
441076374,441076374,Somatropin,Nutropin,For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,03/06/1987,Designated/Approved,,, 10/17/1985 , 10/17/1992 ,,"Genentech, Inc.|460 Point San Bruno Boulevard|South San Francisco|California|94080|United States"
178101641,178101641,Somatropin,Nutropin,For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,03/06/1987,Designated/Approved,,, 10/17/1985 , 10/17/1992 ,,"Genentech, Inc.|460 Point San Bruno Boulevard|South San Francisco|California|94080|United States"
135274454,135274454,Somatropin,Nutropin,For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,03/06/1987,Designated/Approved,,, 10/17/1985 , 10/17/1992 ,,"Genentech, Inc.|460 Point San Bruno Boulevard|South San Francisco|California|94080|United States"
103771423,103771423,Somatropin,Nutropin,For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,03/06/1987,Designated/Approved,,, 10/17/1985 , 10/17/1992 ,,"Genentech, Inc.|460 Point San Bruno Boulevard|South San Francisco|California|94080|United States"
50046577,50046577,Somatropin,Nutropin,For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,03/06/1987,Designated/Approved,,, 10/17/1985 , 10/17/1992 ,,"Genentech, Inc.|460 Point San Bruno Boulevard|South San Francisco|California|94080|United States"
46506010,46506010,Somatropin,Nutropin,For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,03/06/1987,Designated/Approved,,, 10/17/1985 , 10/17/1992 ,,"Genentech, Inc.|460 Point San Bruno Boulevard|South San Francisco|California|94080|United States"
381125242,381125242,Synthetic human secretin,,For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.,C0235974,Pancreatic carcinoma,06/16/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
381125040,381125040,Synthetic human secretin,,For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.,C0235974,Pancreatic carcinoma,06/16/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
347827873,347827873,Synthetic human secretin,,For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.,C0235974,Pancreatic carcinoma,06/16/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
381126435,381126435,ublituximab,,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,C0027873,Neuromyelitis Optica,08/25/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|3 Columbus Circle|15th Floor|New York|New York|10019|United States"
347911248,347911248,ublituximab,,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,C0027873,Neuromyelitis Optica,08/25/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|3 Columbus Circle|15th Floor|New York|New York|10019|United States"
310264701,310264701,ublituximab,,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,C0027873,Neuromyelitis Optica,08/25/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|3 Columbus Circle|15th Floor|New York|New York|10019|United States"
160676946,160676946,ublituximab,,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,C0027873,Neuromyelitis Optica,08/25/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|3 Columbus Circle|15th Floor|New York|New York|10019|United States"
381127735,381127735,Varicella Zoster Immune Globulin (Human),VARIZIG,"Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella","C0008049,C0009566","Varicella , Complications",11/07/2006,Designated/Approved,,Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella, 12/20/2012 , 12/20/2019 ,,"Cangene bioPharma, Inc.|155 Innovation Drive|Winnipeg|Canada"
347911219,347911219,Varicella Zoster Immune Globulin (Human),VARIZIG,"Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella","C0008049,C0009566","Varicella , Complications",11/07/2006,Designated/Approved,,Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella, 12/20/2012 , 12/20/2019 ,,"Cangene bioPharma, Inc.|155 Innovation Drive|Winnipeg|Canada"
440790701,440790701,Botulinum toxin type A,Dysport,Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,"C0007789,C0009917","Cerebral Palsy , Contractures",10/20/1999,Designated/Approved,,Treatment of lower limb spasticity in pediatric patients 2 years of age and older, 07/29/2016 , 07/29/2023 ,Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older,"Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States"
404720407,404720407,Botulinum toxin type A,Dysport,Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,"C0007789,C0009917","Cerebral Palsy , Contractures",10/20/1999,Designated/Approved,,Treatment of lower limb spasticity in pediatric patients 2 years of age and older, 07/29/2016 , 07/29/2023 ,Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older,"Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States"
135351517,135351517,Botulinum toxin type A,Dysport,Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,"C0007789,C0009917","Cerebral Palsy , Contractures",10/20/1999,Designated/Approved,,Treatment of lower limb spasticity in pediatric patients 2 years of age and older, 07/29/2016 , 07/29/2023 ,Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older,"Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States"
81065599,81065599,Botulinum toxin type A,Dysport,Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,"C0007789,C0009917","Cerebral Palsy , Contractures",10/20/1999,Designated/Approved,,Treatment of lower limb spasticity in pediatric patients 2 years of age and older, 07/29/2016 , 07/29/2023 ,Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older,"Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States"
49895113,49895113,Botulinum toxin type A,Dysport,Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,"C0007789,C0009917","Cerebral Palsy , Contractures",10/20/1999,Designated/Approved,,Treatment of lower limb spasticity in pediatric patients 2 years of age and older, 07/29/2016 , 07/29/2023 ,Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older,"Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States"
46505347,46505347,Botulinum toxin type A,Dysport,Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,"C0007789,C0009917","Cerebral Palsy , Contractures",10/20/1999,Designated/Approved,,Treatment of lower limb spasticity in pediatric patients 2 years of age and older, 07/29/2016 , 07/29/2023 ,Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older,"Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States"
10147,10147,Botulinum toxin type A,Dysport,Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,"C0007789,C0009917","Cerebral Palsy , Contractures",10/20/1999,Designated/Approved,,Treatment of lower limb spasticity in pediatric patients 2 years of age and older, 07/29/2016 , 07/29/2023 ,Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older,"Ipsen Biopharmaceuticals, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States"
135289419,135289419,Dornase alfa,Pulmozyme,To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.,C0010674,Cystic Fibrosis,01/16/1991,Designated/Approved,,In conjunction with standard therapies in the management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function., 12/30/1993 , 12/30/2000 ,,"Genentech, Inc.|460 Point San Bruno Boulevard|South San Francisco|California|94080|United States"
103771402,103771402,Dornase alfa,Pulmozyme,To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.,C0010674,Cystic Fibrosis,01/16/1991,Designated/Approved,,In conjunction with standard therapies in the management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function., 12/30/1993 , 12/30/2000 ,,"Genentech, Inc.|460 Point San Bruno Boulevard|South San Francisco|California|94080|United States"
46507792,46507792,Dornase alfa,Pulmozyme,To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.,C0010674,Cystic Fibrosis,01/16/1991,Designated/Approved,,In conjunction with standard therapies in the management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function., 12/30/1993 , 12/30/2000 ,,"Genentech, Inc.|460 Point San Bruno Boulevard|South San Francisco|California|94080|United States"
440790757,440790757,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
404609547,404609547,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
387060186,387060186,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
354355052,354355052,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
329976982,329976982,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
178103466,178103466,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
135288438,135288438,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
103771526,103771526,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
50070199,50070199,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
46505429,46505429,eculizumab,Soliris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,08/20/2003,Designated/Approved,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis, 03/16/2007 , 03/16/2014 ,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
135324553,135324553,immune globulin (human),,Treatment of Guillain-Barre syndrome,C0018378,Guillain-Barre Syndrome,03/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.|121 River Street|Suite 1201|Hoboken|New Jersey|7030|United States"
103771318,103771318,immune globulin (human),,Treatment of Guillain-Barre syndrome,C0018378,Guillain-Barre Syndrome,03/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.|121 River Street|Suite 1201|Hoboken|New Jersey|7030|United States"
46508774,46508774,immune globulin (human),,Treatment of Guillain-Barre syndrome,C0018378,Guillain-Barre Syndrome,03/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.|121 River Street|Suite 1201|Hoboken|New Jersey|7030|United States"
490427,490427,Immune globulin intravenous (human),,Treatment of polymyositis/dermatomyositis.,C0011633,POLYMYOSITIS/DERMATOMYOSITIS,10/13/1992,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.|155 East 56th Street|New York|New York|10022|United States
381126899,381126899,inebilizumab,Uplizna,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders,C0027873,Neuromyelitis Optica,02/10/2016,Designated/Approved,,Uplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/11/2020 , 06/11/2027 ,Indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,Viela Bio|One MedImmune Way|Gaithersburg|Maryland|20878|United States
347911342,347911342,inebilizumab,Uplizna,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders,C0027873,Neuromyelitis Optica,02/10/2016,Designated/Approved,,Uplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/11/2020 , 06/11/2027 ,Indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,Viela Bio|One MedImmune Way|Gaithersburg|Maryland|20878|United States
249565673,249565673,inebilizumab,Uplizna,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders,C0027873,Neuromyelitis Optica,02/10/2016,Designated/Approved,,Uplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/11/2020 , 06/11/2027 ,Indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,Viela Bio|One MedImmune Way|Gaithersburg|Maryland|20878|United States
160682403,160682403,inebilizumab,Uplizna,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders,C0027873,Neuromyelitis Optica,02/10/2016,Designated/Approved,,Uplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/11/2020 , 06/11/2027 ,Indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,Viela Bio|One MedImmune Way|Gaithersburg|Maryland|20878|United States
404771679,404771679,L. reuteri,,"Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams",C0014356,Enterocolitis,08/01/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Infant Bacterial Therapeutics|Kungsbroplan 3A|P. O. Box 3242|Stockholm|Sweden
135347077,135347077,L. reuteri,,"Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams",C0014356,Enterocolitis,08/01/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Infant Bacterial Therapeutics|Kungsbroplan 3A|P. O. Box 3242|Stockholm|Sweden
404719381,404719381,lonapegsomatropin,,Treatment of growth hormone deficiency,C3714796,Growth hormone deficiency,04/13/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Ascendis Pharma Endocrinology Division A/S|12 Tuborg Boulevard|Hellerup|Denmark
381128171,381128171,lonapegsomatropin,,Treatment of growth hormone deficiency,C3714796,Growth hormone deficiency,04/13/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Ascendis Pharma Endocrinology Division A/S|12 Tuborg Boulevard|Hellerup|Denmark
404772201,404772201,mecasermin rinfabate,,Prevention of retinopathy of prematurity in premature infants born at risk for the disease,C0035344,Retinopathy of Prematurity,09/20/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Premacure AB, a member of Shire Group of Companies|Dag Hammarskjolds vag 10B|Uppsala Science Park|Uppsala|Sweden"
135325697,135325697,mecasermin rinfabate,,Prevention of retinopathy of prematurity in premature infants born at risk for the disease,C0035344,Retinopathy of Prematurity,09/20/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Premacure AB, a member of Shire Group of Companies|Dag Hammarskjolds vag 10B|Uppsala Science Park|Uppsala|Sweden"
103771459,103771459,mecasermin rinfabate,,Prevention of retinopathy of prematurity in premature infants born at risk for the disease,C0035344,Retinopathy of Prematurity,09/20/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Premacure AB, a member of Shire Group of Companies|Dag Hammarskjolds vag 10B|Uppsala Science Park|Uppsala|Sweden"
375581026,375581026,satralizumab-mwge,ENSPRYNG,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,C0027873,Neuromyelitis Optica,06/30/2014,Designated/Approved,,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive, 08/14/2020 , 08/14/2027 ,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"GENENTECH, INC.|1 DNA WAY|SOUTH SAN FRANCISCO|California|94080|United States"
315661178,315661178,satralizumab-mwge,ENSPRYNG,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,C0027873,Neuromyelitis Optica,06/30/2014,Designated/Approved,,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive, 08/14/2020 , 08/14/2027 ,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"GENENTECH, INC.|1 DNA WAY|SOUTH SAN FRANCISCO|California|94080|United States"
347910394,347910394,siltuximab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,10/11/2005,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
178103968,178103968,siltuximab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,10/11/2005,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
160687961,160687961,siltuximab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,10/11/2005,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
135263755,135263755,siltuximab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,10/11/2005,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
441076374,441076374,Somatropin,,Treatment of cachexia associated with AIDS.,C0343755,Cachexia associated with AIDS,02/12/1993,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bio-Technology General Corp.|70 Wood Avenue, South|Iselin|New Jersey|8830|United States"
178101641,178101641,Somatropin,,Treatment of cachexia associated with AIDS.,C0343755,Cachexia associated with AIDS,02/12/1993,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bio-Technology General Corp.|70 Wood Avenue, South|Iselin|New Jersey|8830|United States"
135274454,135274454,Somatropin,,Treatment of cachexia associated with AIDS.,C0343755,Cachexia associated with AIDS,02/12/1993,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bio-Technology General Corp.|70 Wood Avenue, South|Iselin|New Jersey|8830|United States"
103771423,103771423,Somatropin,,Treatment of cachexia associated with AIDS.,C0343755,Cachexia associated with AIDS,02/12/1993,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bio-Technology General Corp.|70 Wood Avenue, South|Iselin|New Jersey|8830|United States"
50046577,50046577,Somatropin,,Treatment of cachexia associated with AIDS.,C0343755,Cachexia associated with AIDS,02/12/1993,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bio-Technology General Corp.|70 Wood Avenue, South|Iselin|New Jersey|8830|United States"
46506010,46506010,Somatropin,,Treatment of cachexia associated with AIDS.,C0343755,Cachexia associated with AIDS,02/12/1993,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Bio-Technology General Corp.|70 Wood Avenue, South|Iselin|New Jersey|8830|United States"
405092064,405092064,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
387061215,387061215,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
385327557,385327557,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
385326041,385326041,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
354355060,354355060,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
349016747,349016747,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
347910344,347910344,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
329976997,329976997,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
178103463,178103463,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
135345962,135345962,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
104253153,104253153,tocilizumab,Actemra,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,"C0406810,C0948245","CAR , Cytokine Release Syndrome",08/01/2017,Designated/Approved,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older, 08/30/2017 , 08/30/2024 ,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
178101605,178101605,cardiotrophin-1,,Prevention of ischemia-reperfusion injury in kidney transplant recipients,C0035126,Ischemia-Reperfusion Injury,10/16/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.|Calloe ORENSE No. 85|2nd Floor|Madrid|Spain"
441078173,441078173,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
440791125,440791125,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
349583301,349583301,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
283537479,283537479,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
178103548,178103548,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
135320862,135320862,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
134221887,134221887,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
103771266,103771266,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
49955776,49955776,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
46505833,46505833,Filgrastim,Neupogen,Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,C0746882,Chronic neutropenia,11/07/1990,Designated/Approved,,Treatment of patients with severe chronic neutropenia., 12/19/1994 , 12/19/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
135335137,135335137,indralin,,Prevention of acute radiation syndrome (ARS),C0520799,Acute Radiation Syndrome,06/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Advanced Innovative Partners, Inc.|7947 Brookside Court|Lake Worth|Florida|33467|United States"
379981111,379981111,vibriolysin,,"Debridement of severe, deep dermal burns in hospitalized patients",C0006434,Burns,06/16/2006,Designated,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.|105 Digital Drive|Novato|California|94949|United States
347909969,347909969,vibriolysin,,"Debridement of severe, deep dermal burns in hospitalized patients",C0006434,Burns,06/16/2006,Designated,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.|105 Digital Drive|Novato|California|94949|United States
135277988,135277988,vibriolysin,,"Debridement of severe, deep dermal burns in hospitalized patients",C0006434,Burns,06/16/2006,Designated,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.|105 Digital Drive|Novato|California|94949|United States
135350052,135350052,Virulizin,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,02/01/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"ZOR Pharmaceuticals, LLC|100-A Eastwood Center Drive|Suite 118|Wilmington|North Carolina|28403|United States"
381127086,381127086,bimagrumab,,Treatment of inclusion body myositis,C0238190,INCLUSION BODY MYOSITIS,06/18/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States
347911347,347911347,bimagrumab,,Treatment of inclusion body myositis,C0238190,INCLUSION BODY MYOSITIS,06/18/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States
249565766,249565766,bimagrumab,,Treatment of inclusion body myositis,C0238190,INCLUSION BODY MYOSITIS,06/18/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States
194189084,194189084,bimagrumab,,Treatment of inclusion body myositis,C0238190,INCLUSION BODY MYOSITIS,06/18/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.|One Health Plaza|East Hanover|New Jersey|7936|United States
347910400,347910400,blinatumomab,,Treatment of prolymphocytic leukemia,C0023486,Prolymphocytic Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
178103956,178103956,blinatumomab,,Treatment of prolymphocytic leukemia,C0023486,Prolymphocytic Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
160698788,160698788,blinatumomab,,Treatment of prolymphocytic leukemia,C0023486,Prolymphocytic Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
135330301,135330301,blinatumomab,,Treatment of prolymphocytic leukemia,C0023486,Prolymphocytic Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
347910400,347910400,blinatumomab,,"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement",C0079731,B-Cell Lymphoma,02/06/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
178103956,178103956,blinatumomab,,"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement",C0079731,B-Cell Lymphoma,02/06/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
160698788,160698788,blinatumomab,,"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement",C0079731,B-Cell Lymphoma,02/06/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
135330301,135330301,blinatumomab,,"Treatment of indolent B-cell lymphoma, excluding CLL and NHL with CNS involvement",C0079731,B-Cell Lymphoma,02/06/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
440790483,440790483,canakinumab,,Treatment of adult-onset Still's Disease,C0085253,Adult-Onset Still's Disease,07/31/2017,Designated/Approved,,"ILARIS is indicated for the treatment of active Stills disease, including Adult-Onset Stills Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.", 06/16/2020 , 06/16/2027 ,For the treatment of active adult-onset Stills Disease (AOSD).,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124993,381124993,canakinumab,,Treatment of adult-onset Still's Disease,C0085253,Adult-Onset Still's Disease,07/31/2017,Designated/Approved,,"ILARIS is indicated for the treatment of active Stills disease, including Adult-Onset Stills Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.", 06/16/2020 , 06/16/2027 ,For the treatment of active adult-onset Stills Disease (AOSD).,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124992,381124992,canakinumab,,Treatment of adult-onset Still's Disease,C0085253,Adult-Onset Still's Disease,07/31/2017,Designated/Approved,,"ILARIS is indicated for the treatment of active Stills disease, including Adult-Onset Stills Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.", 06/16/2020 , 06/16/2027 ,For the treatment of active adult-onset Stills Disease (AOSD).,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910340,347910340,canakinumab,,Treatment of adult-onset Still's Disease,C0085253,Adult-Onset Still's Disease,07/31/2017,Designated/Approved,,"ILARIS is indicated for the treatment of active Stills disease, including Adult-Onset Stills Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.", 06/16/2020 , 06/16/2027 ,For the treatment of active adult-onset Stills Disease (AOSD).,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
329976978,329976978,canakinumab,,Treatment of adult-onset Still's Disease,C0085253,Adult-Onset Still's Disease,07/31/2017,Designated/Approved,,"ILARIS is indicated for the treatment of active Stills disease, including Adult-Onset Stills Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.", 06/16/2020 , 06/16/2027 ,For the treatment of active adult-onset Stills Disease (AOSD).,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
178103379,178103379,canakinumab,,Treatment of adult-onset Still's Disease,C0085253,Adult-Onset Still's Disease,07/31/2017,Designated/Approved,,"ILARIS is indicated for the treatment of active Stills disease, including Adult-Onset Stills Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.", 06/16/2020 , 06/16/2027 ,For the treatment of active adult-onset Stills Disease (AOSD).,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
135332926,135332926,canakinumab,,Treatment of adult-onset Still's Disease,C0085253,Adult-Onset Still's Disease,07/31/2017,Designated/Approved,,"ILARIS is indicated for the treatment of active Stills disease, including Adult-Onset Stills Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.", 06/16/2020 , 06/16/2027 ,For the treatment of active adult-onset Stills Disease (AOSD).,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
103771532,103771532,canakinumab,,Treatment of adult-onset Still's Disease,C0085253,Adult-Onset Still's Disease,07/31/2017,Designated/Approved,,"ILARIS is indicated for the treatment of active Stills disease, including Adult-Onset Stills Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.", 06/16/2020 , 06/16/2027 ,For the treatment of active adult-onset Stills Disease (AOSD).,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
440806798,440806798,daratumumab,,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,11/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring hOuse|Pennsylvania|19477|United States"
387060189,387060189,daratumumab,,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,11/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring hOuse|Pennsylvania|19477|United States"
354355058,354355058,daratumumab,,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,11/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring hOuse|Pennsylvania|19477|United States"
347910441,347910441,daratumumab,,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,11/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring hOuse|Pennsylvania|19477|United States"
178103967,178103967,daratumumab,,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,11/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring hOuse|Pennsylvania|19477|United States"
160671954,160671954,daratumumab,,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,11/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring hOuse|Pennsylvania|19477|United States"
135304352,135304352,daratumumab,,Treatment of diffuse large B-cell lymphoma.,C1332201,Diffuse Large B-Cell Lymphoma,11/09/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring hOuse|Pennsylvania|19477|United States"
347911319,347911319,ensituximab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Neogenix Oncology, Inc.|9700 Great Seneca Highway|Rockville|Maryland|20850|United States"
160677289,160677289,ensituximab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Neogenix Oncology, Inc.|9700 Great Seneca Highway|Rockville|Maryland|20850|United States"
135337580,135337580,ensituximab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Neogenix Oncology, Inc.|9700 Great Seneca Highway|Rockville|Maryland|20850|United States"
347911296,347911296,etrolizumab,,Treatment of pediatric Crohn's disease.,C2931133,Pediatric Crohn's disease,07/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 Dna Way|South San Francisco|California|94080|United States"
252166617,252166617,etrolizumab,,Treatment of pediatric Crohn's disease.,C2931133,Pediatric Crohn's disease,07/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 Dna Way|South San Francisco|California|94080|United States"
160704152,160704152,etrolizumab,,Treatment of pediatric Crohn's disease.,C2931133,Pediatric Crohn's disease,07/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 Dna Way|South San Francisco|California|94080|United States"
135292500,135292500,etrolizumab,,Treatment of pediatric Crohn's disease.,C2931133,Pediatric Crohn's disease,07/13/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 Dna Way|South San Francisco|California|94080|United States"
404719648,404719648,idecabtagene vicleucel,Abecma,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/11/2016,Designated/Approved,,"Treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.", 03/26/2021 ,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
441080425,441080425,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
387061213,387061213,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
385327555,385327555,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
384647098,384647098,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
354355049,354355049,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
349020482,349020482,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
347910348,347910348,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
329976972,329976972,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
178101741,178101741,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
136926963,136926963,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
135348342,135348342,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
50069677,50069677,pertuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/08/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS # 355C|South San Francisco|California|94080|United States"
441072526,441072526,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
440790697,440790697,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
387061165,387061165,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
350080043,350080043,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
348480209,348480209,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
329976976,329976976,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
178103377,178103377,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
135329020,135329020,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
103771315,103771315,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
50067187,50067187,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
46504473,46504473,bevacizumab,,Treatment of Coat's disease,C0154832,coat's disease,03/10/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.|Bar Yehuda Street|Nesher|Haifa District|Israel"
440234937,440234937,clervonafusp alfa,,Treatment of Pompe Disease,C0017921,Pompe Disease,10/04/2018,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Valerion Therapeutics, LLC|100 Main Street|Concord|Massachusetts|1742|United States"
381609060,381609060,clervonafusp alfa,,Treatment of Pompe Disease,C0017921,Pompe Disease,10/04/2018,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Valerion Therapeutics, LLC|100 Main Street|Concord|Massachusetts|1742|United States"
96025480,96025480,coagulation factor IX (recombinant),RIXUBIS,Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding),"C0008533,C0019080","Hemophilia B , Bleeding",10/31/2012,Designated/Approved,,"Adults with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.", 06/26/2013 , 06/26/2020 ,Adults with Hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.,"Baxalta US, Inc.|300 Massachusetts Avenue|Cambridge|Massachusetts|2139|United States"
46508858,46508858,coagulation factor IX (recombinant),RIXUBIS,Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding),"C0008533,C0019080","Hemophilia B , Bleeding",10/31/2012,Designated/Approved,,"Adults with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.", 06/26/2013 , 06/26/2020 ,Adults with Hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.,"Baxalta US, Inc.|300 Massachusetts Avenue|Cambridge|Massachusetts|2139|United States"
404720194,404720194,efmitermant alfa,,Treatment of Charcot-Marie-Tooth disease,C0007959,Charcot-Marie-Tooth Disease,02/28/2019,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Acceleron Pharma Inc.|128 Sidney Street|Cambridge|Massachusetts|2139|United States
381609098,381609098,efmitermant alfa,,Treatment of Charcot-Marie-Tooth disease,C0007959,Charcot-Marie-Tooth Disease,02/28/2019,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Acceleron Pharma Inc.|128 Sidney Street|Cambridge|Massachusetts|2139|United States
252166553,252166553,Interferon gamma,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,10/11/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"mondoBIOTECH Laboratories AG|Herrengasse 21, 9490 Vaduz|Liechtenstein|Germany"
178101666,178101666,Interferon gamma,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,10/11/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"mondoBIOTECH Laboratories AG|Herrengasse 21, 9490 Vaduz|Liechtenstein|Germany"
103771226,103771226,Interferon gamma,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,10/11/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"mondoBIOTECH Laboratories AG|Herrengasse 21, 9490 Vaduz|Liechtenstein|Germany"
497569,497569,Interferon gamma,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,10/11/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"mondoBIOTECH Laboratories AG|Herrengasse 21, 9490 Vaduz|Liechtenstein|Germany"
440791159,440791159,Mecasermin,Increlex,Treatment of growth hormone insensitivity syndrome.,C4318479,Growth Hormone Insensitivity Syndrome,12/12/1995,Designated/Approved,,Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone., 08/30/2005 , 08/30/2012 ,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States"
178101669,178101669,Mecasermin,Increlex,Treatment of growth hormone insensitivity syndrome.,C4318479,Growth Hormone Insensitivity Syndrome,12/12/1995,Designated/Approved,,Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone., 08/30/2005 , 08/30/2012 ,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States"
160698630,160698630,Mecasermin,Increlex,Treatment of growth hormone insensitivity syndrome.,C4318479,Growth Hormone Insensitivity Syndrome,12/12/1995,Designated/Approved,,Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone., 08/30/2005 , 08/30/2012 ,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States"
135330509,135330509,Mecasermin,Increlex,Treatment of growth hormone insensitivity syndrome.,C4318479,Growth Hormone Insensitivity Syndrome,12/12/1995,Designated/Approved,,Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone., 08/30/2005 , 08/30/2012 ,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States"
49985113,49985113,Mecasermin,Increlex,Treatment of growth hormone insensitivity syndrome.,C4318479,Growth Hormone Insensitivity Syndrome,12/12/1995,Designated/Approved,,Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone., 08/30/2005 , 08/30/2012 ,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States"
46504889,46504889,Mecasermin,Increlex,Treatment of growth hormone insensitivity syndrome.,C4318479,Growth Hormone Insensitivity Syndrome,12/12/1995,Designated/Approved,,Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone., 08/30/2005 , 08/30/2012 ,,"Ipsen Biopharmaceuticals, Inc.|106 Allen Road|Basking Ridge|New Jersey|7920|United States"
347910398,347910398,metreleptin,MYALEPT,Treatment of metabolic disorders secondary to lipodystrophy,"C0023787,C0025517","Lipodystrophy , Metabolic disorders",08/22/2001,Designated/Approved,,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy., 02/24/2014 , 02/24/2021 ,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,Amryt Pharmaceuticals DAC|45 Mespil Road|Dublin|4|Ireland
178103905,178103905,metreleptin,MYALEPT,Treatment of metabolic disorders secondary to lipodystrophy,"C0023787,C0025517","Lipodystrophy , Metabolic disorders",08/22/2001,Designated/Approved,,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy., 02/24/2014 , 02/24/2021 ,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,Amryt Pharmaceuticals DAC|45 Mespil Road|Dublin|4|Ireland
160676886,160676886,metreleptin,MYALEPT,Treatment of metabolic disorders secondary to lipodystrophy,"C0023787,C0025517","Lipodystrophy , Metabolic disorders",08/22/2001,Designated/Approved,,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy., 02/24/2014 , 02/24/2021 ,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,Amryt Pharmaceuticals DAC|45 Mespil Road|Dublin|4|Ireland
135303712,135303712,metreleptin,MYALEPT,Treatment of metabolic disorders secondary to lipodystrophy,"C0023787,C0025517","Lipodystrophy , Metabolic disorders",08/22/2001,Designated/Approved,,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy., 02/24/2014 , 02/24/2021 ,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,Amryt Pharmaceuticals DAC|45 Mespil Road|Dublin|4|Ireland
347911362,347911362,moxetumomab pasudotox,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,06/28/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
223366010,223366010,moxetumomab pasudotox,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,06/28/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
160704159,160704159,moxetumomab pasudotox,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,06/28/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
135350821,135350821,moxetumomab pasudotox,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,06/28/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
56310988,56310988,pegylated granulocyte colony stimulating factor,,Treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident,C0854467,Myelosuppression,04/30/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"PharmaEssentia|13 F, No.3, YuanQu Street|Taipei|Taiwan"
387061105,387061105,pembrolizumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,02/17/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
385327548,385327548,pembrolizumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,02/17/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
384647091,384647091,pembrolizumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,02/17/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
377483934,377483934,pembrolizumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,02/17/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
354355033,354355033,pembrolizumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,02/17/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
347910395,347910395,pembrolizumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,02/17/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
194140938,194140938,pembrolizumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,02/17/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
187051801,187051801,pembrolizumab,,Treatment of multiple myeloma.,C0026764,Multiple Myeloma,02/17/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
441080425,441080425,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061213,387061213,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385327555,385327555,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
384647098,384647098,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355049,354355049,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
349020482,349020482,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
347910348,347910348,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976972,329976972,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178101741,178101741,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
136926963,136926963,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135348342,135348342,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50069677,50069677,pertuzumab,,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,07/12/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387060193,387060193,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.", 04/21/2014 , 04/21/2021 ,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
385327559,385327559,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.", 04/21/2014 , 04/21/2021 ,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
384647101,384647101,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.", 04/21/2014 , 04/21/2021 ,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
354355038,354355038,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.", 04/21/2014 , 04/21/2021 ,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
347910183,347910183,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.", 04/21/2014 , 04/21/2021 ,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
178103962,178103962,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.", 04/21/2014 , 04/21/2021 ,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
160666631,160666631,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.", 04/21/2014 , 04/21/2021 ,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
135285364,135285364,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.", 04/21/2014 , 04/21/2021 ,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
131408697,131408697,ramucirumab,CYRAMZA,Treatment of gastric cancer,C0024623,Gastric Cancer,02/16/2012,Designated/Approved,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.", 04/21/2014 , 04/21/2021 ,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
347911284,347911284,sotatercept,,Treatment of beta-thalassemia intermedia and major,C0472767,BETA-THALASSEMIA INTERMEDIA,12/05/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
160698801,160698801,sotatercept,,Treatment of beta-thalassemia intermedia and major,C0472767,BETA-THALASSEMIA INTERMEDIA,12/05/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
135278235,135278235,sotatercept,,Treatment of beta-thalassemia intermedia and major,C0472767,BETA-THALASSEMIA INTERMEDIA,12/05/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
381128081,381128081,tisagenlecleucel-T,Kymriah,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,02/03/2015,Designated/Approved,,"KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma", 05/01/2018 , 05/01/2025 ,For treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma after two or more lines of systemic therapy.,"Novartis Pharmaceuticals Corporation|One Health Plaza,|Bldg 315 - Room 3650B|East Hanover|New Jersey|7936|United States"
347911451,347911451,tisagenlecleucel-T,Kymriah,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,02/03/2015,Designated/Approved,,"KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma", 05/01/2018 , 05/01/2025 ,For treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma after two or more lines of systemic therapy.,"Novartis Pharmaceuticals Corporation|One Health Plaza,|Bldg 315 - Room 3650B|East Hanover|New Jersey|7936|United States"
242651775,242651775,tisagenlecleucel-T,Kymriah,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,02/03/2015,Designated/Approved,,"KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma", 05/01/2018 , 05/01/2025 ,For treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma after two or more lines of systemic therapy.,"Novartis Pharmaceuticals Corporation|One Health Plaza,|Bldg 315 - Room 3650B|East Hanover|New Jersey|7936|United States"
347910400,347910400,blinatumomab,,Treatment for hairy cell leukemia.,C0023443,Hairy Cell Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
178103956,178103956,blinatumomab,,Treatment for hairy cell leukemia.,C0023443,Hairy Cell Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
160698788,160698788,blinatumomab,,Treatment for hairy cell leukemia.,C0023443,Hairy Cell Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
135330301,135330301,blinatumomab,,Treatment for hairy cell leukemia.,C0023443,Hairy Cell Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
347910400,347910400,Blinatumomab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
178103956,178103956,Blinatumomab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
160698788,160698788,Blinatumomab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
135330301,135330301,Blinatumomab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,05/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Drive|Thousand Oaks|California|91230|United States"
440790701,440790701,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,03/23/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States"
404720407,404720407,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,03/23/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States"
135351517,135351517,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,03/23/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States"
81065599,81065599,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,03/23/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States"
49895113,49895113,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,03/23/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States"
46505347,46505347,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,03/23/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States"
10147,10147,Botulinum toxin type A,,Treatment of essential blepharospasm.,C2930898,Essential blepharospasm,03/23/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Porton International, Inc.|1155 15th Street, N.W., #315|Washington|District of Columbia|20005|United States"
440790483,440790483,canakinumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
381124993,381124993,canakinumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
381124992,381124992,canakinumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
347910340,347910340,canakinumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
329976978,329976978,canakinumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
178103379,178103379,canakinumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
135332926,135332926,canakinumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
103771532,103771532,canakinumab,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,03/24/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|07936-1080|United States
404770101,404770101,Caplacizumab,CABLIVI,Treatment of thrombotic thrombocytopenic purpura,C0857305,Thrombocytopenic purpura,04/14/2009,Designated/Approved,,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.", 02/06/2019 , 02/06/2026 ,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.","Ablynx, a wholly owned subsidiary of Sanofi Group|55 Corporate Drive|Bridgewater|New Jersey|8807|United States"
381125787,381125787,Caplacizumab,CABLIVI,Treatment of thrombotic thrombocytopenic purpura,C0857305,Thrombocytopenic purpura,04/14/2009,Designated/Approved,,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.", 02/06/2019 , 02/06/2026 ,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.","Ablynx, a wholly owned subsidiary of Sanofi Group|55 Corporate Drive|Bridgewater|New Jersey|8807|United States"
315661208,315661208,Caplacizumab,CABLIVI,Treatment of thrombotic thrombocytopenic purpura,C0857305,Thrombocytopenic purpura,04/14/2009,Designated/Approved,,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.", 02/06/2019 , 02/06/2026 ,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.","Ablynx, a wholly owned subsidiary of Sanofi Group|55 Corporate Drive|Bridgewater|New Jersey|8807|United States"
160671749,160671749,Caplacizumab,CABLIVI,Treatment of thrombotic thrombocytopenic purpura,C0857305,Thrombocytopenic purpura,04/14/2009,Designated/Approved,,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.", 02/06/2019 , 02/06/2026 ,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.","Ablynx, a wholly owned subsidiary of Sanofi Group|55 Corporate Drive|Bridgewater|New Jersey|8807|United States"
440235440,440235440,cirmtuzumab,,Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.,C1302547,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,06/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncternal Therapeutics, Inc.|12230 El Camino Real|Suite 300|SanDiego|California|92130|United States"
404720283,404720283,cirmtuzumab,,Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.,C1302547,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,06/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncternal Therapeutics, Inc.|12230 El Camino Real|Suite 300|SanDiego|California|92130|United States"
160693091,160693091,collagenase clostridium histolyticum,XIAFLEX,Treatment of Peyronie's disease.,C0030848,Peyronie's Disease,03/12/1996,Designated/Approved,,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy., 12/06/2013 , 12/06/2020 ,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.,"Auxilium Pharmaceuticals, Inc.|640 Lee Road|Chesterbrook|Pennsylvania|19087|United States"
135330780,135330780,collagenase clostridium histolyticum,XIAFLEX,Treatment of Peyronie's disease.,C0030848,Peyronie's Disease,03/12/1996,Designated/Approved,,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy., 12/06/2013 , 12/06/2020 ,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.,"Auxilium Pharmaceuticals, Inc.|640 Lee Road|Chesterbrook|Pennsylvania|19087|United States"
46506485,46506485,collagenase clostridium histolyticum,XIAFLEX,Treatment of Peyronie's disease.,C0030848,Peyronie's Disease,03/12/1996,Designated/Approved,,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy., 12/06/2013 , 12/06/2020 ,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.,"Auxilium Pharmaceuticals, Inc.|640 Lee Road|Chesterbrook|Pennsylvania|19087|United States"
381609316,381609316,garadacimab,,Treatment of bradykinin-mediated angioedema,C0002994,Angioedema,04/30/2020,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring|1020 First Avenue|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
46506712,46506712,Interferon alfa-2a (recombinant),,For the treatment of metastatic malignant melanoma in combination with Teceleukin.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
46504899,46504899,Interferon beta-1a (recombinant human),,Treatment of pulmonary fibrosis.,C0034069,Pulmonary Fibrosis,01/07/1999,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen Idec, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
441074980,441074980,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
404772311,404772311,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
178101682,178101682,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135326453,135326453,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135273161,135273161,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
134224740,134224740,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56314519,56314519,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56313513,56313513,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56313163,56313163,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56312547,56312547,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56312196,56312196,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311893,56311893,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311781,56311781,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311685,56311685,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56310774,56310774,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
7978489,7978489,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
7847813,7847813,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
10105,10105,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,05/11/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
526933,526933,Liposomal annamycin,,Treatment of acute lymphoblastic leukemia,C0023449,Acute lymphoblastic leukemia,06/17/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.|420 Lexington Avenue|New York|New York|10170|United States"
387061105,387061105,pembrolizumab,Keytruda,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,10/03/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy., 06/17/2019 , 06/17/2026 ,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.,"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
385327548,385327548,pembrolizumab,Keytruda,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,10/03/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy., 06/17/2019 , 06/17/2026 ,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.,"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
384647091,384647091,pembrolizumab,Keytruda,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,10/03/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy., 06/17/2019 , 06/17/2026 ,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.,"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
377483934,377483934,pembrolizumab,Keytruda,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,10/03/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy., 06/17/2019 , 06/17/2026 ,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.,"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
354355033,354355033,pembrolizumab,Keytruda,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,10/03/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy., 06/17/2019 , 06/17/2026 ,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.,"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
347910395,347910395,pembrolizumab,Keytruda,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,10/03/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy., 06/17/2019 , 06/17/2026 ,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.,"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
194140938,194140938,pembrolizumab,Keytruda,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,10/03/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy., 06/17/2019 , 06/17/2026 ,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.,"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
187051801,187051801,pembrolizumab,Keytruda,Treatment of Small Cell Lung Cancer,C3540630,Small Cell Lung Cancer,10/03/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy., 06/17/2019 , 06/17/2026 ,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.,"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
441076374,441076374,Somatropin,Genotropin,Treatment of adults with growth hormone deficiency.,C3714796,Growth hormone deficiency,09/06/1994,Designated/Approved,,, 10/31/1997 , 10/31/2004 ,,Pharmacia & Upjohn|7000 Portage Road|Kalamazoo|Michigan|49001|United States
178101641,178101641,Somatropin,Genotropin,Treatment of adults with growth hormone deficiency.,C3714796,Growth hormone deficiency,09/06/1994,Designated/Approved,,, 10/31/1997 , 10/31/2004 ,,Pharmacia & Upjohn|7000 Portage Road|Kalamazoo|Michigan|49001|United States
135274454,135274454,Somatropin,Genotropin,Treatment of adults with growth hormone deficiency.,C3714796,Growth hormone deficiency,09/06/1994,Designated/Approved,,, 10/31/1997 , 10/31/2004 ,,Pharmacia & Upjohn|7000 Portage Road|Kalamazoo|Michigan|49001|United States
103771423,103771423,Somatropin,Genotropin,Treatment of adults with growth hormone deficiency.,C3714796,Growth hormone deficiency,09/06/1994,Designated/Approved,,, 10/31/1997 , 10/31/2004 ,,Pharmacia & Upjohn|7000 Portage Road|Kalamazoo|Michigan|49001|United States
50046577,50046577,Somatropin,Genotropin,Treatment of adults with growth hormone deficiency.,C3714796,Growth hormone deficiency,09/06/1994,Designated/Approved,,, 10/31/1997 , 10/31/2004 ,,Pharmacia & Upjohn|7000 Portage Road|Kalamazoo|Michigan|49001|United States
46506010,46506010,Somatropin,Genotropin,Treatment of adults with growth hormone deficiency.,C3714796,Growth hormone deficiency,09/06/1994,Designated/Approved,,, 10/31/1997 , 10/31/2004 ,,Pharmacia & Upjohn|7000 Portage Road|Kalamazoo|Michigan|49001|United States
49988950,49988950,vincristine sulfate liposomes,,Treatment of metastatic uveal melanoma.,C4725091,Metastatic Uveal Melanoma,06/24/2008,Designated,Not FDA Approved for Orphan Indication,,,,,Acrotech Biopharma LLC|279 Princeton Hightstown Road|East Windsor|New Jersey|8520|United States
178101605,178101605,cardiotrophin-1,,Treatment of acute liver failure,C0162557,Acute liver failure,09/13/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.|Calloe ORENSE No. 85|2nd Floor|Madrid|Spain"
347911366,347911366,carlumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,11/08/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
160698790,160698790,carlumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,11/08/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
135350336,135350336,carlumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,11/08/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
404720085,404720085,Coagulation factor VIIa (recombinant),,Prevention of bleeding episodes in Glanzmann's thrombasthenia,C0040015,glanzmann's thrombasthenia,06/18/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|100 College Road West|Princeton|New Jersey|8540|United States"
135284356,135284356,Coagulation factor VIIa (recombinant),,Prevention of bleeding episodes in Glanzmann's thrombasthenia,C0040015,glanzmann's thrombasthenia,06/18/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|100 College Road West|Princeton|New Jersey|8540|United States"
135275129,135275129,Coagulation factor VIIa (recombinant),,Prevention of bleeding episodes in Glanzmann's thrombasthenia,C0040015,glanzmann's thrombasthenia,06/18/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|100 College Road West|Princeton|New Jersey|8540|United States"
46507544,46507544,Coagulation factor VIIa (recombinant),,Prevention of bleeding episodes in Glanzmann's thrombasthenia,C0040015,glanzmann's thrombasthenia,06/18/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|100 College Road West|Princeton|New Jersey|8540|United States"
160693091,160693091,collagenase clostridium histolyticum,Xiaflex,Treatment of advanced (involutional or residual stage) Dupuytren's disease,C0012634,Disease,05/23/1996,Designated/Approved,,Treatment of adult patients with Dupuytren's contracture with a palpable cord, 02/02/2010 , 02/02/2017 ,,"Auxilium Pharmaceuticals, Inc.|40 Valley Stream Parkway|Malvern|Pennsylvania|19335|United States"
135330780,135330780,collagenase clostridium histolyticum,Xiaflex,Treatment of advanced (involutional or residual stage) Dupuytren's disease,C0012634,Disease,05/23/1996,Designated/Approved,,Treatment of adult patients with Dupuytren's contracture with a palpable cord, 02/02/2010 , 02/02/2017 ,,"Auxilium Pharmaceuticals, Inc.|40 Valley Stream Parkway|Malvern|Pennsylvania|19335|United States"
46506485,46506485,collagenase clostridium histolyticum,Xiaflex,Treatment of advanced (involutional or residual stage) Dupuytren's disease,C0012634,Disease,05/23/1996,Designated/Approved,,Treatment of adult patients with Dupuytren's contracture with a palpable cord, 02/02/2010 , 02/02/2017 ,,"Auxilium Pharmaceuticals, Inc.|40 Valley Stream Parkway|Malvern|Pennsylvania|19335|United States"
135285682,135285682,Digoxin immune FAB (Ovine),Digibind,Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.,C0151595,DIGITALIS INTOXICATION,11/01/1984,Designated/Approved,,, 04/22/1986 , 04/22/1993 ,,Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States
46506432,46506432,Digoxin immune FAB (Ovine),Digibind,Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.,C0151595,DIGITALIS INTOXICATION,11/01/1984,Designated/Approved,,, 04/22/1986 , 04/22/1993 ,,Glaxo Wellcome Inc.|5 Moore Drive|Research Triangle Park|North Carolina|27709|United States
252827375,252827375,evinacumab-dgnb,Evkeeza,Treatment of homozygous familial hypercholesterolemia.,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,02/08/2016,Designated/Approved,,"adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)", 02/11/2021 ,,,"Regeneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591-0707|United States"
347911406,347911406,factor XIII concentrate (human),Corifact,Treatment of congenital factor XIII deficiency,C4316906,Factor XIII deficiency,01/16/1985,Designated/Approved,,For the routine prophylactic treatment of congenital factor XIII deficiency, 02/17/2011 , 02/17/2018 ,,CSL Behring LLC|1020 First Ave.|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
135278070,135278070,factor XIII concentrate (human),Corifact,Treatment of congenital factor XIII deficiency,C4316906,Factor XIII deficiency,01/16/1985,Designated/Approved,,For the routine prophylactic treatment of congenital factor XIII deficiency, 02/17/2011 , 02/17/2018 ,,CSL Behring LLC|1020 First Ave.|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
441072528,441072528,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
440790341,440790341,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433791528,433791528,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433790701,433790701,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
387060165,387060165,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
354355050,354355050,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
348825932,348825932,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
329976987,329976987,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
178101701,178101701,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
135305802,135305802,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
103771449,103771449,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
91145133,91145133,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313883,56313883,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313209,56313209,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56311151,56311151,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
50067186,50067186,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
46505602,46505602,infliximab,,Treatment of giant cell arteritis,C0039483,Giant Cell Arteritis,05/06/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
404772412,404772412,margetuximab,,Treatment of gastric and gastroesophageal junction cancer.,C0006826,Cancer,06/03/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.|9704 Medical Center Drive|Rockville|Maryland|20850|United States"
381127049,381127049,margetuximab,,Treatment of gastric and gastroesophageal junction cancer.,C0006826,Cancer,06/03/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.|9704 Medical Center Drive|Rockville|Maryland|20850|United States"
252166886,252166886,margetuximab,,Treatment of gastric and gastroesophageal junction cancer.,C0006826,Cancer,06/03/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.|9704 Medical Center Drive|Rockville|Maryland|20850|United States"
164130400,164130400,margetuximab,,Treatment of gastric and gastroesophageal junction cancer.,C0006826,Cancer,06/03/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.|9704 Medical Center Drive|Rockville|Maryland|20850|United States"
387061105,387061105,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma., 12/18/2015 , 12/18/2022 ,Initial treatment of patients with unresectable or metastatic melanoma,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
385327548,385327548,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma., 12/18/2015 , 12/18/2022 ,Initial treatment of patients with unresectable or metastatic melanoma,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
384647091,384647091,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma., 12/18/2015 , 12/18/2022 ,Initial treatment of patients with unresectable or metastatic melanoma,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
377483934,377483934,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma., 12/18/2015 , 12/18/2022 ,Initial treatment of patients with unresectable or metastatic melanoma,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
354355033,354355033,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma., 12/18/2015 , 12/18/2022 ,Initial treatment of patients with unresectable or metastatic melanoma,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
347910395,347910395,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma., 12/18/2015 , 12/18/2022 ,Initial treatment of patients with unresectable or metastatic melanoma,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
194140938,194140938,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma., 12/18/2015 , 12/18/2022 ,Initial treatment of patients with unresectable or metastatic melanoma,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
187051801,187051801,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,Treatment of patients with unresectable or metastatic melanoma., 12/18/2015 , 12/18/2022 ,Initial treatment of patients with unresectable or metastatic melanoma,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
46506010,46506010,Somatropin (rDNA origin),Nutropin Depot,Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,C0015544,growth failure,10/28/1999,Designated/Approved,,Long-term treatment of growth failure due to a lack of adequate endogenous growth hormone secetion for once- or twice-a-month administration., 12/22/1999 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
404720314,404720314,tilsotolimod sodium,,Treatment of melanoma stages IIb-IV.,C0280209,melanoma stages,06/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Idera Pharmaceuticals, Inc.|505 Eagleview Boulevard|Suite 212|Exton|Pennsylvania|19341|United States"
381128261,381128261,tilsotolimod sodium,,Treatment of melanoma stages IIb-IV.,C0280209,melanoma stages,06/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Idera Pharmaceuticals, Inc.|505 Eagleview Boulevard|Suite 212|Exton|Pennsylvania|19341|United States"
440790971,440790971,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
387060191,387060191,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
385327552,385327552,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
384647095,384647095,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
354355053,354355053,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
349905851,349905851,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
347910190,347910190,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
178103467,178103467,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
135302166,135302166,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
103771533,103771533,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
387124020,387124020,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
377017835,377017835,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
355433663,355433663,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
349984255,349984255,ustekinumab,,Treatment of type 1 diabetes mellitus patients with residual beta-cell function.,C0011854,Type 1 diabetes mellitus,11/29/2010,Designated,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC|902 Route 202 South|Room 1654|Raritan|New Jersey|8869|United States
387060190,387060190,vedolizumab,,Treatment of Pouchitis,C0376620,Pouchitis,03/15/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States"
385327554,385327554,vedolizumab,,Treatment of Pouchitis,C0376620,Pouchitis,03/15/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States"
384647097,384647097,vedolizumab,,Treatment of Pouchitis,C0376620,Pouchitis,03/15/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States"
354355051,354355051,vedolizumab,,Treatment of Pouchitis,C0376620,Pouchitis,03/15/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States"
347910392,347910392,vedolizumab,,Treatment of Pouchitis,C0376620,Pouchitis,03/15/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States"
178104009,178104009,vedolizumab,,Treatment of Pouchitis,C0376620,Pouchitis,03/15/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States"
160666632,160666632,vedolizumab,,Treatment of Pouchitis,C0376620,Pouchitis,03/15/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States"
135277804,135277804,vedolizumab,,Treatment of Pouchitis,C0376620,Pouchitis,03/15/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.|95 Hayden Avenue|Lexington|Massachusetts|2421|United States"
441072527,441072527,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
440790714,440790714,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
387061106,387061106,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
354355046,354355046,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
350080042,350080042,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
348892040,348892040,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
348480208,348480208,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
329976961,329976961,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
178103464,178103464,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
135293496,135293496,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
103771411,103771411,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
56313965,56313965,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
56313468,56313468,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
56312188,56312188,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
46507042,46507042,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
532611,532611,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
495888,495888,cetuximab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/15/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated|33 ImClone Drive|Branchburg|New Jersey|8876|United States
440806798,440806798,daratumumab,,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,08/20/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
387060189,387060189,daratumumab,,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,08/20/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
354355058,354355058,daratumumab,,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,08/20/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
347910441,347910441,daratumumab,,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,08/20/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
178103967,178103967,daratumumab,,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,08/20/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
160671954,160671954,daratumumab,,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,08/20/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
135304352,135304352,daratumumab,,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,08/20/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
402356185,402356185,dupilumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,09/05/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Regneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
402355847,402355847,dupilumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,09/05/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Regneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
377014283,377014283,dupilumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,09/05/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Regneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
347911292,347911292,dupilumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,09/05/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Regneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
223365910,223365910,dupilumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,09/05/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Regneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
160682326,160682326,dupilumab,,Treatment of eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,09/05/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Regneron Pharmaceuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
46508122,46508122,"Erythropoietin (human, recombinant)",,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",11/19/1987,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Organon Teknika Corporation
381609124,381609124,IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL),,Treatment of astrocytic glioma.,C0004114,Astrocytic glioma,04/06/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Medicenna Therapeutics, Inc.|220-1075 West George Street|Vancouver|Canada"
441072528,441072528,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
440790341,440790341,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433791528,433791528,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433790701,433790701,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
387060165,387060165,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
354355050,354355050,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
348825932,348825932,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
329976987,329976987,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
178101701,178101701,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
135305802,135305802,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
103771449,103771449,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
91145133,91145133,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313883,56313883,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313209,56313209,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56311151,56311151,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
50067186,50067186,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
46505602,46505602,infliximab,Remicade,Treatment of Crohn's disease,C0010346,Crohn's Disease,11/14/1995,Designated/Approved,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).", 08/24/1998 , 08/24/2005 ,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
46506712,46506712,Interferon alfa-2a (recombinant),,For use in combination with fluorouracil for the treatment of esophageal carcinoma.,C0152018,Esophageal carcinoma,10/27/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
440790346,440790346,Interferon beta-1b,Betaseron,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,11/17/1988,Designated/Approved,,In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations., 07/23/1993 , 07/23/2000 ,,Chiron Corp. & Berlex Laboratories|4560 Horton Street|Emeryville|California|94608|United States
363907627,363907627,Interferon beta-1b,Betaseron,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,11/17/1988,Designated/Approved,,In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations., 07/23/1993 , 07/23/2000 ,,Chiron Corp. & Berlex Laboratories|4560 Horton Street|Emeryville|California|94608|United States
135350896,135350896,Interferon beta-1b,Betaseron,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,11/17/1988,Designated/Approved,,In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations., 07/23/1993 , 07/23/2000 ,,Chiron Corp. & Berlex Laboratories|4560 Horton Street|Emeryville|California|94608|United States
103771390,103771390,Interferon beta-1b,Betaseron,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,11/17/1988,Designated/Approved,,In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations., 07/23/1993 , 07/23/2000 ,,Chiron Corp. & Berlex Laboratories|4560 Horton Street|Emeryville|California|94608|United States
50069693,50069693,Interferon beta-1b,Betaseron,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,11/17/1988,Designated/Approved,,In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations., 07/23/1993 , 07/23/2000 ,,Chiron Corp. & Berlex Laboratories|4560 Horton Street|Emeryville|California|94608|United States
46504458,46504458,Interferon beta-1b,Betaseron,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,11/17/1988,Designated/Approved,,In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations., 07/23/1993 , 07/23/2000 ,,Chiron Corp. & Berlex Laboratories|4560 Horton Street|Emeryville|California|94608|United States
404772323,404772323,lintuzumab,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,03/20/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
249565664,249565664,lintuzumab,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,03/20/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
160671685,160671685,lintuzumab,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,03/20/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135336964,135336964,lintuzumab,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,03/20/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
354355057,354355057,mepolizumab,NUCALA,For treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,05/28/2004,Designated/Approved,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause, 09/25/2020 , 09/25/2027 ,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC|1250 S. Collegeville Road|Collegeville|Pennsylvania|19426|United States
347910353,347910353,mepolizumab,NUCALA,For treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,05/28/2004,Designated/Approved,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause, 09/25/2020 , 09/25/2027 ,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC|1250 S. Collegeville Road|Collegeville|Pennsylvania|19426|United States
223366020,223366020,mepolizumab,NUCALA,For treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,05/28/2004,Designated/Approved,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause, 09/25/2020 , 09/25/2027 ,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC|1250 S. Collegeville Road|Collegeville|Pennsylvania|19426|United States
160682290,160682290,mepolizumab,NUCALA,For treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,05/28/2004,Designated/Approved,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause, 09/25/2020 , 09/25/2027 ,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC|1250 S. Collegeville Road|Collegeville|Pennsylvania|19426|United States
135278932,135278932,mepolizumab,NUCALA,For treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,05/28/2004,Designated/Approved,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause, 09/25/2020 , 09/25/2027 ,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC|1250 S. Collegeville Road|Collegeville|Pennsylvania|19426|United States
76206305,76206305,mepolizumab,NUCALA,For treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,05/28/2004,Designated/Approved,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause, 09/25/2020 , 09/25/2027 ,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC|1250 S. Collegeville Road|Collegeville|Pennsylvania|19426|United States
377017834,377017834,mepolizumab,NUCALA,For treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,05/28/2004,Designated/Approved,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause, 09/25/2020 , 09/25/2027 ,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC|1250 S. Collegeville Road|Collegeville|Pennsylvania|19426|United States
349977836,349977836,mepolizumab,NUCALA,For treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,05/28/2004,Designated/Approved,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause, 09/25/2020 , 09/25/2027 ,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC|1250 S. Collegeville Road|Collegeville|Pennsylvania|19426|United States
387061103,387061103,nivolumab,,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 4000|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 4000|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 4000|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 4000|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 4000|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 4000|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 4000|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 4000|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,,Treatment of primary mediastinal B-cell lymphoma.,C0079731,B-Cell Lymphoma,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 4000|Princeton|New Jersey|8543|United States
404772212,404772212,risankizumab,,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,11/29/2016,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.|Regulatory Affair|1 North Waukegan Road|North Chicago|Illinois|60044|United States
381127718,381127718,risankizumab,,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,11/29/2016,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.|Regulatory Affair|1 North Waukegan Road|North Chicago|Illinois|60044|United States
374364262,374364262,risankizumab,,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,11/29/2016,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.|Regulatory Affair|1 North Waukegan Road|North Chicago|Illinois|60044|United States
310264703,310264703,risankizumab,,Treatment of pediatric Crohn's disease,C2931133,Pediatric Crohn's disease,11/29/2016,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.|Regulatory Affair|1 North Waukegan Road|North Chicago|Illinois|60044|United States
347911451,347911451,Tisagenlecleucel,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/14/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Novartis Pharmaceuticals Corporation|One Health Plaza,|Bldg 315 - Room 3650B|East Hanover|New Jersey|7936|United States"
242651775,242651775,Tisagenlecleucel,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/14/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Novartis Pharmaceuticals Corporation|One Health Plaza,|Bldg 315 - Room 3650B|East Hanover|New Jersey|7936|United States"
347910400,347910400,blinatumomab,Blincyto,Treatment of acute lymphocytic leukemia,C0023449,Acute lymphocytic leukemia,05/16/2008,Designated/Approved,,BLINCYTO is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children., 03/29/2018 , 03/29/2025 ,For the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children,"Amgen, Inc.|One Amgen Center Dr.|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States"
178103956,178103956,blinatumomab,Blincyto,Treatment of acute lymphocytic leukemia,C0023449,Acute lymphocytic leukemia,05/16/2008,Designated/Approved,,BLINCYTO is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children., 03/29/2018 , 03/29/2025 ,For the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children,"Amgen, Inc.|One Amgen Center Dr.|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States"
160698788,160698788,blinatumomab,Blincyto,Treatment of acute lymphocytic leukemia,C0023449,Acute lymphocytic leukemia,05/16/2008,Designated/Approved,,BLINCYTO is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children., 03/29/2018 , 03/29/2025 ,For the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children,"Amgen, Inc.|One Amgen Center Dr.|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States"
135330301,135330301,blinatumomab,Blincyto,Treatment of acute lymphocytic leukemia,C0023449,Acute lymphocytic leukemia,05/16/2008,Designated/Approved,,BLINCYTO is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children., 03/29/2018 , 03/29/2025 ,For the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children,"Amgen, Inc.|One Amgen Center Dr.|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States"
404719697,404719697,idursulfase beta,,Treatment of Hunter Syndrome (mucopolysaccharidoses),"C0026703,C0026705","Mucopolysaccharidoses , Hunter syndrome",02/11/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Green Cross Corp.|303 Bojeong-dong, Giheung-gu|Gyunggi-Do 446-770|South Korea"
381126852,381126852,idursulfase beta,,Treatment of Hunter Syndrome (mucopolysaccharidoses),"C0026703,C0026705","Mucopolysaccharidoses , Hunter syndrome",02/11/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Green Cross Corp.|303 Bojeong-dong, Giheung-gu|Gyunggi-Do 446-770|South Korea"
387061107,387061107,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
385327547,385327547,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
384647090,384647090,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
354355037,354355037,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
349072362,349072362,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
347910341,347910341,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
329976988,329976988,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
178103470,178103470,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
135287563,135287563,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
131273201,131273201,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,Treatment of unresectable or metastatic melanoma, 03/25/2011 , 03/25/2018 ,,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
402425845,402425845,lenadogene nolparvovec,,Treatment of Leber Hereditary Optic Neuropathy,C0917796,Leber hereditary optic neuropathy,11/20/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Gen Sight Biologics
440790868,440790868,Oprelvekin,Neumega,Prevention of severe chemotherapy-induced thrombocytopenia.,C0040034,Thrombocytopenia,12/17/1996,Designated/Approved,,, 11/25/1997 , 11/25/2004 ,,"Genetics Institute, Inc.|87 Cambridge Park Drive|Cambridge|Massachusetts|2140|United States"
381130880,381130880,Oprelvekin,Neumega,Prevention of severe chemotherapy-induced thrombocytopenia.,C0040034,Thrombocytopenia,12/17/1996,Designated/Approved,,, 11/25/1997 , 11/25/2004 ,,"Genetics Institute, Inc.|87 Cambridge Park Drive|Cambridge|Massachusetts|2140|United States"
178103550,178103550,Oprelvekin,Neumega,Prevention of severe chemotherapy-induced thrombocytopenia.,C0040034,Thrombocytopenia,12/17/1996,Designated/Approved,,, 11/25/1997 , 11/25/2004 ,,"Genetics Institute, Inc.|87 Cambridge Park Drive|Cambridge|Massachusetts|2140|United States"
135350247,135350247,Oprelvekin,Neumega,Prevention of severe chemotherapy-induced thrombocytopenia.,C0040034,Thrombocytopenia,12/17/1996,Designated/Approved,,, 11/25/1997 , 11/25/2004 ,,"Genetics Institute, Inc.|87 Cambridge Park Drive|Cambridge|Massachusetts|2140|United States"
103771380,103771380,Oprelvekin,Neumega,Prevention of severe chemotherapy-induced thrombocytopenia.,C0040034,Thrombocytopenia,12/17/1996,Designated/Approved,,, 11/25/1997 , 11/25/2004 ,,"Genetics Institute, Inc.|87 Cambridge Park Drive|Cambridge|Massachusetts|2140|United States"
50070167,50070167,Oprelvekin,Neumega,Prevention of severe chemotherapy-induced thrombocytopenia.,C0040034,Thrombocytopenia,12/17/1996,Designated/Approved,,, 11/25/1997 , 11/25/2004 ,,"Genetics Institute, Inc.|87 Cambridge Park Drive|Cambridge|Massachusetts|2140|United States"
46506470,46506470,Oprelvekin,Neumega,Prevention of severe chemotherapy-induced thrombocytopenia.,C0040034,Thrombocytopenia,12/17/1996,Designated/Approved,,, 11/25/1997 , 11/25/2004 ,,"Genetics Institute, Inc.|87 Cambridge Park Drive|Cambridge|Massachusetts|2140|United States"
348287571,348287571,Poloxamer 331,,Initial therapy of toxoplasmosis in patients with AIDS.,"C0001175,C0040558","AIDS , Toxoplasmosis",03/21/1991,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation|154 Technology Parkway|Norcross|Georgia|30092|United States
336269933,336269933,Poloxamer 331,,Initial therapy of toxoplasmosis in patients with AIDS.,"C0001175,C0040558","AIDS , Toxoplasmosis",03/21/1991,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation|154 Technology Parkway|Norcross|Georgia|30092|United States
622912,622912,Poloxamer 331,,Initial therapy of toxoplasmosis in patients with AIDS.,"C0001175,C0040558","AIDS , Toxoplasmosis",03/21/1991,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation|154 Technology Parkway|Norcross|Georgia|30092|United States
402314344,402314344,Poloxamer 331,,Initial therapy of toxoplasmosis in patients with AIDS.,"C0001175,C0040558","AIDS , Toxoplasmosis",03/21/1991,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation|154 Technology Parkway|Norcross|Georgia|30092|United States
349994361,349994361,Poloxamer 331,,Initial therapy of toxoplasmosis in patients with AIDS.,"C0001175,C0040558","AIDS , Toxoplasmosis",03/21/1991,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation|154 Technology Parkway|Norcross|Georgia|30092|United States
110201,110201,Poloxamer 331,,Initial therapy of toxoplasmosis in patients with AIDS.,"C0001175,C0040558","AIDS , Toxoplasmosis",03/21/1991,Designated,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation|154 Technology Parkway|Norcross|Georgia|30092|United States
135207091,135207091,polyphenon E,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,07/17/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mitsui Norin Co., Ltd|223-1 Miyabara|426-0133|Fujieda City|Japan"
134224365,134224365,polyphenon E,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,07/17/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mitsui Norin Co., Ltd|223-1 Miyabara|426-0133|Fujieda City|Japan"
50019215,50019215,polyphenon E,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,07/17/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Mitsui Norin Co., Ltd|223-1 Miyabara|426-0133|Fujieda City|Japan"
377483931,377483931,sebelipase alfa,Kanuma,Treatment of lysosomal acid lipase deficiency,C0043208,Lysosomal acid lipase deficiency,07/01/2010,Designated/Approved,,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency, 12/08/2015 , 12/08/2022 ,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency,Alexion Pharmaceuticals|100 College Street|New Haven|Connecticut|6510|United States
347911202,347911202,sebelipase alfa,Kanuma,Treatment of lysosomal acid lipase deficiency,C0043208,Lysosomal acid lipase deficiency,07/01/2010,Designated/Approved,,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency, 12/08/2015 , 12/08/2022 ,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency,Alexion Pharmaceuticals|100 College Street|New Haven|Connecticut|6510|United States
174520437,174520437,sebelipase alfa,Kanuma,Treatment of lysosomal acid lipase deficiency,C0043208,Lysosomal acid lipase deficiency,07/01/2010,Designated/Approved,,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency, 12/08/2015 , 12/08/2022 ,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency,Alexion Pharmaceuticals|100 College Street|New Haven|Connecticut|6510|United States
319259212,319259212,talactoferrin alfa,,For the prevention of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,08/20/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
160676985,160676985,talactoferrin alfa,,For the prevention of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,08/20/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
135286186,135286186,talactoferrin alfa,,For the prevention of graft-versus-host disease,C0018133,Graft-Versus-Host Disease,08/20/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
135305324,135305324,Tissue Plasminogen activator,,Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.,"C0039585,C0948008","AIS , Ischemic stroke",04/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Catherine Amlie-Lefond, MD|University of Washington|4800 Sand Point Way NE - M/S B5552|Seattle|Washington|98105|United States"
134222947,134222947,Tissue Plasminogen activator,,Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.,"C0039585,C0948008","AIS , Ischemic stroke",04/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Catherine Amlie-Lefond, MD|University of Washington|4800 Sand Point Way NE - M/S B5552|Seattle|Washington|98105|United States"
50068525,50068525,Tissue Plasminogen activator,,Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.,"C0039585,C0948008","AIS , Ischemic stroke",04/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Catherine Amlie-Lefond, MD|University of Washington|4800 Sand Point Way NE - M/S B5552|Seattle|Washington|98105|United States"
46507035,46507035,Tissue Plasminogen activator,,Treatment of acute ischemic stroke (AIS) in children age 16 years and younger.,"C0039585,C0948008","AIS , Ischemic stroke",04/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Catherine Amlie-Lefond, MD|University of Washington|4800 Sand Point Way NE - M/S B5552|Seattle|Washington|98105|United States"
404772984,404772984,Zenocutuzumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,07/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Merus N.V.|139 Main Street|Cambridge|Massachusetts|2142|United States
404720332,404720332,Zenocutuzumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,07/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Merus N.V.|139 Main Street|Cambridge|Massachusetts|2142|United States
381128193,381128193,Zenocutuzumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,07/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Merus N.V.|139 Main Street|Cambridge|Massachusetts|2142|United States
404770342,404770342,Catumaxomab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/09/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.|920 Winter Street|Waltham|Massachusetts|2451|United States"
178103957,178103957,Catumaxomab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/09/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.|920 Winter Street|Waltham|Massachusetts|2451|United States"
160698430,160698430,Catumaxomab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/09/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.|920 Winter Street|Waltham|Massachusetts|2451|United States"
135311383,135311383,Catumaxomab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/09/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.|920 Winter Street|Waltham|Massachusetts|2451|United States"
377483933,377483933,dinutuximab,Unituxin,Treatment of neuroblastoma,C0027819,Neuroblastoma,12/20/2010,Designated/Approved,,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy", 03/10/2015 , 03/10/2022 ,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy",United Therapeutics Corporation|55 TW Alexander Drive|Research Triangle Park|North Carolina|27709|United States
347910402,347910402,dinutuximab,Unituxin,Treatment of neuroblastoma,C0027819,Neuroblastoma,12/20/2010,Designated/Approved,,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy", 03/10/2015 , 03/10/2022 ,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy",United Therapeutics Corporation|55 TW Alexander Drive|Research Triangle Park|North Carolina|27709|United States
249565662,249565662,dinutuximab,Unituxin,Treatment of neuroblastoma,C0027819,Neuroblastoma,12/20/2010,Designated/Approved,,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy", 03/10/2015 , 03/10/2022 ,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy",United Therapeutics Corporation|55 TW Alexander Drive|Research Triangle Park|North Carolina|27709|United States
194168552,194168552,dinutuximab,Unituxin,Treatment of neuroblastoma,C0027819,Neuroblastoma,12/20/2010,Designated/Approved,,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy", 03/10/2015 , 03/10/2022 ,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy",United Therapeutics Corporation|55 TW Alexander Drive|Research Triangle Park|North Carolina|27709|United States
160687724,160687724,dinutuximab,Unituxin,Treatment of neuroblastoma,C0027819,Neuroblastoma,12/20/2010,Designated/Approved,,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy", 03/10/2015 , 03/10/2022 ,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy",United Therapeutics Corporation|55 TW Alexander Drive|Research Triangle Park|North Carolina|27709|United States
103771409,103771409,interleukin-1 receptor antagonist anakinra,,Treatment of Still's disease including systemic juvenile idiopathic arithritis and adult-onset Still's disease.,"C0085253,C0087031","Adult-Onset Still's Disease , Still's disease",09/15/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB|SE-112|75 Stockholm|Stockholm|Sweden
46507944,46507944,interleukin-1 receptor antagonist anakinra,,Treatment of Still's disease including systemic juvenile idiopathic arithritis and adult-onset Still's disease.,"C0085253,C0087031","Adult-Onset Still's Disease , Still's disease",09/15/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB|SE-112|75 Stockholm|Stockholm|Sweden
526933,526933,liposomal annamycin,,Treatment of acute myeloid leukemia.,C0023467,Acute myeloid leukemia,03/20/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Moleculin Biotech, Inc.|2575 West Bellfort Avenue|Suite 333|Houston|Texas|77054|United States"
404770141,404770141,nimotuzumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,09/08/2015,Designated,Not FDA Approved for Orphan Indication,,,,,InnoCIMab Pte Ltd|21 Bukit Batok Crescent|WCEGA Tower #14-78|Singapore
349341271,349341271,nimotuzumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,09/08/2015,Designated,Not FDA Approved for Orphan Indication,,,,,InnoCIMab Pte Ltd|21 Bukit Batok Crescent|WCEGA Tower #14-78|Singapore
249565669,249565669,nimotuzumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,09/08/2015,Designated,Not FDA Approved for Orphan Indication,,,,,InnoCIMab Pte Ltd|21 Bukit Batok Crescent|WCEGA Tower #14-78|Singapore
160698394,160698394,nimotuzumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,09/08/2015,Designated,Not FDA Approved for Orphan Indication,,,,,InnoCIMab Pte Ltd|21 Bukit Batok Crescent|WCEGA Tower #14-78|Singapore
135356483,135356483,nimotuzumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,09/08/2015,Designated,Not FDA Approved for Orphan Indication,,,,,InnoCIMab Pte Ltd|21 Bukit Batok Crescent|WCEGA Tower #14-78|Singapore
405243250,405243250,retifanlimab,,Treatment of anal cancer,C0279637,Anal Cancer,03/24/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States
404720524,404720524,retifanlimab,,Treatment of anal cancer,C0279637,Anal Cancer,03/24/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States
440790931,440790931,sargramostim,Leukine,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.","C0027947,C1262018","Neutropenia , Graft failure",05/03/1990,Designated/Approved,,, 03/05/1991 , 03/05/1998 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
312856261,312856261,sargramostim,Leukine,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.","C0027947,C1262018","Neutropenia , Graft failure",05/03/1990,Designated/Approved,,, 03/05/1991 , 03/05/1998 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
249565588,249565588,sargramostim,Leukine,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.","C0027947,C1262018","Neutropenia , Graft failure",05/03/1990,Designated/Approved,,, 03/05/1991 , 03/05/1998 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
135360419,135360419,sargramostim,Leukine,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.","C0027947,C1262018","Neutropenia , Graft failure",05/03/1990,Designated/Approved,,, 03/05/1991 , 03/05/1998 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
135307693,135307693,sargramostim,Leukine,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.","C0027947,C1262018","Neutropenia , Graft failure",05/03/1990,Designated/Approved,,, 03/05/1991 , 03/05/1998 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
103771401,103771401,sargramostim,Leukine,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.","C0027947,C1262018","Neutropenia , Graft failure",05/03/1990,Designated/Approved,,, 03/05/1991 , 03/05/1998 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
50070152,50070152,sargramostim,Leukine,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.","C0027947,C1262018","Neutropenia , Graft failure",05/03/1990,Designated/Approved,,, 03/05/1991 , 03/05/1998 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
46507000,46507000,sargramostim,Leukine,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.","C0027947,C1262018","Neutropenia , Graft failure",05/03/1990,Designated/Approved,,, 03/05/1991 , 03/05/1998 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
793506,793506,sargramostim,Leukine,"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.","C0027947,C1262018","Neutropenia , Graft failure",05/03/1990,Designated/Approved,,, 03/05/1991 , 03/05/1998 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
381126528,381126528,sirukumab,,Treatment of juvenile idiopathic arthritis (JIA) in pediatric patients,"C3495559,C3714757","juvenile idiopathic arthritis , Juvenile idiopathic arthritis",07/03/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
347911243,347911243,sirukumab,,Treatment of juvenile idiopathic arthritis (JIA) in pediatric patients,"C3495559,C3714757","juvenile idiopathic arthritis , Juvenile idiopathic arthritis",07/03/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
249565670,249565670,sirukumab,,Treatment of juvenile idiopathic arthritis (JIA) in pediatric patients,"C3495559,C3714757","juvenile idiopathic arthritis , Juvenile idiopathic arthritis",07/03/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
160698800,160698800,sirukumab,,Treatment of juvenile idiopathic arthritis (JIA) in pediatric patients,"C3495559,C3714757","juvenile idiopathic arthritis , Juvenile idiopathic arthritis",07/03/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
347910376,347910376,brentuximab vedotin,,"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified",C0079774,"Peripheral T-Cell Lymphoma, Not Otherwise Specified",04/15/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
329976977,329976977,brentuximab vedotin,,"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified",C0079774,"Peripheral T-Cell Lymphoma, Not Otherwise Specified",04/15/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
178103378,178103378,brentuximab vedotin,,"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified",C0079774,"Peripheral T-Cell Lymphoma, Not Otherwise Specified",04/15/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135300399,135300399,brentuximab vedotin,,"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified",C0079774,"Peripheral T-Cell Lymphoma, Not Otherwise Specified",04/15/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
131277422,131277422,brentuximab vedotin,,"Treatment of patients with peripheral T-cell lymphoma, not otherwise specified",C0079774,"Peripheral T-Cell Lymphoma, Not Otherwise Specified",04/15/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
347911436,347911436,Coagulation Factor IX (human),AlphaNine,"For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.",C0008533,Hemophilia B,07/05/1990,Designated/Approved,,, 12/31/1990 , 12/31/1997 ,,Alpha Therapeutic Corporation|5555 Valley Boulevard|Los Angeles|California|90032|United States
440790757,440790757,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
404609547,404609547,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
387060186,387060186,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
354355052,354355052,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
329976982,329976982,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
178103466,178103466,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
135288438,135288438,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
103771526,103771526,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
50070199,50070199,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
46505429,46505429,eculizumab,Soliris,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,06/12/2014,Designated/Approved,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive, 10/23/2017 , 10/23/2024 ,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
404772847,404772847,human coagulation factor XI,,Treatment of congenital factor XI deficiency,C0015523,Congenital factor XI deficiency,02/15/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bio Products Laboratory Limited|Dagger Lane|Elstree|Hertfordshire|United Kingdom
135324553,135324553,Immune Globulin (Human),Gamunex-C,Treatment of chronic inflammatory demyelinating polyneuropathy,C0393819,Chronic inflammatory demyelinating polyneuropathy,07/27/2004,Designated/Approved,,Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse, 09/12/2008 , 09/12/2015 ,,"Grifols Therapeutics, Inc.|8368 US 70 Busines Hwy West|Clayton|North Carolina|27520|United States"
103771318,103771318,Immune Globulin (Human),Gamunex-C,Treatment of chronic inflammatory demyelinating polyneuropathy,C0393819,Chronic inflammatory demyelinating polyneuropathy,07/27/2004,Designated/Approved,,Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse, 09/12/2008 , 09/12/2015 ,,"Grifols Therapeutics, Inc.|8368 US 70 Busines Hwy West|Clayton|North Carolina|27520|United States"
46508774,46508774,Immune Globulin (Human),Gamunex-C,Treatment of chronic inflammatory demyelinating polyneuropathy,C0393819,Chronic inflammatory demyelinating polyneuropathy,07/27/2004,Designated/Approved,,Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse, 09/12/2008 , 09/12/2015 ,,"Grifols Therapeutics, Inc.|8368 US 70 Busines Hwy West|Clayton|North Carolina|27520|United States"
318161374,318161374,irinotecan liposome injection,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,05/24/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Bioscience, Inc.|650 East Kendall Street|Cambridge|Massachusetts|2142|United States"
440790931,440790931,sargramostim,,Treatment of pulmonary alveolar proteinosis (PAP).,C0034050,Pulmonary Alveolar Proteinosis,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
312856261,312856261,sargramostim,,Treatment of pulmonary alveolar proteinosis (PAP).,C0034050,Pulmonary Alveolar Proteinosis,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
249565588,249565588,sargramostim,,Treatment of pulmonary alveolar proteinosis (PAP).,C0034050,Pulmonary Alveolar Proteinosis,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
135360419,135360419,sargramostim,,Treatment of pulmonary alveolar proteinosis (PAP).,C0034050,Pulmonary Alveolar Proteinosis,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
135307693,135307693,sargramostim,,Treatment of pulmonary alveolar proteinosis (PAP).,C0034050,Pulmonary Alveolar Proteinosis,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
103771401,103771401,sargramostim,,Treatment of pulmonary alveolar proteinosis (PAP).,C0034050,Pulmonary Alveolar Proteinosis,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
50070152,50070152,sargramostim,,Treatment of pulmonary alveolar proteinosis (PAP).,C0034050,Pulmonary Alveolar Proteinosis,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
46507000,46507000,sargramostim,,Treatment of pulmonary alveolar proteinosis (PAP).,C0034050,Pulmonary Alveolar Proteinosis,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
793506,793506,sargramostim,,Treatment of pulmonary alveolar proteinosis (PAP).,C0034050,Pulmonary Alveolar Proteinosis,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
347910428,347910428,technetium Tc 99m tilmanocept,LYMPHOSEEK,"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck","C0278996,C0677944","Cancer of the Head and Neck , sentinel lymph node",09/17/2014,Designated/Approved,,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.", 06/13/2014 , 06/13/2021 ,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.","Cardinal Health 414, LLC|7200 Cardinal Pl|Dublin|Ohio|43017|United States"
223370389,223370389,technetium Tc 99m tilmanocept,LYMPHOSEEK,"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck","C0278996,C0677944","Cancer of the Head and Neck , sentinel lymph node",09/17/2014,Designated/Approved,,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.", 06/13/2014 , 06/13/2021 ,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.","Cardinal Health 414, LLC|7200 Cardinal Pl|Dublin|Ohio|43017|United States"
160703849,160703849,technetium Tc 99m tilmanocept,LYMPHOSEEK,"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck","C0278996,C0677944","Cancer of the Head and Neck , sentinel lymph node",09/17/2014,Designated/Approved,,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.", 06/13/2014 , 06/13/2021 ,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.","Cardinal Health 414, LLC|7200 Cardinal Pl|Dublin|Ohio|43017|United States"
135282346,135282346,technetium Tc 99m tilmanocept,LYMPHOSEEK,"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck","C0278996,C0677944","Cancer of the Head and Neck , sentinel lymph node",09/17/2014,Designated/Approved,,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.", 06/13/2014 , 06/13/2021 ,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.","Cardinal Health 414, LLC|7200 Cardinal Pl|Dublin|Ohio|43017|United States"
46505696,46505696,Thyrotropin alpha,Thyrogen,As an adjunct in the diagnosis of thyroid cancer.,C0040136,Thyroid cancer,02/24/1992,Designated/Approved,,As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer., 11/30/1998 , 11/30/2005 ,,Genzyme Corporation|One Kendall Square|Cambridge|Massachusetts|2139|United States
349938425,349938425,Butyrylcholinesterase,,Treatment of post-surgical apnea.,C0003578,Apnea,09/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
160723270,160723270,Butyrylcholinesterase,,Treatment of post-surgical apnea.,C0003578,Apnea,09/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
160723259,160723259,Butyrylcholinesterase,,Treatment of post-surgical apnea.,C0003578,Apnea,09/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
160723249,160723249,Butyrylcholinesterase,,Treatment of post-surgical apnea.,C0003578,Apnea,09/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
135354302,135354302,Butyrylcholinesterase,,Treatment of post-surgical apnea.,C0003578,Apnea,09/30/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
347910351,347910351,calfactant,Infasurf,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,C1145670,Respiratory Failure,06/07/1985,Designated/Approved,,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants., 07/01/1998 ,,,ONY Biotech Inc.|1576 Sweet Home Road|Amherst|New York|14228|United States
135339209,135339209,calfactant,Infasurf,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,C1145670,Respiratory Failure,06/07/1985,Designated/Approved,,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants., 07/01/1998 ,,,ONY Biotech Inc.|1576 Sweet Home Road|Amherst|New York|14228|United States
103771275,103771275,calfactant,Infasurf,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,C1145670,Respiratory Failure,06/07/1985,Designated/Approved,,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants., 07/01/1998 ,,,ONY Biotech Inc.|1576 Sweet Home Road|Amherst|New York|14228|United States
85756499,85756499,calfactant,Infasurf,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,C1145670,Respiratory Failure,06/07/1985,Designated/Approved,,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants., 07/01/1998 ,,,ONY Biotech Inc.|1576 Sweet Home Road|Amherst|New York|14228|United States
50070188,50070188,calfactant,Infasurf,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,C1145670,Respiratory Failure,06/07/1985,Designated/Approved,,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants., 07/01/1998 ,,,ONY Biotech Inc.|1576 Sweet Home Road|Amherst|New York|14228|United States
347910398,347910398,metreleptin,,Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy,"C0023787,C4317112","Lipodystrophy , Generalized Lipodystrophy",08/22/2001,Designated,Not FDA Approved for Orphan Indication,,,,,Amryt Pharmaceuticals DAC|45 Mespil Road|Dublin|4|Ireland
178103905,178103905,metreleptin,,Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy,"C0023787,C4317112","Lipodystrophy , Generalized Lipodystrophy",08/22/2001,Designated,Not FDA Approved for Orphan Indication,,,,,Amryt Pharmaceuticals DAC|45 Mespil Road|Dublin|4|Ireland
160676886,160676886,metreleptin,,Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy,"C0023787,C4317112","Lipodystrophy , Generalized Lipodystrophy",08/22/2001,Designated,Not FDA Approved for Orphan Indication,,,,,Amryt Pharmaceuticals DAC|45 Mespil Road|Dublin|4|Ireland
135303712,135303712,metreleptin,,Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy,"C0023787,C4317112","Lipodystrophy , Generalized Lipodystrophy",08/22/2001,Designated,Not FDA Approved for Orphan Indication,,,,,Amryt Pharmaceuticals DAC|45 Mespil Road|Dublin|4|Ireland
162221917,162221917,monosialotetrahexosylganglioside,,Treatment of Huntingtons Disease,C0020179,huntingtons disease,08/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Qilu Pharmaceutical Co., Ltd.|243 Gong Ye Bei Road Jinan|Shandong|China"
347911185,347911185,Protein C concentrate,,For replacement therapy in patients with congenital or acquired protein C deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.,C0398625,Protein C Deficiency,06/19/1992,Designated,Not FDA Approved for Orphan Indication,,,,,"Immuno Clinical Research Corp.|750 Lexington Avenue, 19th Floor|New York|New York|10022|United States"
404772440,404772440,sutimlimab,,Treatment of autoimmune hemolytic anemia (AIHA),C0002880,Autoimmune hemolytic anemia,07/27/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Bioverativ USA, Inc.|951 Gateway Boulevard|South San Francisco|California|94080|United States"
404719623,404719623,sutimlimab,,Treatment of autoimmune hemolytic anemia (AIHA),C0002880,Autoimmune hemolytic anemia,07/27/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Bioverativ USA, Inc.|951 Gateway Boulevard|South San Francisco|California|94080|United States"
381608744,381608744,sutimlimab,,Treatment of autoimmune hemolytic anemia (AIHA),C0002880,Autoimmune hemolytic anemia,07/27/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Bioverativ USA, Inc.|951 Gateway Boulevard|South San Francisco|California|94080|United States"
354702279,354702279,sutimlimab,,Treatment of autoimmune hemolytic anemia (AIHA),C0002880,Autoimmune hemolytic anemia,07/27/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Bioverativ USA, Inc.|951 Gateway Boulevard|South San Francisco|California|94080|United States"
347911228,347911228,vonapanitase,,Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis,"C0003855,C1262018,C1561643,C4553188","Arteriovenous fistula , Graft failure , Chronic Kidney Disease , Chronic kidney disease",04/03/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Proteon Therapeutics, Inc.|200 West Street|Waltham|Massachusetts|2451|United States"
312467920,312467920,vonapanitase,,Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis,"C0003855,C1262018,C1561643,C4553188","Arteriovenous fistula , Graft failure , Chronic Kidney Disease , Chronic kidney disease",04/03/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Proteon Therapeutics, Inc.|200 West Street|Waltham|Massachusetts|2451|United States"
249807668,249807668,vonapanitase,,Prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (CKD) who are receiving hemodialysis or preparing for hemodialysis,"C0003855,C1262018,C1561643,C4553188","Arteriovenous fistula , Graft failure , Chronic Kidney Disease , Chronic kidney disease",04/03/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Proteon Therapeutics, Inc.|200 West Street|Waltham|Massachusetts|2451|United States"
440790483,440790483,canakinumab,Ilaris,Treatment of TNF-receptor associated periodic syndrome (TRAPS),"C0585274,C1275126","Periodic syndrome , TRAPS",09/04/2012,Designated/Approved,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124993,381124993,canakinumab,Ilaris,Treatment of TNF-receptor associated periodic syndrome (TRAPS),"C0585274,C1275126","Periodic syndrome , TRAPS",09/04/2012,Designated/Approved,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124992,381124992,canakinumab,Ilaris,Treatment of TNF-receptor associated periodic syndrome (TRAPS),"C0585274,C1275126","Periodic syndrome , TRAPS",09/04/2012,Designated/Approved,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910340,347910340,canakinumab,Ilaris,Treatment of TNF-receptor associated periodic syndrome (TRAPS),"C0585274,C1275126","Periodic syndrome , TRAPS",09/04/2012,Designated/Approved,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
329976978,329976978,canakinumab,Ilaris,Treatment of TNF-receptor associated periodic syndrome (TRAPS),"C0585274,C1275126","Periodic syndrome , TRAPS",09/04/2012,Designated/Approved,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
178103379,178103379,canakinumab,Ilaris,Treatment of TNF-receptor associated periodic syndrome (TRAPS),"C0585274,C1275126","Periodic syndrome , TRAPS",09/04/2012,Designated/Approved,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
135332926,135332926,canakinumab,Ilaris,Treatment of TNF-receptor associated periodic syndrome (TRAPS),"C0585274,C1275126","Periodic syndrome , TRAPS",09/04/2012,Designated/Approved,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
103771532,103771532,canakinumab,Ilaris,Treatment of TNF-receptor associated periodic syndrome (TRAPS),"C0585274,C1275126","Periodic syndrome , TRAPS",09/04/2012,Designated/Approved,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
440806798,440806798,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma wh", 05/07/2018 , 05/07/2025 ,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
387060189,387060189,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma wh", 05/07/2018 , 05/07/2025 ,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
354355058,354355058,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma wh", 05/07/2018 , 05/07/2025 ,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
347910441,347910441,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma wh", 05/07/2018 , 05/07/2025 ,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
178103967,178103967,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma wh", 05/07/2018 , 05/07/2025 ,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
160671954,160671954,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma wh", 05/07/2018 , 05/07/2025 ,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
135304352,135304352,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma wh", 05/07/2018 , 05/07/2025 ,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
385327558,385327558,durvalumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
384647100,384647100,durvalumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
381127393,381127393,durvalumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
347911229,347911229,durvalumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
249565666,249565666,durvalumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
242651787,242651787,durvalumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
441076314,441076314,elosulfase alfa,Vimizim,Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome),"C0026703,C0086651","Mucopolysaccharidosis , Morquio A syndrome",05/15/2009,Designated/Approved,,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome), 02/14/2014 , 02/14/2021 ,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome),BioMarin Pharmaceutical Inc.|105 Digital Drive|Novato|California|94949|United States
347910399,347910399,elosulfase alfa,Vimizim,Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome),"C0026703,C0086651","Mucopolysaccharidosis , Morquio A syndrome",05/15/2009,Designated/Approved,,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome), 02/14/2014 , 02/14/2021 ,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome),BioMarin Pharmaceutical Inc.|105 Digital Drive|Novato|California|94949|United States
178103964,178103964,elosulfase alfa,Vimizim,Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome),"C0026703,C0086651","Mucopolysaccharidosis , Morquio A syndrome",05/15/2009,Designated/Approved,,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome), 02/14/2014 , 02/14/2021 ,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome),BioMarin Pharmaceutical Inc.|105 Digital Drive|Novato|California|94949|United States
160703842,160703842,elosulfase alfa,Vimizim,Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome),"C0026703,C0086651","Mucopolysaccharidosis , Morquio A syndrome",05/15/2009,Designated/Approved,,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome), 02/14/2014 , 02/14/2021 ,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome),BioMarin Pharmaceutical Inc.|105 Digital Drive|Novato|California|94949|United States
135291291,135291291,elosulfase alfa,Vimizim,Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome),"C0026703,C0086651","Mucopolysaccharidosis , Morquio A syndrome",05/15/2009,Designated/Approved,,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome), 02/14/2014 , 02/14/2021 ,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome),BioMarin Pharmaceutical Inc.|105 Digital Drive|Novato|California|94949|United States
441078173,441078173,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
440791125,440791125,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
349583301,349583301,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
283537479,283537479,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
178103548,178103548,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
135320862,135320862,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
134221887,134221887,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
103771266,103771266,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
49955776,49955776,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
46505833,46505833,Filgrastim,Neupogen,Treatment of neutropenia associated with bone marrow transplants.,C0027947,Neutropenia,10/01/1990,Designated/Approved,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT., 06/15/1994 , 06/15/2001 ,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
404720347,404720347,lumasiran,Oxlumo,Treatment of primary hyperoxaluria type 1,C1412290,primary hyperoxaluria type 1,02/08/2016,Designated/Approved,,treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients, 11/23/2020 , 11/23/2027 ,treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients,"Alnylam Pharmaceuticals, Inc.|300 Third Street|Cambridge|Massachusetts|2142|United States"
381128099,381128099,lumasiran,Oxlumo,Treatment of primary hyperoxaluria type 1,C1412290,primary hyperoxaluria type 1,02/08/2016,Designated/Approved,,treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients, 11/23/2020 , 11/23/2027 ,treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients,"Alnylam Pharmaceuticals, Inc.|300 Third Street|Cambridge|Massachusetts|2142|United States"
354355057,354355057,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)., 06/06/2019 ,,,GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
347910353,347910353,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)., 06/06/2019 ,,,GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
223366020,223366020,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)., 06/06/2019 ,,,GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
160682290,160682290,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)., 06/06/2019 ,,,GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
135278932,135278932,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)., 06/06/2019 ,,,GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
76206305,76206305,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)., 06/06/2019 ,,,GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
377017834,377017834,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)., 06/06/2019 ,,,GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
349977836,349977836,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)., 06/06/2019 ,,,GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
404617350,404617350,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
375758272,375758272,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
348744312,348744312,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
335987561,335987561,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
319299707,319299707,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
313077795,313077795,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
254775499,254775499,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
135023114,135023114,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
134979644,134979644,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
134222261,134222261,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
103771260,103771260,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
49992424,49992424,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
438485410,438485410,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
434303155,434303155,pentosan polysulfate sodium,,Treatment of mucopolysaccharidosis (MPS) type VI,C0026703,Mucopolysaccharidosis,01/05/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Paradigm Biopharmaceuticals Ltd.|Level 15, 500 Collins Street|Melbourne|Victoria|Australia"
404770733,404770733,Ravulizumab-cwvz,ULTOMIRIS,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,01/04/2017,Designated/Approved,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)., 12/21/2018 , 12/21/2025 ,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,"ALEXION PHARMACEUTICALS, INC.|121 SEAPORT BLVD|Boston|Massachusetts|2210|United States"
381118878,381118878,Ravulizumab-cwvz,ULTOMIRIS,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,01/04/2017,Designated/Approved,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)., 12/21/2018 , 12/21/2025 ,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,"ALEXION PHARMACEUTICALS, INC.|121 SEAPORT BLVD|Boston|Massachusetts|2210|United States"
374364184,374364184,Ravulizumab-cwvz,ULTOMIRIS,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,01/04/2017,Designated/Approved,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)., 12/21/2018 , 12/21/2025 ,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,"ALEXION PHARMACEUTICALS, INC.|121 SEAPORT BLVD|Boston|Massachusetts|2210|United States"
440790931,440790931,sargramostim,,Treatment of Stage IIb-IV melanoma,C0025202,melanoma,08/08/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
312856261,312856261,sargramostim,,Treatment of Stage IIb-IV melanoma,C0025202,melanoma,08/08/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
249565588,249565588,sargramostim,,Treatment of Stage IIb-IV melanoma,C0025202,melanoma,08/08/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
135360419,135360419,sargramostim,,Treatment of Stage IIb-IV melanoma,C0025202,melanoma,08/08/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
135307693,135307693,sargramostim,,Treatment of Stage IIb-IV melanoma,C0025202,melanoma,08/08/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
103771401,103771401,sargramostim,,Treatment of Stage IIb-IV melanoma,C0025202,melanoma,08/08/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
50070152,50070152,sargramostim,,Treatment of Stage IIb-IV melanoma,C0025202,melanoma,08/08/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
46507000,46507000,sargramostim,,Treatment of Stage IIb-IV melanoma,C0025202,melanoma,08/08/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
793506,793506,sargramostim,,Treatment of Stage IIb-IV melanoma,C0025202,melanoma,08/08/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
347910350,347910350,C1 esterase inhibitor (human),Cinryze(r),Treatment of angioedema,C0002994,Angioedema,07/16/2004,Designated/Approved,,Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE), 10/10/2008 , 10/10/2015 ,,"ViroPharma Biologics, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
333495402,333495402,C1 esterase inhibitor (human),Cinryze(r),Treatment of angioedema,C0002994,Angioedema,07/16/2004,Designated/Approved,,Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE), 10/10/2008 , 10/10/2015 ,,"ViroPharma Biologics, Inc.|300 Shire Way|Lexington|Massachusetts|2421|United States"
347911406,347911406,factor XIII concentrate (human),Corifact,Treatment of congenital factor XIII deficiency,C4316906,Factor XIII deficiency,01/16/1985,Designated/Approved,,Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency., 01/24/2013 , 01/24/2020 ,Peri-operative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency.,CSL Behring LLC|1020 First Ave.|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
135278070,135278070,factor XIII concentrate (human),Corifact,Treatment of congenital factor XIII deficiency,C4316906,Factor XIII deficiency,01/16/1985,Designated/Approved,,Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency., 01/24/2013 , 01/24/2020 ,Peri-operative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency.,CSL Behring LLC|1020 First Ave.|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
441078173,441078173,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
440791125,440791125,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
349583301,349583301,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
283537479,283537479,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
178103548,178103548,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
135320862,135320862,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
134221887,134221887,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
103771266,103771266,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
49955776,49955776,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
46505833,46505833,Filgrastim,,"Treatment of patients with AIDS who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir","C0001175,C0206178","AIDS , Cytomegalovirus Retinitis",09/03/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
441078173,441078173,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
440791125,440791125,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
349583301,349583301,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
283537479,283537479,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
178103548,178103548,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
135320862,135320862,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
134221887,134221887,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
103771266,103771266,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
49955776,49955776,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
46505833,46505833,Filgrastim,,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,08/30/1990,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|1840 Dehavilland Drive|Thousand Oaks|California|91320|United States"
440809644,440809644,mogamulizumab,,Treatment of peripheral T-cell lymphoma.,C0079774,Peripheral T-Cell Lymphoma,11/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center #101|Princeton|New Jersey|8540|United States"
347911339,347911339,mogamulizumab,,Treatment of peripheral T-cell lymphoma.,C0079774,Peripheral T-Cell Lymphoma,11/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center #101|Princeton|New Jersey|8540|United States"
178103091,178103091,mogamulizumab,,Treatment of peripheral T-cell lymphoma.,C0079774,Peripheral T-Cell Lymphoma,11/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center #101|Princeton|New Jersey|8540|United States"
160704158,160704158,mogamulizumab,,Treatment of peripheral T-cell lymphoma.,C0079774,Peripheral T-Cell Lymphoma,11/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center #101|Princeton|New Jersey|8540|United States"
135317476,135317476,mogamulizumab,,Treatment of peripheral T-cell lymphoma.,C0079774,Peripheral T-Cell Lymphoma,11/02/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center #101|Princeton|New Jersey|8540|United States"
387061103,387061103,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.", 03/10/2020 ,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.", 03/10/2020 ,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.", 03/10/2020 ,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.", 03/10/2020 ,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.", 03/10/2020 ,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.", 03/10/2020 ,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.", 03/10/2020 ,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.", 03/10/2020 ,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.", 03/10/2020 ,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
135288879,135288879,Recombinant human insulin-like growth factor-I,,Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.,C0036992,SHORT-BOWEL SYNDROME,02/16/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"GroPep Pty Ltd.|Gate 11, Victoria Dr.|Adelaide SA 5000|Australia"
441072526,441072526,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
440790697,440790697,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
387061165,387061165,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
350080043,350080043,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
348480209,348480209,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
329976976,329976976,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
178103377,178103377,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
135329020,135329020,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
103771315,103771315,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
50067187,50067187,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
46504473,46504473,bevacizumab,,Treatment of hereditary hemorrhagic telangiectasia,C0039445,hereditary hemorrhagic telangiectasia,10/21/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD|UCSD Medical Center|San Diego|California|92103|United States"
347910376,347910376,brentuximab vedotin,Adcetris,Treatment of mycosis fungoides,C0026948,Mycosis Fungoides,11/19/2012,Designated/Approved,,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
329976977,329976977,brentuximab vedotin,Adcetris,Treatment of mycosis fungoides,C0026948,Mycosis Fungoides,11/19/2012,Designated/Approved,,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
178103378,178103378,brentuximab vedotin,Adcetris,Treatment of mycosis fungoides,C0026948,Mycosis Fungoides,11/19/2012,Designated/Approved,,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
135300399,135300399,brentuximab vedotin,Adcetris,Treatment of mycosis fungoides,C0026948,Mycosis Fungoides,11/19/2012,Designated/Approved,,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
131277422,131277422,brentuximab vedotin,Adcetris,Treatment of mycosis fungoides,C0026948,Mycosis Fungoides,11/19/2012,Designated/Approved,,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
347911440,347911440,cerliponase alfa,Brineura,Treatment of neuronal ceroid lipofuscinosis type 2,C0022340,Neuronal Ceroid Lipofuscinosis Type 2,04/01/2013,Designated/Approved,,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.", 04/27/2017 , 04/27/2024 ,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.","BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
312467771,312467771,cerliponase alfa,Brineura,Treatment of neuronal ceroid lipofuscinosis type 2,C0022340,Neuronal Ceroid Lipofuscinosis Type 2,04/01/2013,Designated/Approved,,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.", 04/27/2017 , 04/27/2024 ,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.","BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
252089514,252089514,cerliponase alfa,Brineura,Treatment of neuronal ceroid lipofuscinosis type 2,C0022340,Neuronal Ceroid Lipofuscinosis Type 2,04/01/2013,Designated/Approved,,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.", 04/27/2017 , 04/27/2024 ,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.","BioMarin Pharmaceutical, Inc.|105 Digital Drive|Novato|California|94949|United States"
354742370,354742370,Cintredekin Besudotox,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
347910067,347910067,Cintredekin Besudotox,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
160676971,160676971,Cintredekin Besudotox,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
135338270,135338270,Cintredekin Besudotox,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
134222771,134222771,Cintredekin Besudotox,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
160763120,160763120,Coagulation factor IX,Mononine,Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.,"C0008533,C0009566","Hemophilia B , Complications",06/27/1989,Designated/Approved,,"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease.", 08/20/1992 , 08/20/1999 ,,"Armour Pharmaceutical Company|500 Arcola Road, P.O. Box 1200|Collegeville|Pennsylvania|19426|United States"
160763111,160763111,Coagulation factor IX,Mononine,Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.,"C0008533,C0009566","Hemophilia B , Complications",06/27/1989,Designated/Approved,,"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease.", 08/20/1992 , 08/20/1999 ,,"Armour Pharmaceutical Company|500 Arcola Road, P.O. Box 1200|Collegeville|Pennsylvania|19426|United States"
160763101,160763101,Coagulation factor IX,Mononine,Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.,"C0008533,C0009566","Hemophilia B , Complications",06/27/1989,Designated/Approved,,"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease.", 08/20/1992 , 08/20/1999 ,,"Armour Pharmaceutical Company|500 Arcola Road, P.O. Box 1200|Collegeville|Pennsylvania|19426|United States"
135341105,135341105,Coagulation factor IX,Mononine,Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.,"C0008533,C0009566","Hemophilia B , Complications",06/27/1989,Designated/Approved,,"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease.", 08/20/1992 , 08/20/1999 ,,"Armour Pharmaceutical Company|500 Arcola Road, P.O. Box 1200|Collegeville|Pennsylvania|19426|United States"
404858999,404858999,crizanlizumab,ADAKVEO,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,07/22/2008,Designated/Approved,,ADAKVEO is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease., 11/15/2019 , 11/15/2026 ,Indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Novartis Pharmaceuticals Corporation|One Health Plaza|Building 337 B11.3D|East Hanover|New Jersey|07936-|United States
404772703,404772703,crizanlizumab,ADAKVEO,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,07/22/2008,Designated/Approved,,ADAKVEO is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease., 11/15/2019 , 11/15/2026 ,Indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Novartis Pharmaceuticals Corporation|One Health Plaza|Building 337 B11.3D|East Hanover|New Jersey|07936-|United States
404719823,404719823,crizanlizumab,ADAKVEO,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,07/22/2008,Designated/Approved,,ADAKVEO is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease., 11/15/2019 , 11/15/2026 ,Indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Novartis Pharmaceuticals Corporation|One Health Plaza|Building 337 B11.3D|East Hanover|New Jersey|07936-|United States
381127936,381127936,crizanlizumab,ADAKVEO,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,07/22/2008,Designated/Approved,,ADAKVEO is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease., 11/15/2019 , 11/15/2026 ,Indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Novartis Pharmaceuticals Corporation|One Health Plaza|Building 337 B11.3D|East Hanover|New Jersey|07936-|United States
405268217,405268217,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
405258026,405258026,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
347909900,347909900,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
341843294,341843294,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
332862116,332862116,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
274115656,274115656,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
223443254,223443254,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
135652137,135652137,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
135266923,135266923,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
49869272,49869272,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
114798,114798,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
438649806,438649806,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
402346025,402346025,Duramycin,,Treatment of cystic fibrosis.,C0010674,Cystic Fibrosis,12/11/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.|100 Europa Drive|Suite 421|Chapel Hill|North Carolina|27517|United States"
404720054,404720054,efgartigimod,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,09/20/2017,Designated,Not FDA Approved for Orphan Indication,,,,,argenx BV|Industriepark Zwijnaarde 7|Zwijnaarde|9052|Belgium
347910184,347910184,farletuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/16/2006,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States
160698793,160698793,farletuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/16/2006,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States
135322590,135322590,farletuzumab,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,06/16/2006,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States
440790806,440790806,idursulfase,Elaprase,Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome),"C0026705,C1415882","Mucopolysaccharidosis II , Hunter syndrome",11/28/2001,Designated/Approved,,"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients", 07/24/2006 , 07/24/2013 ,,"Shire Human Genetic Therapies, Inc.|700 Main Street|Cambridge|Massachusetts|2139|United States"
135290376,135290376,idursulfase,Elaprase,Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome),"C0026705,C1415882","Mucopolysaccharidosis II , Hunter syndrome",11/28/2001,Designated/Approved,,"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients", 07/24/2006 , 07/24/2013 ,,"Shire Human Genetic Therapies, Inc.|700 Main Street|Cambridge|Massachusetts|2139|United States"
103771524,103771524,idursulfase,Elaprase,Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome),"C0026705,C1415882","Mucopolysaccharidosis II , Hunter syndrome",11/28/2001,Designated/Approved,,"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients", 07/24/2006 , 07/24/2013 ,,"Shire Human Genetic Therapies, Inc.|700 Main Street|Cambridge|Massachusetts|2139|United States"
50070138,50070138,idursulfase,Elaprase,Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome),"C0026705,C1415882","Mucopolysaccharidosis II , Hunter syndrome",11/28/2001,Designated/Approved,,"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients", 07/24/2006 , 07/24/2013 ,,"Shire Human Genetic Therapies, Inc.|700 Main Street|Cambridge|Massachusetts|2139|United States"
46507347,46507347,idursulfase,Elaprase,Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome),"C0026705,C1415882","Mucopolysaccharidosis II , Hunter syndrome",11/28/2001,Designated/Approved,,"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients", 07/24/2006 , 07/24/2013 ,,"Shire Human Genetic Therapies, Inc.|700 Main Street|Cambridge|Massachusetts|2139|United States"
381128080,381128080,Nadofaragene firadenovec,,Treatment of malignant mesothelioma,C0345967,Malignant mesothelioma,07/07/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Trizell Ltd|Sanderum House|Oakley Road, Chinnor|Oxon|United Kingdom"
374364274,374364274,Nadofaragene firadenovec,,Treatment of malignant mesothelioma,C0345967,Malignant mesothelioma,07/07/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Trizell Ltd|Sanderum House|Oakley Road, Chinnor|Oxon|United Kingdom"
387061105,387061105,pembrolizumab,Keytruda,Treatment of esophageal carcinoma,C0152018,Esophageal carcinoma,06/15/2017,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.", 07/30/2019 , 07/30/2026 ,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
385327548,385327548,pembrolizumab,Keytruda,Treatment of esophageal carcinoma,C0152018,Esophageal carcinoma,06/15/2017,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.", 07/30/2019 , 07/30/2026 ,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
384647091,384647091,pembrolizumab,Keytruda,Treatment of esophageal carcinoma,C0152018,Esophageal carcinoma,06/15/2017,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.", 07/30/2019 , 07/30/2026 ,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
377483934,377483934,pembrolizumab,Keytruda,Treatment of esophageal carcinoma,C0152018,Esophageal carcinoma,06/15/2017,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.", 07/30/2019 , 07/30/2026 ,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
354355033,354355033,pembrolizumab,Keytruda,Treatment of esophageal carcinoma,C0152018,Esophageal carcinoma,06/15/2017,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.", 07/30/2019 , 07/30/2026 ,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
347910395,347910395,pembrolizumab,Keytruda,Treatment of esophageal carcinoma,C0152018,Esophageal carcinoma,06/15/2017,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.", 07/30/2019 , 07/30/2026 ,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
194140938,194140938,pembrolizumab,Keytruda,Treatment of esophageal carcinoma,C0152018,Esophageal carcinoma,06/15/2017,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.", 07/30/2019 , 07/30/2026 ,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
187051801,187051801,pembrolizumab,Keytruda,Treatment of esophageal carcinoma,C0152018,Esophageal carcinoma,06/15/2017,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.", 07/30/2019 , 07/30/2026 ,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc.|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
160687594,160687594,priliximab,,Treatment of mycosis fungoides (MF),C0026948,Mycosis Fungoides,09/18/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Onco Therapies, Inc.|2265 East Foothill Boulevard|Pasadena|California|91107|United States"
135291776,135291776,priliximab,,Treatment of mycosis fungoides (MF),C0026948,Mycosis Fungoides,09/18/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Onco Therapies, Inc.|2265 East Foothill Boulevard|Pasadena|California|91107|United States"
404772201,404772201,rhIGF-I/rhIGFBP-3,,"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)","C0265344,C0271695,C4313258","Leprechaunism , Rabson-Mendenhall Syndrome , Extreme insulin resistance",12/09/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States"
135325697,135325697,rhIGF-I/rhIGFBP-3,,"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)","C0265344,C0271695,C4313258","Leprechaunism , Rabson-Mendenhall Syndrome , Extreme insulin resistance",12/09/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States"
103771459,103771459,rhIGF-I/rhIGFBP-3,,"Treatment of extreme insulin resistance syndromes (type A, Rabson-Mendenhall syndrome, Leprechaunism, Type B syndrome)","C0265344,C0271695,C4313258","Leprechaunism , Rabson-Mendenhall Syndrome , Extreme insulin resistance",12/09/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.|10 Finderne Ave|Building 10|Bridgewater|New Jersey|8807|United States"
135289419,135289419,dornase alfa,,Treatment of sarcoidosis,C0036202,Sarcoidosis,06/04/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"SarcoMed USA, LLC|1300 Post Oak Boulevard|Suite 760|Houston|Texas|77056|United States"
103771402,103771402,dornase alfa,,Treatment of sarcoidosis,C0036202,Sarcoidosis,06/04/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"SarcoMed USA, LLC|1300 Post Oak Boulevard|Suite 760|Houston|Texas|77056|United States"
46507792,46507792,dornase alfa,,Treatment of sarcoidosis,C0036202,Sarcoidosis,06/04/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"SarcoMed USA, LLC|1300 Post Oak Boulevard|Suite 760|Houston|Texas|77056|United States"
440791136,440791136,golimumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,03/16/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
354355047,354355047,golimumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,03/16/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
349071996,349071996,golimumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,03/16/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
347910358,347910358,golimumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,03/16/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
329976985,329976985,golimumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,03/16/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
178103382,178103382,golimumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,03/16/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
135329319,135329319,golimumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,03/16/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
103771531,103771531,golimumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,03/16/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
381129145,381129145,ixmyelocel-T,,Treatment of dilated cardiomyopathy,C0007193,Dilated cardiomyopathy,01/25/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Vericel Corporation.|64 Sidney Street|Cambridge|Massachusetts|2139|United States
160687629,160687629,ixmyelocel-T,,Treatment of dilated cardiomyopathy,C0007193,Dilated cardiomyopathy,01/25/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Vericel Corporation.|64 Sidney Street|Cambridge|Massachusetts|2139|United States
387060193,387060193,ramucirumab,CYRAMZA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/04/2011,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.", 05/10/2019 , 05/10/2026 ,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
385327559,385327559,ramucirumab,CYRAMZA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/04/2011,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.", 05/10/2019 , 05/10/2026 ,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
384647101,384647101,ramucirumab,CYRAMZA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/04/2011,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.", 05/10/2019 , 05/10/2026 ,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
354355038,354355038,ramucirumab,CYRAMZA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/04/2011,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.", 05/10/2019 , 05/10/2026 ,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
347910183,347910183,ramucirumab,CYRAMZA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/04/2011,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.", 05/10/2019 , 05/10/2026 ,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
178103962,178103962,ramucirumab,CYRAMZA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/04/2011,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.", 05/10/2019 , 05/10/2026 ,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
160666631,160666631,ramucirumab,CYRAMZA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/04/2011,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.", 05/10/2019 , 05/10/2026 ,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
135285364,135285364,ramucirumab,CYRAMZA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/04/2011,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.", 05/10/2019 , 05/10/2026 ,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
131408697,131408697,ramucirumab,CYRAMZA,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,11/04/2011,Designated/Approved,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.", 05/10/2019 , 05/10/2026 ,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
404770733,404770733,RAVULIZUMAB,Ultomiris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,01/04/2017,Designated/Approved,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)., 10/09/2020 ,,,Alexion Pharmaceuticals Inc.|121 SEAPORT BLVD|BOSTON|Massachusetts|2210|United States
381128036,381128036,RAVULIZUMAB,Ultomiris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,01/04/2017,Designated/Approved,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)., 10/09/2020 ,,,Alexion Pharmaceuticals Inc.|121 SEAPORT BLVD|BOSTON|Massachusetts|2210|United States
381118878,381118878,RAVULIZUMAB,Ultomiris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,01/04/2017,Designated/Approved,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)., 10/09/2020 ,,,Alexion Pharmaceuticals Inc.|121 SEAPORT BLVD|BOSTON|Massachusetts|2210|United States
374364184,374364184,RAVULIZUMAB,Ultomiris,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,01/04/2017,Designated/Approved,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)., 10/09/2020 ,,,Alexion Pharmaceuticals Inc.|121 SEAPORT BLVD|BOSTON|Massachusetts|2210|United States
441072531,441072531,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061212,387061212,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385327556,385327556,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
384647099,384647099,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
365372203,365372203,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355036,354355036,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348838049,348838049,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976960,329976960,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319478935,319478935,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319435463,319435463,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103386,178103386,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135341754,135341754,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771410,103771410,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
57288666,57288666,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
56314417,56314417,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50070184,50070184,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46505820,46505820,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ), 04/19/2011 , 04/19/2018 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
404772306,404772306,tadekinig alfa,,Treatment of hemophagocytic lymphohistiocytosis,C0024291,Hemophagocytic lymphohistiocytosis,01/12/2017,Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd|EPFL Innovation Park|Building B|Lausanne|Vaud|Switzerland
375973264,375973264,tadekinig alfa,,Treatment of hemophagocytic lymphohistiocytosis,C0024291,Hemophagocytic lymphohistiocytosis,01/12/2017,Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd|EPFL Innovation Park|Building B|Lausanne|Vaud|Switzerland
160709043,160709043,tadekinig alfa,,Treatment of hemophagocytic lymphohistiocytosis,C0024291,Hemophagocytic lymphohistiocytosis,01/12/2017,Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd|EPFL Innovation Park|Building B|Lausanne|Vaud|Switzerland
135312030,135312030,tadekinig alfa,,Treatment of hemophagocytic lymphohistiocytosis,C0024291,Hemophagocytic lymphohistiocytosis,01/12/2017,Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd|EPFL Innovation Park|Building B|Lausanne|Vaud|Switzerland
381126722,381126722,blisibimod,,Treatment of patients with immunoglobulin A nephropathy,C0017661,Immunoglobulin A Nephropathy,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Anthera Pharmaceuticals, Inc.|25801 Industrial Boulevard|Suite B|Hayward|California|94545|United States"
347911316,347911316,blisibimod,,Treatment of patients with immunoglobulin A nephropathy,C0017661,Immunoglobulin A Nephropathy,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Anthera Pharmaceuticals, Inc.|25801 Industrial Boulevard|Suite B|Hayward|California|94545|United States"
336446905,336446905,blisibimod,,Treatment of patients with immunoglobulin A nephropathy,C0017661,Immunoglobulin A Nephropathy,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Anthera Pharmaceuticals, Inc.|25801 Industrial Boulevard|Suite B|Hayward|California|94545|United States"
160698348,160698348,blisibimod,,Treatment of patients with immunoglobulin A nephropathy,C0017661,Immunoglobulin A Nephropathy,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Anthera Pharmaceuticals, Inc.|25801 Industrial Boulevard|Suite B|Hayward|California|94545|United States"
404771481,404771481,burosumab-twza,Crysvita,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),"C0733682,C3536983,C3540852","X-Linked Hypophosphatemia , vitamin d-resistant rickets , X-Linked Hypophosphatemia",12/14/2009,Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older., 09/27/2019 , 09/27/2026 ,For the treatment of X-linked hypophosphatemia (XLH) in pediatric patients 6 months of age to less than 1 year of age,"Kyowa Kirin, Inc.|135 US Highway 202/206|Suite 6|Bedminster|New Jersey|7921|United States"
342581770,342581770,burosumab-twza,Crysvita,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),"C0733682,C3536983,C3540852","X-Linked Hypophosphatemia , vitamin d-resistant rickets , X-Linked Hypophosphatemia",12/14/2009,Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older., 09/27/2019 , 09/27/2026 ,For the treatment of X-linked hypophosphatemia (XLH) in pediatric patients 6 months of age to less than 1 year of age,"Kyowa Kirin, Inc.|135 US Highway 202/206|Suite 6|Bedminster|New Jersey|7921|United States"
318464563,318464563,burosumab-twza,Crysvita,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),"C0733682,C3536983,C3540852","X-Linked Hypophosphatemia , vitamin d-resistant rickets , X-Linked Hypophosphatemia",12/14/2009,Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older., 09/27/2019 , 09/27/2026 ,For the treatment of X-linked hypophosphatemia (XLH) in pediatric patients 6 months of age to less than 1 year of age,"Kyowa Kirin, Inc.|135 US Highway 202/206|Suite 6|Bedminster|New Jersey|7921|United States"
318164811,318164811,burosumab-twza,Crysvita,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),"C0733682,C3536983,C3540852","X-Linked Hypophosphatemia , vitamin d-resistant rickets , X-Linked Hypophosphatemia",12/14/2009,Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older., 09/27/2019 , 09/27/2026 ,For the treatment of X-linked hypophosphatemia (XLH) in pediatric patients 6 months of age to less than 1 year of age,"Kyowa Kirin, Inc.|135 US Highway 202/206|Suite 6|Bedminster|New Jersey|7921|United States"
440806798,440806798,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients", 09/26/2019 , 09/26/2026 ,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
387060189,387060189,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients", 09/26/2019 , 09/26/2026 ,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
354355058,354355058,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients", 09/26/2019 , 09/26/2026 ,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
347910441,347910441,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients", 09/26/2019 , 09/26/2026 ,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
178103967,178103967,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients", 09/26/2019 , 09/26/2026 ,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
160671954,160671954,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients", 09/26/2019 , 09/26/2026 ,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
135304352,135304352,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients", 09/26/2019 , 09/26/2026 ,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
347911285,347911285,gevokizumab,,"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis","C0042164,C0339317","Uveitis , Non-infectious anterior uveitis",08/20/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
178103966,178103966,gevokizumab,,"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis","C0042164,C0339317","Uveitis , Non-infectious anterior uveitis",08/20/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
160704155,160704155,gevokizumab,,"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis","C0042164,C0339317","Uveitis , Non-infectious anterior uveitis",08/20/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
135322326,135322326,gevokizumab,,"Treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis","C0042164,C0339317","Uveitis , Non-infectious anterior uveitis",08/20/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
440791136,440791136,golimumab,SIMPONI ARIA,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,C4521004,Polyarticular juvenile idiopathic arthritis,04/02/2015,Designated/Approved,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, 09/29/2020 , 09/29/2027 ,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
354355047,354355047,golimumab,SIMPONI ARIA,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,C4521004,Polyarticular juvenile idiopathic arthritis,04/02/2015,Designated/Approved,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, 09/29/2020 , 09/29/2027 ,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
349071996,349071996,golimumab,SIMPONI ARIA,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,C4521004,Polyarticular juvenile idiopathic arthritis,04/02/2015,Designated/Approved,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, 09/29/2020 , 09/29/2027 ,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
347910358,347910358,golimumab,SIMPONI ARIA,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,C4521004,Polyarticular juvenile idiopathic arthritis,04/02/2015,Designated/Approved,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, 09/29/2020 , 09/29/2027 ,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
329976985,329976985,golimumab,SIMPONI ARIA,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,C4521004,Polyarticular juvenile idiopathic arthritis,04/02/2015,Designated/Approved,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, 09/29/2020 , 09/29/2027 ,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
178103382,178103382,golimumab,SIMPONI ARIA,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,C4521004,Polyarticular juvenile idiopathic arthritis,04/02/2015,Designated/Approved,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, 09/29/2020 , 09/29/2027 ,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
135329319,135329319,golimumab,SIMPONI ARIA,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,C4521004,Polyarticular juvenile idiopathic arthritis,04/02/2015,Designated/Approved,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, 09/29/2020 , 09/29/2027 ,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
103771531,103771531,golimumab,SIMPONI ARIA,Treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,C4521004,Polyarticular juvenile idiopathic arthritis,04/02/2015,Designated/Approved,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, 09/29/2020 , 09/29/2027 ,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
440791025,440791025,interferon gamma-1b,,Treatment of Friedreich's Ataxia,C0016719,Friedreich's Ataxia,10/01/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
135032842,135032842,interferon gamma-1b,,Treatment of Friedreich's Ataxia,C0016719,Friedreich's Ataxia,10/01/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
103771226,103771226,interferon gamma-1b,,Treatment of Friedreich's Ataxia,C0016719,Friedreich's Ataxia,10/01/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
46507194,46507194,interferon gamma-1b,,Treatment of Friedreich's Ataxia,C0016719,Friedreich's Ataxia,10/01/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
441074980,441074980,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
404772311,404772311,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
178101682,178101682,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135326453,135326453,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135273161,135273161,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
134224740,134224740,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56314519,56314519,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56313513,56313513,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56313163,56313163,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56312547,56312547,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56312196,56312196,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311893,56311893,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311781,56311781,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311685,56311685,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56310774,56310774,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
7978489,7978489,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
7847813,7847813,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
10105,10105,Interleukin-2,,Treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,02/05/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
381125841,381125841,olipudase alfa,,Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease),"C0028064,C0268242","Sphingomyelinase deficiency , Sphingomyelinase Deficiency",08/03/2000,Designated,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation|55 Corporate Drive|Bridgewater|New Jersey|8807|United States
347911391,347911391,olipudase alfa,,Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease),"C0028064,C0268242","Sphingomyelinase deficiency , Sphingomyelinase Deficiency",08/03/2000,Designated,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation|55 Corporate Drive|Bridgewater|New Jersey|8807|United States
318464595,318464595,olipudase alfa,,Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease),"C0028064,C0268242","Sphingomyelinase deficiency , Sphingomyelinase Deficiency",08/03/2000,Designated,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation|55 Corporate Drive|Bridgewater|New Jersey|8807|United States
404770335,404770335,Pegylated arginine deiminase,,Treatment of invasive malignant melanoma.,C0025202,Malignant Melanoma,04/12/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.|A Polaris Group Company|Suite 106|San Diego|California|92121|United States"
384403250,384403250,Pegylated arginine deiminase,,Treatment of invasive malignant melanoma.,C0025202,Malignant Melanoma,04/12/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.|A Polaris Group Company|Suite 106|San Diego|California|92121|United States"
381127242,381127242,Pegylated arginine deiminase,,Treatment of invasive malignant melanoma.,C0025202,Malignant Melanoma,04/12/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.|A Polaris Group Company|Suite 106|San Diego|California|92121|United States"
347911188,347911188,prothrombin complex concentrate (human),Kcentra,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,C0019080,Bleeding,12/27/2012,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure.", 12/13/2013 , 12/13/2020 ,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure.",CSL Behring|1020 First Avenue|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
402356186,402356186,reslizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,01/12/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
402355848,402355848,reslizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,01/12/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
347910352,347910352,reslizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,01/12/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
249565771,249565771,reslizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,01/12/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
160703747,160703747,reslizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,01/12/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
135337118,135337118,reslizumab,,Treatment of hypereosinophilic syndrome,C1540912,Hypereosinophilic syndrome,01/12/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
404770341,404770341,teplizumab,,Treatment of recent-onset Type I diabetes,C0011854,Type I diabetes,09/29/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Provention Bio, Inc.|Box 666|Oldwick|New Jersey|8858|United States"
160687962,160687962,teplizumab,,Treatment of recent-onset Type I diabetes,C0011854,Type I diabetes,09/29/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Provention Bio, Inc.|Box 666|Oldwick|New Jersey|8858|United States"
135310211,135310211,teplizumab,,Treatment of recent-onset Type I diabetes,C0011854,Type I diabetes,09/29/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Provention Bio, Inc.|Box 666|Oldwick|New Jersey|8858|United States"
347910376,347910376,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
329976977,329976977,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
178103378,178103378,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
135300399,135300399,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
131277422,131277422,brentuximab vedotin,Adcetris,"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranod","C0020981,C0023493,C0079774,C0456889,C1332182","Angioimmunoblastic T-cell lymphoma , adult T-cell leukemia/lymphoma , Peripheral T-Cell Lymphoma , Enteropathy-Associated T-Cell Lymphoma , Anaplastic Large Cell Lymphoma",10/23/2008,Designated/Approved,,The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
404772881,404772881,cenersen,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,05/08/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
381125009,381125009,cenersen,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,05/08/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
349988829,349988829,cenersen,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,05/08/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
252166482,252166482,cenersen,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,05/08/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
160682274,160682274,cenersen,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,05/08/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
135263925,135263925,cenersen,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,05/08/2006,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
440806798,440806798,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy., 06/27/2019 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
387060189,387060189,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy., 06/27/2019 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
354355058,354355058,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy., 06/27/2019 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
347910441,347910441,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy., 06/27/2019 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
178103967,178103967,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy., 06/27/2019 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
160671954,160671954,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy., 06/27/2019 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
135304352,135304352,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy., 06/27/2019 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
441074439,441074439,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
440006193,440006193,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
438636670,438636670,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
438476893,438476893,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
419583074,419583074,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
419501053,419501053,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
406530486,406530486,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
405459531,405459531,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
404847608,404847608,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
404839854,404839854,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
387076541,387076541,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
384440600,384440600,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
384416753,384416753,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
377011928,377011928,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
376126324,376126324,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
375682001,375682001,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
375568326,375568326,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
375297311,375297311,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
374917833,374917833,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
374049617,374049617,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
369085978,369085978,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
363905011,363905011,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
349983001,349983001,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
348809085,348809085,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
348274889,348274889,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
347759355,347759355,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
346440377,346440377,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
341143161,341143161,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
336950928,336950928,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
319557413,319557413,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
318478007,318478007,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
318474007,318474007,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
318464479,318464479,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
312625063,312625063,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
273399544,273399544,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
255344532,255344532,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
250225584,250225584,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
249866519,249866519,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
223703108,223703108,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
162214346,162214346,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
162214212,162214212,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
160697751,160697751,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
135720455,135720455,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
134991990,134991990,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
103770645,103770645,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
85257013,85257013,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
85086573,85086573,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
85086572,85086572,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
56313452,56313452,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
56310857,56310857,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
56310834,56310834,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
56310644,56310644,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
50139225,50139225,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
49969817,49969817,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
49747627,49747627,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
49747626,49747626,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
46504761,46504761,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
853736,853736,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
841130,841130,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
598147,598147,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
556635,556635,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
541164,541164,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
8987,8987,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
376241476,376241476,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
127294178,127294178,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
127294177,127294177,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
127294176,127294176,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
127294175,127294175,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
127294174,127294174,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
127294173,127294173,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
438518468,438518468,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
438459028,438459028,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
434252965,434252965,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
433705116,433705116,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
405109240,405109240,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
404620137,404620137,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
387076540,387076540,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
386623978,386623978,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
385786934,385786934,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
319454761,319454761,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
319359663,319359663,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
319225729,319225729,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
87570469,87570469,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
80846931,80846931,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
53790706,53790706,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
601950,601950,Hemin,Panhematin,"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria.","C0162531,C0162532,C0162565,C1279945,C1457887","Hereditary Coproporphyria , Porphyria Variegata , Acute intermittent porphyria , AIP , Symptoms",03/16/1984,Designated/Approved,,, 07/20/1983 , 07/20/1990 ,,Abbott Laboratories|Diagnostics Division|Abbott Park|Illinois|60064|United States
96025483,96025483,human haptoglobin,,Treatment of sickle cell disease,C0002895,Sickle Cell Disease,11/19/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"BioProducts Laboratory Limited|Dagger Lane, Elstree|Herts|United Kingdom"
387065620,387065620,Luspatercept,REBLOZYL,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,03/18/2013,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)., 04/03/2020 , 04/03/2027 ,For the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS),Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
381127153,381127153,Luspatercept,REBLOZYL,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,03/18/2013,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)., 04/03/2020 , 04/03/2027 ,For the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS),Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
347911311,347911311,Luspatercept,REBLOZYL,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,03/18/2013,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)., 04/03/2020 , 04/03/2027 ,For the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS),Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
174494664,174494664,Luspatercept,REBLOZYL,Treatment of myelodysplastic syndrome,C3463824,MYELODYSPLASTIC SYNDROME,03/18/2013,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)., 04/03/2020 , 04/03/2027 ,For the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS),Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
135277784,135277784,Monoclonal antibody 17-1a,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,04/04/1988,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
50069161,50069161,Monoclonal antibody 17-1a,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,04/04/1988,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
440234683,440234683,nipocalimab,,Prevention of hemolytic disease of the fetus and newborn,C1263988,hemolytic disease,06/26/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.|301 Binney Street|Cambridge|Massachusetts|2142|United States"
385610257,385610257,nipocalimab,,Prevention of hemolytic disease of the fetus and newborn,C1263988,hemolytic disease,06/26/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.|301 Binney Street|Cambridge|Massachusetts|2142|United States"
347910322,347910322,olaratumab,Lartruvo,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/09/2014,Designated/Approved,,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.", 10/19/2016 , 10/19/2023 ,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.","Eli Lilly and Company|Lilly Corporate Center, Drop Code 2543|Indianapolis|Indiana|46285|United States"
315661255,315661255,olaratumab,Lartruvo,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/09/2014,Designated/Approved,,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.", 10/19/2016 , 10/19/2023 ,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.","Eli Lilly and Company|Lilly Corporate Center, Drop Code 2543|Indianapolis|Indiana|46285|United States"
160682611,160682611,olaratumab,Lartruvo,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/09/2014,Designated/Approved,,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.", 10/19/2016 , 10/19/2023 ,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.","Eli Lilly and Company|Lilly Corporate Center, Drop Code 2543|Indianapolis|Indiana|46285|United States"
135279750,135279750,olaratumab,Lartruvo,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,10/09/2014,Designated/Approved,,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.", 10/19/2016 , 10/19/2023 ,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.","Eli Lilly and Company|Lilly Corporate Center, Drop Code 2543|Indianapolis|Indiana|46285|United States"
441072531,441072531,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061212,387061212,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385327556,385327556,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
384647099,384647099,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
365372203,365372203,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355036,354355036,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348838049,348838049,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976960,329976960,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319478935,319478935,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319435463,319435463,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103386,178103386,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135341754,135341754,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771410,103771410,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
57288666,57288666,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
56314417,56314417,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50070184,50070184,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46505820,46505820,rituximab,Rituxan,"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)","C0008728,C2347126,C2717865,C3495801","Churg-Strauss Syndrome , Microscopic Polyangiitis , Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis , Wegener's Granulomatosis",02/14/2006,Designated/Approved,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)", 09/27/2019 , 09/27/2026 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440962803,440962803,Romiplostim,,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/27/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
440790928,440790928,Romiplostim,,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/27/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
349975939,349975939,Romiplostim,,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/27/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
348939083,348939083,Romiplostim,,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/27/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
347910087,347910087,Romiplostim,,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/27/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
178103553,178103553,Romiplostim,,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/27/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
135347108,135347108,Romiplostim,,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/27/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
103771530,103771530,Romiplostim,,Treatment of aplastic anemia,C0002874,Aplastic Anemia,11/27/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
405092064,405092064,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061215,387061215,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385327557,385327557,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385326041,385326041,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355060,354355060,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
349016747,349016747,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
347910344,347910344,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976997,329976997,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103463,178103463,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135345962,135345962,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
104253153,104253153,tocilizumab,Actemra,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,C3495559,juvenile idiopathic arthritis,07/31/2012,Designated/Approved,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older, 05/11/2018 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
381126778,381126778,bovine lactoferrin,,Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams),"C0014356,C0282666","Enterocolitis , Very Low Birth Weight",02/23/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
223727866,223727866,bovine lactoferrin,,Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams),"C0014356,C0282666","Enterocolitis , Very Low Birth Weight",02/23/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
809504,809504,bovine lactoferrin,,Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams),"C0014356,C0282666","Enterocolitis , Very Low Birth Weight",02/23/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
646870,646870,bovine lactoferrin,,Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams),"C0014356,C0282666","Enterocolitis , Very Low Birth Weight",02/23/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
640657,640657,bovine lactoferrin,,Prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams),"C0014356,C0282666","Enterocolitis , Very Low Birth Weight",02/23/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
404720085,404720085,Coagulation factor VIIa (recombinant),NovoSeven,Treatment of bleeding episodes in patients with congenital factor VII deficiency,C0015503,Factor VII Deficiency,09/10/2004,Designated/Approved,,Treatment of bleeding episodes in patients with Factor VII Deficiency, 07/11/2005 , 07/11/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
135284356,135284356,Coagulation factor VIIa (recombinant),NovoSeven,Treatment of bleeding episodes in patients with congenital factor VII deficiency,C0015503,Factor VII Deficiency,09/10/2004,Designated/Approved,,Treatment of bleeding episodes in patients with Factor VII Deficiency, 07/11/2005 , 07/11/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
135275129,135275129,Coagulation factor VIIa (recombinant),NovoSeven,Treatment of bleeding episodes in patients with congenital factor VII deficiency,C0015503,Factor VII Deficiency,09/10/2004,Designated/Approved,,Treatment of bleeding episodes in patients with Factor VII Deficiency, 07/11/2005 , 07/11/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
46507544,46507544,Coagulation factor VIIa (recombinant),NovoSeven,Treatment of bleeding episodes in patients with congenital factor VII deficiency,C0015503,Factor VII Deficiency,09/10/2004,Designated/Approved,,Treatment of bleeding episodes in patients with Factor VII Deficiency, 07/11/2005 , 07/11/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
404772436,404772436,Coversin,,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,09/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc|24 West 40th Street|8th Floor|New York|New York|10018|United States
404719628,404719628,Coversin,,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,09/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc|24 West 40th Street|8th Floor|New York|New York|10018|United States
374366992,374366992,Coversin,,Treatment of paroxysmal nocturnal hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,09/08/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc|24 West 40th Street|8th Floor|New York|New York|10018|United States
347911296,347911296,etrolizumab,,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,08/22/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 Dna Way|South San Francisco|California|94080|United States"
252166617,252166617,etrolizumab,,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,08/22/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 Dna Way|South San Francisco|California|94080|United States"
160704152,160704152,etrolizumab,,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,08/22/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 Dna Way|South San Francisco|California|94080|United States"
135292500,135292500,etrolizumab,,Treatment of pediatric patients with ulcerative colitis,C0009324,Ulcerative Colitis,08/22/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 Dna Way|South San Francisco|California|94080|United States"
381744890,381744890,ibalizumab,Trogarzo,Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy,"C0009450,C0019704","Infection , HIV-1",10/20/2014,Designated/Approved,,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.", 03/06/2018 , 03/06/2025 ,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.",Theratechnologies Inc.|2015 Peel Street|5th Floor|Montreal|Canada
347911363,347911363,ibalizumab,Trogarzo,Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy,"C0009450,C0019704","Infection , HIV-1",10/20/2014,Designated/Approved,,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.", 03/06/2018 , 03/06/2025 ,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.",Theratechnologies Inc.|2015 Peel Street|5th Floor|Montreal|Canada
160671956,160671956,ibalizumab,Trogarzo,Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy,"C0009450,C0019704","Infection , HIV-1",10/20/2014,Designated/Approved,,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.", 03/06/2018 , 03/06/2025 ,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.",Theratechnologies Inc.|2015 Peel Street|5th Floor|Montreal|Canada
135347929,135347929,ibalizumab,Trogarzo,Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy,"C0009450,C0019704","Infection , HIV-1",10/20/2014,Designated/Approved,,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.", 03/06/2018 , 03/06/2025 ,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.",Theratechnologies Inc.|2015 Peel Street|5th Floor|Montreal|Canada
3720768,3720768,ibalizumab,Trogarzo,Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy,"C0009450,C0019704","Infection , HIV-1",10/20/2014,Designated/Approved,,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.", 03/06/2018 , 03/06/2025 ,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.",Theratechnologies Inc.|2015 Peel Street|5th Floor|Montreal|Canada
404772365,404772365,Iboctadekin,,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,06/03/2005,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline LLC|Corporation service Company|Suite 400|Wilmington|Delaware|19808|United States
160671566,160671566,Iboctadekin,,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,06/03/2005,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline LLC|Corporation service Company|Suite 400|Wilmington|Delaware|19808|United States
135350111,135350111,Iboctadekin,,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,06/03/2005,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline LLC|Corporation service Company|Suite 400|Wilmington|Delaware|19808|United States
160682368,160682368,Imciromab pentetate,,Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.,C1265869,Early necrosis,01/25/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|244 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
135303481,135303481,Imciromab pentetate,,Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.,C1265869,Early necrosis,01/25/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|244 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
50070162,50070162,Imciromab pentetate,,Detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.,C1265869,Early necrosis,01/25/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|244 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
490427,490427,Immune Globulin Intravenous (human),,Treatment for Guillain Barre Syndrome,C0018378,GUILLAIN BARRE SYNDROME,05/04/2004,Designated,Not FDA Approved for Orphan Indication,,,,,ZLB Bioplasma AG|Wankdorfstrasse 10|CH-3000 Bern 22|Switzerland
404772201,404772201,mecasermin rinfabate,,Treatment of amyotropic lateral sclerosis,C0154682,Lateral Sclerosis,07/23/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"PCUT BioPartners, Inc.|2196 Glenkirk Drive|San Jose|California|95124|United States"
135325697,135325697,mecasermin rinfabate,,Treatment of amyotropic lateral sclerosis,C0154682,Lateral Sclerosis,07/23/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"PCUT BioPartners, Inc.|2196 Glenkirk Drive|San Jose|California|95124|United States"
103771459,103771459,mecasermin rinfabate,,Treatment of amyotropic lateral sclerosis,C0154682,Lateral Sclerosis,07/23/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"PCUT BioPartners, Inc.|2196 Glenkirk Drive|San Jose|California|95124|United States"
387061103,387061103,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, 05/17/2016 , 05/17/2023 ,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, 05/17/2016 , 05/17/2023 ,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, 05/17/2016 , 05/17/2023 ,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, 05/17/2016 , 05/17/2023 ,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, 05/17/2016 , 05/17/2023 ,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, 05/17/2016 , 05/17/2023 ,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, 05/17/2016 , 05/17/2023 ,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, 05/17/2016 , 05/17/2023 ,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, 05/17/2016 , 05/17/2023 ,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
440798422,440798422,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,06/11/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 214A|South San Francisco|California|94080|United States"
387060188,387060188,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,06/11/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 214A|South San Francisco|California|94080|United States"
385327553,385327553,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,06/11/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 214A|South San Francisco|California|94080|United States"
384647096,384647096,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,06/11/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 214A|South San Francisco|California|94080|United States"
347910388,347910388,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,06/11/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 214A|South San Francisco|California|94080|United States"
178103523,178103523,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,06/11/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 214A|South San Francisco|California|94080|United States"
160682610,160682610,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,06/11/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 214A|South San Francisco|California|94080|United States"
135332744,135332744,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,06/11/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS# 214A|South San Francisco|California|94080|United States"
440798422,440798422,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,08/17/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
387060188,387060188,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,08/17/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
385327553,385327553,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,08/17/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
384647096,384647096,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,08/17/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
347910388,347910388,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,08/17/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
178103523,178103523,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,08/17/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
160682610,160682610,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,08/17/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
135332744,135332744,obinutuzumab,,Treatment of splenic marginal zone lymphoma,C0349632,Splenic marginal zone lymphoma,08/17/2017,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group|1 DNA Way|MS #355e|South San Francisco|California|94080|United States"
387061105,387061105,pembrolizumab,Keytruda,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,12/28/2016,Designated/Approved,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, 12/19/2018 , 12/19/2025 ,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,"Merck, Sharp, and Dohme Corp.|351 North Sumneytown Pike|UG2D-027|North Wales|Pennsylvania|19454|United States"
385327548,385327548,pembrolizumab,Keytruda,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,12/28/2016,Designated/Approved,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, 12/19/2018 , 12/19/2025 ,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,"Merck, Sharp, and Dohme Corp.|351 North Sumneytown Pike|UG2D-027|North Wales|Pennsylvania|19454|United States"
384647091,384647091,pembrolizumab,Keytruda,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,12/28/2016,Designated/Approved,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, 12/19/2018 , 12/19/2025 ,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,"Merck, Sharp, and Dohme Corp.|351 North Sumneytown Pike|UG2D-027|North Wales|Pennsylvania|19454|United States"
377483934,377483934,pembrolizumab,Keytruda,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,12/28/2016,Designated/Approved,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, 12/19/2018 , 12/19/2025 ,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,"Merck, Sharp, and Dohme Corp.|351 North Sumneytown Pike|UG2D-027|North Wales|Pennsylvania|19454|United States"
354355033,354355033,pembrolizumab,Keytruda,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,12/28/2016,Designated/Approved,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, 12/19/2018 , 12/19/2025 ,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,"Merck, Sharp, and Dohme Corp.|351 North Sumneytown Pike|UG2D-027|North Wales|Pennsylvania|19454|United States"
347910395,347910395,pembrolizumab,Keytruda,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,12/28/2016,Designated/Approved,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, 12/19/2018 , 12/19/2025 ,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,"Merck, Sharp, and Dohme Corp.|351 North Sumneytown Pike|UG2D-027|North Wales|Pennsylvania|19454|United States"
194140938,194140938,pembrolizumab,Keytruda,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,12/28/2016,Designated/Approved,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, 12/19/2018 , 12/19/2025 ,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,"Merck, Sharp, and Dohme Corp.|351 North Sumneytown Pike|UG2D-027|North Wales|Pennsylvania|19454|United States"
187051801,187051801,pembrolizumab,Keytruda,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,12/28/2016,Designated/Approved,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, 12/19/2018 , 12/19/2025 ,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,"Merck, Sharp, and Dohme Corp.|351 North Sumneytown Pike|UG2D-027|North Wales|Pennsylvania|19454|United States"
404617350,404617350,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
375758272,375758272,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
348744312,348744312,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
335987561,335987561,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
319299707,319299707,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
313077795,313077795,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
254775499,254775499,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
135023114,135023114,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
134979644,134979644,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
134222261,134222261,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
103771260,103771260,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
49992424,49992424,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
438485410,438485410,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
434303155,434303155,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,11/21/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.|863 Mitten Road|Burlingame|California|94010|United States"
134224295,134224295,polifeprosan 20 with carmustine,Gliadel,Treatment of malignant glioma.,C0555198,Malignant Glioma,12/13/1989,Designated/Approved,,Expanding the indication to include patients with malignant glioma undergoing primary surgical resection., 02/25/2003 , 02/25/2010 ,,"Guilford Pharmaceuticals, Inc.|6611 Tributary Street|Baltimore|Maryland|21224|United States"
347910383,347910383,teduglutide [rDNA origin],GATTEX,Treatment of short bowel syndrome.,C0036992,Short Bowel Syndrome,06/29/2000,Designated/Approved,,Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support, 12/21/2012 , 12/21/2019 ,,"Shire-NPS Pharmaceuticals, Inc.|650 E. Kendall Street|Cambridge|Massachusetts|2142|United States"
404719438,404719438,Tiragolumab,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
381128164,381128164,Tiragolumab,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc.|1 DNA Way, MS #45-1A|South San Francisco|California|94080-4990|United States"
404772881,404772881,cenersen,,Treatment of stage IIB through IV melanoma,C0025202,melanoma,06/18/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
381125009,381125009,cenersen,,Treatment of stage IIB through IV melanoma,C0025202,melanoma,06/18/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
349988829,349988829,cenersen,,Treatment of stage IIB through IV melanoma,C0025202,melanoma,06/18/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
252166482,252166482,cenersen,,Treatment of stage IIB through IV melanoma,C0025202,melanoma,06/18/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
160682274,160682274,cenersen,,Treatment of stage IIB through IV melanoma,C0025202,melanoma,06/18/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
135263925,135263925,cenersen,,Treatment of stage IIB through IV melanoma,C0025202,melanoma,06/18/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
490427,490427,Immune globulin intravenous (human),,Treatment of patients with acute myocarditis.,C0155686,Acute myocarditis,11/22/1993,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immuno Clinical Research Corp.|750 Lexington Avenue, 19th Floor|New York|New York|10022|United States"
404720052,404720052,lisocabtagene maraleucel,Breyanzi,Treatment of primary mediastinal large B-cell lymphoma,C1292754,Primary Mediastinal Large B-Cell Lymphoma,07/12/2018,Designated/Approved,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B", 02/05/2021 , 02/05/2028 ,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy; and treatment of adult patients with relapsed or refractory follicular lymphoma grade 3B after two or more lines of systemic therapy,"Juno Therapeutics, Inc.|400 Dexter Avenue N|Seattle|Washington|98109|United States"
387061103,387061103,nivolumab,OPDIVO,Treatment of small cell lung cancer.,C3540630,Small Cell Lung Cancer,09/15/2015,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy., 08/16/2018 , 08/16/2025 ,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy,Bristol-Myers Squibb Company|5 Research Parkway|Wallingford|Connecticut|6492|United States
385327549,385327549,nivolumab,OPDIVO,Treatment of small cell lung cancer.,C3540630,Small Cell Lung Cancer,09/15/2015,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy., 08/16/2018 , 08/16/2025 ,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy,Bristol-Myers Squibb Company|5 Research Parkway|Wallingford|Connecticut|6492|United States
384647092,384647092,nivolumab,OPDIVO,Treatment of small cell lung cancer.,C3540630,Small Cell Lung Cancer,09/15/2015,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy., 08/16/2018 , 08/16/2025 ,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy,Bristol-Myers Squibb Company|5 Research Parkway|Wallingford|Connecticut|6492|United States
354355034,354355034,nivolumab,OPDIVO,Treatment of small cell lung cancer.,C3540630,Small Cell Lung Cancer,09/15/2015,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy., 08/16/2018 , 08/16/2025 ,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy,Bristol-Myers Squibb Company|5 Research Parkway|Wallingford|Connecticut|6492|United States
349494907,349494907,nivolumab,OPDIVO,Treatment of small cell lung cancer.,C3540630,Small Cell Lung Cancer,09/15/2015,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy., 08/16/2018 , 08/16/2025 ,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy,Bristol-Myers Squibb Company|5 Research Parkway|Wallingford|Connecticut|6492|United States
347910393,347910393,nivolumab,OPDIVO,Treatment of small cell lung cancer.,C3540630,Small Cell Lung Cancer,09/15/2015,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy., 08/16/2018 , 08/16/2025 ,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy,Bristol-Myers Squibb Company|5 Research Parkway|Wallingford|Connecticut|6492|United States
178103907,178103907,nivolumab,OPDIVO,Treatment of small cell lung cancer.,C3540630,Small Cell Lung Cancer,09/15/2015,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy., 08/16/2018 , 08/16/2025 ,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy,Bristol-Myers Squibb Company|5 Research Parkway|Wallingford|Connecticut|6492|United States
160698453,160698453,nivolumab,OPDIVO,Treatment of small cell lung cancer.,C3540630,Small Cell Lung Cancer,09/15/2015,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy., 08/16/2018 , 08/16/2025 ,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy,Bristol-Myers Squibb Company|5 Research Parkway|Wallingford|Connecticut|6492|United States
135341610,135341610,nivolumab,OPDIVO,Treatment of small cell lung cancer.,C3540630,Small Cell Lung Cancer,09/15/2015,Designated/Approved,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy., 08/16/2018 , 08/16/2025 ,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy,Bristol-Myers Squibb Company|5 Research Parkway|Wallingford|Connecticut|6492|United States
387061105,387061105,pembrolizumab,KEYTRUDA,Treatment of Hodgkin lymphoma.,C0019829,Hodgkin Lymphoma,12/30/2015,Designated/Approved,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.", 03/14/2017 , 03/14/2024 ,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.","Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc|126 E. Lincoln Avenue|P. O. Box 2000|Rathway|Pennsylvania|7065|United States"
385327548,385327548,pembrolizumab,KEYTRUDA,Treatment of Hodgkin lymphoma.,C0019829,Hodgkin Lymphoma,12/30/2015,Designated/Approved,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.", 03/14/2017 , 03/14/2024 ,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.","Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc|126 E. Lincoln Avenue|P. O. Box 2000|Rathway|Pennsylvania|7065|United States"
384647091,384647091,pembrolizumab,KEYTRUDA,Treatment of Hodgkin lymphoma.,C0019829,Hodgkin Lymphoma,12/30/2015,Designated/Approved,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.", 03/14/2017 , 03/14/2024 ,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.","Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc|126 E. Lincoln Avenue|P. O. Box 2000|Rathway|Pennsylvania|7065|United States"
377483934,377483934,pembrolizumab,KEYTRUDA,Treatment of Hodgkin lymphoma.,C0019829,Hodgkin Lymphoma,12/30/2015,Designated/Approved,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.", 03/14/2017 , 03/14/2024 ,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.","Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc|126 E. Lincoln Avenue|P. O. Box 2000|Rathway|Pennsylvania|7065|United States"
354355033,354355033,pembrolizumab,KEYTRUDA,Treatment of Hodgkin lymphoma.,C0019829,Hodgkin Lymphoma,12/30/2015,Designated/Approved,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.", 03/14/2017 , 03/14/2024 ,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.","Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc|126 E. Lincoln Avenue|P. O. Box 2000|Rathway|Pennsylvania|7065|United States"
347910395,347910395,pembrolizumab,KEYTRUDA,Treatment of Hodgkin lymphoma.,C0019829,Hodgkin Lymphoma,12/30/2015,Designated/Approved,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.", 03/14/2017 , 03/14/2024 ,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.","Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc|126 E. Lincoln Avenue|P. O. Box 2000|Rathway|Pennsylvania|7065|United States"
194140938,194140938,pembrolizumab,KEYTRUDA,Treatment of Hodgkin lymphoma.,C0019829,Hodgkin Lymphoma,12/30/2015,Designated/Approved,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.", 03/14/2017 , 03/14/2024 ,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.","Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc|126 E. Lincoln Avenue|P. O. Box 2000|Rathway|Pennsylvania|7065|United States"
187051801,187051801,pembrolizumab,KEYTRUDA,Treatment of Hodgkin lymphoma.,C0019829,Hodgkin Lymphoma,12/30/2015,Designated/Approved,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.", 03/14/2017 , 03/14/2024 ,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.","Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc|126 E. Lincoln Avenue|P. O. Box 2000|Rathway|Pennsylvania|7065|United States"
440790931,440790931,sargramostim,Leukine,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),C0520799,Acute Radiation Syndrome,11/09/2016,Designated/Approved,,LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])., 03/29/2018 , 03/29/2025 ,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
312856261,312856261,sargramostim,Leukine,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),C0520799,Acute Radiation Syndrome,11/09/2016,Designated/Approved,,LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])., 03/29/2018 , 03/29/2025 ,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
249565588,249565588,sargramostim,Leukine,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),C0520799,Acute Radiation Syndrome,11/09/2016,Designated/Approved,,LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])., 03/29/2018 , 03/29/2025 ,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
135360419,135360419,sargramostim,Leukine,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),C0520799,Acute Radiation Syndrome,11/09/2016,Designated/Approved,,LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])., 03/29/2018 , 03/29/2025 ,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
135307693,135307693,sargramostim,Leukine,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),C0520799,Acute Radiation Syndrome,11/09/2016,Designated/Approved,,LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])., 03/29/2018 , 03/29/2025 ,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
103771401,103771401,sargramostim,Leukine,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),C0520799,Acute Radiation Syndrome,11/09/2016,Designated/Approved,,LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])., 03/29/2018 , 03/29/2025 ,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
50070152,50070152,sargramostim,Leukine,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),C0520799,Acute Radiation Syndrome,11/09/2016,Designated/Approved,,LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])., 03/29/2018 , 03/29/2025 ,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
46507000,46507000,sargramostim,Leukine,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),C0520799,Acute Radiation Syndrome,11/09/2016,Designated/Approved,,LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])., 03/29/2018 , 03/29/2025 ,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
793506,793506,sargramostim,Leukine,Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),C0520799,Acute Radiation Syndrome,11/09/2016,Designated/Approved,,LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS])., 03/29/2018 , 03/29/2025 ,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.|19 Muzzey Street|Lexington|Massachusetts|2421|United States"
404770442,404770442,Synthetic porcine secretin,,For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.,C0235974,Pancreatic carcinoma,06/18/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
404621644,404621644,Synthetic porcine secretin,,For use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.,C0235974,Pancreatic carcinoma,06/18/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
319259212,319259212,talactoferrin alfa,,For the treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,08/20/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
160676985,160676985,talactoferrin alfa,,For the treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,08/20/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
135286186,135286186,talactoferrin alfa,,For the treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,08/20/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
404771398,404771398,cenegermin-bkbj,Oxervate,Treatment of neurotrophic keratitis,C0339296,Neurotrophic keratitis,06/23/2014,Designated/Approved,,Treatment of neurotrophic keratitis, 08/22/2018 , 08/22/2025 ,Treatment of neurotrophic keratitis,Dompe S.p.A.|Via S. Martino 12-12/A|Milan|Italy
404720361,404720361,cenegermin-bkbj,Oxervate,Treatment of neurotrophic keratitis,C0339296,Neurotrophic keratitis,06/23/2014,Designated/Approved,,Treatment of neurotrophic keratitis, 08/22/2018 , 08/22/2025 ,Treatment of neurotrophic keratitis,Dompe S.p.A.|Via S. Martino 12-12/A|Milan|Italy
350078347,350078347,cenegermin-bkbj,Oxervate,Treatment of neurotrophic keratitis,C0339296,Neurotrophic keratitis,06/23/2014,Designated/Approved,,Treatment of neurotrophic keratitis, 08/22/2018 , 08/22/2025 ,Treatment of neurotrophic keratitis,Dompe S.p.A.|Via S. Martino 12-12/A|Milan|Italy
164133228,164133228,dasiprotimut-T,,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,06/17/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Biovest International, Inc.|324 S. Hyde Park Avenue|Suite 350|Tampa|Florida|33606|United States"
440234513,440234513,DPX-Survivac,,Treatment of ovarian cancer.,C4721610,Ovarian Cancer,07/14/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunovaccine Technologies, Inc.|1344 Summer Street|Halifax|Canada"
441072532,441072532,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
440790288,440790288,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
404336834,404336834,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
349720813,349720813,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
329976984,329976984,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
178103381,178103381,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
135302348,135302348,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
103771356,103771356,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
53787868,53787868,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
46505767,46505767,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy, 05/17/2000 , 05/17/2007 ,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
347911285,347911285,gevokizumab,,Treatment of pyoderma gangrenosum,C0085652,Pyoderma Gangrenosum,02/21/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
178103966,178103966,gevokizumab,,Treatment of pyoderma gangrenosum,C0085652,Pyoderma Gangrenosum,02/21/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
160704155,160704155,gevokizumab,,Treatment of pyoderma gangrenosum,C0085652,Pyoderma Gangrenosum,02/21/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
135322326,135322326,gevokizumab,,Treatment of pyoderma gangrenosum,C0085652,Pyoderma Gangrenosum,02/21/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC|2910 Seventh St.|Berkeley|California|94710|United States
440790345,440790345,Interferon beta-1a,Avonex,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,12/16/1991,Designated/Approved,,Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations., 05/17/1996 , 05/17/2003 ,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
381124371,381124371,Interferon beta-1a,Avonex,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,12/16/1991,Designated/Approved,,Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations., 05/17/1996 , 05/17/2003 ,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
135335764,135335764,Interferon beta-1a,Avonex,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,12/16/1991,Designated/Approved,,Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations., 05/17/1996 , 05/17/2003 ,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
103771353,103771353,Interferon beta-1a,Avonex,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,12/16/1991,Designated/Approved,,Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations., 05/17/1996 , 05/17/2003 ,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
50070200,50070200,Interferon beta-1a,Avonex,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,12/16/1991,Designated/Approved,,Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations., 05/17/1996 , 05/17/2003 ,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
46504899,46504899,Interferon beta-1a,Avonex,Treatment of multiple sclerosis.,C0026769,Multiple Sclerosis,12/16/1991,Designated/Approved,,Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations., 05/17/1996 , 05/17/2003 ,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
347911362,347911362,moxetumomab pasudotox,,Treatment of CD22-positive chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,11/15/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
223366010,223366010,moxetumomab pasudotox,,Treatment of CD22-positive chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,11/15/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
160704159,160704159,moxetumomab pasudotox,,Treatment of CD22-positive chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,11/15/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
135350821,135350821,moxetumomab pasudotox,,Treatment of CD22-positive chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,11/15/2007,Designated,Not FDA Approved for Orphan Indication,,,,,Innate Pharma|117 Avenue de Luminy|BP 30191|Marseille|Provence-Alpes-C_xDC92__xDD60_d'Azur|France
440816710,440816710,naxitamab-gqgk,DANYELZA,Treatment of neuroblastoma,C0027819,Neuroblastoma,06/24/2013,Designated/Approved,,"in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy", 11/25/2020 , 11/25/2027 ,"treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy","Y-mAbs Therapeutics, Inc.|750 3rd Avenue|9th Floor|New York|New York|10017|United States"
404772651,404772651,pozelimab,,Treatment of Paroxysmal Nocturnal Hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,07/22/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
404719659,404719659,pozelimab,,Treatment of Paroxysmal Nocturnal Hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,07/22/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
377483950,377483950,pozelimab,,Treatment of Paroxysmal Nocturnal Hemoglobinuria,C0024790,Paroxysmal nocturnal hemoglobinuria,07/22/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States
347911185,347911185,Protein C concentrate,,For use in the prevention and treatment of purpura fulminans in meningococcemia.,"C0025306,C0085650","Meningococcemia , Purpura Fulminans",04/22/1993,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immuno Clinical Research Corp.|750 Lexington Avenue, 19th Floor|New York|New York|10022|United States"
135252498,135252498,Recombinant bactericidal/permeability-increasing protein,,Treatment of severe meningococcal disease.,C0025303,Meningococcal Disease,06/22/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Xoma (US) LLC|2910 Seventh Street|Berkeley|California|94710|United States
50069488,50069488,Recombinant bactericidal/permeability-increasing protein,,Treatment of severe meningococcal disease.,C0025303,Meningococcal Disease,06/22/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Xoma (US) LLC|2910 Seventh Street|Berkeley|California|94710|United States
642925,642925,Recombinant bactericidal/permeability-increasing protein,,Treatment of severe meningococcal disease.,C0025303,Meningococcal Disease,06/22/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Xoma (US) LLC|2910 Seventh Street|Berkeley|California|94710|United States
381126979,381126979,simtuzumab,,Treatment of primary sclerosing cholangitis,C0566602,Primary sclerosing cholangitis,01/05/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States"
347911289,347911289,simtuzumab,,Treatment of primary sclerosing cholangitis,C0566602,Primary sclerosing cholangitis,01/05/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States"
252166622,252166622,simtuzumab,,Treatment of primary sclerosing cholangitis,C0566602,Primary sclerosing cholangitis,01/05/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States"
160687749,160687749,simtuzumab,,Treatment of primary sclerosing cholangitis,C0566602,Primary sclerosing cholangitis,01/05/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States"
381127467,381127467,somavaratan,,Treatment of growth hormone deficiency,C3714796,Growth hormone deficiency,10/16/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Versartis, Inc.|275 Shoreline Drive|Suite 450|Redwood City|94065|United States"
347911333,347911333,somavaratan,,Treatment of growth hormone deficiency,C3714796,Growth hormone deficiency,10/16/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Versartis, Inc.|275 Shoreline Drive|Suite 450|Redwood City|94065|United States"
318464560,318464560,somavaratan,,Treatment of growth hormone deficiency,C3714796,Growth hormone deficiency,10/16/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Versartis, Inc.|275 Shoreline Drive|Suite 450|Redwood City|94065|United States"
354742370,354742370,cintredekin besudotox,,Treatment of malignant glioma,C0555198,Malignant Glioma,11/02/2001,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
347910067,347910067,cintredekin besudotox,,Treatment of malignant glioma,C0555198,Malignant Glioma,11/02/2001,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
160676971,160676971,cintredekin besudotox,,Treatment of malignant glioma,C0555198,Malignant Glioma,11/02/2001,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
135338270,135338270,cintredekin besudotox,,Treatment of malignant glioma,C0555198,Malignant Glioma,11/02/2001,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
134222771,134222771,cintredekin besudotox,,Treatment of malignant glioma,C0555198,Malignant Glioma,11/02/2001,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.|1333 South Sprectum Blvd, Suite 100|Chandler|Alaska|85286|United States"
404720085,404720085,Coagulation factor VIIa (recombinant),NovoSeven,"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors",C0019069,Hemophilia A,06/18/2004,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX, 08/12/2005 , 08/12/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
135284356,135284356,Coagulation factor VIIa (recombinant),NovoSeven,"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors",C0019069,Hemophilia A,06/18/2004,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX, 08/12/2005 , 08/12/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
135275129,135275129,Coagulation factor VIIa (recombinant),NovoSeven,"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors",C0019069,Hemophilia A,06/18/2004,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX, 08/12/2005 , 08/12/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
46507544,46507544,Coagulation factor VIIa (recombinant),NovoSeven,"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors",C0019069,Hemophilia A,06/18/2004,Designated/Approved,,Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX, 08/12/2005 , 08/12/2012 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
348783015,348783015,crofelemer,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,08/02/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.|201 Mission Street|Suite 2375|San Francisco|California|94105|United States"
347909853,347909853,crofelemer,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,08/02/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.|201 Mission Street|Suite 2375|San Francisco|California|94105|United States"
187051756,187051756,crofelemer,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,08/02/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.|201 Mission Street|Suite 2375|San Francisco|California|94105|United States"
160687558,160687558,crofelemer,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,08/02/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.|201 Mission Street|Suite 2375|San Francisco|California|94105|United States"
135030308,135030308,crofelemer,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,08/02/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.|201 Mission Street|Suite 2375|San Francisco|California|94105|United States"
626630,626630,crofelemer,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,08/02/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.|201 Mission Street|Suite 2375|San Francisco|California|94105|United States"
355426570,355426570,crofelemer,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,08/02/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.|201 Mission Street|Suite 2375|San Francisco|California|94105|United States"
349983993,349983993,crofelemer,,Treatment of short bowel syndrome,C0036992,Short Bowel Syndrome,08/02/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.|201 Mission Street|Suite 2375|San Francisco|California|94105|United States"
318160739,318160739,cytarabine liposome,,Treatment of gliomas,C0017638,gliomas,01/30/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Bruce Frankel, MD|Medical University of South Carolina|96 Jonathan Lucas Street, Suite 428 CSB|Charleston|South Carolina|29425|United States"
490427,490427,Immune globulin intravenous (human),,Treatment of juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,12/16/1992,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immuno Clinical Research Corp.|750 Lexington Avenue, 19th Floor|New York|New York|10022|United States"
440790862,440790862,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
384440626,384440626,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
349974947,349974947,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
347945230,347945230,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
341140052,341140052,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
194141199,194141199,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
134990603,134990603,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
134990274,134990274,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
53788117,53788117,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
51025331,51025331,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
386623567,386623567,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
385786560,385786560,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
419581073,419581073,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
348283022,348283022,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
319348027,319348027,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
46508965,46508965,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
8145943,8145943,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
9478,9478,Nitroprusside,,Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,"C0038525,C0265110","Subarachnoid Hemorrhage , Cerebral Vasospasm",02/21/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan|Thomas Jefferson University and Wills Neurosensory|834 Walnut Street, Suite 650|Philadelphia|Pennsylvania|19107|United States"
387061103,387061103,nivolumab,,Treatment of glioblastoma,C0017636,Glioblastoma,08/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co|P. O. Box 4000|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,,Treatment of glioblastoma,C0017636,Glioblastoma,08/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co|P. O. Box 4000|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,,Treatment of glioblastoma,C0017636,Glioblastoma,08/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co|P. O. Box 4000|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,,Treatment of glioblastoma,C0017636,Glioblastoma,08/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co|P. O. Box 4000|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,,Treatment of glioblastoma,C0017636,Glioblastoma,08/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co|P. O. Box 4000|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,,Treatment of glioblastoma,C0017636,Glioblastoma,08/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co|P. O. Box 4000|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,,Treatment of glioblastoma,C0017636,Glioblastoma,08/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co|P. O. Box 4000|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,,Treatment of glioblastoma,C0017636,Glioblastoma,08/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co|P. O. Box 4000|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,,Treatment of glioblastoma,C0017636,Glioblastoma,08/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co|P. O. Box 4000|Princeton|New Jersey|8543|United States
387061103,387061103,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 09/22/2017 , 09/22/2024 ,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 09/22/2017 , 09/22/2024 ,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 09/22/2017 , 09/22/2024 ,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 09/22/2017 , 09/22/2024 ,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 09/22/2017 , 09/22/2024 ,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 09/22/2017 , 09/22/2024 ,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 09/22/2017 , 09/22/2024 ,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 09/22/2017 , 09/22/2024 ,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,OPDIVO,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,09/02/2015,Designated/Approved,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 09/22/2017 , 09/22/2024 ,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
134224295,134224295,polifeprosan 20 with carmustine,Gliadel,Treatment of malignant glioma.,C0555198,Malignant Glioma,12/13/1989,Designated/Approved,,As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated, 09/23/1996 , 09/23/2003 ,,"Guilford Pharmaceuticals, Inc.|6611 Tributary Street|Baltimore|Maryland|21224|United States"
387060192,387060192,secukinumab,,Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression,"C0009450,C0042164,C4048329","Infectious , Uveitis , Immunosuppression",03/26/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation|One Health Plaza|Bldg 404/470|East Hanover|New Jersey|7936|United States
354355044,354355044,secukinumab,,Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression,"C0009450,C0042164,C4048329","Infectious , Uveitis , Immunosuppression",03/26/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation|One Health Plaza|Bldg 404/470|East Hanover|New Jersey|7936|United States
348644151,348644151,secukinumab,,Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression,"C0009450,C0042164,C4048329","Infectious , Uveitis , Immunosuppression",03/26/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation|One Health Plaza|Bldg 404/470|East Hanover|New Jersey|7936|United States
347910391,347910391,secukinumab,,Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression,"C0009450,C0042164,C4048329","Infectious , Uveitis , Immunosuppression",03/26/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation|One Health Plaza|Bldg 404/470|East Hanover|New Jersey|7936|United States
249565758,249565758,secukinumab,,Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression,"C0009450,C0042164,C4048329","Infectious , Uveitis , Immunosuppression",03/26/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation|One Health Plaza|Bldg 404/470|East Hanover|New Jersey|7936|United States
160677295,160677295,secukinumab,,Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression,"C0009450,C0042164,C4048329","Infectious , Uveitis , Immunosuppression",03/26/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation|One Health Plaza|Bldg 404/470|East Hanover|New Jersey|7936|United States
135288104,135288104,secukinumab,,Adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression,"C0009450,C0042164,C4048329","Infectious , Uveitis , Immunosuppression",03/26/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation|One Health Plaza|Bldg 404/470|East Hanover|New Jersey|7936|United States
404772487,404772487,Toripalimab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,05/18/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.|9430 Key West Ave, Suite 125|Rockville|Maryland|20850|United States"
404719502,404719502,Toripalimab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,05/18/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.|9430 Key West Ave, Suite 125|Rockville|Maryland|20850|United States"
381128166,381128166,Toripalimab,,Treatment of nasopharyngeal carcinoma,C2931822,Nasopharyngeal carcinoma,05/18/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.|9430 Key West Ave, Suite 125|Rockville|Maryland|20850|United States"
441072533,441072533,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790663,440790663,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
438447953,438447953,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061211,387061211,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
375567394,375567394,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
365372316,365372316,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355040,354355040,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080044,350080044,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348846999,348846999,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480210,348480210,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976959,329976959,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319478933,319478933,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319436173,319436173,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178101775,178101775,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135301230,135301230,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771413,103771413,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067185,50067185,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46507516,46507516,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
521856,521856,trastuzumab,,Treatment of patients with pancreatic cancer that overexpress p185HER2.,C0235974,PANCREATIC CANCER,12/14/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
441072526,441072526,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Treatment of malignant glioma,C0555198,Malignant Glioma,05/26/2006,Designated/Approved,,Treatment of glioblastoma with progressive disease following prior therapy, 05/05/2009 , 05/05/2016 ,,"Genentech, Inc.|1 DNA Way, MS 241B|South San Francisco|California|94080|United States"
440790483,440790483,canakinumab,ILARIS,Treatment of familial mediterranean fever,C0031069,Familial Mediterranean Fever,12/05/2013,Designated/Approved,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124993,381124993,canakinumab,ILARIS,Treatment of familial mediterranean fever,C0031069,Familial Mediterranean Fever,12/05/2013,Designated/Approved,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124992,381124992,canakinumab,ILARIS,Treatment of familial mediterranean fever,C0031069,Familial Mediterranean Fever,12/05/2013,Designated/Approved,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910340,347910340,canakinumab,ILARIS,Treatment of familial mediterranean fever,C0031069,Familial Mediterranean Fever,12/05/2013,Designated/Approved,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
329976978,329976978,canakinumab,ILARIS,Treatment of familial mediterranean fever,C0031069,Familial Mediterranean Fever,12/05/2013,Designated/Approved,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
178103379,178103379,canakinumab,ILARIS,Treatment of familial mediterranean fever,C0031069,Familial Mediterranean Fever,12/05/2013,Designated/Approved,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
135332926,135332926,canakinumab,ILARIS,Treatment of familial mediterranean fever,C0031069,Familial Mediterranean Fever,12/05/2013,Designated/Approved,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
103771532,103771532,canakinumab,ILARIS,Treatment of familial mediterranean fever,C0031069,Familial Mediterranean Fever,12/05/2013,Designated/Approved,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
404772163,404772163,elapegademase-lvlr,Revcovi,Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency.,"C0085110,C0268124","Severe Combined Immunodeficiency , Adenosine deaminase deficiency",03/19/2015,Designated/Approved,,Treatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID)., 10/05/2018 , 10/05/2025 ,treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.,Chiesi USA Inc.|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States
374363835,374363835,elapegademase-lvlr,Revcovi,Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency.,"C0085110,C0268124","Severe Combined Immunodeficiency , Adenosine deaminase deficiency",03/19/2015,Designated/Approved,,Treatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID)., 10/05/2018 , 10/05/2025 ,treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.,Chiesi USA Inc.|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States
348350489,348350489,elapegademase-lvlr,Revcovi,Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency.,"C0085110,C0268124","Severe Combined Immunodeficiency , Adenosine deaminase deficiency",03/19/2015,Designated/Approved,,Treatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID)., 10/05/2018 , 10/05/2025 ,treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.,Chiesi USA Inc.|175 Regency Woods Place|Suite 600|Cary|North Carolina|27518|United States
440791025,440791025,interferon gamma-1b,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,09/12/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"InterMune, Inc.|3280 Bayshore Boulevard|Brisbane|California|94005|United States"
135032842,135032842,interferon gamma-1b,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,09/12/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"InterMune, Inc.|3280 Bayshore Boulevard|Brisbane|California|94005|United States"
103771226,103771226,interferon gamma-1b,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,09/12/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"InterMune, Inc.|3280 Bayshore Boulevard|Brisbane|California|94005|United States"
46507194,46507194,interferon gamma-1b,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,09/12/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"InterMune, Inc.|3280 Bayshore Boulevard|Brisbane|California|94005|United States"
438446899,438446899,meplazumab,,Treatment of malaria,C0024530,Malaria,03/15/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Pacific-Meinuoke Bio-pharmaceutical Co., Ltd.|No. 128, Hehai West Rd|Xinbei District|Changzhou|Jiangsu|China"
405560467,405560467,meplazumab,,Treatment of malaria,C0024530,Malaria,03/15/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Pacific-Meinuoke Bio-pharmaceutical Co., Ltd.|No. 128, Hehai West Rd|Xinbei District|Changzhou|Jiangsu|China"
162221917,162221917,monosialotetrahexosylganglioside,,Treatment of Amyotrophic Lateral Sclerosis,C0002736,Amyotrophic Lateral Sclerosis,03/09/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Innomedica Schweiz AG|Gesellschaftsstrasse 16|Bern|CH- 3012|Switzerland
387061105,387061105,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.", 09/04/2014 , 09/04/2021 ,,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
385327548,385327548,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.", 09/04/2014 , 09/04/2021 ,,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
384647091,384647091,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.", 09/04/2014 , 09/04/2021 ,,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
377483934,377483934,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.", 09/04/2014 , 09/04/2021 ,,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
354355033,354355033,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.", 09/04/2014 , 09/04/2021 ,,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
347910395,347910395,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.", 09/04/2014 , 09/04/2021 ,,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
194140938,194140938,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.", 09/04/2014 , 09/04/2021 ,,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
187051801,187051801,pembrolizumab,KEYTRUDA,Treatment of Stage IIB through IV malignant melanoma,C0025202,Malignant Melanoma,11/19/2012,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.", 09/04/2014 , 09/04/2021 ,,"Merck, Sharp & Dohme Corp.|351 North Sumneytown Pike|North Wales|Pennsylvania|19454|United States"
135294547,135294547,recombinant human interleukin-12,,Treatment of acute radiation syndrome,C0520799,Acute Radiation Syndrome,08/22/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Neumedicines, Inc.|133 Altadena Drive|Suite 133|Pasadena|California|91107|United States"
381125242,381125242,Synthetic human secretin,Chirostim,For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.,"C0017150,C0043515","Gastrinoma , Zollinger-Ellison syndrome",06/16/1999,Designated/Approved,,"Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography", 04/09/2004 ,,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
381125040,381125040,Synthetic human secretin,Chirostim,For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.,"C0017150,C0043515","Gastrinoma , Zollinger-Ellison syndrome",06/16/1999,Designated/Approved,,"Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography", 04/09/2004 ,,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
347827873,347827873,Synthetic human secretin,Chirostim,For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.,"C0017150,C0043515","Gastrinoma , Zollinger-Ellison syndrome",06/16/1999,Designated/Approved,,"Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography", 04/09/2004 ,,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
381125911,381125911,taberminogene vadenovec,,Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.,C0020507,Hyperplasia,10/24/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Finvector Vision Therapies, Ltd.|1 Fitzroy Mews|London|United Kingdom"
347909890,347909890,taberminogene vadenovec,,Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.,C0020507,Hyperplasia,10/24/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Finvector Vision Therapies, Ltd.|1 Fitzroy Mews|London|United Kingdom"
160676912,160676912,taberminogene vadenovec,,Prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.,C0020507,Hyperplasia,10/24/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Finvector Vision Therapies, Ltd.|1 Fitzroy Mews|London|United Kingdom"
404720085,404720085,Coagulation Factor VIIa (Recombinant),,Treatment of bleeding in patients experiencing intracranial hemorrhage.,C0151699,Intracranial Hemorrhage,10/03/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P. O. Box 846|Plainsboro|New Jersey|8536|United States"
135284356,135284356,Coagulation Factor VIIa (Recombinant),,Treatment of bleeding in patients experiencing intracranial hemorrhage.,C0151699,Intracranial Hemorrhage,10/03/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P. O. Box 846|Plainsboro|New Jersey|8536|United States"
135275129,135275129,Coagulation Factor VIIa (Recombinant),,Treatment of bleeding in patients experiencing intracranial hemorrhage.,C0151699,Intracranial Hemorrhage,10/03/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P. O. Box 846|Plainsboro|New Jersey|8536|United States"
46507544,46507544,Coagulation Factor VIIa (Recombinant),,Treatment of bleeding in patients experiencing intracranial hemorrhage.,C0151699,Intracranial Hemorrhage,10/03/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P. O. Box 846|Plainsboro|New Jersey|8536|United States"
404772656,404772656,flotetuzumab,,Treatment of acute myeloid leukemia (AML),C0023467,Acute myeloid leukemia,12/22/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.|9704 Medical Center Drive|Rockville|Maryland|20850|United States"
381127915,381127915,flotetuzumab,,Treatment of acute myeloid leukemia (AML),C0023467,Acute myeloid leukemia,12/22/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.|9704 Medical Center Drive|Rockville|Maryland|20850|United States"
374363967,374363967,flotetuzumab,,Treatment of acute myeloid leukemia (AML),C0023467,Acute myeloid leukemia,12/22/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.|9704 Medical Center Drive|Rockville|Maryland|20850|United States"
490427,490427,immune globulin intravenous (human),Gammaplex,Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia),"C0242584,C0398650","Immune thrombocytopenia , IDIOPATHIC THROMBOCYTOPENIC PURPURA",04/29/2011,Designated/Approved,,Idiopathic thrombocytopenic purpura, 03/08/2013 ,,,Bio Products Laboratory|Dagger Lane|Hertfordshire|England|United Kingdom
347911343,347911343,mavrilimumab,,Treatment of Giant Cell Arteritis,C0039483,Giant Cell Arteritis,09/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
223366117,223366117,mavrilimumab,,Treatment of Giant Cell Arteritis,C0039483,Giant Cell Arteritis,09/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
160693417,160693417,mavrilimumab,,Treatment of Giant Cell Arteritis,C0039483,Giant Cell Arteritis,09/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
135326482,135326482,mavrilimumab,,Treatment of Giant Cell Arteritis,C0039483,Giant Cell Arteritis,09/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
76505709,76505709,"N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine",,Treatment of malaria.,C0024530,Malaria,10/29/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Donald J. Krogstad, MD|1430 Tulane Ave., #8317|J.B. Johnson Building|New Orleans|Louisiana|70112|United States"
404772880,404772880,Naratuximab emtansine,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,05/12/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Debiopharm International S.A.|Forum ""apres-demain""|Chemin Messidor 5-7, CP 5911|Switzerland"
381127693,381127693,Naratuximab emtansine,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,05/12/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Debiopharm International S.A.|Forum ""apres-demain""|Chemin Messidor 5-7, CP 5911|Switzerland"
374883836,374883836,Naratuximab emtansine,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,05/12/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Debiopharm International S.A.|Forum ""apres-demain""|Chemin Messidor 5-7, CP 5911|Switzerland"
160687707,160687707,Naratuximab emtansine,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,05/12/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Debiopharm International S.A.|Forum ""apres-demain""|Chemin Messidor 5-7, CP 5911|Switzerland"
404772953,404772953,onasemnogene abeparvovec,ZOLGENSMA,Treatment of spinal muscular atrophy,C0026847,Spinal Muscular Atrophy,09/30/2014,Designated/Approved,,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene., 05/24/2019 , 05/24/2026 ,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,"AveXis, Inc.|2275 Half Day Road|Suite 200|Bannockburn|Illinois|60015|United States"
404719956,404719956,onasemnogene abeparvovec,ZOLGENSMA,Treatment of spinal muscular atrophy,C0026847,Spinal Muscular Atrophy,09/30/2014,Designated/Approved,,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene., 05/24/2019 , 05/24/2026 ,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,"AveXis, Inc.|2275 Half Day Road|Suite 200|Bannockburn|Illinois|60015|United States"
381128165,381128165,onasemnogene abeparvovec,ZOLGENSMA,Treatment of spinal muscular atrophy,C0026847,Spinal Muscular Atrophy,09/30/2014,Designated/Approved,,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene., 05/24/2019 , 05/24/2026 ,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,"AveXis, Inc.|2275 Half Day Road|Suite 200|Bannockburn|Illinois|60015|United States"
404770733,404770733,Ravulizumab,,Treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy,C2717961,Thrombotic microangiopathy,11/25/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
381128036,381128036,Ravulizumab,,Treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy,C2717961,Thrombotic microangiopathy,11/25/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
381118878,381118878,Ravulizumab,,Treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy,C2717961,Thrombotic microangiopathy,11/25/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
374364184,374364184,Ravulizumab,,Treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy,C2717961,Thrombotic microangiopathy,11/25/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
405243250,405243250,Retifanlimab,,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,10/26/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States
404720524,404720524,Retifanlimab,,Treatment of Merkel cell carcinoma,C0007129,Merkel cell carcinoma,10/26/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation|1801 Augustine Cut-Off|Wilmington|Delaware|19803|United States
441072531,441072531,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
387061212,387061212,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
385327556,385327556,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
384647099,384647099,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
365372203,365372203,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
354355036,354355036,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
348838049,348838049,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
329976960,329976960,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
319478935,319478935,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
319435463,319435463,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
178103386,178103386,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
135341754,135341754,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
103771410,103771410,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
57288666,57288666,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
56314417,56314417,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
50070184,50070184,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
46505820,46505820,rituximab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,11/12/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Taxon Therapeutics Ltd.|122 Bar Kokhva St,|Herzliya|4600728|Israel"
223369697,223369697,Satumomab pendetide,Oncoscint CR/OV,Detection of ovarian carcinoma.,C4721610,Ovarian carcinoma,09/25/1989,Designated/Approved,,For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer., 12/29/1992 , 12/29/1999 ,,Cytogen Corporation|600 College Road East|Princeton|New Jersey|8540|United States
131279415,131279415,Satumomab pendetide,Oncoscint CR/OV,Detection of ovarian carcinoma.,C4721610,Ovarian carcinoma,09/25/1989,Designated/Approved,,For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer., 12/29/1992 , 12/29/1999 ,,Cytogen Corporation|600 College Road East|Princeton|New Jersey|8540|United States
387060190,387060190,vedolizumab,,Prevention of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,08/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
385327554,385327554,vedolizumab,,Prevention of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,08/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
384647097,384647097,vedolizumab,,Prevention of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,08/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
354355051,354355051,vedolizumab,,Prevention of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,08/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
347910392,347910392,vedolizumab,,Prevention of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,08/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
178104009,178104009,vedolizumab,,Prevention of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,08/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
160666632,160666632,vedolizumab,,Prevention of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,08/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
135277804,135277804,vedolizumab,,Prevention of graft versus host disease.,C0018133,GRAFT VERSUS HOST DISEASE,08/04/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
347910351,347910351,calfactant,,Treatment of acute respiratory distress syndrome (ARDS),"C0035222,C0748355","Acute respiratory distress syndrome , Acute respiratory distress syndrome",09/05/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"ONY, Inc.|Baird Research Park|Suite 114|Amherst|New York|14228|United States"
135339209,135339209,calfactant,,Treatment of acute respiratory distress syndrome (ARDS),"C0035222,C0748355","Acute respiratory distress syndrome , Acute respiratory distress syndrome",09/05/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"ONY, Inc.|Baird Research Park|Suite 114|Amherst|New York|14228|United States"
103771275,103771275,calfactant,,Treatment of acute respiratory distress syndrome (ARDS),"C0035222,C0748355","Acute respiratory distress syndrome , Acute respiratory distress syndrome",09/05/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"ONY, Inc.|Baird Research Park|Suite 114|Amherst|New York|14228|United States"
85756499,85756499,calfactant,,Treatment of acute respiratory distress syndrome (ARDS),"C0035222,C0748355","Acute respiratory distress syndrome , Acute respiratory distress syndrome",09/05/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"ONY, Inc.|Baird Research Park|Suite 114|Amherst|New York|14228|United States"
50070188,50070188,calfactant,,Treatment of acute respiratory distress syndrome (ARDS),"C0035222,C0748355","Acute respiratory distress syndrome , Acute respiratory distress syndrome",09/05/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"ONY, Inc.|Baird Research Park|Suite 114|Amherst|New York|14228|United States"
440790483,440790483,canakinumab,ILARIS,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,09/30/2008,Designated/Approved,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older., 05/09/2013 , 05/09/2020 ,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 135-566G|East Hanover|New Jersey|7936|United States
381124993,381124993,canakinumab,ILARIS,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,09/30/2008,Designated/Approved,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older., 05/09/2013 , 05/09/2020 ,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 135-566G|East Hanover|New Jersey|7936|United States
381124992,381124992,canakinumab,ILARIS,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,09/30/2008,Designated/Approved,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older., 05/09/2013 , 05/09/2020 ,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 135-566G|East Hanover|New Jersey|7936|United States
347910340,347910340,canakinumab,ILARIS,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,09/30/2008,Designated/Approved,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older., 05/09/2013 , 05/09/2020 ,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 135-566G|East Hanover|New Jersey|7936|United States
329976978,329976978,canakinumab,ILARIS,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,09/30/2008,Designated/Approved,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older., 05/09/2013 , 05/09/2020 ,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 135-566G|East Hanover|New Jersey|7936|United States
178103379,178103379,canakinumab,ILARIS,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,09/30/2008,Designated/Approved,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older., 05/09/2013 , 05/09/2020 ,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 135-566G|East Hanover|New Jersey|7936|United States
135332926,135332926,canakinumab,ILARIS,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,09/30/2008,Designated/Approved,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older., 05/09/2013 , 05/09/2020 ,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 135-566G|East Hanover|New Jersey|7936|United States
103771532,103771532,canakinumab,ILARIS,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,09/30/2008,Designated/Approved,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older., 05/09/2013 , 05/09/2020 ,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation|One Health Plaza|Bldg 135-566G|East Hanover|New Jersey|7936|United States
381125586,381125586,Desmoglein 3 synthetic peptide (PI-0824),,Treatment of pemphigus vulgaris,C0030809,Pemphigus Vulgaris,10/26/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"Peptimmune, Inc.|64 Sidney Street|Cambridge|Massachusetts|2139|United States"
319423538,319423538,Epoetin alpha,,Treatment of HIV associated anemia related to HIV infection or HIV treatment.,"C0002871,C0019693","Anemia , HIV infection",03/07/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"R. W. Johnson Pharmaceutical Research Institute|Route 202, P.O. Box 300|Raritan|New Jersey|8869|United States"
135310353,135310353,Epoetin alpha,,Treatment of HIV associated anemia related to HIV infection or HIV treatment.,"C0002871,C0019693","Anemia , HIV infection",03/07/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"R. W. Johnson Pharmaceutical Research Institute|Route 202, P.O. Box 300|Raritan|New Jersey|8869|United States"
49965745,49965745,Epoetin alpha,,Treatment of HIV associated anemia related to HIV infection or HIV treatment.,"C0002871,C0019693","Anemia , HIV infection",03/07/1989,Designated,Not FDA Approved for Orphan Indication,,,,,"R. W. Johnson Pharmaceutical Research Institute|Route 202, P.O. Box 300|Raritan|New Jersey|8869|United States"
347910296,347910296,inotuzumab ozogamicin,,Treatment of B-cell acute lymphoblastic leukemia,C1292769,B-cell acute lymphoblastic leukemia,03/25/2013,Designated/Approved,,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), 08/17/2017 , 08/17/2024 ,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),"Pfizer, Inc.|10646 Science Center Drive|San Diego|California|92121|United States"
252166478,252166478,inotuzumab ozogamicin,,Treatment of B-cell acute lymphoblastic leukemia,C1292769,B-cell acute lymphoblastic leukemia,03/25/2013,Designated/Approved,,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), 08/17/2017 , 08/17/2024 ,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),"Pfizer, Inc.|10646 Science Center Drive|San Diego|California|92121|United States"
160687610,160687610,inotuzumab ozogamicin,,Treatment of B-cell acute lymphoblastic leukemia,C1292769,B-cell acute lymphoblastic leukemia,03/25/2013,Designated/Approved,,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), 08/17/2017 , 08/17/2024 ,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),"Pfizer, Inc.|10646 Science Center Drive|San Diego|California|92121|United States"
135298753,135298753,inotuzumab ozogamicin,,Treatment of B-cell acute lymphoblastic leukemia,C1292769,B-cell acute lymphoblastic leukemia,03/25/2013,Designated/Approved,,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), 08/17/2017 , 08/17/2024 ,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),"Pfizer, Inc.|10646 Science Center Drive|San Diego|California|92121|United States"
404772323,404772323,lintuzumab,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,09/09/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.|34801 Campus Drive|Fremont|California|94555|United States"
249565664,249565664,lintuzumab,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,09/09/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.|34801 Campus Drive|Fremont|California|94555|United States"
160671685,160671685,lintuzumab,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,09/09/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.|34801 Campus Drive|Fremont|California|94555|United States"
135336964,135336964,lintuzumab,,Treatment of acute myelogenous leukemia,C0023467,Acute myelogenous leukemia,09/09/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.|34801 Campus Drive|Fremont|California|94555|United States"
404720052,404720052,lisocabtagene maraleucel,,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,04/01/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc.|400 Dexter Avenue N|400 Dexter Avenue N|Seattle|Washington|98109|United States"
381128031,381128031,recombinant human alpha-N-acetylglucosaminidase,,Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome),"C0026703,C0086648,C4521791","Mucopolysaccharidosis , Sanfilippo B syndrome , IIIB",04/15/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|100 College Street|Hew Haven|Connecticut|6510|United States"
381127585,381127585,recombinant human alpha-N-acetylglucosaminidase,,Treatment of mucopolysaccharidosis IIIB (Sanfilippo B syndrome),"C0026703,C0086648,C4521791","Mucopolysaccharidosis , Sanfilippo B syndrome , IIIB",04/15/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|100 College Street|Hew Haven|Connecticut|6510|United States"
160682331,160682331,toralizumab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/14/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Biogen IDEC Inc.|3030 Callan Road|San Diego|California|92121|United States
135287061,135287061,toralizumab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/14/2002,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Biogen IDEC Inc.|3030 Callan Road|San Diego|California|92121|United States
347910350,347910350,C1 esterase inhibitor (human),,Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.,C0002994,Angioedema,08/21/1996,Designated,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation|5555 Valley Boulevard|Los Angeles|California|90032|United States
333495402,333495402,C1 esterase inhibitor (human),,Treatment and prevention of angioedema caused by C1-esterase inhibitor deficiency.,C0002994,Angioedema,08/21/1996,Designated,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation|5555 Valley Boulevard|Los Angeles|California|90032|United States
46508122,46508122,Erythropoietin (recombinant human),,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",08/19/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"McDonnell Douglas Corp|P.O. Box 516, 107/2 MS10|St. Louis|Missouri|63166|United States"
441072528,441072528,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
440790341,440790341,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433791528,433791528,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433790701,433790701,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
387060165,387060165,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
354355050,354355050,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
348825932,348825932,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
329976987,329976987,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
178101701,178101701,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
135305802,135305802,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
103771449,103771449,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
91145133,91145133,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313883,56313883,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313209,56313209,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56311151,56311151,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
50067186,50067186,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
46505602,46505602,infliximab,,Treatment of juvenile rheumatoid arthritis,C3495559,Juvenile rheumatoid arthritis,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
440790923,440790923,rilonacept,,Treatment of familial Mediterranean fever,C0031069,Familial Mediterranean Fever,01/09/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Philip J Hashkes, MD, MSc.|Head, Section of Pediatric Rheumatology|9500 Euclid Avenue|Cleveland|Ohio|44195|United States"
349081322,349081322,rilonacept,,Treatment of familial Mediterranean fever,C0031069,Familial Mediterranean Fever,01/09/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Philip J Hashkes, MD, MSc.|Head, Section of Pediatric Rheumatology|9500 Euclid Avenue|Cleveland|Ohio|44195|United States"
347910349,347910349,rilonacept,,Treatment of familial Mediterranean fever,C0031069,Familial Mediterranean Fever,01/09/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Philip J Hashkes, MD, MSc.|Head, Section of Pediatric Rheumatology|9500 Euclid Avenue|Cleveland|Ohio|44195|United States"
178103396,178103396,rilonacept,,Treatment of familial Mediterranean fever,C0031069,Familial Mediterranean Fever,01/09/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Philip J Hashkes, MD, MSc.|Head, Section of Pediatric Rheumatology|9500 Euclid Avenue|Cleveland|Ohio|44195|United States"
135350808,135350808,rilonacept,,Treatment of familial Mediterranean fever,C0031069,Familial Mediterranean Fever,01/09/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Philip J Hashkes, MD, MSc.|Head, Section of Pediatric Rheumatology|9500 Euclid Avenue|Cleveland|Ohio|44195|United States"
103771528,103771528,rilonacept,,Treatment of familial Mediterranean fever,C0031069,Familial Mediterranean Fever,01/09/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Philip J Hashkes, MD, MSc.|Head, Section of Pediatric Rheumatology|9500 Euclid Avenue|Cleveland|Ohio|44195|United States"
441072531,441072531,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
387061212,387061212,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
385327556,385327556,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
384647099,384647099,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
365372203,365372203,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
354355036,354355036,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
348838049,348838049,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
329976960,329976960,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
319478935,319478935,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
319435463,319435463,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
178103386,178103386,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
135341754,135341754,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
103771410,103771410,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
57288666,57288666,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
56314417,56314417,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
50070184,50070184,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
46505820,46505820,rituximab,Rituxan,Treatment of non-Hodgkin's B-cell lymphoma,C0079731,non-Hodgkin's B-cell lymphoma,06/13/1994,Designated/Approved,,, 11/26/1997 , 11/26/2004 ,,"Genentech, Inc.|1 DNA Way, MS 242|South San Francisco|California|94080|United States"
381126435,381126435,ublituximab,,Treatment of Nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,09/05/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue, 48th Floor|New York|New York|10019|United States"
347911248,347911248,ublituximab,,Treatment of Nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,09/05/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue, 48th Floor|New York|New York|10019|United States"
310264701,310264701,ublituximab,,Treatment of Nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,09/05/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue, 48th Floor|New York|New York|10019|United States"
160676946,160676946,ublituximab,,Treatment of Nodal marginal zone lymphoma,C0242647,Nodal marginal zone lymphoma,09/05/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue, 48th Floor|New York|New York|10019|United States"
404770048,404770048,veltuzumab,,Treatment of pemphigus,C0030807,Pemphigus,11/17/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 The American Rd.|Morris Plains|New Jersey|7950|United States"
349278123,349278123,veltuzumab,,Treatment of pemphigus,C0030807,Pemphigus,11/17/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 The American Rd.|Morris Plains|New Jersey|7950|United States"
252166480,252166480,veltuzumab,,Treatment of pemphigus,C0030807,Pemphigus,11/17/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 The American Rd.|Morris Plains|New Jersey|7950|United States"
160687965,160687965,veltuzumab,,Treatment of pemphigus,C0030807,Pemphigus,11/17/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 The American Rd.|Morris Plains|New Jersey|7950|United States"
135330261,135330261,veltuzumab,,Treatment of pemphigus,C0030807,Pemphigus,11/17/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 The American Rd.|Morris Plains|New Jersey|7950|United States"
440790701,440790701,Botulinum toxin type A,Botox,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,08/20/1986,Designated/Approved,,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia., 12/21/2000 , 12/21/2007 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States"
404720407,404720407,Botulinum toxin type A,Botox,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,08/20/1986,Designated/Approved,,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia., 12/21/2000 , 12/21/2007 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States"
135351517,135351517,Botulinum toxin type A,Botox,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,08/20/1986,Designated/Approved,,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia., 12/21/2000 , 12/21/2007 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States"
81065599,81065599,Botulinum toxin type A,Botox,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,08/20/1986,Designated/Approved,,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia., 12/21/2000 , 12/21/2007 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States"
49895113,49895113,Botulinum toxin type A,Botox,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,08/20/1986,Designated/Approved,,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia., 12/21/2000 , 12/21/2007 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States"
46505347,46505347,Botulinum toxin type A,Botox,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,08/20/1986,Designated/Approved,,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia., 12/21/2000 , 12/21/2007 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States"
10147,10147,Botulinum toxin type A,Botox,Treatment of cervical dystonia.,C0152116,Cervical Dystonia,08/20/1986,Designated/Approved,,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia., 12/21/2000 , 12/21/2007 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92623|United States"
96025480,96025480,coagulation factor IX (recombinant),RIXUBIS,Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding),"C0008533,C0019080","Hemophilia B , Bleeding",10/31/2012,Designated/Approved,,"Adults and children with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis", 09/12/2014 , 09/12/2021 ,Children with hemophilia B for routine prophylaxis.,"Baxalta US, Inc.|300 Massachusetts Avenue|Cambridge|Massachusetts|2139|United States"
46508858,46508858,coagulation factor IX (recombinant),RIXUBIS,Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding),"C0008533,C0019080","Hemophilia B , Bleeding",10/31/2012,Designated/Approved,,"Adults and children with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis", 09/12/2014 , 09/12/2021 ,Children with hemophilia B for routine prophylaxis.,"Baxalta US, Inc.|300 Massachusetts Avenue|Cambridge|Massachusetts|2139|United States"
440806798,440806798,daratumumab,DARZALEX,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy., 08/20/2020 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
387060189,387060189,daratumumab,DARZALEX,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy., 08/20/2020 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
354355058,354355058,daratumumab,DARZALEX,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy., 08/20/2020 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
347910441,347910441,daratumumab,DARZALEX,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy., 08/20/2020 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
178103967,178103967,daratumumab,DARZALEX,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy., 08/20/2020 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
160671954,160671954,daratumumab,DARZALEX,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy., 08/20/2020 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
135304352,135304352,daratumumab,DARZALEX,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy., 08/20/2020 ,,,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
385327558,385327558,durvalumab,IMFINZI,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,07/10/2019,Designated/Approved,,"IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).", 03/27/2020 , 03/27/2027 ,"Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
384647100,384647100,durvalumab,IMFINZI,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,07/10/2019,Designated/Approved,,"IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).", 03/27/2020 , 03/27/2027 ,"Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
381127393,381127393,durvalumab,IMFINZI,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,07/10/2019,Designated/Approved,,"IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).", 03/27/2020 , 03/27/2027 ,"Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
347911229,347911229,durvalumab,IMFINZI,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,07/10/2019,Designated/Approved,,"IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).", 03/27/2020 , 03/27/2027 ,"Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
249565666,249565666,durvalumab,IMFINZI,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,07/10/2019,Designated/Approved,,"IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).", 03/27/2020 , 03/27/2027 ,"Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
242651787,242651787,durvalumab,IMFINZI,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,07/10/2019,Designated/Approved,,"IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).", 03/27/2020 , 03/27/2027 ,"Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
404720054,404720054,efgartigimod,,Treatment of Primary Immune Thrombocytopenia (ITP),"C0242584,C0398650","Immune thrombocytopenia , Immune Thrombocytopenia",02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,argenx BVBA|7 Industriepark-Zwijnaarde|Gent|Vlaanderen|Belgium
349272539,349272539,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
347827764,347827764,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
135263533,135263533,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
104234375,104234375,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
386330730,386330730,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
349995325,349995325,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
349980335,349980335,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
341169549,341169549,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
319392962,319392962,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
440790775,440790775,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
438456323,438456323,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
434252117,434252117,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
162064792,162064792,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
134979978,134979978,ferumoxytol,,For use in MR imaging for the mangement of brain tumors,C0006118,Brain Tumors,04/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD|3181 SW Sam Jackson Park Road|Portland|Oregon|97239|United States"
404772847,404772847,human coagulation factor XI,,Treatment of severe congential Factor XI deficiency.,C4321502,Factor XI Deficiency,11/08/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Laboratoire francais du Fractionnement et des Biot|3 Avenue des Tropiques|B.P. 305-Les Ulis|Courtaboeuf Cedex|France
49857433,49857433,Ibuprofen i.v. solution,,Prevention of patent ductus arteriosus.,C0013274,Patent ductus arteriosus,10/29/1996,Designated,Not FDA Approved for Orphan Indication,,,,,"Farmacon-IL, LLC|1720 Post Road East|Suite 213|Westport|Connecticut|6880|United States"
440790345,440790345,Interferon beta-1a,,Treatment of patients with secondary progressive multiple sclerosis,C0751965,Secondary progressive multiple sclerosis,03/11/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
381124371,381124371,Interferon beta-1a,,Treatment of patients with secondary progressive multiple sclerosis,C0751965,Secondary progressive multiple sclerosis,03/11/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
135335764,135335764,Interferon beta-1a,,Treatment of patients with secondary progressive multiple sclerosis,C0751965,Secondary progressive multiple sclerosis,03/11/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
103771353,103771353,Interferon beta-1a,,Treatment of patients with secondary progressive multiple sclerosis,C0751965,Secondary progressive multiple sclerosis,03/11/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
50070200,50070200,Interferon beta-1a,,Treatment of patients with secondary progressive multiple sclerosis,C0751965,Secondary progressive multiple sclerosis,03/11/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
46504899,46504899,Interferon beta-1a,,Treatment of patients with secondary progressive multiple sclerosis,C0751965,Secondary progressive multiple sclerosis,03/11/1996,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
404772791,404772791,Istiratumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/22/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Merrimack Pharmaceuticals, Inc.|One Kendall Square|Suite B7201|Cambridge|Massachusetts|2139|United States"
381127577,381127577,Istiratumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/22/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Merrimack Pharmaceuticals, Inc.|One Kendall Square|Suite B7201|Cambridge|Massachusetts|2139|United States"
374364061,374364061,Istiratumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/22/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Merrimack Pharmaceuticals, Inc.|One Kendall Square|Suite B7201|Cambridge|Massachusetts|2139|United States"
310264711,310264711,Istiratumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/22/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Merrimack Pharmaceuticals, Inc.|One Kendall Square|Suite B7201|Cambridge|Massachusetts|2139|United States"
387061105,387061105,pembrolizumab,,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,06/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Access Road|Whitehouse Station|New Jersey|8889|United States"
385327548,385327548,pembrolizumab,,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,06/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Access Road|Whitehouse Station|New Jersey|8889|United States"
384647091,384647091,pembrolizumab,,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,06/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Access Road|Whitehouse Station|New Jersey|8889|United States"
377483934,377483934,pembrolizumab,,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,06/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Access Road|Whitehouse Station|New Jersey|8889|United States"
354355033,354355033,pembrolizumab,,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,06/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Access Road|Whitehouse Station|New Jersey|8889|United States"
347910395,347910395,pembrolizumab,,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,06/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Access Road|Whitehouse Station|New Jersey|8889|United States"
194140938,194140938,pembrolizumab,,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,06/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Access Road|Whitehouse Station|New Jersey|8889|United States"
187051801,187051801,pembrolizumab,,Treatment of follicular lymphoma.,C0024301,follicular lymphoma,06/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Access Road|Whitehouse Station|New Jersey|8889|United States"
404772511,404772511,Pexastimogene Devacirepvec,,Treatment of stage IIB-IV melanoma,C0025202,melanoma,09/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"SillaJen, Inc.|6F, 111, Hyoyeol-ro|Suite 200|Buk-gu|Busan|South Korea"
174489633,174489633,Pexastimogene Devacirepvec,,Treatment of stage IIB-IV melanoma,C0025202,melanoma,09/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"SillaJen, Inc.|6F, 111, Hyoyeol-ro|Suite 200|Buk-gu|Busan|South Korea"
135314152,135314152,Pexastimogene Devacirepvec,,Treatment of stage IIB-IV melanoma,C0025202,melanoma,09/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"SillaJen, Inc.|6F, 111, Hyoyeol-ro|Suite 200|Buk-gu|Busan|South Korea"
347911301,347911301,polatuzumab vedotin-piiq,POLIVY,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,12/12/2016,Designated/Approved,,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.", 06/10/2019 , 06/10/2026 ,"In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.","Genentech, Inc.|1 DNA Way|MS# 451A|South San Francisco|California|94080|United States"
295369351,295369351,polatuzumab vedotin-piiq,POLIVY,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,12/12/2016,Designated/Approved,,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.", 06/10/2019 , 06/10/2026 ,"In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.","Genentech, Inc.|1 DNA Way|MS# 451A|South San Francisco|California|94080|United States"
252166614,252166614,polatuzumab vedotin-piiq,POLIVY,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,12/12/2016,Designated/Approved,,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.", 06/10/2019 , 06/10/2026 ,"In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.","Genentech, Inc.|1 DNA Way|MS# 451A|South San Francisco|California|94080|United States"
242651783,242651783,polatuzumab vedotin-piiq,POLIVY,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,12/12/2016,Designated/Approved,,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.", 06/10/2019 , 06/10/2026 ,"In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.","Genentech, Inc.|1 DNA Way|MS# 451A|South San Francisco|California|94080|United States"
347909856,347909856,Ranpirnase,,Treatment of Ebola virus disease (EVD),C0282687,Ebola Virus Disease,07/14/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Tamir Biotechnology, Inc.|51 John F Kennedy Parkway|1st Floor West|Short Hills|New Jersey|7078|United States"
160693068,160693068,Ranpirnase,,Treatment of Ebola virus disease (EVD),C0282687,Ebola Virus Disease,07/14/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Tamir Biotechnology, Inc.|51 John F Kennedy Parkway|1st Floor West|Short Hills|New Jersey|7078|United States"
135330577,135330577,Ranpirnase,,Treatment of Ebola virus disease (EVD),C0282687,Ebola Virus Disease,07/14/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Tamir Biotechnology, Inc.|51 John F Kennedy Parkway|1st Floor West|Short Hills|New Jersey|7078|United States"
91145206,91145206,Ranpirnase,,Treatment of Ebola virus disease (EVD),C0282687,Ebola Virus Disease,07/14/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Tamir Biotechnology, Inc.|51 John F Kennedy Parkway|1st Floor West|Short Hills|New Jersey|7078|United States"
404622793,404622793,rSP-C lung surfactant,,Treatment of adult respiratory distress syndrome.,C0035222,ADULT RESPIRATORY DISTRESS SYNDROME,04/03/2000,Designated,Not FDA Approved for Orphan Indication,,,,,Byk Gulden Pharmaceuticals|Byk-Gulden StraBe 2|Konstanz|Germany
440790931,440790931,Sargramostim,Leukine,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,"C0023467,C0023530,C0027947,C0750394,C4722467","Acute myelogenous leukemia , NEUTROPENIA , Neutropenia , Leukopenia , DEATH",03/06/1995,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death., 09/15/1995 , 09/15/2002 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
312856261,312856261,Sargramostim,Leukine,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,"C0023467,C0023530,C0027947,C0750394,C4722467","Acute myelogenous leukemia , NEUTROPENIA , Neutropenia , Leukopenia , DEATH",03/06/1995,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death., 09/15/1995 , 09/15/2002 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
249565588,249565588,Sargramostim,Leukine,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,"C0023467,C0023530,C0027947,C0750394,C4722467","Acute myelogenous leukemia , NEUTROPENIA , Neutropenia , Leukopenia , DEATH",03/06/1995,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death., 09/15/1995 , 09/15/2002 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
135360419,135360419,Sargramostim,Leukine,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,"C0023467,C0023530,C0027947,C0750394,C4722467","Acute myelogenous leukemia , NEUTROPENIA , Neutropenia , Leukopenia , DEATH",03/06/1995,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death., 09/15/1995 , 09/15/2002 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
135307693,135307693,Sargramostim,Leukine,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,"C0023467,C0023530,C0027947,C0750394,C4722467","Acute myelogenous leukemia , NEUTROPENIA , Neutropenia , Leukopenia , DEATH",03/06/1995,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death., 09/15/1995 , 09/15/2002 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
103771401,103771401,Sargramostim,Leukine,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,"C0023467,C0023530,C0027947,C0750394,C4722467","Acute myelogenous leukemia , NEUTROPENIA , Neutropenia , Leukopenia , DEATH",03/06/1995,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death., 09/15/1995 , 09/15/2002 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
50070152,50070152,Sargramostim,Leukine,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,"C0023467,C0023530,C0027947,C0750394,C4722467","Acute myelogenous leukemia , NEUTROPENIA , Neutropenia , Leukopenia , DEATH",03/06/1995,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death., 09/15/1995 , 09/15/2002 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
46507000,46507000,Sargramostim,Leukine,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,"C0023467,C0023530,C0027947,C0750394,C4722467","Acute myelogenous leukemia , NEUTROPENIA , Neutropenia , Leukopenia , DEATH",03/06/1995,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death., 09/15/1995 , 09/15/2002 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
793506,793506,Sargramostim,Leukine,To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,"C0023467,C0023530,C0027947,C0750394,C4722467","Acute myelogenous leukemia , NEUTROPENIA , Neutropenia , Leukopenia , DEATH",03/06/1995,Designated/Approved,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death., 09/15/1995 , 09/15/2002 ,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
404772367,404772367,Tislelizumab,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,11/06/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
404720526,404720526,Tislelizumab,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,11/06/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
377483943,377483943,Tislelizumab,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,11/06/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
340590223,340590223,Tislelizumab,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,11/06/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
347911239,347911239,tremelimumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
252166672,252166672,tremelimumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
160698442,160698442,tremelimumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
135304002,135304002,tremelimumab,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,01/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
440790701,440790701,botulinum toxin type A,Botox,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients,"C0007789,C0009917","Cerebral Palsy , Muscle contracture",12/06/1991,Designated/Approved,,BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age., 06/20/2019 , 06/20/2026 ,For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age,"Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States"
404720407,404720407,botulinum toxin type A,Botox,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients,"C0007789,C0009917","Cerebral Palsy , Muscle contracture",12/06/1991,Designated/Approved,,BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age., 06/20/2019 , 06/20/2026 ,For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age,"Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States"
135351517,135351517,botulinum toxin type A,Botox,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients,"C0007789,C0009917","Cerebral Palsy , Muscle contracture",12/06/1991,Designated/Approved,,BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age., 06/20/2019 , 06/20/2026 ,For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age,"Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States"
81065599,81065599,botulinum toxin type A,Botox,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients,"C0007789,C0009917","Cerebral Palsy , Muscle contracture",12/06/1991,Designated/Approved,,BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age., 06/20/2019 , 06/20/2026 ,For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age,"Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States"
49895113,49895113,botulinum toxin type A,Botox,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients,"C0007789,C0009917","Cerebral Palsy , Muscle contracture",12/06/1991,Designated/Approved,,BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age., 06/20/2019 , 06/20/2026 ,For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age,"Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States"
46505347,46505347,botulinum toxin type A,Botox,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients,"C0007789,C0009917","Cerebral Palsy , Muscle contracture",12/06/1991,Designated/Approved,,BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age., 06/20/2019 , 06/20/2026 ,For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age,"Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States"
10147,10147,botulinum toxin type A,Botox,Treatment of dynamic muscle contracture in pediatric cerebral palsy patients,"C0007789,C0009917","Cerebral Palsy , Muscle contracture",12/06/1991,Designated/Approved,,BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age., 06/20/2019 , 06/20/2026 ,For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age,"Allergan, Inc.|2525 Dupont Drive|T1-2A|Irvine|California|92623|United States"
441074980,441074980,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
404772311,404772311,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
178101682,178101682,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135326453,135326453,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135273161,135273161,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
134224740,134224740,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56314519,56314519,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56313513,56313513,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56313163,56313163,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56312547,56312547,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56312196,56312196,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311893,56311893,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311781,56311781,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311685,56311685,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56310774,56310774,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
7978489,7978489,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
7847813,7847813,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
10105,10105,Interleukin-2,,Treatment of metastatic malignant melanoma.,C0860594,Metastatic malignant melanoma,02/06/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
328083521,328083521,itolizumab,,Prevention of acute graft versus host disease,C0856825,Acute Graft Versus Host Disease,02/05/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.|2223 Avenida De La Playa|Suite 108|San Diego|California|92037|United States"
160677292,160677292,itolizumab,,Prevention of acute graft versus host disease,C0856825,Acute Graft Versus Host Disease,02/05/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.|2223 Avenida De La Playa|Suite 108|San Diego|California|92037|United States"
135346059,135346059,itolizumab,,Prevention of acute graft versus host disease,C0856825,Acute Graft Versus Host Disease,02/05/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.|2223 Avenida De La Playa|Suite 108|San Diego|California|92037|United States"
440790866,440790866,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine, 10/26/2009 , 10/26/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
387060162,387060162,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine, 10/26/2009 , 10/26/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910355,347910355,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine, 10/26/2009 , 10/26/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
329976991,329976991,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine, 10/26/2009 , 10/26/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
178103384,178103384,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine, 10/26/2009 , 10/26/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
135302238,135302238,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine, 10/26/2009 , 10/26/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
103771534,103771534,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine, 10/26/2009 , 10/26/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
426391582,426391582,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine, 10/26/2009 , 10/26/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
349995626,349995626,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine, 10/26/2009 , 10/26/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
134224294,134224294,Pegylated recombinant human megakaryocyte growth and development factor,,For reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.,C0040034,Thrombocytopenia,10/20/1997,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
441072531,441072531,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061212,387061212,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385327556,385327556,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
384647099,384647099,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
365372203,365372203,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355036,354355036,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348838049,348838049,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976960,329976960,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319478935,319478935,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319435463,319435463,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103386,178103386,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135341754,135341754,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771410,103771410,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
57288666,57288666,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
56314417,56314417,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50070184,50070184,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46505820,46505820,rituximab,Rituxan(r); MabThera(r),Treatment of pemphigus vulgaris.,C0030809,Pemphigus Vulgaris,02/23/2015,Designated/Approved,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris., 06/07/2018 , 06/07/2025 ,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440962803,440962803,romiplostim,,Treatment of chemotherapy-induced thrombocytopenia,C0040034,Thrombocytopenia,01/25/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
440790928,440790928,romiplostim,,Treatment of chemotherapy-induced thrombocytopenia,C0040034,Thrombocytopenia,01/25/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
349975939,349975939,romiplostim,,Treatment of chemotherapy-induced thrombocytopenia,C0040034,Thrombocytopenia,01/25/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
348939083,348939083,romiplostim,,Treatment of chemotherapy-induced thrombocytopenia,C0040034,Thrombocytopenia,01/25/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
347910087,347910087,romiplostim,,Treatment of chemotherapy-induced thrombocytopenia,C0040034,Thrombocytopenia,01/25/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
178103553,178103553,romiplostim,,Treatment of chemotherapy-induced thrombocytopenia,C0040034,Thrombocytopenia,01/25/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
135347108,135347108,romiplostim,,Treatment of chemotherapy-induced thrombocytopenia,C0040034,Thrombocytopenia,01/25/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
103771530,103771530,romiplostim,,Treatment of chemotherapy-induced thrombocytopenia,C0040034,Thrombocytopenia,01/25/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop 27-2-D|Thousand Oaks|California|91320|United States
440962803,440962803,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 10/17/2019 , 10/17/2026 ,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
440790928,440790928,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 10/17/2019 , 10/17/2026 ,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
349975939,349975939,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 10/17/2019 , 10/17/2026 ,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
348939083,348939083,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 10/17/2019 , 10/17/2026 ,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
347910087,347910087,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 10/17/2019 , 10/17/2026 ,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
178103553,178103553,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 10/17/2019 , 10/17/2026 ,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
135347108,135347108,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 10/17/2019 , 10/17/2026 ,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
103771530,103771530,romiplostim,Nplate,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/27/2003,Designated/Approved,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy", 10/17/2019 , 10/17/2026 ,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320|United States"
404772306,404772306,tadekinig alfa,,"Treatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)","C0085253,C0087031,C1384600","Adult-Onset Still's Disease , Still's disease , Systemic juvenile idiopathic arthritis",07/03/2017,Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd|EPFL Innovation Park|Building B|Lausanne|Vaud|Switzerland
375973264,375973264,tadekinig alfa,,"Treatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)","C0085253,C0087031,C1384600","Adult-Onset Still's Disease , Still's disease , Systemic juvenile idiopathic arthritis",07/03/2017,Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd|EPFL Innovation Park|Building B|Lausanne|Vaud|Switzerland
160709043,160709043,tadekinig alfa,,"Treatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)","C0085253,C0087031,C1384600","Adult-Onset Still's Disease , Still's disease , Systemic juvenile idiopathic arthritis",07/03/2017,Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd|EPFL Innovation Park|Building B|Lausanne|Vaud|Switzerland
135312030,135312030,tadekinig alfa,,"Treatment of Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA)","C0085253,C0087031,C1384600","Adult-Onset Still's Disease , Still's disease , Systemic juvenile idiopathic arthritis",07/03/2017,Designated,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd|EPFL Innovation Park|Building B|Lausanne|Vaud|Switzerland
319259212,319259212,Talactoferrin alfa,,Treatment of stage III/IV non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,08/08/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
160676985,160676985,Talactoferrin alfa,,Treatment of stage III/IV non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,08/08/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
135286186,135286186,Talactoferrin alfa,,Treatment of stage III/IV non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,08/08/2007,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
347911451,347911451,tisagenlecleucel,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,09/16/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
242651775,242651775,tisagenlecleucel,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,09/16/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910376,347910376,brentuximab vedotin,,Treatment of enteropathy-associated T-cell lymphoma.,C0456889,Enteropathy-Associated T-Cell Lymphoma,07/07/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
329976977,329976977,brentuximab vedotin,,Treatment of enteropathy-associated T-cell lymphoma.,C0456889,Enteropathy-Associated T-Cell Lymphoma,07/07/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
178103378,178103378,brentuximab vedotin,,Treatment of enteropathy-associated T-cell lymphoma.,C0456889,Enteropathy-Associated T-Cell Lymphoma,07/07/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135300399,135300399,brentuximab vedotin,,Treatment of enteropathy-associated T-cell lymphoma.,C0456889,Enteropathy-Associated T-Cell Lymphoma,07/07/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
131277422,131277422,brentuximab vedotin,,Treatment of enteropathy-associated T-cell lymphoma.,C0456889,Enteropathy-Associated T-Cell Lymphoma,07/07/2016,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
404771481,404771481,burosumab-twza,Crysvita,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),"C0733682,C3536983,C3540852","X-Linked Hypophosphatemia , vitamin d-resistant rickets , X-Linked Hypophosphatemia",12/14/2009,Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older, 04/17/2018 , 04/17/2025 ,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,"Kyowa Kirin, Inc.|135 US Highway 202/206|Suite 6|Bedminster|New Jersey|7921|United States"
342581770,342581770,burosumab-twza,Crysvita,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),"C0733682,C3536983,C3540852","X-Linked Hypophosphatemia , vitamin d-resistant rickets , X-Linked Hypophosphatemia",12/14/2009,Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older, 04/17/2018 , 04/17/2025 ,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,"Kyowa Kirin, Inc.|135 US Highway 202/206|Suite 6|Bedminster|New Jersey|7921|United States"
318464563,318464563,burosumab-twza,Crysvita,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),"C0733682,C3536983,C3540852","X-Linked Hypophosphatemia , vitamin d-resistant rickets , X-Linked Hypophosphatemia",12/14/2009,Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older, 04/17/2018 , 04/17/2025 ,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,"Kyowa Kirin, Inc.|135 US Highway 202/206|Suite 6|Bedminster|New Jersey|7921|United States"
318164811,318164811,burosumab-twza,Crysvita,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),"C0733682,C3536983,C3540852","X-Linked Hypophosphatemia , vitamin d-resistant rickets , X-Linked Hypophosphatemia",12/14/2009,Designated/Approved,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older, 04/17/2018 , 04/17/2025 ,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,"Kyowa Kirin, Inc.|135 US Highway 202/206|Suite 6|Bedminster|New Jersey|7921|United States"
135305092,135305092,Cystic fibrosis transmembrane conductance regulator,,For cystic fibrosis transmembrane conductance regulator protein replacement therapy in cystic fibrosis patients.,C0010674,Cystic Fibrosis,01/14/1992,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation|One Mountain Road|P.O. Box 9322|Framingham|Massachusetts|1701|United States
349991504,349991504,dacetuzumab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/06/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
347911348,347911348,dacetuzumab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/06/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
160666624,160666624,dacetuzumab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/06/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135323347,135323347,dacetuzumab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,10/06/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
404771395,404771395,emicizumab-kxwh,Hemlibra,Treatment of hemophilia A,C0019069,Hemophilia A,01/10/2014,Designated/Approved,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors, 11/16/2017 , 11/16/2024 ,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors,Genentech|1 DNA Way|MS 355e|South San Francisco|California|94080|United States
381127716,381127716,emicizumab-kxwh,Hemlibra,Treatment of hemophilia A,C0019069,Hemophilia A,01/10/2014,Designated/Approved,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors, 11/16/2017 , 11/16/2024 ,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors,Genentech|1 DNA Way|MS 355e|South San Francisco|California|94080|United States
354702217,354702217,emicizumab-kxwh,Hemlibra,Treatment of hemophilia A,C0019069,Hemophilia A,01/10/2014,Designated/Approved,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors, 11/16/2017 , 11/16/2024 ,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors,Genentech|1 DNA Way|MS 355e|South San Francisco|California|94080|United States
347911441,347911441,human coagulation factor VIII,,Immune tolerance induction in hemophilia A patients with inhibitors,"C0019069,C0020963","Hemophilia A , Immune Tolerance",12/03/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OCTAPHARMA USA, Inc.|121 River Street|12th Floor|Hoboken|New Jersey|7030|United States"
254561551,254561551,Matrix metalloproteinase inhibitor,,Treatment of corneal ulcers.,C0010043,corneal ulcers,12/05/1991,Designated,Not FDA Approved for Orphan Indication,,,,,"Glycomed, Inc|860 Atlantic Avenue|Alameda|California|94501|United States"
349976299,349976299,Reviparin sodium,,Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,"C0034065,C0149871","Pulmonary Embolism , Deep Vein Thrombosis",06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
347910423,347910423,Reviparin sodium,,Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,"C0034065,C0149871","Pulmonary Embolism , Deep Vein Thrombosis",06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
160676892,160676892,Reviparin sodium,,Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,"C0034065,C0149871","Pulmonary Embolism , Deep Vein Thrombosis",06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
135297230,135297230,Reviparin sodium,,Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,"C0034065,C0149871","Pulmonary Embolism , Deep Vein Thrombosis",06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
134224897,134224897,Reviparin sodium,,Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,"C0034065,C0149871","Pulmonary Embolism , Deep Vein Thrombosis",06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
49975203,49975203,Reviparin sodium,,Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,"C0034065,C0149871","Pulmonary Embolism , Deep Vein Thrombosis",06/18/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Abbott|Abbott Laboratories, Dept. 389, Bldg. J-45|200 Abbott Park Rd.|Abbott Park|Illinois|60064|United States"
441076374,441076374,Somatropin,Norditropin,Treatment of short stature in patients with Noonan syndrome,"C0013336,C0028326","Short stature , Noonan Syndrome",08/09/2006,Designated/Approved,,Treatment of short stature in patients with Noonan syndrome, 05/31/2007 , 05/31/2014 ,,Novo Nordisk Inc.|100 College Road West|Princeton|New Jersey|8540|United States
178101641,178101641,Somatropin,Norditropin,Treatment of short stature in patients with Noonan syndrome,"C0013336,C0028326","Short stature , Noonan Syndrome",08/09/2006,Designated/Approved,,Treatment of short stature in patients with Noonan syndrome, 05/31/2007 , 05/31/2014 ,,Novo Nordisk Inc.|100 College Road West|Princeton|New Jersey|8540|United States
135274454,135274454,Somatropin,Norditropin,Treatment of short stature in patients with Noonan syndrome,"C0013336,C0028326","Short stature , Noonan Syndrome",08/09/2006,Designated/Approved,,Treatment of short stature in patients with Noonan syndrome, 05/31/2007 , 05/31/2014 ,,Novo Nordisk Inc.|100 College Road West|Princeton|New Jersey|8540|United States
103771423,103771423,Somatropin,Norditropin,Treatment of short stature in patients with Noonan syndrome,"C0013336,C0028326","Short stature , Noonan Syndrome",08/09/2006,Designated/Approved,,Treatment of short stature in patients with Noonan syndrome, 05/31/2007 , 05/31/2014 ,,Novo Nordisk Inc.|100 College Road West|Princeton|New Jersey|8540|United States
50046577,50046577,Somatropin,Norditropin,Treatment of short stature in patients with Noonan syndrome,"C0013336,C0028326","Short stature , Noonan Syndrome",08/09/2006,Designated/Approved,,Treatment of short stature in patients with Noonan syndrome, 05/31/2007 , 05/31/2014 ,,Novo Nordisk Inc.|100 College Road West|Princeton|New Jersey|8540|United States
46506010,46506010,Somatropin,Norditropin,Treatment of short stature in patients with Noonan syndrome,"C0013336,C0028326","Short stature , Noonan Syndrome",08/09/2006,Designated/Approved,,Treatment of short stature in patients with Noonan syndrome, 05/31/2007 , 05/31/2014 ,,Novo Nordisk Inc.|100 College Road West|Princeton|New Jersey|8540|United States
441076374,441076374,Somatropin,Humatrope,Treatment of short stature associated with Turner syndrome.,"C0013336,C0041408","Short stature , Turner Syndrome",05/08/1990,Designated/Approved,,Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed., 12/30/1996 , 12/30/2003 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
178101641,178101641,Somatropin,Humatrope,Treatment of short stature associated with Turner syndrome.,"C0013336,C0041408","Short stature , Turner Syndrome",05/08/1990,Designated/Approved,,Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed., 12/30/1996 , 12/30/2003 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
135274454,135274454,Somatropin,Humatrope,Treatment of short stature associated with Turner syndrome.,"C0013336,C0041408","Short stature , Turner Syndrome",05/08/1990,Designated/Approved,,Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed., 12/30/1996 , 12/30/2003 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
103771423,103771423,Somatropin,Humatrope,Treatment of short stature associated with Turner syndrome.,"C0013336,C0041408","Short stature , Turner Syndrome",05/08/1990,Designated/Approved,,Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed., 12/30/1996 , 12/30/2003 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
50046577,50046577,Somatropin,Humatrope,Treatment of short stature associated with Turner syndrome.,"C0013336,C0041408","Short stature , Turner Syndrome",05/08/1990,Designated/Approved,,Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed., 12/30/1996 , 12/30/2003 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
46506010,46506010,Somatropin,Humatrope,Treatment of short stature associated with Turner syndrome.,"C0013336,C0041408","Short stature , Turner Syndrome",05/08/1990,Designated/Approved,,Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed., 12/30/1996 , 12/30/2003 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
404772338,404772338,spartalizumab,,Treatment of Stage IIB-IV melanoma,C0025202,melanoma,10/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|Office 337 A13.5B|East Hanover|New Jersey|7936|United States
404720473,404720473,spartalizumab,,Treatment of Stage IIB-IV melanoma,C0025202,melanoma,10/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|Office 337 A13.5B|East Hanover|New Jersey|7936|United States
381128172,381128172,spartalizumab,,Treatment of Stage IIB-IV melanoma,C0025202,melanoma,10/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|Office 337 A13.5B|East Hanover|New Jersey|7936|United States
381118850,381118850,spartalizumab,,Treatment of Stage IIB-IV melanoma,C0025202,melanoma,10/18/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|Office 337 A13.5B|East Hanover|New Jersey|7936|United States
135334152,135334152,Tositumomab and iodine I 131 tositumomab,Bexxar,Treatment of non-Hodgkin's B-cell lymphoma.,C0079731,non-Hodgkin's B-cell lymphoma,05/16/1994,Designated/Approved,,"Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy", 06/27/2003 , 06/27/2010 ,,"GlaxoSmithKline LLC|Corporation Service Company|2711 Centerville Road, Suite 400|Wilmington|Delaware|19808|United States"
347910400,347910400,blinatumomab,,Treatment of diffuse large B-cell lymphoma (DLBCL),"C0079744,C1332201","Diffuse Large B-Cell Lymphoma , Diffuse Large B-Cell Lymphoma",07/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|1 Amgen Center Drive|Thousand Oaks|California|91320|United States
178103956,178103956,blinatumomab,,Treatment of diffuse large B-cell lymphoma (DLBCL),"C0079744,C1332201","Diffuse Large B-Cell Lymphoma , Diffuse Large B-Cell Lymphoma",07/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|1 Amgen Center Drive|Thousand Oaks|California|91320|United States
160698788,160698788,blinatumomab,,Treatment of diffuse large B-cell lymphoma (DLBCL),"C0079744,C1332201","Diffuse Large B-Cell Lymphoma , Diffuse Large B-Cell Lymphoma",07/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|1 Amgen Center Drive|Thousand Oaks|California|91320|United States
135330301,135330301,blinatumomab,,Treatment of diffuse large B-cell lymphoma (DLBCL),"C0079744,C1332201","Diffuse Large B-Cell Lymphoma , Diffuse Large B-Cell Lymphoma",07/06/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|1 Amgen Center Drive|Thousand Oaks|California|91320|United States
387061103,387061103,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT., 04/25/2017 , 04/25/2024 ,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT., 04/25/2017 , 04/25/2024 ,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT., 04/25/2017 , 04/25/2024 ,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT., 04/25/2017 , 04/25/2024 ,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT., 04/25/2017 , 04/25/2024 ,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT., 04/25/2017 , 04/25/2024 ,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT., 04/25/2017 , 04/25/2024 ,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT., 04/25/2017 , 04/25/2024 ,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,OPDIVO,Treatment of Hodgkin lymphoma,C0019829,Hodgkin Lymphoma,08/07/2014,Designated/Approved,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT., 04/25/2017 , 04/25/2024 ,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company|Route 206 & Province Line Road|P. O. Box 4000|Princeton|New Jersey|8543|United States
404719952,404719952,recombinant nematode anticoagulant protein c2 (rNAPc2),,Treatment of viral hemorrhagic fever post-exposure to Ebola virus (treatment of Ebola),"C0019104,C0282687,C3854117","Viral Hemorrhagic Fever , Ebola , Exposure to Ebola virus",12/08/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ARCA Biopharma, Inc.|11080 Circle Point Rd.|Suite 140|Westminster|Colorado|80020|United States"
274915867,274915867,cyclocreatine phosphate,,Prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation.,C3263722,Injury,01/17/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Nour Heart Therapeutics, LLC|121 Locust Street, SW|Vienna|Virginia|22180|United States"
319149516,319149516,cyclocreatine phosphate,,Prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation.,C3263722,Injury,01/17/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Nour Heart Therapeutics, LLC|121 Locust Street, SW|Vienna|Virginia|22180|United States"
135082039,135082039,cyclocreatine phosphate,,Prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation.,C3263722,Injury,01/17/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Nour Heart Therapeutics, LLC|121 Locust Street, SW|Vienna|Virginia|22180|United States"
440806798,440806798,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent, 11/16/2015 , 11/16/2022 ,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
387060189,387060189,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent, 11/16/2015 , 11/16/2022 ,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
354355058,354355058,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent, 11/16/2015 , 11/16/2022 ,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
347910441,347910441,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent, 11/16/2015 , 11/16/2022 ,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
178103967,178103967,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent, 11/16/2015 , 11/16/2022 ,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
160671954,160671954,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent, 11/16/2015 , 11/16/2022 ,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
135304352,135304352,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent, 11/16/2015 , 11/16/2022 ,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
404719965,404719965,fish oil triglycerides,Omegaven,Treatment of parenteral nutrition-associated liver disease,C0267792,Liver Disease,02/27/2008,Designated/Approved,,Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC), 07/27/2018 , 07/27/2025 ,Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC),"Fresenius Kabi USA, LLC|3 Corporate Drive|Lake Zurich|Illinois|60047|United States"
223727442,223727442,Heat Shock Protein 70,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,03/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"ALS Biopharma, LLC|3805 Old Easton Rd|Doylestown|Pennsylvania|18902|United States"
440809644,440809644,mogamulizumab,POTELIGEO,Treatment of patients with cutaneous T-cell lymphoma.,C0079773,cutaneous T-cell lymphoma,11/02/2010,Designated/Approved,,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy., 08/08/2018 , 08/08/2025 ,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy.,Kyowa Kirin Pharmaceutical Development Inc.|212 Carnegie Center # 101|Princeton|New Jersey|8540|United States
347911339,347911339,mogamulizumab,POTELIGEO,Treatment of patients with cutaneous T-cell lymphoma.,C0079773,cutaneous T-cell lymphoma,11/02/2010,Designated/Approved,,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy., 08/08/2018 , 08/08/2025 ,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy.,Kyowa Kirin Pharmaceutical Development Inc.|212 Carnegie Center # 101|Princeton|New Jersey|8540|United States
178103091,178103091,mogamulizumab,POTELIGEO,Treatment of patients with cutaneous T-cell lymphoma.,C0079773,cutaneous T-cell lymphoma,11/02/2010,Designated/Approved,,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy., 08/08/2018 , 08/08/2025 ,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy.,Kyowa Kirin Pharmaceutical Development Inc.|212 Carnegie Center # 101|Princeton|New Jersey|8540|United States
160704158,160704158,mogamulizumab,POTELIGEO,Treatment of patients with cutaneous T-cell lymphoma.,C0079773,cutaneous T-cell lymphoma,11/02/2010,Designated/Approved,,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy., 08/08/2018 , 08/08/2025 ,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy.,Kyowa Kirin Pharmaceutical Development Inc.|212 Carnegie Center # 101|Princeton|New Jersey|8540|United States
135317476,135317476,mogamulizumab,POTELIGEO,Treatment of patients with cutaneous T-cell lymphoma.,C0079773,cutaneous T-cell lymphoma,11/02/2010,Designated/Approved,,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy., 08/08/2018 , 08/08/2025 ,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S麡ry syndrome (SS) after at least one prior systemic therapy.,Kyowa Kirin Pharmaceutical Development Inc.|212 Carnegie Center # 101|Princeton|New Jersey|8540|United States
404771405,404771405,Nonacog beta pegol,,Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease),C0008533,Hemophilia B,03/18/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|100 College Road West|Princeton|8540|United States"
160703802,160703802,Nonacog beta pegol,,Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease),C0008533,Hemophilia B,03/18/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|100 College Road West|Princeton|8540|United States"
135298307,135298307,Nonacog beta pegol,,Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease),C0008533,Hemophilia B,03/18/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|100 College Road West|Princeton|8540|United States"
404772397,404772397,pamrevlumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/19/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.|409 Illinois Street|San Francisco|California|94158|United States"
310264709,310264709,pamrevlumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/19/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.|409 Illinois Street|San Francisco|California|94158|United States"
160709238,160709238,pamrevlumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/19/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.|409 Illinois Street|San Francisco|California|94158|United States"
135282565,135282565,pamrevlumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,06/19/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.|409 Illinois Street|San Francisco|California|94158|United States"
440790901,440790901,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
348283348,348283348,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
135015958,135015958,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
104222302,104222302,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
53787421,53787421,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
386634024,386634024,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
385639808,385639808,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
319100261,319100261,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
75587323,75587323,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
50065422,50065422,porfimer,Photofrin,For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy,C1333324,Dysplasia in Barrett's Esophagus,10/19/2001,Designated/Approved,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy, 08/01/2003 , 08/01/2010 ,,Axcan Scandipharm Inc.|22 Inverness Parkway|Suite 310|Birmingham|Alabama|35242|United States
135294547,135294547,Recombinant human interleukin-12,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,10/20/1997,Designated,Not FDA Approved for Orphan Indication,,,,,"Genetics Institute, Inc.|87 Cambridge Park Drive|Cambridge|Massachusetts|2140|United States"
441076374,441076374,Somatropin,,"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures.","C0021359,C0022735,C0404585","Infertility , Hypogonadotropic Hypogonadism , Unexplained infertility",09/01/1987,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Pharmaceuticals|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States
178101641,178101641,Somatropin,,"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures.","C0021359,C0022735,C0404585","Infertility , Hypogonadotropic Hypogonadism , Unexplained infertility",09/01/1987,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Pharmaceuticals|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States
135274454,135274454,Somatropin,,"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures.","C0021359,C0022735,C0404585","Infertility , Hypogonadotropic Hypogonadism , Unexplained infertility",09/01/1987,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Pharmaceuticals|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States
103771423,103771423,Somatropin,,"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures.","C0021359,C0022735,C0404585","Infertility , Hypogonadotropic Hypogonadism , Unexplained infertility",09/01/1987,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Pharmaceuticals|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States
50046577,50046577,Somatropin,,"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures.","C0021359,C0022735,C0404585","Infertility , Hypogonadotropic Hypogonadism , Unexplained infertility",09/01/1987,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Pharmaceuticals|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States
46506010,46506010,Somatropin,,"Adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures.","C0021359,C0022735,C0404585","Infertility , Hypogonadotropic Hypogonadism , Unexplained infertility",09/01/1987,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Pharmaceuticals|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States
440790701,440790701,Botulinum toxin type A,,Treatment of spasmodic torticollis (cervical dystonia).,C0152116,Spasmodic torticollis,08/12/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom"
404720407,404720407,Botulinum toxin type A,,Treatment of spasmodic torticollis (cervical dystonia).,C0152116,Spasmodic torticollis,08/12/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom"
135351517,135351517,Botulinum toxin type A,,Treatment of spasmodic torticollis (cervical dystonia).,C0152116,Spasmodic torticollis,08/12/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom"
81065599,81065599,Botulinum toxin type A,,Treatment of spasmodic torticollis (cervical dystonia).,C0152116,Spasmodic torticollis,08/12/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom"
49895113,49895113,Botulinum toxin type A,,Treatment of spasmodic torticollis (cervical dystonia).,C0152116,Spasmodic torticollis,08/12/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom"
46505347,46505347,Botulinum toxin type A,,Treatment of spasmodic torticollis (cervical dystonia).,C0152116,Spasmodic torticollis,08/12/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom"
10147,10147,Botulinum toxin type A,,Treatment of spasmodic torticollis (cervical dystonia).,C0152116,Spasmodic torticollis,08/12/1998,Designated,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharm Limited|1 Bath Road|Maidenhead|Berkshire, SL6 4UH|United Kingdom"
404771481,404771481,burosumab-twza,,Treatment of tumor-induced osteomalacia (TIO) syndrome,C1274103,Tumor-induced osteomalacia,06/15/2017,Designated/Approved,,Crysvita (burosumab-twza) is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized., 06/18/2020 ,,,"Kyowa Kirin, Inc.|135 US Highway 202 206|Suite 6|Bedminster Township|New Jersey|7921|United States"
342581770,342581770,burosumab-twza,,Treatment of tumor-induced osteomalacia (TIO) syndrome,C1274103,Tumor-induced osteomalacia,06/15/2017,Designated/Approved,,Crysvita (burosumab-twza) is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized., 06/18/2020 ,,,"Kyowa Kirin, Inc.|135 US Highway 202 206|Suite 6|Bedminster Township|New Jersey|7921|United States"
318464563,318464563,burosumab-twza,,Treatment of tumor-induced osteomalacia (TIO) syndrome,C1274103,Tumor-induced osteomalacia,06/15/2017,Designated/Approved,,Crysvita (burosumab-twza) is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized., 06/18/2020 ,,,"Kyowa Kirin, Inc.|135 US Highway 202 206|Suite 6|Bedminster Township|New Jersey|7921|United States"
318164811,318164811,burosumab-twza,,Treatment of tumor-induced osteomalacia (TIO) syndrome,C1274103,Tumor-induced osteomalacia,06/15/2017,Designated/Approved,,Crysvita (burosumab-twza) is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized., 06/18/2020 ,,,"Kyowa Kirin, Inc.|135 US Highway 202 206|Suite 6|Bedminster Township|New Jersey|7921|United States"
440806798,440806798,daratumumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,08/06/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
387060189,387060189,daratumumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,08/06/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
354355058,354355058,daratumumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,08/06/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
347910441,347910441,daratumumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,08/06/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
178103967,178103967,daratumumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,08/06/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
160671954,160671954,daratumumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,08/06/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
135304352,135304352,daratumumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,08/06/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
440791103,440791103,denileukin diftitox,,Treatment of peripheral T-cell lymphoma (PTCL),C0079774,Peripheral T-Cell Lymphoma,06/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|155 Tice Blvd.|Woodcliff Lake|New Jersey|5271|United States"
381127241,381127241,denileukin diftitox,,Treatment of peripheral T-cell lymphoma (PTCL),C0079774,Peripheral T-Cell Lymphoma,06/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|155 Tice Blvd.|Woodcliff Lake|New Jersey|5271|United States"
178103623,178103623,denileukin diftitox,,Treatment of peripheral T-cell lymphoma (PTCL),C0079774,Peripheral T-Cell Lymphoma,06/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|155 Tice Blvd.|Woodcliff Lake|New Jersey|5271|United States"
135318399,135318399,denileukin diftitox,,Treatment of peripheral T-cell lymphoma (PTCL),C0079774,Peripheral T-Cell Lymphoma,06/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|155 Tice Blvd.|Woodcliff Lake|New Jersey|5271|United States"
125240988,125240988,denileukin diftitox,,Treatment of peripheral T-cell lymphoma (PTCL),C0079774,Peripheral T-Cell Lymphoma,06/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|155 Tice Blvd.|Woodcliff Lake|New Jersey|5271|United States"
103771199,103771199,denileukin diftitox,,Treatment of peripheral T-cell lymphoma (PTCL),C0079774,Peripheral T-Cell Lymphoma,06/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|155 Tice Blvd.|Woodcliff Lake|New Jersey|5271|United States"
50070181,50070181,denileukin diftitox,,Treatment of peripheral T-cell lymphoma (PTCL),C0079774,Peripheral T-Cell Lymphoma,06/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|155 Tice Blvd.|Woodcliff Lake|New Jersey|5271|United States"
46506950,46506950,denileukin diftitox,,Treatment of peripheral T-cell lymphoma (PTCL),C0079774,Peripheral T-Cell Lymphoma,06/29/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|155 Tice Blvd.|Woodcliff Lake|New Jersey|5271|United States"
441078173,441078173,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
440791125,440791125,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
349583301,349583301,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
283537479,283537479,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
178103548,178103548,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
135320862,135320862,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
134221887,134221887,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
103771266,103771266,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
49955776,49955776,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
46505833,46505833,filgrastim,Neupogen,Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,C0854467,Myelosuppression,11/20/2013,Designated/Approved,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)., 03/30/2015 , 03/30/2022 ,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.|One Amgen Center Drive|M/S 17-1-C|Thousand Oaks|California|91320|United States"
347911330,347911330,fresolimumab,,Treatment of primary focal segmental glomerulosclerosis,C1709661,Primary Focal Segmental Glomerulosclerosis,10/21/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genzyme, a Sanofi Company|200 Crossing Boulevard|Framingham|Massachusetts|1702|United States"
252166476,252166476,fresolimumab,,Treatment of primary focal segmental glomerulosclerosis,C1709661,Primary Focal Segmental Glomerulosclerosis,10/21/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genzyme, a Sanofi Company|200 Crossing Boulevard|Framingham|Massachusetts|1702|United States"
160687956,160687956,fresolimumab,,Treatment of primary focal segmental glomerulosclerosis,C1709661,Primary Focal Segmental Glomerulosclerosis,10/21/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genzyme, a Sanofi Company|200 Crossing Boulevard|Framingham|Massachusetts|1702|United States"
135281361,135281361,fresolimumab,,Treatment of primary focal segmental glomerulosclerosis,C1709661,Primary Focal Segmental Glomerulosclerosis,10/21/2010,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genzyme, a Sanofi Company|200 Crossing Boulevard|Framingham|Massachusetts|1702|United States"
440791136,440791136,golimumab,,Treatment of sarcoidosis,C0036202,Sarcoidosis,05/21/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
354355047,354355047,golimumab,,Treatment of sarcoidosis,C0036202,Sarcoidosis,05/21/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
349071996,349071996,golimumab,,Treatment of sarcoidosis,C0036202,Sarcoidosis,05/21/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
347910358,347910358,golimumab,,Treatment of sarcoidosis,C0036202,Sarcoidosis,05/21/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
329976985,329976985,golimumab,,Treatment of sarcoidosis,C0036202,Sarcoidosis,05/21/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
178103382,178103382,golimumab,,Treatment of sarcoidosis,C0036202,Sarcoidosis,05/21/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
135329319,135329319,golimumab,,Treatment of sarcoidosis,C0036202,Sarcoidosis,05/21/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
103771531,103771531,golimumab,,Treatment of sarcoidosis,C0036202,Sarcoidosis,05/21/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|200 Great Vallley Parkway|Malvern|Pennsylvania|19355|United States"
46506712,46506712,Interferon alfa-2a (recombinant),,For the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.,C0009404,Colorectal Cancer,05/14/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
440791040,440791040,Peginterferon alfa-2a,,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,09/30/1999,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
135347948,135347948,Peginterferon alfa-2a,,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,09/30/1999,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
103771381,103771381,Peginterferon alfa-2a,,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,09/30/1999,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
85286088,85286088,Peginterferon alfa-2a,,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,09/30/1999,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
46504860,46504860,Peginterferon alfa-2a,,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,09/30/1999,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
375580195,375580195,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
363868008,363868008,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
162219590,162219590,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
440003429,440003429,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
438486314,438486314,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
434304638,434304638,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
405456767,405456767,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
406865871,406865871,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
377599008,377599008,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
377359784,377359784,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
404615628,404615628,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
381393671,381393671,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
376241424,376241424,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
355076591,355076591,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
347260688,347260688,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
319306860,319306860,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
252216063,252216063,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
135104978,135104978,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
56459417,56459417,photochlor,,Treatment of Esophageal Cancer,C0014859,esophageal cancer,05/24/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC|701 Ellicott Street|Center of Excellence|Buffalo|New York|14203|United States"
404720535,404720535,sintilimab,,Treatment of T-cell lymphoma,C0079772,T-Cell Lymphoma,03/24/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Innovent Biologics (Suzhou) Co. Ltd|168 Dongping Street|Suzhou Industrial Park|Jiangsu Province|China
381128253,381128253,sintilimab,,Treatment of T-cell lymphoma,C0079772,T-Cell Lymphoma,03/24/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Innovent Biologics (Suzhou) Co. Ltd|168 Dongping Street|Suzhou Industrial Park|Jiangsu Province|China
440813738,440813738,talimogene laherparepvec,IMLYGIC,Treatment of stage IIb-stage IV melanoma,C0278883,stage iv melanoma,03/14/2011,Designated/Approved,,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery", 10/27/2015 , 10/27/2022 ,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery","BioVex, Inc. (subsidiary of Amgen)|Amgen|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States"
347911465,347911465,talimogene laherparepvec,IMLYGIC,Treatment of stage IIb-stage IV melanoma,C0278883,stage iv melanoma,03/14/2011,Designated/Approved,,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery", 10/27/2015 , 10/27/2022 ,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery","BioVex, Inc. (subsidiary of Amgen)|Amgen|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States"
160698451,160698451,talimogene laherparepvec,IMLYGIC,Treatment of stage IIb-stage IV melanoma,C0278883,stage iv melanoma,03/14/2011,Designated/Approved,,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery", 10/27/2015 , 10/27/2022 ,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery","BioVex, Inc. (subsidiary of Amgen)|Amgen|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States"
135343059,135343059,talimogene laherparepvec,IMLYGIC,Treatment of stage IIb-stage IV melanoma,C0278883,stage iv melanoma,03/14/2011,Designated/Approved,,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery", 10/27/2015 , 10/27/2022 ,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery","BioVex, Inc. (subsidiary of Amgen)|Amgen|Mail Stop 17-2-B|Thousand Oaks|California|91320|United States"
405092064,405092064,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061215,387061215,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385327557,385327557,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385326041,385326041,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355060,354355060,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
349016747,349016747,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
347910344,347910344,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976997,329976997,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103463,178103463,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135345962,135345962,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
104253153,104253153,tocilizumab,Actemra,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,04/17/2013,Designated/Approved,,Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), 03/04/2021 ,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
441072526,441072526,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens", 11/14/2014 , 11/14/2021 ,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178101605,178101605,cardiotrophin-1,,To protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.,C0035126,Ischemia-Reperfusion Injury,06/24/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.|Calloe ORENSE No. 85|2nd Floor|Madrid|Spain"
347911366,347911366,carlumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/24/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley PArkway|Malvern|Pennsylvania|19355|United States"
160698790,160698790,carlumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/24/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley PArkway|Malvern|Pennsylvania|19355|United States"
135350336,135350336,carlumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,10/24/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley PArkway|Malvern|Pennsylvania|19355|United States"
440816813,440816813,casimersen,Amondys 45,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,06/04/2019,Designated/Approved,,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping, 02/25/2021 ,,,"Sarepta Therapeutics, Inc.|215 First Street|Cambridge|Massachusetts|2142|United States"
404772429,404772429,casimersen,Amondys 45,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,06/04/2019,Designated/Approved,,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping, 02/25/2021 ,,,"Sarepta Therapeutics, Inc.|215 First Street|Cambridge|Massachusetts|2142|United States"
404719388,404719388,casimersen,Amondys 45,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,06/04/2019,Designated/Approved,,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping, 02/25/2021 ,,,"Sarepta Therapeutics, Inc.|215 First Street|Cambridge|Massachusetts|2142|United States"
377716579,377716579,casimersen,Amondys 45,Treatment of Duchenne muscular dystrophy,C0013264,DUCHENNE MUSCULAR DYSTROPHY,06/04/2019,Designated/Approved,,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping, 02/25/2021 ,,,"Sarepta Therapeutics, Inc.|215 First Street|Cambridge|Massachusetts|2142|United States"
347911432,347911432,Coagulation factor X (human),COAGADEX,Treatment of hereditary factor X deficiency,C0272327,Hereditary Factor X Deficiency,11/08/2007,Designated/Approved,,Treatment of adults and adolescents (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild hereditary Factor X deficiency, 10/20/2015 , 10/20/2022 ,Treatment of adults and adolescents (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild hereditary Factor X deficiency,Bio Products Laboratory Limited|Dagger Lane|Elstree|Hertfordshire|United Kingdom
347909859,347909859,epratuzumab,,Treatment of non-Hodgkin's lymphoma,C0024305,Non-Hodgkin's Lymphoma,07/13/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
249565768,249565768,epratuzumab,,Treatment of non-Hodgkin's lymphoma,C0024305,Non-Hodgkin's Lymphoma,07/13/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
160682287,160682287,epratuzumab,,Treatment of non-Hodgkin's lymphoma,C0024305,Non-Hodgkin's Lymphoma,07/13/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
135308971,135308971,epratuzumab,,Treatment of non-Hodgkin's lymphoma,C0024305,Non-Hodgkin's Lymphoma,07/13/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
440790345,440790345,interferon Beta-1a,,Treatment of juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,10/14/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
381124371,381124371,interferon Beta-1a,,Treatment of juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,10/14/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
135335764,135335764,interferon Beta-1a,,Treatment of juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,10/14/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
103771353,103771353,interferon Beta-1a,,Treatment of juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,10/14/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
50070200,50070200,interferon Beta-1a,,Treatment of juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,10/14/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
46504899,46504899,interferon Beta-1a,,Treatment of juvenile rheumatoid arthritis.,C3495559,Juvenile rheumatoid arthritis,10/14/1998,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
404622439,404622439,mifamuritide,,Treatment of osteosarcoma,C0029463,Osteosarcoma,06/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.|40 Landsdowne Street|Cambridge|Massachusetts|2139|United States"
387061103,387061103,nivolumab,,Treatment of gastric cancer and gastro-esophageal junction cancer.,C0024623,Gastric Cancer,12/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,,Treatment of gastric cancer and gastro-esophageal junction cancer.,C0024623,Gastric Cancer,12/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,,Treatment of gastric cancer and gastro-esophageal junction cancer.,C0024623,Gastric Cancer,12/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,,Treatment of gastric cancer and gastro-esophageal junction cancer.,C0024623,Gastric Cancer,12/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,,Treatment of gastric cancer and gastro-esophageal junction cancer.,C0024623,Gastric Cancer,12/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,,Treatment of gastric cancer and gastro-esophageal junction cancer.,C0024623,Gastric Cancer,12/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,,Treatment of gastric cancer and gastro-esophageal junction cancer.,C0024623,Gastric Cancer,12/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,,Treatment of gastric cancer and gastro-esophageal junction cancer.,C0024623,Gastric Cancer,12/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,,Treatment of gastric cancer and gastro-esophageal junction cancer.,C0024623,Gastric Cancer,12/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
404772367,404772367,tislelizumab,,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",C0024623,Gastric Cancer,05/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
404720526,404720526,tislelizumab,,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",C0024623,Gastric Cancer,05/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
377483943,377483943,tislelizumab,,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",C0024623,Gastric Cancer,05/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
340590223,340590223,tislelizumab,,"Treatment of gastric cancer, including cancer of the gastroesophageal junction",C0024623,Gastric Cancer,05/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.|2955 Campus Drive|Suite 200|San Mateo|California|94403|United States"
404719522,404719522,Tominersen,,Treatment of Huntington's disease,C0020179,Huntington's Disease,12/29/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
402425700,402425700,Tominersen,,Treatment of Huntington's disease,C0020179,Huntington's Disease,12/29/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
381126435,381126435,ublituximab,,"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)","C0242647,C1367654","marginal zone lymphoma , Marginal zone lymphoma",09/05/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue, 48th Floor|New York|New York|10019|United States"
347911248,347911248,ublituximab,,"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)","C0242647,C1367654","marginal zone lymphoma , Marginal zone lymphoma",09/05/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue, 48th Floor|New York|New York|10019|United States"
310264701,310264701,ublituximab,,"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)","C0242647,C1367654","marginal zone lymphoma , Marginal zone lymphoma",09/05/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue, 48th Floor|New York|New York|10019|United States"
160676946,160676946,ublituximab,,"Treatment of Extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, MALT)","C0242647,C1367654","marginal zone lymphoma , Marginal zone lymphoma",09/05/2013,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue, 48th Floor|New York|New York|10019|United States"
347910376,347910376,brentuximab vedotin,,Treatment of extranodal NK/T-cell lymphoma (ENKTL),C0079772,T-Cell Lymphoma,11/13/2018,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
329976977,329976977,brentuximab vedotin,,Treatment of extranodal NK/T-cell lymphoma (ENKTL),C0079772,T-Cell Lymphoma,11/13/2018,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
178103378,178103378,brentuximab vedotin,,Treatment of extranodal NK/T-cell lymphoma (ENKTL),C0079772,T-Cell Lymphoma,11/13/2018,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135300399,135300399,brentuximab vedotin,,Treatment of extranodal NK/T-cell lymphoma (ENKTL),C0079772,T-Cell Lymphoma,11/13/2018,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
131277422,131277422,brentuximab vedotin,,Treatment of extranodal NK/T-cell lymphoma (ENKTL),C0079772,T-Cell Lymphoma,11/13/2018,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
440791103,440791103,denileukin diftitox,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
381127241,381127241,denileukin diftitox,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
178103623,178103623,denileukin diftitox,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
135318399,135318399,denileukin diftitox,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
125240988,125240988,denileukin diftitox,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
103771199,103771199,denileukin diftitox,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
50070181,50070181,denileukin diftitox,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
46506950,46506950,denileukin diftitox,,Treatment of peripheral T-cell lymphoma,C0079774,Peripheral T-Cell Lymphoma,04/30/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
404772673,404772673,elezanumab,,Treatment of acute spinal cord injury,C0878589,acute spinal cord injury,03/17/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.|1 North Waukegan Road|North Chicago|Illinois|60044|United States
404719524,404719524,elezanumab,,Treatment of acute spinal cord injury,C0878589,acute spinal cord injury,03/17/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.|1 North Waukegan Road|North Chicago|Illinois|60044|United States
381127993,381127993,elezanumab,,Treatment of acute spinal cord injury,C0878589,acute spinal cord injury,03/17/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.|1 North Waukegan Road|North Chicago|Illinois|60044|United States
318164809,318164809,elezanumab,,Treatment of acute spinal cord injury,C0878589,acute spinal cord injury,03/17/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.|1 North Waukegan Road|North Chicago|Illinois|60044|United States
404617350,404617350,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
375758272,375758272,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
348744312,348744312,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
335987561,335987561,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
319299707,319299707,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
313077795,313077795,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
254775499,254775499,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
135023114,135023114,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
134979644,134979644,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
134222261,134222261,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
103771260,103771260,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
49992424,49992424,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
438485410,438485410,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
434303155,434303155,pentosan polysulfate sodium,,Treatment of sickle cell disease.,C0002895,Sickle Cell Disease,09/16/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.|108 Eagle Trace Drive|Half Moon Bay|California|94019|United States"
49978882,49978882,pentostatin for injection,Nipent,Treatment of hairy cell leukemia,C0023443,Hairy Cell Leukemia,09/10/1987,Designated/Approved,,Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia., 10/11/1991 , 10/11/1998 ,,"SuperGen, Inc.|4140 Dublin Blvd.|Suite 200|Dublin|California|94568|United States"
404772364,404772364,Rozanolixizumab,,Treatment of immune thrombocytopenic purpura (ITP),C0398650,Immune thrombocytopenic purpura,04/30/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.|1950 Lake Park Drive Building 2100|Smyrna|Georgia|30080|United States"
404719939,404719939,Rozanolixizumab,,Treatment of immune thrombocytopenic purpura (ITP),C0398650,Immune thrombocytopenic purpura,04/30/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.|1950 Lake Park Drive Building 2100|Smyrna|Georgia|30080|United States"
381127650,381127650,Rozanolixizumab,,Treatment of immune thrombocytopenic purpura (ITP),C0398650,Immune thrombocytopenic purpura,04/30/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.|1950 Lake Park Drive Building 2100|Smyrna|Georgia|30080|United States"
354702273,354702273,Rozanolixizumab,,Treatment of immune thrombocytopenic purpura (ITP),C0398650,Immune thrombocytopenic purpura,04/30/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.|1950 Lake Park Drive Building 2100|Smyrna|Georgia|30080|United States"
440790971,440790971,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
387060191,387060191,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
385327552,385327552,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
384647095,384647095,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
354355053,354355053,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
349905851,349905851,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
347910190,347910190,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
178103467,178103467,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
135302166,135302166,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
103771533,103771533,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
387124020,387124020,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
377017835,377017835,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
355433663,355433663,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
349984255,349984255,ustekinumab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,12/28/2011,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|800 & 850 Ridgeview Drive|Horsham|Pennsylvania|19044|United States"
349632300,349632300,cholera toxin B subunit,,Treatment of ulcerative colitis in pediatric patients,C0009324,Ulcerative Colitis,11/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Aliment Wellness LLC|9462 Brownsboro Road|Suite 340|Louisville|Kentucky|40241|United States
162228219,162228219,cholera toxin B subunit,,Treatment of ulcerative colitis in pediatric patients,C0009324,Ulcerative Colitis,11/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Aliment Wellness LLC|9462 Brownsboro Road|Suite 340|Louisville|Kentucky|40241|United States
53787834,53787834,cholera toxin B subunit,,Treatment of ulcerative colitis in pediatric patients,C0009324,Ulcerative Colitis,11/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Aliment Wellness LLC|9462 Brownsboro Road|Suite 340|Louisville|Kentucky|40241|United States
381126731,381126731,demcizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,04/30/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
347911369,347911369,demcizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,04/30/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
252166661,252166661,demcizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,04/30/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
160703930,160703930,demcizumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,04/30/2014,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
347910347,347910347,elotuzumab,Empliciti,Treatment of multiple myeloma,C0026764,Multiple Myeloma,09/01/2011,Designated/Approved,,EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor., 11/06/2018 , 11/06/2025 ,"Indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, excluding adult patients covered by Emplicitis previously approved indication for multiple myeloma.",Bristol-Myers Squibb Co.|P.O. Box 5326|Princeton|New Jersey|8543|United States
252166573,252166573,elotuzumab,Empliciti,Treatment of multiple myeloma,C0026764,Multiple Myeloma,09/01/2011,Designated/Approved,,EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor., 11/06/2018 , 11/06/2025 ,"Indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, excluding adult patients covered by Emplicitis previously approved indication for multiple myeloma.",Bristol-Myers Squibb Co.|P.O. Box 5326|Princeton|New Jersey|8543|United States
160666625,160666625,elotuzumab,Empliciti,Treatment of multiple myeloma,C0026764,Multiple Myeloma,09/01/2011,Designated/Approved,,EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor., 11/06/2018 , 11/06/2025 ,"Indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, excluding adult patients covered by Emplicitis previously approved indication for multiple myeloma.",Bristol-Myers Squibb Co.|P.O. Box 5326|Princeton|New Jersey|8543|United States
135312351,135312351,elotuzumab,Empliciti,Treatment of multiple myeloma,C0026764,Multiple Myeloma,09/01/2011,Designated/Approved,,EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor., 11/06/2018 , 11/06/2025 ,"Indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, excluding adult patients covered by Emplicitis previously approved indication for multiple myeloma.",Bristol-Myers Squibb Co.|P.O. Box 5326|Princeton|New Jersey|8543|United States
160698499,160698499,Epoetin beta,,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",10/22/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Chugai-USA, Inc.|3780 Hawthorn Court|Waukegan|Illinois|60087|United States"
135362249,135362249,Epoetin beta,,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",10/22/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Chugai-USA, Inc.|3780 Hawthorn Court|Waukegan|Illinois|60087|United States"
135362212,135362212,Epoetin beta,,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",10/22/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Chugai-USA, Inc.|3780 Hawthorn Court|Waukegan|Illinois|60087|United States"
134221730,134221730,Epoetin beta,,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",10/22/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Chugai-USA, Inc.|3780 Hawthorn Court|Waukegan|Illinois|60087|United States"
49965746,49965746,Epoetin beta,,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",10/22/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Chugai-USA, Inc.|3780 Hawthorn Court|Waukegan|Illinois|60087|United States"
46508122,46508122,Epoetin beta,,Treatment of anemia associated with end stage renal disease.,"C0002871,C0022661","Anemia , End stage renal disease",10/22/1987,Designated,Not FDA Approved for Orphan Indication,,,,,"Chugai-USA, Inc.|3780 Hawthorn Court|Waukegan|Illinois|60087|United States"
160687626,160687626,golnerminogene pradenovec,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,10/28/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"GenVec, Inc.|65 West Watkins Mill Road|Gaithersburg|Maryland|20878|United States"
135302199,135302199,golnerminogene pradenovec,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,10/28/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"GenVec, Inc.|65 West Watkins Mill Road|Gaithersburg|Maryland|20878|United States"
349441571,349441571,milatuzumab,,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,06/24/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
347911409,347911409,milatuzumab,,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,06/24/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
252166479,252166479,milatuzumab,,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,06/24/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
160682609,160682609,milatuzumab,,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,06/24/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
135306496,135306496,milatuzumab,,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,06/24/2008,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
404772815,404772815,monoclonal antibody 3F8,,Treatment of neuroblastoma,C0027819,Neuroblastoma,10/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,United Therapeutics Corporation|55 TW Alexander Drive|P. O. Box 14186|Research Triangle Park|North Carolina|27709|United States
381124865,381124865,monoclonal antibody 3F8,,Treatment of neuroblastoma,C0027819,Neuroblastoma,10/16/2008,Designated,Not FDA Approved for Orphan Indication,,,,,United Therapeutics Corporation|55 TW Alexander Drive|P. O. Box 14186|Research Triangle Park|North Carolina|27709|United States
404720043,404720043,neihulizumab,,Treatment of acute graft-versus-host disease (aGvHD),C0856825,Acute graft-versus-host disease,01/25/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"AltruBio Inc. (formerly AbGenomics International, Inc.)|5050 El Camino Real|Suite #105|Los Altos|California|94022|United States"
375973203,375973203,neihulizumab,,Treatment of acute graft-versus-host disease (aGvHD),C0856825,Acute graft-versus-host disease,01/25/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"AltruBio Inc. (formerly AbGenomics International, Inc.)|5050 El Camino Real|Suite #105|Los Altos|California|94022|United States"
404772217,404772217,Peginterferon lambda-1a,,Treatment of hepatitis Delta virus infection,"C0011220,C0042769","Hepatitis Delta Virus , Virus Infection",08/25/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Eiger BioPharmaceuticals, Inc.|350 Cambridge Avenue|Suite 350|Palo Alto|California|94306|United States"
315246216,315246216,Peginterferon lambda-1a,,Treatment of hepatitis Delta virus infection,"C0011220,C0042769","Hepatitis Delta Virus , Virus Infection",08/25/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Eiger BioPharmaceuticals, Inc.|350 Cambridge Avenue|Suite 350|Palo Alto|California|94306|United States"
160682330,160682330,Peginterferon lambda-1a,,Treatment of hepatitis Delta virus infection,"C0011220,C0042769","Hepatitis Delta Virus , Virus Infection",08/25/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Eiger BioPharmaceuticals, Inc.|350 Cambridge Avenue|Suite 350|Palo Alto|California|94306|United States"
387061105,387061105,pembrolizumab,,Treatment of Biliary Tract Carcinoma,C4745063,Biliary Tract Carcinoma,10/09/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
385327548,385327548,pembrolizumab,,Treatment of Biliary Tract Carcinoma,C4745063,Biliary Tract Carcinoma,10/09/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
384647091,384647091,pembrolizumab,,Treatment of Biliary Tract Carcinoma,C4745063,Biliary Tract Carcinoma,10/09/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
377483934,377483934,pembrolizumab,,Treatment of Biliary Tract Carcinoma,C4745063,Biliary Tract Carcinoma,10/09/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
354355033,354355033,pembrolizumab,,Treatment of Biliary Tract Carcinoma,C4745063,Biliary Tract Carcinoma,10/09/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
347910395,347910395,pembrolizumab,,Treatment of Biliary Tract Carcinoma,C4745063,Biliary Tract Carcinoma,10/09/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
194140938,194140938,pembrolizumab,,Treatment of Biliary Tract Carcinoma,C4745063,Biliary Tract Carcinoma,10/09/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
187051801,187051801,pembrolizumab,,Treatment of Biliary Tract Carcinoma,C4745063,Biliary Tract Carcinoma,10/09/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
440790923,440790923,rilonacept,Arcalyst,Treatment of pericarditis,C0031046,Pericarditis,07/14/2020,Designated/Approved,,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older., 03/18/2021 ,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
349081322,349081322,rilonacept,Arcalyst,Treatment of pericarditis,C0031046,Pericarditis,07/14/2020,Designated/Approved,,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older., 03/18/2021 ,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
347910349,347910349,rilonacept,Arcalyst,Treatment of pericarditis,C0031046,Pericarditis,07/14/2020,Designated/Approved,,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older., 03/18/2021 ,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
178103396,178103396,rilonacept,Arcalyst,Treatment of pericarditis,C0031046,Pericarditis,07/14/2020,Designated/Approved,,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older., 03/18/2021 ,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
135350808,135350808,rilonacept,Arcalyst,Treatment of pericarditis,C0031046,Pericarditis,07/14/2020,Designated/Approved,,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older., 03/18/2021 ,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
103771528,103771528,rilonacept,Arcalyst,Treatment of pericarditis,C0031046,Pericarditis,07/14/2020,Designated/Approved,,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older., 03/18/2021 ,,,"Kiniksa Pharmaceuticals, Ltd.|c/o Kiniksa Pharmaceuticals Corp.|100 Hayden Avenue|Lexington|Massachusetts|2421|United States"
441072526,441072526,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,11/06/2003,Designated/Approved,,Treatment of renal cell carcinoma in combination with interferon alfa, 07/31/2009 , 07/31/2016 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440234681,440234681,brexucabtagene autoleucel,,Treatment of chronic lymphocytic leukemia.,C0023434,Chronic Lymphocytic Leukemia,04/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
440806798,440806798,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received", 06/16/2017 , 06/16/2024 ,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immun","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
387060189,387060189,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received", 06/16/2017 , 06/16/2024 ,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immun","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
354355058,354355058,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received", 06/16/2017 , 06/16/2024 ,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immun","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
347910441,347910441,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received", 06/16/2017 , 06/16/2024 ,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immun","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
178103967,178103967,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received", 06/16/2017 , 06/16/2024 ,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immun","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
160671954,160671954,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received", 06/16/2017 , 06/16/2024 ,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immun","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
135304352,135304352,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received", 06/16/2017 , 06/16/2024 ,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immun","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
347910347,347910347,elotuzumab,Empliciti,Treatment of multiple myeloma,C0026764,Multiple Myeloma,09/01/2011,Designated/Approved,,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies, 11/30/2015 , 11/30/2022 ,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,Bristol-Myers Squibb Co.|P.O. Box 5326|Princeton|New Jersey|8543|United States
252166573,252166573,elotuzumab,Empliciti,Treatment of multiple myeloma,C0026764,Multiple Myeloma,09/01/2011,Designated/Approved,,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies, 11/30/2015 , 11/30/2022 ,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,Bristol-Myers Squibb Co.|P.O. Box 5326|Princeton|New Jersey|8543|United States
160666625,160666625,elotuzumab,Empliciti,Treatment of multiple myeloma,C0026764,Multiple Myeloma,09/01/2011,Designated/Approved,,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies, 11/30/2015 , 11/30/2022 ,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,Bristol-Myers Squibb Co.|P.O. Box 5326|Princeton|New Jersey|8543|United States
135312351,135312351,elotuzumab,Empliciti,Treatment of multiple myeloma,C0026764,Multiple Myeloma,09/01/2011,Designated/Approved,,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies, 11/30/2015 , 11/30/2022 ,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,Bristol-Myers Squibb Co.|P.O. Box 5326|Princeton|New Jersey|8543|United States
160693060,160693060,inolimomab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,ElsaLys Biotech SAS|317 Avenue Jean Jaures|Batiment Accinov|Lyon|France
135325590,135325590,inolimomab,,Treatment of graft versus host disease,C0018133,GRAFT VERSUS HOST DISEASE,10/23/2002,Designated,Not FDA Approved for Orphan Indication,,,,,ElsaLys Biotech SAS|317 Avenue Jean Jaures|Batiment Accinov|Lyon|France
46504899,46504899,Interferon beta-1a (recombinant human),,"Treatment of acute non-A, non-B hepatitis.",C0019196,"Non-A, Non-B Hepatitis",07/24/1992,Designated,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.|14 Cambridge Center|Cambridge|Massachusetts|2142|United States"
135287563,135287563,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
131273201,131273201,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
387061107,387061107,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
385327547,385327547,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
384647090,384647090,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
354355037,354355037,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
349072362,349072362,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
347910341,347910341,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
329976988,329976988,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
178103470,178103470,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.", 10/28/2015 , 10/28/2022 ,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
387061107,387061107,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
385327547,385327547,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
384647090,384647090,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
354355037,354355037,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
349072362,349072362,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
347910341,347910341,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
329976988,329976988,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
178103470,178103470,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
135287563,135287563,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
131273201,131273201,ipilimumab,Yervoy,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",C0278883,stage iv melanoma,06/03/2004,Designated/Approved,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older), 07/21/2017 , 07/21/2024 ,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company|P. O. Box 4000|Princeton|New Jersey|8543|United States
440801540,440801540,isatuximab,Sarclisa,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/22/2014,Designated/Approved,,"SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.", 03/02/2020 , 03/02/2027 ,"Indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.","Sanofi U.S. Services, Inc.|500 Kendall Street|Cambridge|Massachusetts|2142|United States"
404772261,404772261,isatuximab,Sarclisa,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/22/2014,Designated/Approved,,"SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.", 03/02/2020 , 03/02/2027 ,"Indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.","Sanofi U.S. Services, Inc.|500 Kendall Street|Cambridge|Massachusetts|2142|United States"
381127523,381127523,isatuximab,Sarclisa,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/22/2014,Designated/Approved,,"SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.", 03/02/2020 , 03/02/2027 ,"Indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.","Sanofi U.S. Services, Inc.|500 Kendall Street|Cambridge|Massachusetts|2142|United States"
312467981,312467981,isatuximab,Sarclisa,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/22/2014,Designated/Approved,,"SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.", 03/02/2020 , 03/02/2027 ,"Indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.","Sanofi U.S. Services, Inc.|500 Kendall Street|Cambridge|Massachusetts|2142|United States"
252827377,252827377,isatuximab,Sarclisa,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/22/2014,Designated/Approved,,"SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.", 03/02/2020 , 03/02/2027 ,"Indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.","Sanofi U.S. Services, Inc.|500 Kendall Street|Cambridge|Massachusetts|2142|United States"
440809644,440809644,mogamulizumab,,Treatment of adult T-cell leukemia/lymphoma (ATLL).,C0023493,adult T-cell leukemia/lymphoma,07/14/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center|Suite 101|Princeton|New Jersey|8540|United States"
347911339,347911339,mogamulizumab,,Treatment of adult T-cell leukemia/lymphoma (ATLL).,C0023493,adult T-cell leukemia/lymphoma,07/14/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center|Suite 101|Princeton|New Jersey|8540|United States"
178103091,178103091,mogamulizumab,,Treatment of adult T-cell leukemia/lymphoma (ATLL).,C0023493,adult T-cell leukemia/lymphoma,07/14/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center|Suite 101|Princeton|New Jersey|8540|United States"
160704158,160704158,mogamulizumab,,Treatment of adult T-cell leukemia/lymphoma (ATLL).,C0023493,adult T-cell leukemia/lymphoma,07/14/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center|Suite 101|Princeton|New Jersey|8540|United States"
135317476,135317476,mogamulizumab,,Treatment of adult T-cell leukemia/lymphoma (ATLL).,C0023493,adult T-cell leukemia/lymphoma,07/14/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.|212 Carnegie Center|Suite 101|Princeton|New Jersey|8540|United States"
440234683,440234683,nipocalimab,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,02/11/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.|301 Binney Street|Cambridge|Massachusetts|2142|United States"
385610257,385610257,nipocalimab,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,02/11/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.|301 Binney Street|Cambridge|Massachusetts|2142|United States"
440234683,440234683,nipocalimab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,12/05/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.|301 Binney Street|Cambridge|Massachusetts|2142|United States"
385610257,385610257,nipocalimab,,Treatment of autoimmune hemolytic anemia,C0002880,Autoimmune hemolytic anemia,12/05/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.|301 Binney Street|Cambridge|Massachusetts|2142|United States"
440235223,440235223,Nivatrotamab,,Treatment of neuroblastoma,C0027819,Neuroblastoma,09/25/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Y-mAbs Therapeutics, Inc.|230 Park Avenue, Suite 3350|New York|New York|10169|United States"
387061105,387061105,pembrolizumab,Keytruda,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/16/2015,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.", 09/22/2017 , 09/22/2024 ,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesop",Merck Research Laboratories|351 North Sumneytown Pike|UG2C-50|North Wales|Pennsylvania|19454|United States
385327548,385327548,pembrolizumab,Keytruda,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/16/2015,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.", 09/22/2017 , 09/22/2024 ,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesop",Merck Research Laboratories|351 North Sumneytown Pike|UG2C-50|North Wales|Pennsylvania|19454|United States
384647091,384647091,pembrolizumab,Keytruda,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/16/2015,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.", 09/22/2017 , 09/22/2024 ,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesop",Merck Research Laboratories|351 North Sumneytown Pike|UG2C-50|North Wales|Pennsylvania|19454|United States
377483934,377483934,pembrolizumab,Keytruda,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/16/2015,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.", 09/22/2017 , 09/22/2024 ,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesop",Merck Research Laboratories|351 North Sumneytown Pike|UG2C-50|North Wales|Pennsylvania|19454|United States
354355033,354355033,pembrolizumab,Keytruda,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/16/2015,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.", 09/22/2017 , 09/22/2024 ,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesop",Merck Research Laboratories|351 North Sumneytown Pike|UG2C-50|North Wales|Pennsylvania|19454|United States
347910395,347910395,pembrolizumab,Keytruda,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/16/2015,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.", 09/22/2017 , 09/22/2024 ,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesop",Merck Research Laboratories|351 North Sumneytown Pike|UG2C-50|North Wales|Pennsylvania|19454|United States
194140938,194140938,pembrolizumab,Keytruda,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/16/2015,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.", 09/22/2017 , 09/22/2024 ,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesop",Merck Research Laboratories|351 North Sumneytown Pike|UG2C-50|North Wales|Pennsylvania|19454|United States
187051801,187051801,pembrolizumab,Keytruda,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","C0024623,C1332166","Gastric Cancer , Gastroesophageal Junction Adenocarcinoma",06/16/2015,Designated/Approved,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.", 09/22/2017 , 09/22/2024 ,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesop",Merck Research Laboratories|351 North Sumneytown Pike|UG2C-50|North Wales|Pennsylvania|19454|United States
404770226,404770226,siplizumab,,Treatment of T-cell lymphomas,C0079772,T-Cell Lymphomas,07/15/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
160703851,160703851,siplizumab,,Treatment of T-cell lymphomas,C0079772,T-Cell Lymphomas,07/15/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
135287612,135287612,siplizumab,,Treatment of T-cell lymphomas,C0079772,T-Cell Lymphomas,07/15/2003,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC|One MedImmune Way|Gaithersburg|Maryland|20878|United States"
347911284,347911284,sotatercept,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,09/05/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Acceleron Pharma Inc.|128 Sidney Street|Cambridge|Massachusetts|2139|United States
160698801,160698801,sotatercept,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,09/05/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Acceleron Pharma Inc.|128 Sidney Street|Cambridge|Massachusetts|2139|United States
135278235,135278235,sotatercept,,Treatment of pulmonary arterial hypertension,C3203102,PULMONARY ARTERIAL HYPERTENSION,09/05/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Acceleron Pharma Inc.|128 Sidney Street|Cambridge|Massachusetts|2139|United States
440806798,440806798,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.", 11/21/2016 , 11/21/2023 ,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
387060189,387060189,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.", 11/21/2016 , 11/21/2023 ,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
354355058,354355058,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.", 11/21/2016 , 11/21/2023 ,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
347910441,347910441,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.", 11/21/2016 , 11/21/2023 ,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
178103967,178103967,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.", 11/21/2016 , 11/21/2023 ,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
160671954,160671954,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.", 11/21/2016 , 11/21/2023 ,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
135304352,135304352,daratumumab,Darzalex,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/06/2013,Designated/Approved,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.", 11/21/2016 , 11/21/2023 ,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.|920 Route 202 South|PO Box 300|Raritan|New Jersey|8869|United States"
440790757,440790757,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
404609547,404609547,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
387060186,387060186,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
354355052,354355052,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
329976982,329976982,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
178103466,178103466,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
135288438,135288438,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
103771526,103771526,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
50070199,50070199,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
46505429,46505429,eculizumab,,Treatment of Shiga-Toxin producing escherichia coli hemolytic uremic syndrome,C0019061,HEMOLYTIC UREMIC SYNDROME,10/18/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
404771395,404771395,emicizumab-kxwh,Hemlibra,Treatment of hemophilia A,C0019069,Hemophilia A,01/10/2014,Designated/Approved,,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors., 10/04/2018 , 10/04/2025 ,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.,Genentech|1 DNA Way|MS 355e|South San Francisco|California|94080|United States
381127716,381127716,emicizumab-kxwh,Hemlibra,Treatment of hemophilia A,C0019069,Hemophilia A,01/10/2014,Designated/Approved,,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors., 10/04/2018 , 10/04/2025 ,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.,Genentech|1 DNA Way|MS 355e|South San Francisco|California|94080|United States
354702217,354702217,emicizumab-kxwh,Hemlibra,Treatment of hemophilia A,C0019069,Hemophilia A,01/10/2014,Designated/Approved,,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors., 10/04/2018 , 10/04/2025 ,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.,Genentech|1 DNA Way|MS 355e|South San Francisco|California|94080|United States
381127748,381127748,Engineered variant of recombinant human fibroblast growth factor 19,,Treatment of primary biliary cirrhosis,C0008312,Primary Biliary Cirrhosis,02/06/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"NGM Biopharmaceuticals, Inc.|630 Gateway Blvd|South San Francisco|California|94080|United States"
135324553,135324553,immune globulin (human),,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,12/12/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.|79 TW Alexander Drive|Research Triangle Park|North Carolina|27709|United States"
103771318,103771318,immune globulin (human),,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,12/12/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.|79 TW Alexander Drive|Research Triangle Park|North Carolina|27709|United States"
46508774,46508774,immune globulin (human),,Treatment of Myasthenia Gravis,C0026896,Myasthenia Gravis,12/12/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.|79 TW Alexander Drive|Research Triangle Park|North Carolina|27709|United States"
404770335,404770335,pegargiminase,,Treatment of mesothelioma.,C0025500,Mesothelioma,07/21/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Group|Polaris Pharmaceuticals, Inc.|9373 Town Centre Dr., Suite 150|San Diego|California|92121|United States"
381127242,381127242,pegargiminase,,Treatment of mesothelioma.,C0025500,Mesothelioma,07/21/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Group|Polaris Pharmaceuticals, Inc.|9373 Town Centre Dr., Suite 150|San Diego|California|92121|United States"
194189083,194189083,pegargiminase,,Treatment of mesothelioma.,C0025500,Mesothelioma,07/21/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Group|Polaris Pharmaceuticals, Inc.|9373 Town Centre Dr., Suite 150|San Diego|California|92121|United States"
381127197,381127197,pelareorep,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,02/10/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
312467919,312467919,pelareorep,,Treatment of ovarian cancer,C4721610,Ovarian Cancer,02/10/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
404772651,404772651,pozelimab,,Treatment of CD55-deficient protein-losing enteropathy,C0033680,Protein-Losing Enteropathy,04/13/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
404719659,404719659,pozelimab,,Treatment of CD55-deficient protein-losing enteropathy,C0033680,Protein-Losing Enteropathy,04/13/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
377483950,377483950,pozelimab,,Treatment of CD55-deficient protein-losing enteropathy,C0033680,Protein-Losing Enteropathy,04/13/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.|777 Old Saw Mill River Road|Tarrytown|New York|10591|United States"
349127786,349127786,raxibacumab,ABthraxTM,Treatment of anthrax,C0004589,anthrax,11/12/2003,Designated/Approved,,"Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,", 12/14/2012 , 12/14/2019 ,,"Human Genome Sciences, Inc.|14200 Shady Grove Road|Rockville|Maryland|20850|United States"
347910384,347910384,raxibacumab,ABthraxTM,Treatment of anthrax,C0004589,anthrax,11/12/2003,Designated/Approved,,"Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,", 12/14/2012 , 12/14/2019 ,,"Human Genome Sciences, Inc.|14200 Shady Grove Road|Rockville|Maryland|20850|United States"
160687615,160687615,raxibacumab,ABthraxTM,Treatment of anthrax,C0004589,anthrax,11/12/2003,Designated/Approved,,"Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,", 12/14/2012 , 12/14/2019 ,,"Human Genome Sciences, Inc.|14200 Shady Grove Road|Rockville|Maryland|20850|United States"
135308664,135308664,raxibacumab,ABthraxTM,Treatment of anthrax,C0004589,anthrax,11/12/2003,Designated/Approved,,"Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,", 12/14/2012 , 12/14/2019 ,,"Human Genome Sciences, Inc.|14200 Shady Grove Road|Rockville|Maryland|20850|United States"
135288879,135288879,Recombinant human insulin-like growth factor-I,,Treatment of post-poliomyelitis syndrome.,C0080040,Post-Poliomyelitis Syndrome,10/13/1995,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Product R&D, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States"
135272107,135272107,Recombinant urate oxidase,,Prophylaxis of chemotherapy-induced hyperuricemia.,C0740394,Hyperuricemia,10/11/2000,Designated,Not FDA Approved for Orphan Indication,,,,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
50067710,50067710,Recombinant urate oxidase,,Prophylaxis of chemotherapy-induced hyperuricemia.,C0740394,Hyperuricemia,10/11/2000,Designated,Not FDA Approved for Orphan Indication,,,,,Sanofi-Synthelabo Research|9 Great Valley Parkway|Malvern|Pennsylvania|19355|United States
440790483,440790483,canakinumab,ILARIS,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,C0398691,Hyperimmunoglobulinemia D And Periodic Fever Syndrome,12/05/2013,Designated/Approved,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124993,381124993,canakinumab,ILARIS,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,C0398691,Hyperimmunoglobulinemia D And Periodic Fever Syndrome,12/05/2013,Designated/Approved,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124992,381124992,canakinumab,ILARIS,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,C0398691,Hyperimmunoglobulinemia D And Periodic Fever Syndrome,12/05/2013,Designated/Approved,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910340,347910340,canakinumab,ILARIS,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,C0398691,Hyperimmunoglobulinemia D And Periodic Fever Syndrome,12/05/2013,Designated/Approved,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
329976978,329976978,canakinumab,ILARIS,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,C0398691,Hyperimmunoglobulinemia D And Periodic Fever Syndrome,12/05/2013,Designated/Approved,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
178103379,178103379,canakinumab,ILARIS,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,C0398691,Hyperimmunoglobulinemia D And Periodic Fever Syndrome,12/05/2013,Designated/Approved,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
135332926,135332926,canakinumab,ILARIS,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,C0398691,Hyperimmunoglobulinemia D And Periodic Fever Syndrome,12/05/2013,Designated/Approved,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
103771532,103771532,canakinumab,ILARIS,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,C0398691,Hyperimmunoglobulinemia D And Periodic Fever Syndrome,12/05/2013,Designated/Approved,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients, 09/23/2016 , 09/23/2023 ,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
440235304,440235304,cavrotolimod,,Treatment of merkel cell carcinoma,C0007129,Merkel cell carcinoma,03/02/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Exicure, Inc.|2430 N. Halsted Street, 4th Floor|Chicago|Illinois|60614|United States"
438569805,438569805,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
386974820,386974820,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
355256567,355256567,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276501,348276501,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276500,348276500,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276499,348276499,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276498,348276498,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276497,348276497,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276496,348276496,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276494,348276494,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276493,348276493,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276492,348276492,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
272905041,272905041,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
268737906,268737906,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
254788936,254788936,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
252215122,252215122,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
175442953,175442953,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
170474130,170474130,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
103405507,103405507,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
92303614,92303614,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
81058765,81058765,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
53788801,53788801,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
50105927,50105927,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
24702115,24702115,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
3495,3495,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
386483748,386483748,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
385647348,385647348,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
375933688,375933688,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
318152877,318152877,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
163687306,163687306,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
26759549,26759549,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
381341086,381341086,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
127269519,127269519,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
127269518,127269518,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
7890560,7890560,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
386393077,386393077,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
382159772,382159772,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
376192238,376192238,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348964523,348964523,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
348276495,348276495,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
315707078,315707078,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
241181861,241181861,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
135252244,135252244,ceramide,,Treatment of Pancreatic Cancer,C0235974,PANCREATIC CANCER,11/13/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.|1981 Pine Hall Road|State College|Pennsylvania|16801|United States"
404720085,404720085,Coagulation factor VIIa (recombinant),NovoSeven,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,"C0019069,C1366370","Hemophilia A , hemophilia A",06/06/1988,Designated/Approved,,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX., 03/25/1999 , 03/25/2006 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
135284356,135284356,Coagulation factor VIIa (recombinant),NovoSeven,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,"C0019069,C1366370","Hemophilia A , hemophilia A",06/06/1988,Designated/Approved,,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX., 03/25/1999 , 03/25/2006 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
135275129,135275129,Coagulation factor VIIa (recombinant),NovoSeven,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,"C0019069,C1366370","Hemophilia A , hemophilia A",06/06/1988,Designated/Approved,,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX., 03/25/1999 , 03/25/2006 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
46507544,46507544,Coagulation factor VIIa (recombinant),NovoSeven,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,"C0019069,C1366370","Hemophilia A , hemophilia A",06/06/1988,Designated/Approved,,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX., 03/25/1999 , 03/25/2006 ,,"Novo Nordisk, Inc.|100 Overlook Center|Suite 200|Princeton|New Jersey|8540|United States"
404770310,404770310,Gavilimomab,,Acute graft-versus-host disease (aGVHD),C0018133,Graft-Versus-Host Disease,11/20/2000,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Amgen|One Amgen Center Drive|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States
160693150,160693150,Gavilimomab,,Acute graft-versus-host disease (aGVHD),C0018133,Graft-Versus-Host Disease,11/20/2000,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Amgen|One Amgen Center Drive|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States
135277347,135277347,Gavilimomab,,Acute graft-versus-host disease (aGVHD),C0018133,Graft-Versus-Host Disease,11/20/2000,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Amgen|One Amgen Center Drive|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States
381127112,381127112,idarucizumab,,To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure,C0019080,Bleeding,05/28/2015,Designated/Approved,,For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding, 10/16/2015 , 10/16/2022 ,For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding,"Boehringer Ingelheim Pharmaceuticals, Inc.|PO Box 368|900 Ridgebury Road|Ridgefield|Connecticut|6877|United States"
347910427,347910427,idarucizumab,,To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure,C0019080,Bleeding,05/28/2015,Designated/Approved,,For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding, 10/16/2015 , 10/16/2022 ,For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding,"Boehringer Ingelheim Pharmaceuticals, Inc.|PO Box 368|900 Ridgebury Road|Ridgefield|Connecticut|6877|United States"
312467846,312467846,idarucizumab,,To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure,C0019080,Bleeding,05/28/2015,Designated/Approved,,For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding, 10/16/2015 , 10/16/2022 ,For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding,"Boehringer Ingelheim Pharmaceuticals, Inc.|PO Box 368|900 Ridgebury Road|Ridgefield|Connecticut|6877|United States"
252166510,252166510,idarucizumab,,To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure,C0019080,Bleeding,05/28/2015,Designated/Approved,,For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding, 10/16/2015 , 10/16/2022 ,For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding,"Boehringer Ingelheim Pharmaceuticals, Inc.|PO Box 368|900 Ridgebury Road|Ridgefield|Connecticut|6877|United States"
440790342,440790342,Interferon alfa-2a,Roferon A,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,06/06/1989,Designated/Approved,,Treatment of chronic myelogenous leukemia., 10/19/1995 , 10/19/2002 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
376229565,376229565,Interferon alfa-2a,Roferon A,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,06/06/1989,Designated/Approved,,Treatment of chronic myelogenous leukemia., 10/19/1995 , 10/19/2002 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
363907666,363907666,Interferon alfa-2a,Roferon A,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,06/06/1989,Designated/Approved,,Treatment of chronic myelogenous leukemia., 10/19/1995 , 10/19/2002 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
349302953,349302953,Interferon alfa-2a,Roferon A,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,06/06/1989,Designated/Approved,,Treatment of chronic myelogenous leukemia., 10/19/1995 , 10/19/2002 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
160698420,160698420,Interferon alfa-2a,Roferon A,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,06/06/1989,Designated/Approved,,Treatment of chronic myelogenous leukemia., 10/19/1995 , 10/19/2002 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135340642,135340642,Interferon alfa-2a,Roferon A,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,06/06/1989,Designated/Approved,,Treatment of chronic myelogenous leukemia., 10/19/1995 , 10/19/2002 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135321952,135321952,Interferon alfa-2a,Roferon A,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,06/06/1989,Designated/Approved,,Treatment of chronic myelogenous leukemia., 10/19/1995 , 10/19/2002 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
49856351,49856351,Interferon alfa-2a,Roferon A,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,06/06/1989,Designated/Approved,,Treatment of chronic myelogenous leukemia., 10/19/1995 , 10/19/2002 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
46506712,46506712,Interferon alfa-2a,Roferon A,Treatment of chronic myelogenous leukemia.,C0023473,Chronic myelogenous leukemia,06/06/1989,Designated/Approved,,Treatment of chronic myelogenous leukemia., 10/19/1995 , 10/19/2002 ,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
404720052,404720052,lisocabtagene maraleucel,Breyanzi,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,04/27/2016,Designated/Approved,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B", 02/05/2021 , 02/05/2028 ,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy; and treatment of adult patients with relapsed or refractory follicular lymphoma grade 3B after two or more lines of systemic therapy,"Juno Therapeutics, Inc.|400 Dexter Avenue North|Suite 1200|Seattle|Washington|98109|United States"
349441571,349441571,milatuzumab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,03/10/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
347911409,347911409,milatuzumab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,03/10/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
252166479,252166479,milatuzumab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,03/10/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
160682609,160682609,milatuzumab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,03/10/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
135306496,135306496,milatuzumab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,03/10/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
441076374,441076374,Somatropin,Humatrope,Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency,"C0013336,C0017337,C1420041","Short stature , Gene , SHORT STATURE HOMEOBOX",12/15/2005,Designated/Approved,,Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed, 11/01/2006 , 11/01/2013 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
178101641,178101641,Somatropin,Humatrope,Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency,"C0013336,C0017337,C1420041","Short stature , Gene , SHORT STATURE HOMEOBOX",12/15/2005,Designated/Approved,,Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed, 11/01/2006 , 11/01/2013 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
135274454,135274454,Somatropin,Humatrope,Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency,"C0013336,C0017337,C1420041","Short stature , Gene , SHORT STATURE HOMEOBOX",12/15/2005,Designated/Approved,,Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed, 11/01/2006 , 11/01/2013 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
103771423,103771423,Somatropin,Humatrope,Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency,"C0013336,C0017337,C1420041","Short stature , Gene , SHORT STATURE HOMEOBOX",12/15/2005,Designated/Approved,,Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed, 11/01/2006 , 11/01/2013 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
50046577,50046577,Somatropin,Humatrope,Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency,"C0013336,C0017337,C1420041","Short stature , Gene , SHORT STATURE HOMEOBOX",12/15/2005,Designated/Approved,,Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed, 11/01/2006 , 11/01/2013 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
46506010,46506010,Somatropin,Humatrope,Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency,"C0013336,C0017337,C1420041","Short stature , Gene , SHORT STATURE HOMEOBOX",12/15/2005,Designated/Approved,,Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed, 11/01/2006 , 11/01/2013 ,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
404772487,404772487,Toripalimab,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,09/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.|9430 Key West Ave|Suite 125|Rockville|Maryland|20850|United States"
404719502,404719502,Toripalimab,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,09/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.|9430 Key West Ave|Suite 125|Rockville|Maryland|20850|United States"
381128166,381128166,Toripalimab,,Treatment of soft tissue sarcoma,C1261473,Soft tissue sarcoma,09/15/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.|9430 Key West Ave|Suite 125|Rockville|Maryland|20850|United States"
319386216,319386216,Cannabidiol and delta-9-tetrahydrocannabinol,,Treatment of amyotrophic lateral sclerosis,C0002736,Amyotrophic Lateral Sclerosis,03/15/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.|265 Eastchester Drive|Suite 133, #201|High Point|North Carolina|27262|United States"
404772444,404772444,diannexin,,Prevention of ischemia-reperfusion injury in solid organ transplants,C0035126,Ischemia-Reperfusion Injury,10/28/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.|Three Parkway North|Deerfield|Illinois|60015|United States"
381127059,381127059,diannexin,,Prevention of ischemia-reperfusion injury in solid organ transplants,C0035126,Ischemia-Reperfusion Injury,10/28/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.|Three Parkway North|Deerfield|Illinois|60015|United States"
347911298,347911298,ganitumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,11/23/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States"
160698795,160698795,ganitumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,11/23/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States"
135310814,135310814,ganitumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,11/23/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States"
135032842,135032842,Interferon gamma 1-b,Actimmune,Treatment of chronic granulomatous disease.,C0018203,Chronic granulomatous disease,09/30/1988,Designated/Approved,,, 12/20/1990 , 12/20/1997 ,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
46507194,46507194,Interferon gamma 1-b,Actimmune,Treatment of chronic granulomatous disease.,C0018203,Chronic granulomatous disease,09/30/1988,Designated/Approved,,, 12/20/1990 , 12/20/1997 ,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
440791159,440791159,mecasermin,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,08/05/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States"
178101669,178101669,mecasermin,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,08/05/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States"
160698630,160698630,mecasermin,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,08/05/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States"
135330509,135330509,mecasermin,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,08/05/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States"
49985113,49985113,mecasermin,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,08/05/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States"
46504889,46504889,mecasermin,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,08/05/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.|41 Moores Road|Frazer|Pennsylvania|19355|United States"
404772861,404772861,mosunetuzumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,12/17/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 355G|South San Francisco|California|94080|United States"
404720369,404720369,mosunetuzumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,12/17/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 355G|South San Francisco|California|94080|United States"
381128154,381128154,mosunetuzumab,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,12/17/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|MS 355G|South San Francisco|California|94080|United States"
387061103,387061103,nivolumab,,Treatment of anal cancer,C0279637,Anal Cancer,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,,Treatment of anal cancer,C0279637,Anal Cancer,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,,Treatment of anal cancer,C0279637,Anal Cancer,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,,Treatment of anal cancer,C0279637,Anal Cancer,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,,Treatment of anal cancer,C0279637,Anal Cancer,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,,Treatment of anal cancer,C0279637,Anal Cancer,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,,Treatment of anal cancer,C0279637,Anal Cancer,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,,Treatment of anal cancer,C0279637,Anal Cancer,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,,Treatment of anal cancer,C0279637,Anal Cancer,08/07/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
404772436,404772436,nomacopan,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,09/12/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc|24 West 40th Street|8th Floor|New York|New York|10018|United States
404719628,404719628,nomacopan,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,09/12/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc|24 West 40th Street|8th Floor|New York|New York|10018|United States
374366992,374366992,nomacopan,,Treatment of bullous pemphigoid,C0030805,Bullous pemphigoid,09/12/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc|24 West 40th Street|8th Floor|New York|New York|10018|United States
349272539,349272539,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
347827764,347827764,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
135263533,135263533,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
104234375,104234375,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
386330730,386330730,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
349995325,349995325,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
349980335,349980335,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
341169549,341169549,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
319392962,319392962,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
440790775,440790775,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
438456323,438456323,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
434252117,434252117,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
162064792,162064792,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
134979978,134979978,ferumoxytol,,For use in magnetic resonance imaging in brain metastases,C0220650,brain metastases,10/07/2011,Designated,Not FDA Approved for Orphan Indication,,,,,Oregon Health & Science University|3181 SW Sam Jackson Pk Road|Mailcode L603|Portland|Oregon|97239|United States
441078173,441078173,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
440791125,440791125,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
349583301,349583301,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
283537479,283537479,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
178103548,178103548,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
135320862,135320862,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
134221887,134221887,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
103771266,103771266,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
49955776,49955776,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
46505833,46505833,Filgrastim,Neupogen,"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.","C0015967,C0023467,C0027947","Fever , Acute myeloid leukemia , Neutropenia",11/07/1996,Designated/Approved,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.", 04/02/1998 , 04/02/2005 ,,"Amgen, Inc.|One Amgen Center Dr.|Thousand Oaks|California|91320|United States"
404772049,404772049,lanadelumab-flyo,Takhzyro,Treatment of angioedema,C0002994,Angioedema,11/26/2013,Designated/Approved,,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older, 08/23/2018 , 08/23/2025 ,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older,Dyax Corporation|300 Shire Way|Lexington|Massachusetts|2421|United States
376219019,376219019,lanadelumab-flyo,Takhzyro,Treatment of angioedema,C0002994,Angioedema,11/26/2013,Designated/Approved,,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older, 08/23/2018 , 08/23/2025 ,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older,Dyax Corporation|300 Shire Way|Lexington|Massachusetts|2421|United States
315661179,315661179,lanadelumab-flyo,Takhzyro,Treatment of angioedema,C0002994,Angioedema,11/26/2013,Designated/Approved,,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older, 08/23/2018 , 08/23/2025 ,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older,Dyax Corporation|300 Shire Way|Lexington|Massachusetts|2421|United States
354355057,354355057,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA), 12/12/2017 , 12/12/2024 ,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
347910353,347910353,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA), 12/12/2017 , 12/12/2024 ,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
223366020,223366020,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA), 12/12/2017 , 12/12/2024 ,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
160682290,160682290,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA), 12/12/2017 , 12/12/2024 ,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
135278932,135278932,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA), 12/12/2017 , 12/12/2024 ,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
76206305,76206305,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA), 12/12/2017 , 12/12/2024 ,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
377017834,377017834,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA), 12/12/2017 , 12/12/2024 ,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
349977836,349977836,mepolizumab,NUCALA,Treatment of Churg-Strauss Syndrome,C0008728,Churg-Strauss Syndrome,07/14/2011,Designated/Approved,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA), 12/12/2017 , 12/12/2024 ,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC|Corporation Service Company|1250 S. Collegeville Rd.|Collegeville|Pennsylvania|19426|United States
381128139,381128139,monoclonal antibody Hu3F8,,Treatment of osteosarcoma,C0029463,Osteosarcoma,01/10/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Memorial Sloan-Kettering Cancer Center|1275 York Avenue|New York|New York|10065|United States
440798422,440798422,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen", 02/26/2016 , 02/26/2023 ,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
387060188,387060188,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen", 02/26/2016 , 02/26/2023 ,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
385327553,385327553,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen", 02/26/2016 , 02/26/2023 ,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
384647096,384647096,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen", 02/26/2016 , 02/26/2023 ,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
347910388,347910388,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen", 02/26/2016 , 02/26/2023 ,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
178103523,178103523,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen", 02/26/2016 , 02/26/2023 ,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
160682610,160682610,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen", 02/26/2016 , 02/26/2023 ,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
135332744,135332744,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen", 02/26/2016 , 02/26/2023 ,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
349079441,349079441,pritumumab,,Treatment of glioma,C0017638,Glioma,10/28/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.|10246 Parkdale Avenue|San Diego|California|92126|United States"
160709042,160709042,pritumumab,,Treatment of glioma,C0017638,Glioma,10/28/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.|10246 Parkdale Avenue|San Diego|California|92126|United States"
135322397,135322397,pritumumab,,Treatment of glioma,C0017638,Glioma,10/28/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.|10246 Parkdale Avenue|San Diego|California|92126|United States"
440234933,440234933,revusiran,,Treatment of transthyretin amyloidosis,C2751492,Transthyretin Amyloidosis,05/18/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alnylam Pharmaceuticals, Inc.|300 Third Street|Cambridge|Massachusetts|2142|United States"
381127422,381127422,revusiran,,Treatment of transthyretin amyloidosis,C2751492,Transthyretin Amyloidosis,05/18/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Alnylam Pharmaceuticals, Inc.|300 Third Street|Cambridge|Massachusetts|2142|United States"
402426141,402426141,rexlemestrocel-L,,Prevention of post-LVAD (left ventricular assist device) implantation mucosal bleeding,C2748540,Mucosal bleeding,06/19/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Mesoblast|505 5th Avenue|3rd Floor|New York|New York|10017|United States
312468168,312468168,rexlemestrocel-L,,Prevention of post-LVAD (left ventricular assist device) implantation mucosal bleeding,C2748540,Mucosal bleeding,06/19/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Mesoblast|505 5th Avenue|3rd Floor|New York|New York|10017|United States
404719845,404719845,Romilkimab,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,08/21/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Sanofi U.S. Service Inc.|55 Corporate Drive|Mail Stop: 55C-300|Bridgewater|New Jersey|8807|United States
381127251,381127251,Romilkimab,,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,08/21/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Sanofi U.S. Service Inc.|55 Corporate Drive|Mail Stop: 55C-300|Bridgewater|New Jersey|8807|United States
96025480,96025480,Coagulation Factor IX (recombinant),BeneFix,Treatment of hemophilia B.,C0008533,Hemophilia B,10/03/1994,Designated/Approved,,For routine prophylaxis to reduce the frequency of bleeding episodes in adults with hemophilia B (congenital factor IX deficiency or Christmas disease)., 06/26/2020 ,,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.|35 E. 42nd St 219/9/1|New York|New York|10017|United States"
46508858,46508858,Coagulation Factor IX (recombinant),BeneFix,Treatment of hemophilia B.,C0008533,Hemophilia B,10/03/1994,Designated/Approved,,For routine prophylaxis to reduce the frequency of bleeding episodes in adults with hemophilia B (congenital factor IX deficiency or Christmas disease)., 06/26/2020 ,,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.|35 E. 42nd St 219/9/1|New York|New York|10017|United States"
347910055,347910055,hepatitis B immune globulin (human),HepaGam B,Prevention of hepatitis B recurrence following orthotopic liver transplant,C0019163,Hepatitis B,03/24/2008,Designated/Approved,,Prevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients, 04/06/2007 , 04/06/2014 ,,Cangene Corporation|155 Innovation Drive|Winnipeg|Canada
135316435,135316435,hepatitis B immune globulin (human),HepaGam B,Prevention of hepatitis B recurrence following orthotopic liver transplant,C0019163,Hepatitis B,03/24/2008,Designated/Approved,,Prevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients, 04/06/2007 , 04/06/2014 ,,Cangene Corporation|155 Innovation Drive|Winnipeg|Canada
404771538,404771538,"Interleukin-1 alpha, human recombinant",,For hematopoietic potentiation in aplastic anemia.,C0002874,Aplastic Anemia,06/17/1991,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation|51 University Street|Seattle|Washington|98101|United States
404772373,404772373,Lacnotuzumab,,"Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath","C0017525,C0039106","Giant Cell Tumor , Pigmented villonodular synovitis",08/19/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp|One Health Plaza|East Hanover|New Jersey|7936|United States
381128094,381128094,Lacnotuzumab,,"Treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath","C0017525,C0039106","Giant Cell Tumor , Pigmented villonodular synovitis",08/19/2014,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp|One Health Plaza|East Hanover|New Jersey|7936|United States
526933,526933,Liposomal annamycin,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,06/17/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.|420 Lexington Avenue|New York|New York|10170|United States"
404720052,404720052,lisocabtagene maraleucel,Breyanzi,Treatment of follicular lymphoma (FL),C0024301,follicular lymphoma,09/07/2017,Designated/Approved,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B", 02/05/2021 , 02/05/2028 ,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy; and treatment of adult patients with relapsed or refractory follicular lymphoma grade 3B after two or more lines of systemic therapy,"Juno Therapeutics, Inc.|400 Dexter Avenue N|Seattle|Washington|98109|United States"
404772743,404772743,orilanolimab,,Treatment of pemphigus,C0030807,Pemphigus,09/10/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Syntimmune, Inc.|116 Huntington Avenue|Suite 301|Boston|Massachusetts|2116|United States"
404720518,404720518,orilanolimab,,Treatment of pemphigus,C0030807,Pemphigus,09/10/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Syntimmune, Inc.|116 Huntington Avenue|Suite 301|Boston|Massachusetts|2116|United States"
381128248,381128248,orilanolimab,,Treatment of pemphigus,C0030807,Pemphigus,09/10/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Syntimmune, Inc.|116 Huntington Avenue|Suite 301|Boston|Massachusetts|2116|United States"
441072533,441072533,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790663,440790663,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
438447953,438447953,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061211,387061211,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
375567394,375567394,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
365372316,365372316,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355040,354355040,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080044,350080044,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348846999,348846999,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480210,348480210,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976959,329976959,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319478933,319478933,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319436173,319436173,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178101775,178101775,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135301230,135301230,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771413,103771413,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067185,50067185,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46507516,46507516,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
521856,521856,trastuzumab,Herceptin,"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction","C0278701,C5204526","adenocarcinoma of the stomach , Advanced Adenocarcinoma",10/13/2009,Designated/Approved,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease", 10/20/2010 , 10/20/2017 ,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
404336835,404336835,trastuzumab emtansine,,For the treatment of gastric cancer including gastroesophageal junction cancer.,"C0006826,C0024623","Cancer , Gastric Cancer",10/25/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genethech, Inc.|1 DNA Way|south San Francisco|California|94080|United States"
347910224,347910224,trastuzumab emtansine,,For the treatment of gastric cancer including gastroesophageal junction cancer.,"C0006826,C0024623","Cancer , Gastric Cancer",10/25/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genethech, Inc.|1 DNA Way|south San Francisco|California|94080|United States"
252216509,252216509,trastuzumab emtansine,,For the treatment of gastric cancer including gastroesophageal junction cancer.,"C0006826,C0024623","Cancer , Gastric Cancer",10/25/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genethech, Inc.|1 DNA Way|south San Francisco|California|94080|United States"
178103510,178103510,trastuzumab emtansine,,For the treatment of gastric cancer including gastroesophageal junction cancer.,"C0006826,C0024623","Cancer , Gastric Cancer",10/25/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genethech, Inc.|1 DNA Way|south San Francisco|California|94080|United States"
160698804,160698804,trastuzumab emtansine,,For the treatment of gastric cancer including gastroesophageal junction cancer.,"C0006826,C0024623","Cancer , Gastric Cancer",10/25/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genethech, Inc.|1 DNA Way|south San Francisco|California|94080|United States"
136368305,136368305,trastuzumab emtansine,,For the treatment of gastric cancer including gastroesophageal junction cancer.,"C0006826,C0024623","Cancer , Gastric Cancer",10/25/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genethech, Inc.|1 DNA Way|south San Francisco|California|94080|United States"
135353969,135353969,trastuzumab emtansine,,For the treatment of gastric cancer including gastroesophageal junction cancer.,"C0006826,C0024623","Cancer , Gastric Cancer",10/25/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genethech, Inc.|1 DNA Way|south San Francisco|California|94080|United States"
404770048,404770048,veltuzumab,,Treatment of immune thrombocytopenic purpura.,C0398650,Immune thrombocytopenic purpura,07/28/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
349278123,349278123,veltuzumab,,Treatment of immune thrombocytopenic purpura.,C0398650,Immune thrombocytopenic purpura,07/28/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
252166480,252166480,veltuzumab,,Treatment of immune thrombocytopenic purpura.,C0398650,Immune thrombocytopenic purpura,07/28/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
160687965,160687965,veltuzumab,,Treatment of immune thrombocytopenic purpura.,C0398650,Immune thrombocytopenic purpura,07/28/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
135330261,135330261,veltuzumab,,Treatment of immune thrombocytopenic purpura.,C0398650,Immune thrombocytopenic purpura,07/28/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.|300 American Road|Morris Plains|New Jersey|7950|United States"
440790483,440790483,canakinumab,Ilaris,Treatment of cryopyrin-associated periodic syndromes,C2316212,cryopyrin-associated periodic syndrome,12/18/2007,Designated/Approved,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.", 06/17/2009 , 06/17/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124993,381124993,canakinumab,Ilaris,Treatment of cryopyrin-associated periodic syndromes,C2316212,cryopyrin-associated periodic syndrome,12/18/2007,Designated/Approved,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.", 06/17/2009 , 06/17/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381124992,381124992,canakinumab,Ilaris,Treatment of cryopyrin-associated periodic syndromes,C2316212,cryopyrin-associated periodic syndrome,12/18/2007,Designated/Approved,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.", 06/17/2009 , 06/17/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910340,347910340,canakinumab,Ilaris,Treatment of cryopyrin-associated periodic syndromes,C2316212,cryopyrin-associated periodic syndrome,12/18/2007,Designated/Approved,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.", 06/17/2009 , 06/17/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
329976978,329976978,canakinumab,Ilaris,Treatment of cryopyrin-associated periodic syndromes,C2316212,cryopyrin-associated periodic syndrome,12/18/2007,Designated/Approved,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.", 06/17/2009 , 06/17/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
178103379,178103379,canakinumab,Ilaris,Treatment of cryopyrin-associated periodic syndromes,C2316212,cryopyrin-associated periodic syndrome,12/18/2007,Designated/Approved,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.", 06/17/2009 , 06/17/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
135332926,135332926,canakinumab,Ilaris,Treatment of cryopyrin-associated periodic syndromes,C2316212,cryopyrin-associated periodic syndrome,12/18/2007,Designated/Approved,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.", 06/17/2009 , 06/17/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
103771532,103771532,canakinumab,Ilaris,Treatment of cryopyrin-associated periodic syndromes,C2316212,cryopyrin-associated periodic syndrome,12/18/2007,Designated/Approved,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.", 06/17/2009 , 06/17/2016 ,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
381129584,381129584,"Coagulation factor IX (recombinant), Fc fusion protein",ALPROLIX,Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease),"C0008533,C1366464,C2674164","Hemophilia B , hemophilia B , Hemorrhagic episodes",10/30/2008,Designated/Approved,,"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.", 03/28/2014 , 03/28/2021 ,"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","Bioverativ Therapeutics, Inc.|225 2nd Avenue|Waltham|Massachusetts|2451|United States"
441072528,441072528,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
440790341,440790341,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433791528,433791528,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433790701,433790701,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
387060165,387060165,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
354355050,354355050,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
348825932,348825932,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
329976987,329976987,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
178101701,178101701,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
135305802,135305802,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
103771449,103771449,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
91145133,91145133,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313883,56313883,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313209,56313209,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56311151,56311151,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
50067186,50067186,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
46505602,46505602,infliximab,Remicade,Treatment of pediatric (0 to 16 years of age) ulcerative colitis,C0009324,Ulcerative Colitis,11/12/2003,Designated/Approved,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, 09/23/2011 , 09/23/2018 ,,"Janssen Biotech, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
404771073,404771073,Nebacumab,,Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.,C0744471,gram-negative bacteremia,10/01/1986,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
160703905,160703905,Nebacumab,,Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.,C0744471,gram-negative bacteremia,10/01/1986,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
135307186,135307186,Nebacumab,,Treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.,C0744471,gram-negative bacteremia,10/01/1986,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
387061103,387061103,nivolumab,,Treatment of mesothelioma,C0025500,Mesothelioma,08/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,,Treatment of mesothelioma,C0025500,Mesothelioma,08/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,,Treatment of mesothelioma,C0025500,Mesothelioma,08/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,,Treatment of mesothelioma,C0025500,Mesothelioma,08/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,,Treatment of mesothelioma,C0025500,Mesothelioma,08/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,,Treatment of mesothelioma,C0025500,Mesothelioma,08/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,,Treatment of mesothelioma,C0025500,Mesothelioma,08/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,,Treatment of mesothelioma,C0025500,Mesothelioma,08/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,,Treatment of mesothelioma,C0025500,Mesothelioma,08/16/2017,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P. O. Box 5326|Princeton|New Jersey|8543|United States
349079441,349079441,pritumumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,04/06/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.|8400 Miramar Road|Suite 247|San Diego|California|92126|United States"
160709042,160709042,pritumumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,04/06/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.|8400 Miramar Road|Suite 247|San Diego|California|92126|United States"
135322397,135322397,pritumumab,,Treatment of pancreatic cancer.,C0235974,PANCREATIC CANCER,04/06/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.|8400 Miramar Road|Suite 247|San Diego|California|92126|United States"
404770226,404770226,Siplizumab,,Prevention of solid organ transplant rejection,C0345468,organ transplant rejection,02/15/2018,Designated,Not FDA Approved for Orphan Indication,,,,,ITB-MED AB|15 V䳴ra Tr䤧岤sgatan|Norrmalm|Stockholms l䮍|Sweden
160703851,160703851,Siplizumab,,Prevention of solid organ transplant rejection,C0345468,organ transplant rejection,02/15/2018,Designated,Not FDA Approved for Orphan Indication,,,,,ITB-MED AB|15 V䳴ra Tr䤧岤sgatan|Norrmalm|Stockholms l䮍|Sweden
135287612,135287612,Siplizumab,,Prevention of solid organ transplant rejection,C0345468,organ transplant rejection,02/15/2018,Designated,Not FDA Approved for Orphan Indication,,,,,ITB-MED AB|15 V䳴ra Tr䤧岤sgatan|Norrmalm|Stockholms l䮍|Sweden
347910377,347910377,Taliglucerase alfa,ELELYSO for injection,Treatment of Gaucher's disease,C0017205,Gaucher's Disease,09/03/2009,Designated/Approved,,Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease, 05/01/2012 ,,,"Pfizer, Inc.|235 East 42nd Street|New York|New York|10017|United States"
178104016,178104016,Taliglucerase alfa,ELELYSO for injection,Treatment of Gaucher's disease,C0017205,Gaucher's Disease,09/03/2009,Designated/Approved,,Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease, 05/01/2012 ,,,"Pfizer, Inc.|235 East 42nd Street|New York|New York|10017|United States"
136942423,136942423,Taliglucerase alfa,ELELYSO for injection,Treatment of Gaucher's disease,C0017205,Gaucher's Disease,09/03/2009,Designated/Approved,,Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease, 05/01/2012 ,,,"Pfizer, Inc.|235 East 42nd Street|New York|New York|10017|United States"
135318890,135318890,Taliglucerase alfa,ELELYSO for injection,Treatment of Gaucher's disease,C0017205,Gaucher's Disease,09/03/2009,Designated/Approved,,Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease, 05/01/2012 ,,,"Pfizer, Inc.|235 East 42nd Street|New York|New York|10017|United States"
56312283,56312283,Transforming growth factor-beta 2,,Treatment of full thickness macular holes.,C0024441,Macular Holes,12/18/1992,Designated,Not FDA Approved for Orphan Indication,,,,,"Celtrix Pharmaceuticals, Inc.|3055 Patrick Henry Drive|Santa Clara|California|95054|United States"
347910376,347910376,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
329976977,329976977,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
178103378,178103378,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
135300399,135300399,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
131277422,131277422,brentuximab vedotin,Adcetris,Treatment of Hodgkin's lymphoma,C0019829,hodgkin's lymphoma,01/30/2007,Designated/Approved,,The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, 08/19/2011 , 08/19/2018 ,,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
347911432,347911432,Coagulation factor X (human),COAGADEX,Treatment of hereditary factor X deficiency,C0272327,Hereditary Factor X Deficiency,11/08/2007,Designated/Approved,,COAGADEX is indicated in adults and children with hereditary Factor X deficiency for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patients with mild and moderate hereditary Factor X deficiency., 09/21/2018 , 09/21/2025 ,Coagadex is indicated for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hereditary Factor X deficiency; on-demand treatment and control of bleeding episodes in children under the age of 12 years with hereditary Factor X deficiency; perioperative management of bleeding in children under the age of 12 years with mild hereditary factor X deficiency; perioperative management of bleeding in adults and children with moderate hereditary Factor X deficiency,Bio Products Laboratory Limited|Dagger Lane|Elstree|Hertfordshire|United Kingdom
434122242,434122242,concizumab,,Treatment of hemophilia A,C0019069,Hemophilia A,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P.O Box 846|Plainsboro|New Jersey|8536|United States"
404719421,404719421,concizumab,,Treatment of hemophilia A,C0019069,Hemophilia A,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P.O Box 846|Plainsboro|New Jersey|8536|United States"
381126946,381126946,concizumab,,Treatment of hemophilia A,C0019069,Hemophilia A,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P.O Box 846|Plainsboro|New Jersey|8536|United States"
347911387,347911387,concizumab,,Treatment of hemophilia A,C0019069,Hemophilia A,10/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.|P.O Box 846|Plainsboro|New Jersey|8536|United States"
135285682,135285682,digoxin immune fab (ovine),,Treatment of severe preeclampsia and eclampsia,"C0341950,C0810330","Severe Preeclampsia , preeclampsia and eclampsia",02/03/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"AMAG Pharmaceuticals, Inc.|1100 Winter Street|Waltham|Massachusetts|2451|United States"
46506432,46506432,digoxin immune fab (ovine),,Treatment of severe preeclampsia and eclampsia,"C0341950,C0810330","Severe Preeclampsia , preeclampsia and eclampsia",02/03/2012,Designated,Not FDA Approved for Orphan Indication,,,,,"AMAG Pharmaceuticals, Inc.|1100 Winter Street|Waltham|Massachusetts|2451|United States"
385327558,385327558,Durvalumab,,Treatment of Biliary Tract Cancer,C0750952,Biliary Tract Cancer,12/10/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
384647100,384647100,Durvalumab,,Treatment of Biliary Tract Cancer,C0750952,Biliary Tract Cancer,12/10/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
381127393,381127393,Durvalumab,,Treatment of Biliary Tract Cancer,C0750952,Biliary Tract Cancer,12/10/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
347911229,347911229,Durvalumab,,Treatment of Biliary Tract Cancer,C0750952,Biliary Tract Cancer,12/10/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
249565666,249565666,Durvalumab,,Treatment of Biliary Tract Cancer,C0750952,Biliary Tract Cancer,12/10/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
242651787,242651787,Durvalumab,,Treatment of Biliary Tract Cancer,C0750952,Biliary Tract Cancer,12/10/2020,Designated,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP|1800 Concord Pike|Wilmington|Delaware|19803|United States
404772175,404772175,Emapalumab,,Prevention of graft failure following hematopoietic stem cell transplantation,C1262018,Graft failure,09/25/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Sobi AG|12 Chemin des Aulx|Plan-Les-Ouates|Geneva|1228|Switzerland
381127967,381127967,Emapalumab,,Prevention of graft failure following hematopoietic stem cell transplantation,C1262018,Graft failure,09/25/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Sobi AG|12 Chemin des Aulx|Plan-Les-Ouates|Geneva|1228|Switzerland
374364232,374364232,Emapalumab,,Prevention of graft failure following hematopoietic stem cell transplantation,C1262018,Graft failure,09/25/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Sobi AG|12 Chemin des Aulx|Plan-Les-Ouates|Geneva|1228|Switzerland
318164814,318164814,Emapalumab,,Prevention of graft failure following hematopoietic stem cell transplantation,C1262018,Graft failure,09/25/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Sobi AG|12 Chemin des Aulx|Plan-Les-Ouates|Geneva|1228|Switzerland
404773017,404773017,golodirsen,VYONDYS 53,Treatment of Duchenne muscular dystrophy (DMD),C0013264,DUCHENNE MUSCULAR DYSTROPHY,05/22/2018,Designated/Approved,,VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping., 12/12/2019 , 12/12/2026 ,Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,"Sarepta Therapeutics, Inc.|215 First Street|Cambridge|Massachusetts|2142|United States"
404720379,404720379,golodirsen,VYONDYS 53,Treatment of Duchenne muscular dystrophy (DMD),C0013264,DUCHENNE MUSCULAR DYSTROPHY,05/22/2018,Designated/Approved,,VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping., 12/12/2019 , 12/12/2026 ,Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,"Sarepta Therapeutics, Inc.|215 First Street|Cambridge|Massachusetts|2142|United States"
377716578,377716578,golodirsen,VYONDYS 53,Treatment of Duchenne muscular dystrophy (DMD),C0013264,DUCHENNE MUSCULAR DYSTROPHY,05/22/2018,Designated/Approved,,VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping., 12/12/2019 , 12/12/2026 ,Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,"Sarepta Therapeutics, Inc.|215 First Street|Cambridge|Massachusetts|2142|United States"
46506712,46506712,Interferon alfa-2a (recombinant),,For the concomitant administration with Teceleukin for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/02/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
441072531,441072531,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
387061212,387061212,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
385327556,385327556,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
384647099,384647099,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
365372203,365372203,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
354355036,354355036,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
348838049,348838049,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
329976960,329976960,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
319478935,319478935,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
319435463,319435463,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
178103386,178103386,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
135341754,135341754,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
103771410,103771410,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
57288666,57288666,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
56314417,56314417,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
50070184,50070184,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
46505820,46505820,rituximab,,Treatment of Rasmussen's encephalitis,C0393484,Rasmussen Encephalitis,11/09/2016,Designated,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences|535 Watson Drive|Claremont|California|91711|United States
319259212,319259212,talactoferrin alfa,,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,09/29/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
160676985,160676985,talactoferrin alfa,,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,09/29/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
135286186,135286186,talactoferrin alfa,,Treatment of renal cell carcinoma,C0007134,Renal Cell Carcinoma,09/29/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.|8 Greenway Plaza|Suite 910|Houston|Texas|77046|United States"
17398232,17398232,Branched chain amino acids,,Treatment of amyotrophic lateral sclerosis.,C0002736,Amyotrophic Lateral Sclerosis,12/23/1988,Designated,Not FDA Approved for Orphan Indication,,,,,Mount Sinai Medical Center|One Gustave L. Levy Place|New York|New York|10029|United States
347910376,347910376,brentuximab vedotin,,Treatment of patients with angioimmunoblastic T-cell lymphoma,C0020981,Angioimmunoblastic T-cell lymphoma,09/13/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
329976977,329976977,brentuximab vedotin,,Treatment of patients with angioimmunoblastic T-cell lymphoma,C0020981,Angioimmunoblastic T-cell lymphoma,09/13/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
178103378,178103378,brentuximab vedotin,,Treatment of patients with angioimmunoblastic T-cell lymphoma,C0020981,Angioimmunoblastic T-cell lymphoma,09/13/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
135300399,135300399,brentuximab vedotin,,Treatment of patients with angioimmunoblastic T-cell lymphoma,C0020981,Angioimmunoblastic T-cell lymphoma,09/13/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
131277422,131277422,brentuximab vedotin,,Treatment of patients with angioimmunoblastic T-cell lymphoma,C0020981,Angioimmunoblastic T-cell lymphoma,09/13/2013,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States"
440791103,440791103,denileukin diftitox,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,07/12/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States
381127241,381127241,denileukin diftitox,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,07/12/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States
178103623,178103623,denileukin diftitox,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,07/12/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States
135318399,135318399,denileukin diftitox,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,07/12/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States
125240988,125240988,denileukin diftitox,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,07/12/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States
103771199,103771199,denileukin diftitox,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,07/12/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States
50070181,50070181,denileukin diftitox,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,07/12/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States
46506950,46506950,denileukin diftitox,,Treatment of cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,07/12/2013,Designated,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.|155 Tice Blvd|Woodcliff Lake|New Jersey|7677|United States
404772690,404772690,Imlifidase,,Treatment of anti-glomerular basement membrane (anti-GBM) disease,C0012634,Disease,07/03/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Hansa Medical AB|Scheelev䧥n 22, P. O. Box 785|SE-220 07|Lund|Sweden"
404720323,404720323,Imlifidase,,Treatment of anti-glomerular basement membrane (anti-GBM) disease,C0012634,Disease,07/03/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Hansa Medical AB|Scheelev䧥n 22, P. O. Box 785|SE-220 07|Lund|Sweden"
377716581,377716581,Imlifidase,,Treatment of anti-glomerular basement membrane (anti-GBM) disease,C0012634,Disease,07/03/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"Hansa Medical AB|Scheelev䧥n 22, P. O. Box 785|SE-220 07|Lund|Sweden"
441074980,441074980,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
404772311,404772311,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
178101682,178101682,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135326453,135326453,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
135273161,135273161,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
134224740,134224740,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56314519,56314519,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56313513,56313513,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56313163,56313163,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56312547,56312547,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56312196,56312196,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311893,56311893,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311781,56311781,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56311685,56311685,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
56310774,56310774,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
7978489,7978489,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
7847813,7847813,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
10105,10105,Interleukin-2,,In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,C0278678,metastatic renal cell carcinoma,05/03/1990,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
404770335,404770335,pegylated arginine deiminase,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,03/26/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.|A Polaris Group Company|6370 Nancy Ridge Drive|San Diego|California|92121|United States"
384403250,384403250,pegylated arginine deiminase,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,03/26/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.|A Polaris Group Company|6370 Nancy Ridge Drive|San Diego|California|92121|United States"
381127242,381127242,pegylated arginine deiminase,,Treatment of hepatocellular carcinoma,C2239176,HEPATOCELLULAR CARCINOMA,03/26/1999,Designated,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.|A Polaris Group Company|6370 Nancy Ridge Drive|San Diego|California|92121|United States"
387061105,387061105,pembrolizumab,Keytruda,Treatment of hepatocellular carcinoma (HCC),C2239176,HEPATOCELLULAR CARCINOMA,06/12/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 11/09/2018 , 11/09/2025 ,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
385327548,385327548,pembrolizumab,Keytruda,Treatment of hepatocellular carcinoma (HCC),C2239176,HEPATOCELLULAR CARCINOMA,06/12/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 11/09/2018 , 11/09/2025 ,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
384647091,384647091,pembrolizumab,Keytruda,Treatment of hepatocellular carcinoma (HCC),C2239176,HEPATOCELLULAR CARCINOMA,06/12/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 11/09/2018 , 11/09/2025 ,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
377483934,377483934,pembrolizumab,Keytruda,Treatment of hepatocellular carcinoma (HCC),C2239176,HEPATOCELLULAR CARCINOMA,06/12/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 11/09/2018 , 11/09/2025 ,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
354355033,354355033,pembrolizumab,Keytruda,Treatment of hepatocellular carcinoma (HCC),C2239176,HEPATOCELLULAR CARCINOMA,06/12/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 11/09/2018 , 11/09/2025 ,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
347910395,347910395,pembrolizumab,Keytruda,Treatment of hepatocellular carcinoma (HCC),C2239176,HEPATOCELLULAR CARCINOMA,06/12/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 11/09/2018 , 11/09/2025 ,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
194140938,194140938,pembrolizumab,Keytruda,Treatment of hepatocellular carcinoma (HCC),C2239176,HEPATOCELLULAR CARCINOMA,06/12/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 11/09/2018 , 11/09/2025 ,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
187051801,187051801,pembrolizumab,Keytruda,Treatment of hepatocellular carcinoma (HCC),C2239176,HEPATOCELLULAR CARCINOMA,06/12/2017,Designated/Approved,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib, 11/09/2018 , 11/09/2025 ,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,"Merck, Sharp & Dohme Corp|1 Merck Drive|Whitehouse Station|New Jersey|8889|United States"
381127094,381127094,tarextumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,01/26/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
347911283,347911283,tarextumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,01/26/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
252166663,252166663,tarextumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,01/26/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
242651788,242651788,tarextumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,01/26/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
441072526,441072526,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,,In combination with a platinum and 5-FU or capecitabine for the treatment of stomach cancer.,C0024623,stomach cancer,11/20/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135318227,135318227,Botulism immune globulin,BabyBIG,Treatment of infant botulism.,C0238027,Infant Botulism,01/31/1989,Designated/Approved,,Indicated for treatment of infant botulism caused by type A or type B Clostridium botulinum., 10/23/2003 , 10/23/2010 ,,California Department of Health Services|2151 Berkeley Way|Berkeley|California|94704|United States
381128027,381128027,Coxsackievirus A21,,"Treatment of stage II (T4), stage III, and stage IV melanoma",C0278883,stage iv melanoma,12/15/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Viralytics Limited|P. O. Box 1045|Unit 8/33 Ryde Road,|Pymble,|NSW|Australia"
404772542,404772542,cusatuzumab,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,01/14/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States"
404720275,404720275,cusatuzumab,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,01/14/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States"
381128124,381128124,cusatuzumab,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,01/14/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States"
354702251,354702251,cusatuzumab,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,01/14/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|920 Route 202 South|Raritan|New Jersey|8869|United States"
336908604,336908604,galinpepimut-S,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,05/08/2018,Designated,Not FDA Approved for Orphan Indication,,,,,"SELLAS Life Sciences Group, Inc.|315 Madison Avenue|4th floor|New York|New York|10017|United States"
404720535,404720535,Sintilimab,,Treatment of esophageal cancer,C0014859,esophageal cancer,04/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Innovent Biologics (Suzhou) Co. Ltd|168 Dongping Street|Suzhou Industrial Park|Jiangsu Province|China
381128253,381128253,Sintilimab,,Treatment of esophageal cancer,C0014859,esophageal cancer,04/14/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Innovent Biologics (Suzhou) Co. Ltd|168 Dongping Street|Suzhou Industrial Park|Jiangsu Province|China
347911293,347911293,tralokinumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,07/24/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,MedImmune Ltd.|Milstein Building|Granta Park|Cambridge|United Kingdom
249565681,249565681,tralokinumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,07/24/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,MedImmune Ltd.|Milstein Building|Granta Park|Cambridge|United Kingdom
160687963,160687963,tralokinumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,07/24/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,MedImmune Ltd.|Milstein Building|Granta Park|Cambridge|United Kingdom
135339998,135339998,tralokinumab,,Treatment of idiopathic pulmonary fibrosis,C1800706,Idiopathic Pulmonary Fibrosis,07/24/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,MedImmune Ltd.|Milstein Building|Granta Park|Cambridge|United Kingdom
441072526,441072526,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,Avastin,Therapeutic treatment of patients with ovarian cancer,C4721610,Ovarian Cancer,02/09/2006,Designated/Approved,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensi", 12/06/2016 , 12/06/2023 ,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
404770342,404770342,catumaxomab,,Treatment of gastric cancer,C0024623,Gastric Cancer,07/01/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.|920 Winter Street|Waltham|Massachusetts|2451|United States"
178103957,178103957,catumaxomab,,Treatment of gastric cancer,C0024623,Gastric Cancer,07/01/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.|920 Winter Street|Waltham|Massachusetts|2451|United States"
160698430,160698430,catumaxomab,,Treatment of gastric cancer,C0024623,Gastric Cancer,07/01/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.|920 Winter Street|Waltham|Massachusetts|2451|United States"
135311383,135311383,catumaxomab,,Treatment of gastric cancer,C0024623,Gastric Cancer,07/01/2009,Designated,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.|920 Winter Street|Waltham|Massachusetts|2451|United States"
404772881,404772881,cenersen,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/27/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
381125009,381125009,cenersen,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/27/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
349988829,349988829,cenersen,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/27/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
252166482,252166482,cenersen,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/27/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
160682274,160682274,cenersen,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/27/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
135263925,135263925,cenersen,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/27/2008,Designated,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.|1001 Twelve Oaks Center Drive|Suite 1002|Wayzata|Minnesota|55391|United States"
440790757,440790757,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
404609547,404609547,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
387060186,387060186,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
354355052,354355052,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
329976982,329976982,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
178103466,178103466,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
135288438,135288438,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
103771526,103771526,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
50070199,50070199,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
46505429,46505429,eculizumab,,Treatment of idiopathic membranous glomerular nephropathy,C0022658,Nephropathy,03/05/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
387061107,387061107,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
385327547,385327547,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
384647090,384647090,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
354355037,354355037,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
349072362,349072362,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
347910341,347910341,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
329976988,329976988,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
178103470,178103470,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
135287563,135287563,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
131273201,131273201,ipilimumab,,Treatment of small cell lung cancer,C3540630,Small Cell Lung Cancer,11/07/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company|P.O. Box 5326|Princeton|New Jersey|8543|United States
377483932,377483932,obiltoxaximab,Anthim,Treatment of exposure to B. anthracis spores,C0004589,B. anthracis,06/09/2006,Designated/Approved,,Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or are not appropriate., 03/18/2016 , 03/18/2023 ,"1) Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and (2) for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.","Elusys Therapeutics, Inc.|25 Riverside Drive|P.O. Box 102|Pine Brook|New Jersey|7058|United States"
347910089,347910089,obiltoxaximab,Anthim,Treatment of exposure to B. anthracis spores,C0004589,B. anthracis,06/09/2006,Designated/Approved,,Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or are not appropriate., 03/18/2016 , 03/18/2023 ,"1) Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and (2) for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.","Elusys Therapeutics, Inc.|25 Riverside Drive|P.O. Box 102|Pine Brook|New Jersey|7058|United States"
312467776,312467776,obiltoxaximab,Anthim,Treatment of exposure to B. anthracis spores,C0004589,B. anthracis,06/09/2006,Designated/Approved,,Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or are not appropriate., 03/18/2016 , 03/18/2023 ,"1) Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and (2) for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.","Elusys Therapeutics, Inc.|25 Riverside Drive|P.O. Box 102|Pine Brook|New Jersey|7058|United States"
440798422,440798422,obinutuzumab,GAZYVA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/17/2012,Designated/Approved,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).", 11/01/2013 , 11/01/2020 ,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
387060188,387060188,obinutuzumab,GAZYVA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/17/2012,Designated/Approved,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).", 11/01/2013 , 11/01/2020 ,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
385327553,385327553,obinutuzumab,GAZYVA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/17/2012,Designated/Approved,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).", 11/01/2013 , 11/01/2020 ,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
384647096,384647096,obinutuzumab,GAZYVA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/17/2012,Designated/Approved,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).", 11/01/2013 , 11/01/2020 ,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
347910388,347910388,obinutuzumab,GAZYVA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/17/2012,Designated/Approved,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).", 11/01/2013 , 11/01/2020 ,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
178103523,178103523,obinutuzumab,GAZYVA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/17/2012,Designated/Approved,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).", 11/01/2013 , 11/01/2020 ,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
160682610,160682610,obinutuzumab,GAZYVA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/17/2012,Designated/Approved,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).", 11/01/2013 , 11/01/2020 ,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
135332744,135332744,obinutuzumab,GAZYVA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,02/17/2012,Designated/Approved,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).", 11/01/2013 , 11/01/2020 ,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
347911188,347911188,prothrombin complex concentrate (human),Kcentra,Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures,C0019080,Bleeding,12/27/2012,Designated/Approved,,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.", 04/29/2013 , 04/29/2020 ,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",CSL Behring|1020 First Avenue|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
404859059,404859059,teprotumumab,,Treatment of active thyroid eye disease,C0339143,Thyroid eye disease,05/06/2013,Designated/Approved,,TEPEZZA is indicated for the treatment of Thyroid Eye Disease., 01/21/2020 , 01/21/2027 ,For the treatment of active Thyroid Eye Disease,"Horizon Pharma Ireland, Ltd.|Horizon Pharma USA Inc.|150 South Saunders Road|Lake Forest|Illinois|60045|United States"
404770209,404770209,teprotumumab,,Treatment of active thyroid eye disease,C0339143,Thyroid eye disease,05/06/2013,Designated/Approved,,TEPEZZA is indicated for the treatment of Thyroid Eye Disease., 01/21/2020 , 01/21/2027 ,For the treatment of active Thyroid Eye Disease,"Horizon Pharma Ireland, Ltd.|Horizon Pharma USA Inc.|150 South Saunders Road|Lake Forest|Illinois|60045|United States"
381126121,381126121,teprotumumab,,Treatment of active thyroid eye disease,C0339143,Thyroid eye disease,05/06/2013,Designated/Approved,,TEPEZZA is indicated for the treatment of Thyroid Eye Disease., 01/21/2020 , 01/21/2027 ,For the treatment of active Thyroid Eye Disease,"Horizon Pharma Ireland, Ltd.|Horizon Pharma USA Inc.|150 South Saunders Road|Lake Forest|Illinois|60045|United States"
160682616,160682616,teprotumumab,,Treatment of active thyroid eye disease,C0339143,Thyroid eye disease,05/06/2013,Designated/Approved,,TEPEZZA is indicated for the treatment of Thyroid Eye Disease., 01/21/2020 , 01/21/2027 ,For the treatment of active Thyroid Eye Disease,"Horizon Pharma Ireland, Ltd.|Horizon Pharma USA Inc.|150 South Saunders Road|Lake Forest|Illinois|60045|United States"
381126435,381126435,ublituximab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,08/06/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue|48th Floor|New York|New York|10019|United States"
347911248,347911248,ublituximab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,08/06/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue|48th Floor|New York|New York|10019|United States"
310264701,310264701,ublituximab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,08/06/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue|48th Floor|New York|New York|10019|United States"
160676946,160676946,ublituximab,,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,08/06/2010,Designated,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.|787 Seventh Avenue|48th Floor|New York|New York|10019|United States"
349938425,349938425,Butyrylcholinesterase,,For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.,C0029944,Drug Overdose,03/25/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
160723270,160723270,Butyrylcholinesterase,,For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.,C0029944,Drug Overdose,03/25/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
160723259,160723259,Butyrylcholinesterase,,For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.,C0029944,Drug Overdose,03/25/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
160723249,160723249,Butyrylcholinesterase,,For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.,C0029944,Drug Overdose,03/25/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
135354302,135354302,Butyrylcholinesterase,,For the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.,C0029944,Drug Overdose,03/25/1992,Designated,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.|1550 East Gude Drive|Rockville|Maryland|20850|United States
440790757,440790757,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
404609547,404609547,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
387060186,387060186,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
354355052,354355052,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
329976982,329976982,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
178103466,178103466,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
135288438,135288438,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
103771526,103771526,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
50070199,50070199,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
46505429,46505429,Eculizumab,,Treatment of dermatomyositis,C0011633,Dermatomyositis,09/21/2000,Designated,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
441078173,441078173,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
440791125,440791125,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
349583301,349583301,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
283537479,283537479,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
178103548,178103548,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
135320862,135320862,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
134221887,134221887,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
103771266,103771266,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
49955776,49955776,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
46505833,46505833,filgrastim,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,01/27/2015,Designated,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH|Emil-Geis Str. 4|Grunwald|Germany
404772346,404772346,inclisiran,,Treatment of homozygous familial hypercholesterolemia (HoFH),C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,01/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7932|United States
381127835,381127835,inclisiran,,Treatment of homozygous familial hypercholesterolemia (HoFH),C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,01/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7932|United States
374364239,374364239,inclisiran,,Treatment of homozygous familial hypercholesterolemia (HoFH),C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,01/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7932|United States
316908538,316908538,inclisiran,,Treatment of homozygous familial hypercholesterolemia (HoFH),C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,01/22/2018,Designated,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7932|United States
441072528,441072528,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
440790341,440790341,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433791528,433791528,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
433790701,433790701,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
387060165,387060165,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
354355050,354355050,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
348825932,348825932,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
329976987,329976987,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
178101701,178101701,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
135305802,135305802,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
103771449,103771449,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
91145133,91145133,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313883,56313883,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56313209,56313209,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
56311151,56311151,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
50067186,50067186,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
46505602,46505602,Infliximab,,Treatment of chronic sarcoidosis,C0036202,Sarcoidosis,05/21/2003,Designated,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.|200 Great Valley Parkway|Malvern|Pennsylvania|19355|United States"
328083521,328083521,itolizumab,,Treatment of acute graft versus host disease,C0856825,Acute Graft Versus Host Disease,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.|2223 Avenida De La Playa|Suite 108|San Diego|California|92037|United States"
160677292,160677292,itolizumab,,Treatment of acute graft versus host disease,C0856825,Acute Graft Versus Host Disease,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.|2223 Avenida De La Playa|Suite 108|San Diego|California|92037|United States"
135346059,135346059,itolizumab,,Treatment of acute graft versus host disease,C0856825,Acute Graft Versus Host Disease,02/01/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.|2223 Avenida De La Playa|Suite 108|San Diego|California|92037|United States"
387065620,387065620,luspatercept,,Treatment of myelofibrosis,C0026987,myelofibrosis,01/16/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
381127153,381127153,luspatercept,,Treatment of myelofibrosis,C0026987,myelofibrosis,01/16/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
347911311,347911311,luspatercept,,Treatment of myelofibrosis,C0026987,myelofibrosis,01/16/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
174494664,174494664,luspatercept,,Treatment of myelofibrosis,C0026987,myelofibrosis,01/16/2020,Designated,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
347911341,347911341,Molgramostim,,"Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir.",C0027947,Neutropenia,01/24/1989,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States
160682377,160682377,Molgramostim,,"Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir.",C0027947,Neutropenia,01/24/1989,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States
135351789,135351789,Molgramostim,,"Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir.",C0027947,Neutropenia,01/24/1989,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States
53787494,53787494,Molgramostim,,"Treatment of AIDS patients with neutropenia due to the disease, AZTor ganciclovir.",C0027947,Neutropenia,01/24/1989,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Schering Corporation|2000 Galloping Hill Road|Kenilworth|New Jersey|7033|United States
440798422,440798422,obinutuzumab,,Treatment of Membranous Nephropathy,C0017665,membranous nephropathy,06/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
387060188,387060188,obinutuzumab,,Treatment of Membranous Nephropathy,C0017665,membranous nephropathy,06/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
385327553,385327553,obinutuzumab,,Treatment of Membranous Nephropathy,C0017665,membranous nephropathy,06/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
384647096,384647096,obinutuzumab,,Treatment of Membranous Nephropathy,C0017665,membranous nephropathy,06/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
347910388,347910388,obinutuzumab,,Treatment of Membranous Nephropathy,C0017665,membranous nephropathy,06/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
178103523,178103523,obinutuzumab,,Treatment of Membranous Nephropathy,C0017665,membranous nephropathy,06/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
160682610,160682610,obinutuzumab,,Treatment of Membranous Nephropathy,C0017665,membranous nephropathy,06/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
135332744,135332744,obinutuzumab,,Treatment of Membranous Nephropathy,C0017665,membranous nephropathy,06/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group|1 DNA Way|MS# 241B|South San Francisco|California|94080|United States"
404617350,404617350,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
375758272,375758272,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
348744312,348744312,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
335987561,335987561,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
319299707,319299707,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
313077795,313077795,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
254775499,254775499,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
135023114,135023114,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
134979644,134979644,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
134222261,134222261,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
103771260,103771260,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
49992424,49992424,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
438485410,438485410,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
434303155,434303155,Pentosan polysulfate sodium,Elmiron,Treatment of interstitial cystitis.,C0282488,Interstitial Cystitis,08/07/1985,Designated/Approved,,Relief of bladder pain or discomfort associated with interstitial cystitis., 09/26/1996 , 09/26/2003 ,,Alza Corporation|950 Page Mill Rd.|PO Box 10950|Palo Alto|California|94303|United States
347910109,347910109,rindopepimut,,Treatment of EGFRvIII-expressing glioblastoma multiforme,C0017636,Glioblastoma multiforme,11/19/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Celldex Therapeutics, Inc.|119 Fourth Avenue|Needham|Massachusetts|2494|United States"
160687516,160687516,rindopepimut,,Treatment of EGFRvIII-expressing glioblastoma multiforme,C0017636,Glioblastoma multiforme,11/19/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Celldex Therapeutics, Inc.|119 Fourth Avenue|Needham|Massachusetts|2494|United States"
135326939,135326939,rindopepimut,,Treatment of EGFRvIII-expressing glioblastoma multiforme,C0017636,Glioblastoma multiforme,11/19/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Celldex Therapeutics, Inc.|119 Fourth Avenue|Needham|Massachusetts|2494|United States"
441072531,441072531,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061212,387061212,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
385327556,385327556,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
384647099,384647099,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
365372203,365372203,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
354355036,354355036,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348838049,348838049,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976960,329976960,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319478935,319478935,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
319435463,319435463,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103386,178103386,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135341754,135341754,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771410,103771410,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
57288666,57288666,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
56314417,56314417,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50070184,50070184,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46505820,46505820,rituximab,,Treatment of immune thrombocytopenic purpura,C0398650,Immune thrombocytopenic purpura,03/12/2002,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
404770442,404770442,Synthetic porcine secretin,Secreflo,For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.,"C0017150,C0043515","Gastrinoma , Zollinger-Ellison syndrome",06/18/1999,Designated/Approved,,Use in secretin stimulation testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, 04/04/2002 , 04/04/2009 ,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
404621644,404621644,Synthetic porcine secretin,Secreflo,For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.,"C0017150,C0043515","Gastrinoma , Zollinger-Ellison syndrome",06/18/1999,Designated/Approved,,Use in secretin stimulation testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, 04/04/2002 , 04/04/2009 ,,"ChiRhoClin, Inc.|15500 Gallaudet Ave.|Silver Spring|Maryland|20905|United States"
440790971,440790971,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
387060191,387060191,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
385327552,385327552,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
384647095,384647095,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
354355053,354355053,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
349905851,349905851,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
347910190,347910190,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
178103467,178103467,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
135302166,135302166,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
103771533,103771533,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
387124020,387124020,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
377017835,377017835,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
355433663,355433663,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
349984255,349984255,ustekinumab,,Treatment of pediatric ulcerative colitis,C2931173,Pediatric ulcerative colitis,02/22/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.|1400 McKean Road|Spring House|Pennsylvania|19477|United States"
440234681,440234681,brexucabtagene autoleucel,,Treatment of acute lymphoblastic leukemia. (ALL).,"C0023449,C3542401","Acute lymphoblastic leukemia , Acute Lymphoblastic Leukemia",04/20/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.|2225 Colorado Avenue|Santa Monica|California|90404|United States"
440234681,440234681,brexucabtagene autoleucel,TECARTUS,Treatment of mantle cell lymphoma.,C4721414,Mantle cell lymphoma,04/28/2016,Designated/Approved,,TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), 07/24/2020 , 07/24/2027 ,TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL),"Kite Pharma, Inc.|199 E Blaine St|Seattle|Washington|98102|United States"
96025480,96025480,Coagulation Factor IX (recombinant),BeneFix,Treatment of hemophilia B.,C0008533,Hemophilia B,10/03/1994,Designated/Approved,,"For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas disease), including control and prevention of bleeding in surgical settings.", 02/11/1997 , 02/11/2004 ,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.|35 E. 42nd St 219/9/1|New York|New York|10017|United States"
46508858,46508858,Coagulation Factor IX (recombinant),BeneFix,Treatment of hemophilia B.,C0008533,Hemophilia B,10/03/1994,Designated/Approved,,"For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas disease), including control and prevention of bleeding in surgical settings.", 02/11/1997 , 02/11/2004 ,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.|35 E. 42nd St 219/9/1|New York|New York|10017|United States"
354355039,354355039,denosumab,,Treatment of osteogenesis imperfecta,C0029434,Osteogenesis Imperfecta,02/02/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320-1799|United States
347910354,347910354,denosumab,,Treatment of osteogenesis imperfecta,C0029434,Osteogenesis Imperfecta,02/02/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320-1799|United States
342576979,342576979,denosumab,,Treatment of osteogenesis imperfecta,C0029434,Osteogenesis Imperfecta,02/02/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320-1799|United States
329976981,329976981,denosumab,,Treatment of osteogenesis imperfecta,C0029434,Osteogenesis Imperfecta,02/02/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320-1799|United States
178103468,178103468,denosumab,,Treatment of osteogenesis imperfecta,C0029434,Osteogenesis Imperfecta,02/02/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320-1799|United States
135285955,135285955,denosumab,,Treatment of osteogenesis imperfecta,C0029434,Osteogenesis Imperfecta,02/02/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320-1799|United States
104253154,104253154,denosumab,,Treatment of osteogenesis imperfecta,C0029434,Osteogenesis Imperfecta,02/02/2021,Designated,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.|One Amgen Center Drive|Mail Stop: 27-2-D|Thousand Oaks|California|91320-1799|United States
441072534,441072534,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
440790407,440790407,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
387061216,387061216,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
384060698,384060698,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
384060466,384060466,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
329976962,329976962,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
178103395,178103395,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
135343504,135343504,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
103771203,103771203,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
50059111,50059111,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
46506732,46506732,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
7979194,7979194,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
10099,10099,etanercept,Enbrel,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,C3495559,Juvenile rheumatoid arthritis,10/27/1998,Designated/Approved,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older, 05/27/1999 , 05/27/2006 ,,Immunex Corporation|One Amgen Center Drive|Thousand Oaks|California|91320|United States
46506712,46506712,Interferon alfa-2a (recombinant),,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,04/18/1988,Designated,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.|340 Kingsland Street|Nutley|New Jersey|7110|United States"
441073673,441073673,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
433909878,433909878,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
385327532,385327532,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
384647013,384647013,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
349443906,349443906,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
342556399,342556399,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
340125444,340125444,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
178103919,178103919,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
160709173,160709173,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
135362876,135362876,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
56313553,56313553,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
56313524,56313524,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
56312824,56312824,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
56311130,56311130,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
56311127,56311127,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
56311123,56311123,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
49872007,49872007,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
46507633,46507633,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
445367,445367,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
420815,420815,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
408433,408433,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
407017,407017,L-asparaginase,,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,03/27/2014,Designated,Not FDA Approved for Orphan Indication,,,,,"ERYTECH Pharma S.A.|Batiment Adenine|60, avenue Rockefeller|Lyon|France"
440791041,440791041,Pegvisomant,Somavert,Treatment of acromegaly.,C0001206,Acromegaly,06/24/1997,Designated/Approved,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate", 03/25/2003 , 03/25/2010 ,,"Sensus Corporation|Suite 430,|98 San Jacinto Boulevard|Austin|Texas|78701|United States"
187051788,187051788,Pegvisomant,Somavert,Treatment of acromegaly.,C0001206,Acromegaly,06/24/1997,Designated/Approved,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate", 03/25/2003 , 03/25/2010 ,,"Sensus Corporation|Suite 430,|98 San Jacinto Boulevard|Austin|Texas|78701|United States"
135349977,135349977,Pegvisomant,Somavert,Treatment of acromegaly.,C0001206,Acromegaly,06/24/1997,Designated/Approved,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate", 03/25/2003 , 03/25/2010 ,,"Sensus Corporation|Suite 430,|98 San Jacinto Boulevard|Austin|Texas|78701|United States"
103771306,103771306,Pegvisomant,Somavert,Treatment of acromegaly.,C0001206,Acromegaly,06/24/1997,Designated/Approved,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate", 03/25/2003 , 03/25/2010 ,,"Sensus Corporation|Suite 430,|98 San Jacinto Boulevard|Austin|Texas|78701|United States"
99222748,99222748,Pegvisomant,Somavert,Treatment of acromegaly.,C0001206,Acromegaly,06/24/1997,Designated/Approved,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate", 03/25/2003 , 03/25/2010 ,,"Sensus Corporation|Suite 430,|98 San Jacinto Boulevard|Austin|Texas|78701|United States"
50046579,50046579,Pegvisomant,Somavert,Treatment of acromegaly.,C0001206,Acromegaly,06/24/1997,Designated/Approved,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate", 03/25/2003 , 03/25/2010 ,,"Sensus Corporation|Suite 430,|98 San Jacinto Boulevard|Austin|Texas|78701|United States"
46505507,46505507,Pegvisomant,Somavert,Treatment of acromegaly.,C0001206,Acromegaly,06/24/1997,Designated/Approved,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate", 03/25/2003 , 03/25/2010 ,,"Sensus Corporation|Suite 430,|98 San Jacinto Boulevard|Austin|Texas|78701|United States"
7980266,7980266,Pegvisomant,Somavert,Treatment of acromegaly.,C0001206,Acromegaly,06/24/1997,Designated/Approved,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate", 03/25/2003 , 03/25/2010 ,,"Sensus Corporation|Suite 430,|98 San Jacinto Boulevard|Austin|Texas|78701|United States"
381127197,381127197,pelareorep,,Treatment of fallopian tube cancer,C0238122,Fallopian Tube Cancer,02/24/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
312467919,312467919,pelareorep,,Treatment of fallopian tube cancer,C0238122,Fallopian Tube Cancer,02/24/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
440234581,440234581,Teclistamab,,Treatment of Multiple Myeloma,C0026764,Multiple Myeloma,11/24/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|920 Route 202|Raritan|New Jersey|8869|United States"
381609131,381609131,Teclistamab,,Treatment of Multiple Myeloma,C0026764,Multiple Myeloma,11/24/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|920 Route 202|Raritan|New Jersey|8869|United States"
135275129,135275129,coagulation factor VIIa (recombinant),NovoSeven RT,Treatment of bleeding episodes in Glanzmann's thrombasthenia,C0040015,glanzmann's thrombasthenia,06/18/2004,Designated/Approved,,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.", 07/02/2014 , 07/02/2021 ,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.",Novo Nordisk Inc.|800 Scudders Mill Rd.|Plainsboro|New Jersey|8536|United States
46507544,46507544,coagulation factor VIIa (recombinant),NovoSeven RT,Treatment of bleeding episodes in Glanzmann's thrombasthenia,C0040015,glanzmann's thrombasthenia,06/18/2004,Designated/Approved,,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.", 07/02/2014 , 07/02/2021 ,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.",Novo Nordisk Inc.|800 Scudders Mill Rd.|Plainsboro|New Jersey|8536|United States
404720085,404720085,coagulation factor VIIa (recombinant),NovoSeven RT,Treatment of bleeding episodes in Glanzmann's thrombasthenia,C0040015,glanzmann's thrombasthenia,06/18/2004,Designated/Approved,,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.", 07/02/2014 , 07/02/2021 ,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.",Novo Nordisk Inc.|800 Scudders Mill Rd.|Plainsboro|New Jersey|8536|United States
135284356,135284356,coagulation factor VIIa (recombinant),NovoSeven RT,Treatment of bleeding episodes in Glanzmann's thrombasthenia,C0040015,glanzmann's thrombasthenia,06/18/2004,Designated/Approved,,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.", 07/02/2014 , 07/02/2021 ,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.",Novo Nordisk Inc.|800 Scudders Mill Rd.|Plainsboro|New Jersey|8536|United States
404772436,404772436,nomacopan,,Treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy,C2717961,Thrombotic microangiopathy,08/28/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc|24 West 40th Street|8th Floor|New York|New York|10018|United States
404719628,404719628,nomacopan,,Treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy,C2717961,Thrombotic microangiopathy,08/28/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc|24 West 40th Street|8th Floor|New York|New York|10018|United States
374366992,374366992,nomacopan,,Treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy,C2717961,Thrombotic microangiopathy,08/28/2019,Designated,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc|24 West 40th Street|8th Floor|New York|New York|10018|United States
440790866,440790866,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL., 01/19/2016 , 01/19/2023 ,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
387060162,387060162,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL., 01/19/2016 , 01/19/2023 ,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
347910355,347910355,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL., 01/19/2016 , 01/19/2023 ,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
329976991,329976991,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL., 01/19/2016 , 01/19/2023 ,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
178103384,178103384,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL., 01/19/2016 , 01/19/2023 ,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
135302238,135302238,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL., 01/19/2016 , 01/19/2023 ,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
103771534,103771534,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL., 01/19/2016 , 01/19/2023 ,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
426391582,426391582,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL., 01/19/2016 , 01/19/2023 ,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
349995626,349995626,ofatumumab,ARZERRA,Treatment of chronic lymphocytic leukemia,C0023434,Chronic Lymphocytic Leukemia,03/10/2009,Designated/Approved,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL., 01/19/2016 , 01/19/2023 ,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation|One Health Plaza|East Hanover|New Jersey|7936|United States
440791040,440791040,Peginterferon alfa-2a,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,07/13/1998,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
135347948,135347948,Peginterferon alfa-2a,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,07/13/1998,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
103771381,103771381,Peginterferon alfa-2a,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,07/13/1998,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
85286088,85286088,Peginterferon alfa-2a,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,07/13/1998,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
46504860,46504860,Peginterferon alfa-2a,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,07/13/1998,Designated,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.|340 Kingsland St.|Nutley|New Jersey|7110|United States
387061105,387061105,pembrolizumab,Keytruda,Treatment of primary mediastinal B cell lymphoma.,C0079731,B Cell Lymphoma,01/14/2016,Designated/Approved,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy", 06/13/2018 , 06/13/2025 ,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy","Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
385327548,385327548,pembrolizumab,Keytruda,Treatment of primary mediastinal B cell lymphoma.,C0079731,B Cell Lymphoma,01/14/2016,Designated/Approved,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy", 06/13/2018 , 06/13/2025 ,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy","Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
384647091,384647091,pembrolizumab,Keytruda,Treatment of primary mediastinal B cell lymphoma.,C0079731,B Cell Lymphoma,01/14/2016,Designated/Approved,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy", 06/13/2018 , 06/13/2025 ,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy","Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
377483934,377483934,pembrolizumab,Keytruda,Treatment of primary mediastinal B cell lymphoma.,C0079731,B Cell Lymphoma,01/14/2016,Designated/Approved,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy", 06/13/2018 , 06/13/2025 ,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy","Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
354355033,354355033,pembrolizumab,Keytruda,Treatment of primary mediastinal B cell lymphoma.,C0079731,B Cell Lymphoma,01/14/2016,Designated/Approved,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy", 06/13/2018 , 06/13/2025 ,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy","Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
347910395,347910395,pembrolizumab,Keytruda,Treatment of primary mediastinal B cell lymphoma.,C0079731,B Cell Lymphoma,01/14/2016,Designated/Approved,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy", 06/13/2018 , 06/13/2025 ,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy","Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
194140938,194140938,pembrolizumab,Keytruda,Treatment of primary mediastinal B cell lymphoma.,C0079731,B Cell Lymphoma,01/14/2016,Designated/Approved,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy", 06/13/2018 , 06/13/2025 ,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy","Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
187051801,187051801,pembrolizumab,Keytruda,Treatment of primary mediastinal B cell lymphoma.,C0079731,B Cell Lymphoma,01/14/2016,Designated/Approved,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy", 06/13/2018 , 06/13/2025 ,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy","Merck, Sharp & Dohme Corp.|One Merck Drive|Whitehouse Station|New Jersey|8889|United States"
46506010,46506010,Somatropin (rDNA origin),Saizen,Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.,"C0015544,C3898072","growth failure , Organic Growth Hormone Deficiency",03/06/1987,Designated/Approved,,Long term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone., 10/08/1996 ,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
347910400,347910400,blinatumomab,Blincyto,Treatment of acute lymphocytic leukemia,C0023449,Acute lymphocytic leukemia,05/16/2008,Designated/Approved,,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)., 12/03/2014 , 12/03/2021 ,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,"Amgen, Inc.|One Amgen Center Dr.|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States"
178103956,178103956,blinatumomab,Blincyto,Treatment of acute lymphocytic leukemia,C0023449,Acute lymphocytic leukemia,05/16/2008,Designated/Approved,,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)., 12/03/2014 , 12/03/2021 ,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,"Amgen, Inc.|One Amgen Center Dr.|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States"
160698788,160698788,blinatumomab,Blincyto,Treatment of acute lymphocytic leukemia,C0023449,Acute lymphocytic leukemia,05/16/2008,Designated/Approved,,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)., 12/03/2014 , 12/03/2021 ,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,"Amgen, Inc.|One Amgen Center Dr.|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States"
135330301,135330301,blinatumomab,Blincyto,Treatment of acute lymphocytic leukemia,C0023449,Acute lymphocytic leukemia,05/16/2008,Designated/Approved,,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)., 12/03/2014 , 12/03/2021 ,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,"Amgen, Inc.|One Amgen Center Dr.|Mail Stop 17-2-A|Thousand Oaks|California|91320|United States"
381126778,381126778,bovine lactoferrin,,Prevention of late-onset sepsis in very low birth weight infants,"C0243026,C0282666","Sepsis , Very Low Birth Weight",02/19/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
223727866,223727866,bovine lactoferrin,,Prevention of late-onset sepsis in very low birth weight infants,"C0243026,C0282666","Sepsis , Very Low Birth Weight",02/19/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
809504,809504,bovine lactoferrin,,Prevention of late-onset sepsis in very low birth weight infants,"C0243026,C0282666","Sepsis , Very Low Birth Weight",02/19/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
646870,646870,bovine lactoferrin,,Prevention of late-onset sepsis in very low birth weight infants,"C0243026,C0282666","Sepsis , Very Low Birth Weight",02/19/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
640657,640657,bovine lactoferrin,,Prevention of late-onset sepsis in very low birth weight infants,"C0243026,C0282666","Sepsis , Very Low Birth Weight",02/19/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC|2502 Avenue I|Brooklyn|New York|11210|United States"
440235440,440235440,cirmtuzumab,,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,06/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncternal Therapeutics, Inc.|12230 El Camino Real|Suite 300|SanDiego|California|92130|United States"
404720283,404720283,cirmtuzumab,,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,06/22/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncternal Therapeutics, Inc.|12230 El Camino Real|Suite 300|SanDiego|California|92130|United States"
160774920,160774920,complement factor H,,Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,C2931788,Atypical Hemolytic Uremic Syndrome,12/07/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"LFB Biotechnologies S.A.|3, avenue des Tropiques|Courtaboeuf Cedex|France"
160774919,160774919,complement factor H,,Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,C2931788,Atypical Hemolytic Uremic Syndrome,12/07/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"LFB Biotechnologies S.A.|3, avenue des Tropiques|Courtaboeuf Cedex|France"
160774918,160774918,complement factor H,,Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,C2931788,Atypical Hemolytic Uremic Syndrome,12/07/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"LFB Biotechnologies S.A.|3, avenue des Tropiques|Courtaboeuf Cedex|France"
135358760,135358760,complement factor H,,Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,C2931788,Atypical Hemolytic Uremic Syndrome,12/07/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"LFB Biotechnologies S.A.|3, avenue des Tropiques|Courtaboeuf Cedex|France"
4661,4661,complement factor H,,Treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,C2931788,Atypical Hemolytic Uremic Syndrome,12/07/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"LFB Biotechnologies S.A.|3, avenue des Tropiques|Courtaboeuf Cedex|France"
381128236,381128236,Dalcinonacog Alfa,,Treatment for hemophilia B,C0008533,Hemophilia B,09/20/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Catalyst Biosciences, Inc.|260 Littlefield Avenue|South San Francisco|California|94080|United States"
347911298,347911298,ganitumab,,Treatment of Ewing sarcoma.,C0553580,ewing sarcoma,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States"
160698795,160698795,ganitumab,,Treatment of Ewing sarcoma.,C0553580,ewing sarcoma,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States"
135310814,135310814,ganitumab,,Treatment of Ewing sarcoma.,C0553580,ewing sarcoma,03/21/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"ImmunityBio, Inc.|9920 Jefferson Boulevard|Culver City|California|90232|United States"
381128138,381128138,Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through a protease cleavable valine-alanine linker,,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,06/08/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"ADC Therapeutics SA|Route de la Corniche, 3B|Epalinges|Vaud|Switzerland"
381128138,381128138,Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through a protease cleavable valine-alanine linker,,Treatment of mantle cell lymphoma,C4721414,Mantle cell lymphoma,06/08/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"ADC Therapeutics SA|Route de la Corniche, 3B|Epalinges|Vaud|Switzerland"
433982542,433982542,imsidolimab,,Treatment of generalized pustular psoriasis,C4759670,GENERALIZED PUSTULAR PSORIASIS,07/07/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"AnaptysBio, Inc.|10421 Pacific Center Court|Suite 200|San Diego|California|92121|United States"
440791025,440791025,Interferon gamma-1b,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,12/04/1995,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
135032842,135032842,Interferon gamma-1b,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,12/04/1995,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
103771226,103771226,Interferon gamma-1b,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,12/04/1995,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
46507194,46507194,Interferon gamma-1b,,Treatment of renal cell carcinoma.,C0007134,Renal Cell Carcinoma,12/04/1995,Designated,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutic Ireland DAC|Connaught House, 1st Floor|1 Burlington Road|Dublin 4|Ireland"
440798422,440798422,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma", 11/16/2017 , 11/16/2024 ,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
387060188,387060188,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma", 11/16/2017 , 11/16/2024 ,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
385327553,385327553,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma", 11/16/2017 , 11/16/2024 ,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
384647096,384647096,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma", 11/16/2017 , 11/16/2024 ,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
347910388,347910388,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma", 11/16/2017 , 11/16/2024 ,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
178103523,178103523,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma", 11/16/2017 , 11/16/2024 ,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
160682610,160682610,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma", 11/16/2017 , 11/16/2024 ,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
135332744,135332744,obinutuzumab,GAZYVA,Treatment of follicular lymphoma,C0024301,follicular lymphoma,04/15/2015,Designated/Approved,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma", 11/16/2017 , 11/16/2024 ,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group|1 DNA Way|South San Francisco|California|94080|United States"
347910173,347910173,otelixizumab,,Treatment of new-onset type I diabetes mellitus,C0011854,type i diabetes mellitus,02/06/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline|2301 Renaissance Blvd (RN0420)|P. O. Box 61540|King of Prussia|Pennsylvania|19406|United States
252166668,252166668,otelixizumab,,Treatment of new-onset type I diabetes mellitus,C0011854,type i diabetes mellitus,02/06/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline|2301 Renaissance Blvd (RN0420)|P. O. Box 61540|King of Prussia|Pennsylvania|19406|United States
160666629,160666629,otelixizumab,,Treatment of new-onset type I diabetes mellitus,C0011854,type i diabetes mellitus,02/06/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline|2301 Renaissance Blvd (RN0420)|P. O. Box 61540|King of Prussia|Pennsylvania|19406|United States
135329349,135329349,otelixizumab,,Treatment of new-onset type I diabetes mellitus,C0011854,type i diabetes mellitus,02/06/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline|2301 Renaissance Blvd (RN0420)|P. O. Box 61540|King of Prussia|Pennsylvania|19406|United States
347911185,347911185,Protein C concentrate,Ceprotin,"For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.","C0085650,C0302148,C0398625","Purpura Fulminans , Thrombosis , Protein C Deficiency",06/23/1992,Designated/Approved,,Prevention and treatment of venous thrombosis and purpura fulminans, 03/30/2007 , 03/30/2014 ,,"Baxalta US, Inc.|One Baxter Way|West Lake Village|California|91362|United States"
375581026,375581026,satralizumab-mwge,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,02/23/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
315661178,315661178,satralizumab-mwge,,Treatment of myasthenia gravis,C0026896,Myasthenia Gravis,02/23/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080-4990|United States"
434122191,434122191,tafasitamab-cxix,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"MorphoSys US Inc.|470 Atlantic Avenue 14th Floor, Suite 1401|Boston|Massachusetts|2210|United States"
405226468,405226468,tafasitamab-cxix,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"MorphoSys US Inc.|470 Atlantic Avenue 14th Floor, Suite 1401|Boston|Massachusetts|2210|United States"
404720167,404720167,tafasitamab-cxix,,Treatment of follicular lymphoma,C0024301,follicular lymphoma,01/07/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"MorphoSys US Inc.|470 Atlantic Avenue 14th Floor, Suite 1401|Boston|Massachusetts|2210|United States"
440235434,440235434,cevostamab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,02/03/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
404719745,404719745,cevostamab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,02/03/2021,Designated,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
347910434,347910434,coagulation factor XIII A-subunit (recombinant),TRETTEN,Prophylaxis of bleeding associated with congential factor XIII deficiency,C4316906,Factor XIII deficiency,11/06/2003,Designated/Approved,,Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency., 12/23/2013 , 12/23/2020 ,Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.,"Novo Nordisk, Inc.|800 Scudders Mill Rd.|Plainsboro|New Jersey|8536|United States"
440790757,440790757,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
404609547,404609547,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
387060186,387060186,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
354355052,354355052,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
329976982,329976982,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
178103466,178103466,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
135288438,135288438,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
103771526,103771526,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
50070199,50070199,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
46505429,46505429,eculizumab,Soliris,Treatment of neuromyelitis optica,C0027873,Neuromyelitis Optica,06/24/2013,Designated/Approved,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive., 06/27/2019 , 06/27/2026 ,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.|121 Seaport Boulevard|Boston|Massachusetts|2210|United States"
375758234,375758234,eteplirsen,Exondys 51,Treatment of Duchenne Muscular Dystrophy.,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/23/2007,Designated/Approved,,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping, 09/19/2016 , 09/19/2023 ,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,"Sarepta Therapeutics, Inc.|215 First Street|Suite 415|Cambridge|Massachusetts|2142|United States"
347910319,347910319,eteplirsen,Exondys 51,Treatment of Duchenne Muscular Dystrophy.,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/23/2007,Designated/Approved,,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping, 09/19/2016 , 09/19/2023 ,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,"Sarepta Therapeutics, Inc.|215 First Street|Suite 415|Cambridge|Massachusetts|2142|United States"
335987599,335987599,eteplirsen,Exondys 51,Treatment of Duchenne Muscular Dystrophy.,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/23/2007,Designated/Approved,,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping, 09/19/2016 , 09/19/2023 ,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,"Sarepta Therapeutics, Inc.|215 First Street|Suite 415|Cambridge|Massachusetts|2142|United States"
187051835,187051835,eteplirsen,Exondys 51,Treatment of Duchenne Muscular Dystrophy.,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/23/2007,Designated/Approved,,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping, 09/19/2016 , 09/19/2023 ,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,"Sarepta Therapeutics, Inc.|215 First Street|Suite 415|Cambridge|Massachusetts|2142|United States"
160693047,160693047,eteplirsen,Exondys 51,Treatment of Duchenne Muscular Dystrophy.,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/23/2007,Designated/Approved,,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping, 09/19/2016 , 09/19/2023 ,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,"Sarepta Therapeutics, Inc.|215 First Street|Suite 415|Cambridge|Massachusetts|2142|United States"
135267507,135267507,eteplirsen,Exondys 51,Treatment of Duchenne Muscular Dystrophy.,C0013264,DUCHENNE MUSCULAR DYSTROPHY,10/23/2007,Designated/Approved,,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping, 09/19/2016 , 09/19/2023 ,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,"Sarepta Therapeutics, Inc.|215 First Street|Suite 415|Cambridge|Massachusetts|2142|United States"
387060184,387060184,evolocumab,Repatha,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,09/12/2013,Designated/Approved,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.", 08/27/2015 , 08/27/2022 ,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.|One Amgen Center Drive|M/S 17 2 B|Thousand Oaks|California|91320|United States
381126776,381126776,evolocumab,Repatha,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,09/12/2013,Designated/Approved,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.", 08/27/2015 , 08/27/2022 ,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.|One Amgen Center Drive|M/S 17 2 B|Thousand Oaks|California|91320|United States
354355042,354355042,evolocumab,Repatha,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,09/12/2013,Designated/Approved,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.", 08/27/2015 , 08/27/2022 ,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.|One Amgen Center Drive|M/S 17 2 B|Thousand Oaks|California|91320|United States
348661241,348661241,evolocumab,Repatha,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,09/12/2013,Designated/Approved,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.", 08/27/2015 , 08/27/2022 ,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.|One Amgen Center Drive|M/S 17 2 B|Thousand Oaks|California|91320|United States
347910432,347910432,evolocumab,Repatha,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,09/12/2013,Designated/Approved,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.", 08/27/2015 , 08/27/2022 ,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.|One Amgen Center Drive|M/S 17 2 B|Thousand Oaks|California|91320|United States
178103915,178103915,evolocumab,Repatha,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,09/12/2013,Designated/Approved,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.", 08/27/2015 , 08/27/2022 ,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.|One Amgen Center Drive|M/S 17 2 B|Thousand Oaks|California|91320|United States
164141659,164141659,evolocumab,Repatha,Treatment of homozygous familial hypercholesterolemia,C0020445,FAMILIAL HYPERCHOLESTEROLEMIA,09/12/2013,Designated/Approved,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.", 08/27/2015 , 08/27/2022 ,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.|One Amgen Center Drive|M/S 17 2 B|Thousand Oaks|California|91320|United States
441072532,441072532,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
440790288,440790288,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
404336834,404336834,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
349720813,349720813,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
329976984,329976984,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
178103381,178103381,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
135302348,135302348,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
103771356,103771356,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
53787868,53787868,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
46505767,46505767,Gemtuzumab ozogamicin,Mylotarg,Treatment of acute myeloid leukemia,C0023467,Acute myeloid leukemia,11/24/1999,Designated/Approved,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older, 09/01/2017 , 09/01/2024 ,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company|10646 Science Center Drive|San Diego|California|92121|United States"
404720298,404720298,Magrolimab,,Treatment of Myelodysplastic Syndrome,C3463824,MYELODYSPLASTIC SYNDROME,12/18/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States"
381608663,381608663,Magrolimab,,Treatment of Myelodysplastic Syndrome,C3463824,MYELODYSPLASTIC SYNDROME,12/18/2019,Designated,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.|333 Lakeside Drive|Foster City|California|94404|United States"
160676897,160676897,opium tincture,,Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment,"C0036992,C0401151,C1704632","Short Bowel Syndrome , Chronic diarrhea , Response",12/02/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Valeant Pharmaceuticals International, Inc.|400 Somerset Corporate Blvd|Bridgewater|New Jersey|8807|United States"
135297271,135297271,opium tincture,,Treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment,"C0036992,C0401151,C1704632","Short Bowel Syndrome , Chronic diarrhea , Response",12/02/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Valeant Pharmaceuticals International, Inc.|400 Somerset Corporate Blvd|Bridgewater|New Jersey|8807|United States"
441072526,441072526,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790697,440790697,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
387061165,387061165,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
350080043,350080043,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
348480209,348480209,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
329976976,329976976,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
178103377,178103377,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
135329020,135329020,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
103771315,103771315,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
50067187,50067187,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
46504473,46504473,bevacizumab,,Treatment of melanoma stages IIb through IV as part of a combination chemotherapy regimen,C0280209,melanoma stages,10/13/2009,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.|1 DNA Way|South San Francisco|California|94080|United States"
440790701,440790701,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above), 12/29/1989 , 12/29/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
404720407,404720407,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above), 12/29/1989 , 12/29/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
135351517,135351517,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above), 12/29/1989 , 12/29/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
81065599,81065599,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above), 12/29/1989 , 12/29/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
49895113,49895113,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above), 12/29/1989 , 12/29/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
46505347,46505347,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above), 12/29/1989 , 12/29/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
10147,10147,Botulinum toxin type A,Botox,Treatment of strabismus and blepharospasms,"C0005747,C0038379","Blepharospasms , Strabismus",03/22/1984,Designated/Approved,,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above), 12/29/1989 , 12/29/1996 ,,"Allergan, Inc.|2525 Dupont Drive|P.O. Box 19534|Irvine|California|92713|United States"
440791103,440791103,denileukin diftitox,Ontak,Treatment of patients with cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,08/21/1996,Designated/Approved,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor., 02/05/1999 , 02/05/2006 ,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
381127241,381127241,denileukin diftitox,Ontak,Treatment of patients with cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,08/21/1996,Designated/Approved,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor., 02/05/1999 , 02/05/2006 ,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
178103623,178103623,denileukin diftitox,Ontak,Treatment of patients with cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,08/21/1996,Designated/Approved,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor., 02/05/1999 , 02/05/2006 ,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
135318399,135318399,denileukin diftitox,Ontak,Treatment of patients with cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,08/21/1996,Designated/Approved,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor., 02/05/1999 , 02/05/2006 ,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
125240988,125240988,denileukin diftitox,Ontak,Treatment of patients with cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,08/21/1996,Designated/Approved,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor., 02/05/1999 , 02/05/2006 ,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
103771199,103771199,denileukin diftitox,Ontak,Treatment of patients with cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,08/21/1996,Designated/Approved,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor., 02/05/1999 , 02/05/2006 ,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
50070181,50070181,denileukin diftitox,Ontak,Treatment of patients with cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,08/21/1996,Designated/Approved,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor., 02/05/1999 , 02/05/2006 ,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
46506950,46506950,denileukin diftitox,Ontak,Treatment of patients with cutaneous T-cell lymphoma,C0079773,cutaneous T-cell lymphoma,08/21/1996,Designated/Approved,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor., 02/05/1999 , 02/05/2006 ,,"Eisai, Inc.|300 Tice Boulevard|Woodcliff Lake|New Jersey|7677|United States"
354355039,354355039,denosumab,XGEVA,Treatment of hypercalcemia in malignancy,C0006826,Malignancy,09/11/2013,Designated/Approved,,To treat hypercalcemia of malignancy refractory to biphosphonate therapy., 12/05/2014 , 12/05/2021 ,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,"Amgen, Inc.|One Amgen Center Drive|MS 17-2-C|Thousand Oaks|California|91320|United States"
347910354,347910354,denosumab,XGEVA,Treatment of hypercalcemia in malignancy,C0006826,Malignancy,09/11/2013,Designated/Approved,,To treat hypercalcemia of malignancy refractory to biphosphonate therapy., 12/05/2014 , 12/05/2021 ,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,"Amgen, Inc.|One Amgen Center Drive|MS 17-2-C|Thousand Oaks|California|91320|United States"
342576979,342576979,denosumab,XGEVA,Treatment of hypercalcemia in malignancy,C0006826,Malignancy,09/11/2013,Designated/Approved,,To treat hypercalcemia of malignancy refractory to biphosphonate therapy., 12/05/2014 , 12/05/2021 ,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,"Amgen, Inc.|One Amgen Center Drive|MS 17-2-C|Thousand Oaks|California|91320|United States"
329976981,329976981,denosumab,XGEVA,Treatment of hypercalcemia in malignancy,C0006826,Malignancy,09/11/2013,Designated/Approved,,To treat hypercalcemia of malignancy refractory to biphosphonate therapy., 12/05/2014 , 12/05/2021 ,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,"Amgen, Inc.|One Amgen Center Drive|MS 17-2-C|Thousand Oaks|California|91320|United States"
178103468,178103468,denosumab,XGEVA,Treatment of hypercalcemia in malignancy,C0006826,Malignancy,09/11/2013,Designated/Approved,,To treat hypercalcemia of malignancy refractory to biphosphonate therapy., 12/05/2014 , 12/05/2021 ,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,"Amgen, Inc.|One Amgen Center Drive|MS 17-2-C|Thousand Oaks|California|91320|United States"
135285955,135285955,denosumab,XGEVA,Treatment of hypercalcemia in malignancy,C0006826,Malignancy,09/11/2013,Designated/Approved,,To treat hypercalcemia of malignancy refractory to biphosphonate therapy., 12/05/2014 , 12/05/2021 ,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,"Amgen, Inc.|One Amgen Center Drive|MS 17-2-C|Thousand Oaks|California|91320|United States"
104253154,104253154,denosumab,XGEVA,Treatment of hypercalcemia in malignancy,C0006826,Malignancy,09/11/2013,Designated/Approved,,To treat hypercalcemia of malignancy refractory to biphosphonate therapy., 12/05/2014 , 12/05/2021 ,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,"Amgen, Inc.|One Amgen Center Drive|MS 17-2-C|Thousand Oaks|California|91320|United States"
404772175,404772175,Emapalumab-lzsg,GAMIFANT,Treatment of hemophagocytic lymphohistiocytosis,C0024291,Hemophagocytic lymphohistiocytosis,03/26/2010,Designated/Approved,,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.", 11/20/2018 , 11/20/2025 ,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",Swedish Orphan Biovitrum AB|SE-112|75 Stockholm|Stockholm|Sweden
376219044,376219044,Emapalumab-lzsg,GAMIFANT,Treatment of hemophagocytic lymphohistiocytosis,C0024291,Hemophagocytic lymphohistiocytosis,03/26/2010,Designated/Approved,,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.", 11/20/2018 , 11/20/2025 ,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",Swedish Orphan Biovitrum AB|SE-112|75 Stockholm|Stockholm|Sweden
374364232,374364232,Emapalumab-lzsg,GAMIFANT,Treatment of hemophagocytic lymphohistiocytosis,C0024291,Hemophagocytic lymphohistiocytosis,03/26/2010,Designated/Approved,,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.", 11/20/2018 , 11/20/2025 ,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",Swedish Orphan Biovitrum AB|SE-112|75 Stockholm|Stockholm|Sweden
318164814,318164814,Emapalumab-lzsg,GAMIFANT,Treatment of hemophagocytic lymphohistiocytosis,C0024291,Hemophagocytic lymphohistiocytosis,03/26/2010,Designated/Approved,,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.", 11/20/2018 , 11/20/2025 ,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",Swedish Orphan Biovitrum AB|SE-112|75 Stockholm|Stockholm|Sweden
349988458,349988458,Indium-111 pentetreotide,,Treatment of neuroendocrine tumors,C0206754,Neuroendocrine Tumors,06/16/2006,Designated,Not FDA Approved for Orphan Indication,,,,,RadioIsotope Therapy of America (RITA) Foundation|9701 Richmond Avenue|Houston|Texas|77042|United States
441076846,441076846,lactobacillus plantarum,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,11/30/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"New Biotic, LLC|19546 Rogan Court|Rowland Heights|California|91748|United States"
347911199,347911199,lactobacillus plantarum,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,11/30/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"New Biotic, LLC|19546 Rogan Court|Rowland Heights|California|91748|United States"
135330102,135330102,lactobacillus plantarum,,Treatment of amyotrophic lateral sclerosis (ALS),C0002736,Amyotrophic Lateral Sclerosis,11/30/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"New Biotic, LLC|19546 Rogan Court|Rowland Heights|California|91748|United States"
347910381,347910381,Recombinant human microplasmin,,Treatment of peripheral arterial occlusion,C0264995,Arterial occlusion,01/23/2006,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"ThromboGenics Ltd|Unit 14, Bridgecourt Office Park|Dublin|Ireland"
402356186,402356186,reslizumab,,Treatment of children with eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,12/19/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
402355848,402355848,reslizumab,,Treatment of children with eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,12/19/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
347910352,347910352,reslizumab,,Treatment of children with eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,12/19/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
249565771,249565771,reslizumab,,Treatment of children with eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,12/19/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
160703747,160703747,reslizumab,,Treatment of children with eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,12/19/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
135337118,135337118,reslizumab,,Treatment of children with eosinophilic esophagitis,C0341106,Eosinophilic esophagitis,12/19/2007,Designated,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC|145 Brandywine Pkwy.|West Chester|Pennsylvania|19380|United States"
381127000,381127000,seribantumab,,Treatment of heregulin-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,10/25/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.|888 7th Avenue|Suite 30|New York|New York|10106|United States"
347911251,347911251,seribantumab,,Treatment of heregulin-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,10/25/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.|888 7th Avenue|Suite 30|New York|New York|10106|United States"
312467921,312467921,seribantumab,,Treatment of heregulin-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,10/25/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.|888 7th Avenue|Suite 30|New York|New York|10106|United States"
252166509,252166509,seribantumab,,Treatment of heregulin-positive non-small cell lung cancer,C3539721,Non-Small Cell Lung Cancer,10/25/2017,Designated,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.|888 7th Avenue|Suite 30|New York|New York|10106|United States"
381126367,381126367,tabalumab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,11/19/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
347911223,347911223,tabalumab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,11/19/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
249565680,249565680,tabalumab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,11/19/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
160693420,160693420,tabalumab,,Treatment of multiple myeloma,C0026764,Multiple Myeloma,11/19/2012,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company|Lilly Corporate Center|Indianapolis|Indiana|46285|United States
434122191,434122191,tafasitamab,MONJUVI,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,12/01/2014,Designated/Approved,,"MONJUVI is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)", 07/31/2020 , 07/31/2027 ,"indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",MorphoSys AG|Semmelweisstrasse 7|Plannegg|Germany
404772488,404772488,tafasitamab,MONJUVI,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,12/01/2014,Designated/Approved,,"MONJUVI is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)", 07/31/2020 , 07/31/2027 ,"indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",MorphoSys AG|Semmelweisstrasse 7|Plannegg|Germany
404720167,404720167,tafasitamab,MONJUVI,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,12/01/2014,Designated/Approved,,"MONJUVI is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)", 07/31/2020 , 07/31/2027 ,"indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",MorphoSys AG|Semmelweisstrasse 7|Plannegg|Germany
381127365,381127365,tafasitamab,MONJUVI,Treatment of diffuse large B-cell lymphoma,C1332201,Diffuse Large B-Cell Lymphoma,12/01/2014,Designated/Approved,,"MONJUVI is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)", 07/31/2020 , 07/31/2027 ,"indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",MorphoSys AG|Semmelweisstrasse 7|Plannegg|Germany
347910383,347910383,teduglutide [rDNA origin],GATTEX,Treatment of short bowel syndrome.,C0036992,Short Bowel Syndrome,06/29/2000,Designated/Approved,,GATTEX is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support., 05/16/2019 , 05/16/2026 ,Treatment of pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.,"Shire-NPS Pharmaceuticals, Inc.|650 E. Kendall Street|Cambridge|Massachusetts|2142|United States"
440790971,440790971,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
387060191,387060191,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
385327552,385327552,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
384647095,384647095,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
354355053,354355053,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
349905851,349905851,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
347910190,347910190,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
178103467,178103467,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
135302166,135302166,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
103771533,103771533,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
387124020,387124020,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
377017835,377017835,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
355433663,355433663,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
349984255,349984255,ustekinumab,,Treatment of pediatric Crohn's disease (0 through 16 years of age),C2931133,Pediatric Crohn's disease,05/18/2016,Designated,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC|1400 McKean Road|P.O. Box 776|Spring House|Pennsylvania|19477|United States"
404772407,404772407,fam-trastuzumab deruxtecan-nxki,Enhertu,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,05/20/2020,Designated/Approved,,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen, 01/15/2021 , 01/15/2028 ,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,"Daiichi Sankyo, Inc.|211 Mount Airy Road|Basking Ridge|New Jersey|7920|United States"
404719727,404719727,fam-trastuzumab deruxtecan-nxki,Enhertu,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,05/20/2020,Designated/Approved,,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen, 01/15/2021 , 01/15/2028 ,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,"Daiichi Sankyo, Inc.|211 Mount Airy Road|Basking Ridge|New Jersey|7920|United States"
384585505,384585505,fam-trastuzumab deruxtecan-nxki,Enhertu,"Treatment of gastric cancer, including gastroesophageal junction cancer",C0024623,Gastric Cancer,05/20/2020,Designated/Approved,,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen, 01/15/2021 , 01/15/2028 ,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,"Daiichi Sankyo, Inc.|211 Mount Airy Road|Basking Ridge|New Jersey|7920|United States"
381126899,381126899,inebilizumab,,Treatment of scleroderma,C0036421,scleroderma,12/03/2009,Designated,Not FDA Approved for Orphan Indication,,,,,Viela Bio|One MedImmune Way|Gaithersburg|Maryland|20878|United States
347911342,347911342,inebilizumab,,Treatment of scleroderma,C0036421,scleroderma,12/03/2009,Designated,Not FDA Approved for Orphan Indication,,,,,Viela Bio|One MedImmune Way|Gaithersburg|Maryland|20878|United States
249565673,249565673,inebilizumab,,Treatment of scleroderma,C0036421,scleroderma,12/03/2009,Designated,Not FDA Approved for Orphan Indication,,,,,Viela Bio|One MedImmune Way|Gaithersburg|Maryland|20878|United States
160682403,160682403,inebilizumab,,Treatment of scleroderma,C0036421,scleroderma,12/03/2009,Designated,Not FDA Approved for Orphan Indication,,,,,Viela Bio|One MedImmune Way|Gaithersburg|Maryland|20878|United States
252166553,252166553,interferon gamma,,Treatment of Friedreich's ataxia,C0016719,Friedreich's Ataxia,11/04/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Roberto Testi, MD|School of Medicine|via Michelini-Tocci 82|Rome|Italy"
178101666,178101666,interferon gamma,,Treatment of Friedreich's ataxia,C0016719,Friedreich's Ataxia,11/04/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Roberto Testi, MD|School of Medicine|via Michelini-Tocci 82|Rome|Italy"
103771226,103771226,interferon gamma,,Treatment of Friedreich's ataxia,C0016719,Friedreich's Ataxia,11/04/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Roberto Testi, MD|School of Medicine|via Michelini-Tocci 82|Rome|Italy"
497569,497569,interferon gamma,,Treatment of Friedreich's ataxia,C0016719,Friedreich's Ataxia,11/04/2011,Designated,Not FDA Approved for Orphan Indication,,,,,"Roberto Testi, MD|School of Medicine|via Michelini-Tocci 82|Rome|Italy"
526933,526933,liposomal annamycin,,Treatment of soft tissue sarcomas,C1261473,Soft Tissue Sarcomas,12/28/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"Moleculin Biotech, Inc.|5300 Memorial Drive, Suite 950|Houston|Texas|77007|United States"
405226567,405226567,Luspatercept-aamt,REBLOZYL,Treatment of B-thalassemia,C0039730,Thalassemia,03/11/2013,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions., 11/08/2019 , 11/08/2026 ,Indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
387065620,387065620,Luspatercept-aamt,REBLOZYL,Treatment of B-thalassemia,C0039730,Thalassemia,03/11/2013,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions., 11/08/2019 , 11/08/2026 ,Indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
347911311,347911311,Luspatercept-aamt,REBLOZYL,Treatment of B-thalassemia,C0039730,Thalassemia,03/11/2013,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions., 11/08/2019 , 11/08/2026 ,Indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
174494664,174494664,Luspatercept-aamt,REBLOZYL,Treatment of B-thalassemia,C0039730,Thalassemia,03/11/2013,Designated/Approved,,REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions., 11/08/2019 , 11/08/2026 ,Indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,Celgene Corporation|86 Morris Avenue|Summit|New Jersey|7901|United States
347910462,347910462,necitumumab,,Treatment of squamous non-small cell lung cancer,C4509816,Squamous non-small cell lung cancer,11/20/2015,Designated/Approved,,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer.", 11/24/2015 , 11/24/2022 ,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. PORTRAZZA is not indicated for treatment of non-squamous, non-small cell lung cancer",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
249565770,249565770,necitumumab,,Treatment of squamous non-small cell lung cancer,C4509816,Squamous non-small cell lung cancer,11/20/2015,Designated/Approved,,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer.", 11/24/2015 , 11/24/2022 ,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. PORTRAZZA is not indicated for treatment of non-squamous, non-small cell lung cancer",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
160698797,160698797,necitumumab,,Treatment of squamous non-small cell lung cancer,C4509816,Squamous non-small cell lung cancer,11/20/2015,Designated/Approved,,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer.", 11/24/2015 , 11/24/2022 ,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. PORTRAZZA is not indicated for treatment of non-squamous, non-small cell lung cancer",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
135263756,135263756,necitumumab,,Treatment of squamous non-small cell lung cancer,C4509816,Squamous non-small cell lung cancer,11/20/2015,Designated/Approved,,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer.", 11/24/2015 , 11/24/2022 ,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. PORTRAZZA is not indicated for treatment of non-squamous, non-small cell lung cancer",Eli Lilly and Company|33 ImClone Drive|Branchburg|New Jersey|8876|United States
347909845,347909845,sitimagene ceradenovec,,Use with gancyclovir in the treatment of malignant glioma,C0555198,Malignant Glioma,07/31/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Gliotherapy, Ltd.|Sanderum House|Oakley Road|London|United Kingdom"
160709090,160709090,sitimagene ceradenovec,,Use with gancyclovir in the treatment of malignant glioma,C0555198,Malignant Glioma,07/31/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Gliotherapy, Ltd.|Sanderum House|Oakley Road|London|United Kingdom"
135357028,135357028,sitimagene ceradenovec,,Use with gancyclovir in the treatment of malignant glioma,C0555198,Malignant Glioma,07/31/2001,Designated,Not FDA Approved for Orphan Indication,,,,,"Gliotherapy, Ltd.|Sanderum House|Oakley Road|London|United Kingdom"
381127094,381127094,tarextumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,01/26/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
347911283,347911283,tarextumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,01/26/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
252166663,252166663,tarextumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,01/26/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
242651788,242651788,tarextumab,,Treatment of pancreatic cancer,C0235974,PANCREATIC CANCER,01/26/2015,Designated/Withdrawn,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.|800 Chesapeake Drive|Redwood City|California|94063|United States"
347910376,347910376,Brentuximab vedotin,Adcetris,Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders,C0024314,Lymphoproliferative Disorders,09/07/2016,Designated/Approved,,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
329976977,329976977,Brentuximab vedotin,Adcetris,Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders,C0024314,Lymphoproliferative Disorders,09/07/2016,Designated/Approved,,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
178103378,178103378,Brentuximab vedotin,Adcetris,Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders,C0024314,Lymphoproliferative Disorders,09/07/2016,Designated/Approved,,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
135300399,135300399,Brentuximab vedotin,Adcetris,Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders,C0024314,Lymphoproliferative Disorders,09/07/2016,Designated/Approved,,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
131277422,131277422,Brentuximab vedotin,Adcetris,Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders,C0024314,Lymphoproliferative Disorders,09/07/2016,Designated/Approved,,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy, 11/09/2017 , 11/09/2024 ,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy,Seagen Inc.|21823 30th Drive Southeast|Bothell|Washington|98021|United States
381129570,381129570,ex vivo cultured adult human mesenchymal stem cells,,Treatment of acute graft versus host disease,C0856825,Acute Graft Versus Host Disease,12/14/2005,Designated,Not FDA Approved for Orphan Indication,,,,,"Mesoblast, Inc.|505 Fifth Avenue|Third Floor|New York|New York|10017|United States"
46506231,46506231,human insulin (rDNA),,Treatment of short bowel syndrome (SBS).,C0036992,Short Bowel Syndrome,04/06/2015,Designated,Not FDA Approved for Orphan Indication,,,,,ELGAN Pharma Ltd.|13 wadi el hadj|Nazareth|17111|Israel
490427,490427,Immune Globulin Intravenous (Human),,Treatment of systemic sclerosis,C0036421,Systemic sclerosis,01/28/2020,Designated,Not FDA Approved for Orphan Indication,,,,,CSL Behring|1020 First Avenue|PO Box 61501|King of Prussia|Pennsylvania|19406|United States
387061103,387061103,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", 12/22/2014 , 12/22/2021 ,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
385327549,385327549,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", 12/22/2014 , 12/22/2021 ,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
384647092,384647092,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", 12/22/2014 , 12/22/2021 ,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
354355034,354355034,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", 12/22/2014 , 12/22/2021 ,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
349494907,349494907,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", 12/22/2014 , 12/22/2021 ,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
347910393,347910393,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", 12/22/2014 , 12/22/2021 ,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
178103907,178103907,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", 12/22/2014 , 12/22/2021 ,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
160698453,160698453,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", 12/22/2014 , 12/22/2021 ,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
135341610,135341610,nivolumab,Opdivo,Treatment of Stage IIb to IV melanoma,C0025202,melanoma,01/23/2013,Designated/Approved,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor", 12/22/2014 , 12/22/2021 ,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.|P. O. Box 4000|Princeton|New Jersey|8543|United States
381127197,381127197,pelareorep,,Treatment of primary peritoneal cancer,C1514428,Primary Peritoneal Cancer,02/24/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
312467919,312467919,pelareorep,,Treatment of primary peritoneal cancer,C1514428,Primary Peritoneal Cancer,02/24/2015,Designated,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.|210, 1167 Kensington Crescent NW|Calgary|Canada"
441076374,441076374,Somatropin,,Treatment of patients with HIV-associated adipose redistribution syndrome,"C0019682,C0039082","HIV , Syndrome",03/16/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
178101641,178101641,Somatropin,,Treatment of patients with HIV-associated adipose redistribution syndrome,"C0019682,C0039082","HIV , Syndrome",03/16/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
135274454,135274454,Somatropin,,Treatment of patients with HIV-associated adipose redistribution syndrome,"C0019682,C0039082","HIV , Syndrome",03/16/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
103771423,103771423,Somatropin,,Treatment of patients with HIV-associated adipose redistribution syndrome,"C0019682,C0039082","HIV , Syndrome",03/16/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
50046577,50046577,Somatropin,,Treatment of patients with HIV-associated adipose redistribution syndrome,"C0019682,C0039082","HIV , Syndrome",03/16/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
46506010,46506010,Somatropin,,Treatment of patients with HIV-associated adipose redistribution syndrome,"C0019682,C0039082","HIV , Syndrome",03/16/2004,Designated,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.|One Technology Place|Rockland|Massachusetts|2370|United States"
440234507,440234507,sugemalimab,,treatment of T-cell lymphoma,C0079772,T-Cell Lymphoma,10/08/2020,Designated,Not FDA Approved for Orphan Indication,,,,,"CStone Pharmaceuticals (Suzhou) Co., Ltd.|1000 Zhangheng Road|Building 25|Shanghai|201203|China"
404771404,404771404,voretigene neparvovec-rzyl,LUXTURNA,Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations,C0854723,retinal dystrophy,03/18/2015,Designated/Approved,,an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells determined by a treating physician, 12/19/2017 , 12/19/2024 ,Treatment of patients with confirmed biallelic RPE65 mutation-associated retinal distrophy. Patients must have viable retinal cells determined by a treating physician.,"Spark Therapeutics, Inc.|3737 Market Street|Suite 1300|Philadelphia|Pennsylvania|19104|United States"
342581844,342581844,voretigene neparvovec-rzyl,LUXTURNA,Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations,C0854723,retinal dystrophy,03/18/2015,Designated/Approved,,an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells determined by a treating physician, 12/19/2017 , 12/19/2024 ,Treatment of patients with confirmed biallelic RPE65 mutation-associated retinal distrophy. Patients must have viable retinal cells determined by a treating physician.,"Spark Therapeutics, Inc.|3737 Market Street|Suite 1300|Philadelphia|Pennsylvania|19104|United States"
